[{"id": 139001, "ingredient1": "Insulin human (zinc)", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139160/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139002, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139161/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139003, "ingredient1": "Iodipamide", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139162/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, More", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 139004, "ingredient1": "Iodixanol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139163/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 139005, "ingredient1": "Iohexol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139164/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 139006, "ingredient1": "Ioversol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139165/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 139007, "ingredient1": "Ioxilan", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139166/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 139008, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Irinotecan-induced vomiting or diarrhea may increase the risk and/or severity of dehydration produced by diuretics.", "source": "DDInter", "management_text": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "mechanism_text": "Others", "recommendation": "Concomitant use of diuretics during irinotecan administration or during periods of vomiting or diarrhea that may follow is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139167/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vincristine, Vinblastine, Topotecan, Teniposide, Vinorelbine, Etoposide", "updated_at": 1767369485}, {"id": 139009, "ingredient1": "Isoetharine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.", "source": "DDInter", "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139168/", "reference_text": "[1] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[3] Lipworth BJ, McDevitt DG, Struthers AD \"Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol.\" Am J Med 86 (1989): 653-7[4] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[5] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[6] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[7] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[8] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139010, "ingredient1": "Metolazone", "ingredient2": "Lactitol", "severity": "Moderate", "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139169/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E \"Drug-induced hypomagnesaemia : scope and management.\" Drug Saf 28 (2005): 763-88[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 139011, "ingredient1": "Metolazone", "ingredient2": "Lactulose", "severity": "Moderate", "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139170/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E \"Drug-induced hypomagnesaemia : scope and management.\" Drug Saf 28 (2005): 763-88[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Darunavir, Tioconazole, Furazolidone, Diiodohydroxyquinoline, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 139012, "ingredient1": "Metolazone", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Levomethadyl acetate can cause QT interval prolongation and torsades de pointes. Coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in an elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.", "source": "DDInter", "management_text": "Caution is advised if levomethadyl acetate must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with levomethadyl acetate. A 12-lead ECG should be performed before initiating therapy, 12 to 14 days after initiating therapy, and periodically thereafter. Patients should be advised to immediately seek medical attention if they experience palpitations, dizziness, lightheadedness, fainting, or seizures.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if levomethadyl acetate must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139171/", "reference_text": "[1] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[2] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[3] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991): 919-25[4] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[5] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992): 520-3[6] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975): 431-6[7] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Trichlormethiazide, Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Clindamycin, Trichlormethiazide, Ciclopirox, More", "alternatives_b": "Nalmefene, Disulfiram, Acamprosate", "updated_at": 1767369485}, {"id": 139013, "ingredient1": "Metolazone", "ingredient2": "Licorice", "severity": "Moderate", "effect": "Chronic use of licorice may potentiate the hypokalemic effects of some diuretics and other drugs that deplete potassium (e.g., amphotericin B, cation exchange resins). Glycyrrhizic acid, a component of licorice, possesses mineralocorticoid activity and can induce hypokalemia. Severe hypokalemia can lead to muscle paralysis, rhabdomyolysis, metabolic alkalosis, cardiac arrhythmias, and respiratory arrest.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, chronic use of licorice and licorice-containing products should be avoided in patients treated with potassium-depleting drugs. During concomitant use, patients should be advised to contact their physician if they experience signs and symptoms of hypokalemia such as fatigue, myalgia, muscle weakness, abdominal pain, hypoventilation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139172/", "reference_text": "[1] Nielsen I, Pedersen RS \"Life-threatening hypokalaemia caused by liquorice ingestion.\" Lancet 1 (1984): 1305[2] Edwards CR \"Lessons from licorice.\" N Engl J Med 325 (1991): 1242-3[3] Cumming AM, Boddy K, Brown JJ, et al \"Severe hypokalaemia with paralysis induced by small doses of liquorice.\" Postgrad Med J 56 (1980): 526-9[4] Clyburn EB, DiPette DJ \"Hypertension induced by drugs and other substances.\" Semin Nephrol 15 (1995): 72-86[5] Rosseel M, Schoors D \"Chewing gum and hypokalaemia.\" Lancet 341 (1993): 175[6] Cumming A \"Severe reduction of serum potassium induced by licorice.\" Nurs Times 72 (1976): 367-70[7] Elinav E, Chajek-Shaul T \"Licorice consumption causing severe hypokalemic paralysis.\" Mayo Clin Proc 78 (2003): 767-8[8] Farese RV, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R \"Licorice-induced hypermineralocorticoidism.\" N Engl J Med 325 (1991): 1223-7[9] de Klerk GJ, Nieuwenhuis MG, Beutler JJ \"Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum.\" BMJ 314 (1997): 731[10] Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR \"Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age.\" Lancet 2 (1987): 821-4", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139014, "ingredient1": "Metolazone", "ingredient2": "Magnesium citrate", "severity": "Moderate", "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139173/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E \"Drug-induced hypomagnesaemia : scope and management.\" Drug Saf 28 (2005): 763-88[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Sorbitol, Sulfamethizole, Sodium citrate, Sodium chloride, Chlorhexidine, Neomycin, Magnesium gluconate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, More", "updated_at": 1767369485}, {"id": 139015, "ingredient1": "Metolazone", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139174/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E \"Drug-induced hypomagnesaemia : scope and management.\" Drug Saf 28 (2005): 763-88[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, More", "updated_at": 1767369485}, {"id": 139016, "ingredient1": "Metolazone", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.", "source": "DDInter", "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.", "mechanism_text": "Antagonism", "recommendation": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139175/", "reference_text": "[1] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV \"Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.\" Eur J Clin Pharmacol 48 (1995): 247-51[2] Favre L, Glasson P, Vallotton MB \"Reversible acute renal failure from combined triamterene and indomethacin.\" Ann Intern Med 96 (1982): 317-20[3] Bennett WM \"Drug interactions and consequences of sodium restriction.\" Am J Clin Nutr 65 (1997): S678-81[4] Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA \"The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.\" Int J Clin Pharmacol Ther 32 (1994): 12-8[5] Allan SG, Knox J, Kerr F \"Interaction between diuretics and indomethacin.\" Br Med J 283 (1981): 1611[6] Mor R, Pitlik S, Rosenfeld JB \"Indomethacin- and Moduretic--induced hyperkalemia.\" Isr J Med Sci 19 (1983): 535-7[7] Desaulles E, Schwartz J \"A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.\" Br J Pharmacol 65 (1979): 193-6[8] Watkins J, Abbot EC, Hensby CN, Webster J, Dollery CT \"Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.\" Br Med J 281 (1980): 702-5[9] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981): 663-7[10] Gehr T, Sica DA, Steigler BW, Marshall C \"Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I).\" Clin Pharmacol Ther 47 (1990): 200[11] Ahmad S \"Indomethacin-bumetanide interaction: an alert.\" Am J Cardiol 54 (1984): 246-7[12] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[13] Gurwitz JH, Everitt DE, Monane M, et al \"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.\" J Gerontol A Biol Sci Med Sci 51 (1996): m74-9[14] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A \"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.\" Arch Intern Med 158 (1998): 1108-12[15] McCarthy JT, Torres VE, Romero JC, et al \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982): 289-96[16] Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA \"The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.\" Br J Clin Pharmacol 23 (1987): 55-63[17] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988): 58-62[18] Smith DE, Brater DC, Lin ET, Benet LZ \"Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.\" J Pharmacokinet Biopharm 7 (1979): 265-74[19] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[20] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[21] Brater DC, Fox WR, Chennavasin P \"Interaction studies with bumetanide and furosemide: effects of probenecid and of indomethacin on response to bumetanide in man.\" J Clin Pharmacol 21 (1981): 647-53[22] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[23] Poe TE, Scott RB, Keith JF Jr \"Interaction of indomethacin with furosemide.\" J Fam Pract 16 (1983): 610-6[24] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983): 407-15[25] Pedrinelli R, Magagna A, Arzilli F, et al \"Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.\" Clin Pharmacol Ther 28 (1980): 722-31[26] Weinberg MS, Quigg RJ, Salant DJ, Bernard DB \"Anuric renal failure precipitated by indomethacin and triamterene.\" Nephron 40 (1985): 216-8", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Misoprostol, Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 139017, "ingredient1": "Metolazone", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139176/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Halazepam, Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, More", "alternatives_b": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 139018, "ingredient1": "Metolazone", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.", "source": "DDInter", "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139177/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Darunavir, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 139019, "ingredient1": "Metolazone", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139178/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "updated_at": 1767369485}, {"id": 139020, "ingredient1": "Metolazone", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139179/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 139021, "ingredient1": "Metolazone", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139180/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Trichlormethiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139022, "ingredient1": "Metoprolol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139181/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Ivabradine, Esmolol, Carteolol, Penbutolol, Penbutolol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139023, "ingredient1": "Midazolam", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139182/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Rosuvastatin, Sulfadiazine, Lactic acid, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, Lemborexant, More", "updated_at": 1767369485}, {"id": 139024, "ingredient1": "Miglitol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139183/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "updated_at": 1767369485}, {"id": 139025, "ingredient1": "Milnacipran", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139184/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 139026, "ingredient1": "Mineral oil", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139185/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E \"Drug-induced hypomagnesaemia : scope and management.\" Drug Saf 28 (2005): 763-88[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 139027, "ingredient1": "Mirtazapine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139186/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Ciclopirox, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 139028, "ingredient1": "Nateglinide", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139187/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Ascorbic acid, Oxytetracycline, Amphotericin B, Clindamycin, Ciclopirox, Zonisamide, Vemurafenib, Tioconazole, Econazole, Chloramphenicol, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 139029, "ingredient1": "Nefazodone", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Nefazodone may potentiate the hypotensive effect of many drugs including vasodilators and antihypertensive agents. Orthostatic hypotension may occur.", "source": "DDInter", "management_text": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139188/", "reference_text": "[1] \"Product Information. Serzone (nefazodone).\" Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Darunavir, Probenecid, Tioconazole, Brinzolamide, Clotrimazole, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 139030, "ingredient1": "Olanzapine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139189/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Pimavanserin", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Ciclopirox, Darunavir, Tioconazole, Brinzolamide, Furazolidone, More", "updated_at": 1767369485}, {"id": 139031, "ingredient1": "Oliceridine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139190/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Probenecid, More", "alternatives_b": "Tapentadol, Naloxone, Dezocine, Oxymorphone", "updated_at": 1767369485}, {"id": 139032, "ingredient1": "Olopatadine (nasal)", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139191/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Furosemide, Trichlormethiazide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139033, "ingredient1": "Opium", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139192/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Eluxadoline, Diphenoxylate, Difenoxin, Tapentadol, Naloxone, Dezocine, Oxymorphone", "updated_at": 1767369485}, {"id": 139034, "ingredient1": "Oxazepam", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139193/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, Ketoconazole, Tioconazole, More", "alternatives_b": "Halazepam", "updated_at": 1767369485}, {"id": 139035, "ingredient1": "Oxybutynin", "ingredient2": "Metolazone", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139194/", "reference_text": "[1] Osman MA, Welling PG \"Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide.\" Curr Ther Res Clin Exp 34 (1983): 404-8[2] Beermann B, Groschinsky-Grind M \"Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline.\" Eur J Clin Pharmacol 13 (1978): 385-7", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, Vemurafenib, Probenecid, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 139036, "ingredient1": "Oxytetracycline", "ingredient2": "Metolazone", "severity": "Minor", "effect": "The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN). Usually, no clinical intervention is necessary, unless decreases in renal function occur. If renal function deteriorates, discontinuation of one or both agents may be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139195/", "reference_text": "[1] Jick H, Slone D, Shapiro S, et al \"Tetracycline and drug-attributed rises in blood urea nitrogen: a report from the Boston Collaborative Drug Surveillance Program.\" JAMA 220 (1972): 377-9[2] Alexander MR \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972): 713-4[3] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[4] Tannenberg AM \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972): 713[5] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[6] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "Tigecycline, Sarecycline, Omadacycline, Eravacycline, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Netilmicin, Polymyxin B, Cefuroxime, More", "updated_at": 1767369485}, {"id": 139037, "ingredient1": "Ozanimod", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139196/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Darunavir, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 139038, "ingredient1": "Pancuronium", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139197/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139039, "ingredient1": "Pantoprazole", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.", "source": "DDInter", "management_text": "Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139198/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm.\" ([2011 Mar 2]):[2] \"Product Information. Nexium (esomeprazole)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Tinidazole, Levofloxacin, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Nizatidine, Vonoprazan, Amoxicillin", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Methazolamide, Vemurafenib, Darunavir, Tioconazole, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139040, "ingredient1": "Paraldehyde", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139199/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, Lemborexant, More", "updated_at": 1767369485}, {"id": 139041, "ingredient1": "Paricalcitol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139200/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Bumetanide, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Etelcalcetide, Salmon calcitonin", "updated_at": 1767369485}, {"id": 139042, "ingredient1": "Paroxetine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139201/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Sulfamethoxazole, Sulfamethizole, Simeprevir, Diazoxide, Sulfadiazine, Probenecid, Chloramphenicol, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 139043, "ingredient1": "Pentoxifylline", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pentoxifylline is used in combination with hypotensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139202/", "reference_text": "[1] \"Product Information. Trental (pentoxifylline).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Darunavir, More", "alternatives_b": "Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, More", "updated_at": 1767369485}, {"id": 139044, "ingredient1": "Perphenazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.", "source": "DDInter", "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139203/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 139045, "ingredient1": "Phenelzine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139204/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 139046, "ingredient1": "Phenolphthalein", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139205/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E \"Drug-induced hypomagnesaemia : scope and management.\" Drug Saf 28 (2005): 763-88[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61", "alternatives_a": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 139047, "ingredient1": "Phenylbutazone", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.", "source": "DDInter", "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.", "mechanism_text": "Antagonism", "recommendation": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139206/", "reference_text": "[1] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV \"Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.\" Eur J Clin Pharmacol 48 (1995): 247-51[2] Favre L, Glasson P, Vallotton MB \"Reversible acute renal failure from combined triamterene and indomethacin.\" Ann Intern Med 96 (1982): 317-20[3] Bennett WM \"Drug interactions and consequences of sodium restriction.\" Am J Clin Nutr 65 (1997): S678-81[4] Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA \"The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.\" Int J Clin Pharmacol Ther 32 (1994): 12-8[5] Allan SG, Knox J, Kerr F \"Interaction between diuretics and indomethacin.\" Br Med J 283 (1981): 1611[6] Mor R, Pitlik S, Rosenfeld JB \"Indomethacin- and Moduretic--induced hyperkalemia.\" Isr J Med Sci 19 (1983): 535-7[7] Desaulles E, Schwartz J \"A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.\" Br J Pharmacol 65 (1979): 193-6[8] Watkins J, Abbot EC, Hensby CN, Webster J, Dollery CT \"Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.\" Br Med J 281 (1980): 702-5[9] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981): 663-7[10] Gehr T, Sica DA, Steigler BW, Marshall C \"Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I).\" Clin Pharmacol Ther 47 (1990): 200[11] Ahmad S \"Indomethacin-bumetanide interaction: an alert.\" Am J Cardiol 54 (1984): 246-7[12] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[13] Gurwitz JH, Everitt DE, Monane M, et al \"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.\" J Gerontol A Biol Sci Med Sci 51 (1996): m74-9[14] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A \"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.\" Arch Intern Med 158 (1998): 1108-12[15] McCarthy JT, Torres VE, Romero JC, et al \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982): 289-96[16] Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA \"The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.\" Br J Clin Pharmacol 23 (1987): 55-63[17] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988): 58-62[18] Smith DE, Brater DC, Lin ET, Benet LZ \"Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.\" J Pharmacokinet Biopharm 7 (1979): 265-74[19] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[20] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[21] Brater DC, Fox WR, Chennavasin P \"Interaction studies with bumetanide and furosemide: effects of probenecid and of indomethacin on response to bumetanide in man.\" J Clin Pharmacol 21 (1981): 647-53[22] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[23] Poe TE, Scott RB, Keith JF Jr \"Interaction of indomethacin with furosemide.\" J Fam Pract 16 (1983): 610-6[24] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983): 407-15[25] Pedrinelli R, Magagna A, Arzilli F, et al \"Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.\" Clin Pharmacol Ther 28 (1980): 722-31[26] Weinberg MS, Quigg RJ, Salant DJ, Bernard DB \"Anuric renal failure precipitated by indomethacin and triamterene.\" Nephron 40 (1985): 216-8", "alternatives_a": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Misoprostol, Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 139048, "ingredient1": "Pimozide", "ingredient2": "Metolazone", "severity": "Major", "effect": "Pimozide can cause dose-related prolongation of the QT interval. While clinical data are lacking, the coadministration of pimozide and agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential.", "source": "DDInter", "management_text": "Caution is advised when pimozide must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with pimozide.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when pimozide must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139207/", "reference_text": "[1] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[2] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[3] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 139049, "ingredient1": "Pindolol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139208/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Penbutolol, Esmolol, Carteolol, Penbutolol", "updated_at": 1767369485}, {"id": 139050, "ingredient1": "Pioglitazone", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139209/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Tioconazole, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 139051, "ingredient1": "Pipecuronium", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139210/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Trichlormethiazide, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139052, "ingredient1": "Piroxicam", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.", "source": "DDInter", "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.", "mechanism_text": "Antagonism", "recommendation": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139211/", "reference_text": "[1] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV \"Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.\" Eur J Clin Pharmacol 48 (1995): 247-51[2] Favre L, Glasson P, Vallotton MB \"Reversible acute renal failure from combined triamterene and indomethacin.\" Ann Intern Med 96 (1982): 317-20[3] Bennett WM \"Drug interactions and consequences of sodium restriction.\" Am J Clin Nutr 65 (1997): S678-81[4] Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA \"The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.\" Int J Clin Pharmacol Ther 32 (1994): 12-8[5] Allan SG, Knox J, Kerr F \"Interaction between diuretics and indomethacin.\" Br Med J 283 (1981): 1611[6] Mor R, Pitlik S, Rosenfeld JB \"Indomethacin- and Moduretic--induced hyperkalemia.\" Isr J Med Sci 19 (1983): 535-7[7] Desaulles E, Schwartz J \"A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.\" Br J Pharmacol 65 (1979): 193-6[8] Watkins J, Abbot EC, Hensby CN, Webster J, Dollery CT \"Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.\" Br Med J 281 (1980): 702-5[9] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981): 663-7[10] Gehr T, Sica DA, Steigler BW, Marshall C \"Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I).\" Clin Pharmacol Ther 47 (1990): 200[11] Ahmad S \"Indomethacin-bumetanide interaction: an alert.\" Am J Cardiol 54 (1984): 246-7[12] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[13] Gurwitz JH, Everitt DE, Monane M, et al \"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.\" J Gerontol A Biol Sci Med Sci 51 (1996): m74-9[14] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A \"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.\" Arch Intern Med 158 (1998): 1108-12[15] McCarthy JT, Torres VE, Romero JC, et al \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982): 289-96[16] Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA \"The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.\" Br J Clin Pharmacol 23 (1987): 55-63[17] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988): 58-62[18] Smith DE, Brater DC, Lin ET, Benet LZ \"Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.\" J Pharmacokinet Biopharm 7 (1979): 265-74[19] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[20] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[21] Brater DC, Fox WR, Chennavasin P \"Interaction studies with bumetanide and furosemide: effects of probenecid and of indomethacin on response to bumetanide in man.\" J Clin Pharmacol 21 (1981): 647-53[22] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[23] Poe TE, Scott RB, Keith JF Jr \"Interaction of indomethacin with furosemide.\" J Fam Pract 16 (1983): 610-6[24] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983): 407-15[25] Pedrinelli R, Magagna A, Arzilli F, et al \"Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.\" Clin Pharmacol Ther 28 (1980): 722-31[26] Weinberg MS, Quigg RJ, Salant DJ, Bernard DB \"Anuric renal failure precipitated by indomethacin and triamterene.\" Nephron 40 (1985): 216-8", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, More", "alternatives_b": "Misoprostol, Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide, Fluocinolone acetonide, Salicylic acid, Fluorometholone", "updated_at": 1767369485}, {"id": 139053, "ingredient1": "Polyethylene glycol (3350)", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139212/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E \"Drug-induced hypomagnesaemia : scope and management.\" Drug Saf 28 (2005): 763-88[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139054, "ingredient1": "Porfimer sodium", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.", "source": "DDInter", "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139213/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Photofrin (porfimer).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[3] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivityan update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019): 827-47[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020): 589-600[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 139055, "ingredient1": "Pramlintide", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139214/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 139056, "ingredient1": "Prazosin", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139215/", "reference_text": "[1] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[2] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991): 919-25[3] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[4] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992): 520-3[5] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975): 431-6", "alternatives_a": "Bumetanide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139057, "ingredient1": "Prednisolone", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).", "source": "DDInter", "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.", "mechanism_text": "Synergism", "recommendation": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139216/", "reference_text": "[1] Morris GC, Egan JG, Jones MK \"Hypokalaemic paralysis induced by bolus prednisolone in Graves' disease.\" Aust N Z J Med 22 (1992): 312[2] Thomas TP \"The complications of systemic corticosteroid therapy in the elderly.\" Gerontology 30 (1984): 60-5[3] \"Product Information. Hydeltrasol (prednisolone).\" Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7[5] Powell JR \"Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application.\" Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW \"Clinical considerations in the use of corticosteroids.\" N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA \"Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial.\" JAMA 269 (1993): 2110-2", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Tioconazole, Furazolidone, Diiodohydroxyquinoline, More", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, Fluorometholone, Epinephrine, More", "updated_at": 1767369485}, {"id": 139058, "ingredient1": "Prednisone", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).", "source": "DDInter", "management_text": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.", "mechanism_text": "Synergism", "recommendation": "Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139217/", "reference_text": "[1] Morris GC, Egan JG, Jones MK \"Hypokalaemic paralysis induced by bolus prednisolone in Graves' disease.\" Aust N Z J Med 22 (1992): 312[2] Thomas TP \"The complications of systemic corticosteroid therapy in the elderly.\" Gerontology 30 (1984): 60-5[3] \"Product Information. Hydeltrasol (prednisolone).\" Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995): 656-7[5] Powell JR \"Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application.\" Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW \"Clinical considerations in the use of corticosteroids.\" N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA \"Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial.\" JAMA 269 (1993): 2110-2", "alternatives_a": "Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Sulfamethoxazole, Sulfamethizole, Simeprevir, Vemurafenib, Econazole, Chloramphenicol, Povidone-iodine, More", "alternatives_b": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Mesalazine", "updated_at": 1767369485}, {"id": 139059, "ingredient1": "Procarbazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139218/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 139060, "ingredient1": "Procyclidine", "ingredient2": "Metolazone", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139219/", "reference_text": "[1] Osman MA, Welling PG \"Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide.\" Curr Ther Res Clin Exp 34 (1983): 404-8[2] Beermann B, Groschinsky-Grind M \"Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline.\" Eur J Clin Pharmacol 13 (1978): 385-7", "alternatives_a": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139061, "ingredient1": "Promazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.", "source": "DDInter", "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139220/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pimavanserin", "alternatives_b": "Trichlormethiazide, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 139062, "ingredient1": "Propantheline", "ingredient2": "Metolazone", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139221/", "reference_text": "[1] Osman MA, Welling PG \"Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide.\" Curr Ther Res Clin Exp 34 (1983): 404-8[2] Beermann B, Groschinsky-Grind M \"Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline.\" Eur J Clin Pharmacol 13 (1978): 385-7", "alternatives_a": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Papaverine, Alosetron, Isometheptene", "updated_at": 1767369485}, {"id": 139063, "ingredient1": "Propiomazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139222/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, Lemborexant, More", "updated_at": 1767369485}, {"id": 139064, "ingredient1": "Propranolol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139223/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Tinidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Ciclopirox, Darunavir, Probenecid, Tioconazole, Brinzolamide, More", "alternatives_b": "Ivabradine, Esmolol, Carteolol, Penbutolol", "updated_at": 1767369485}, {"id": 139065, "ingredient1": "Quetiapine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139224/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 139066, "ingredient1": "Ramipril", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Although they are frequently combined in clinical practice, diuretics and angiotensin converting enzyme (ACE) inhibitors may have additive effects. Coadministration makes hypotension and hypovolemia more likely than does either drug alone. Some ACE inhibitors may attenuate the increase in the urinary excretion of sodium caused by some loop diuretics. Some patients on diuretics, especially those on dialysis or a dietary salt restriction, may experience acute hypotension with lightheadedness and dizziness after receiving the first dose of the ACE inhibitor. In addition, ACE inhibitors may cause renal insufficiency or acute renal failure in patients with sodium depletion or renal artery stenosis.", "source": "DDInter", "management_text": "Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration. The possibility of first-dose hypotensive effects may be minimized by initiating therapy with small doses of the ACE inhibitor, or either discontinuing the diuretic temporarily or increasing the salt intake approximately one week prior to initiating an ACE inhibitor. Alternatively, the patient may remain under medical supervision for at least two hours after the first dose of the ACE inhibitor, or until blood pressure has stabilized.", "mechanism_text": "Synergism", "recommendation": "Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139225/", "reference_text": "[1] Murphy BF, Whitworth JA, Kincaid-Smith P \"Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics.\" Br Med J 288 (1984): 844-5[2] Sudoh T, Fujimura A, Shiga T, et al. \"Influence of lisinopril on urinary electrolytes excretion after furosemide in healthy subjects.\" J Clin Pharmacol 33 (1993): 640-3[3] \"Product Information. Lexxel (enalapril-felodipine).\" Astra Pharmaceuticals, Wayne, PA.[4] Hume AL, Murphy JL, Lauerman SE \"Angiotensin-converting enzyme inhibitor-induced cough.\" Pharmacotherapy 9 (1989): 88-90[5] DeQuattro V \"Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide.\" Clin Cardiol 14 (1991): iv28-32;[6] Funck-Brentano C, Chatellier G, Alexandre JM \"Reversible renal failure after combined treatment with enalapril and furosemide in a patient with congestive heart failure.\" Br Heart J 55 (1986): 596-8[7] Weisser K, Schloos J, Jakob S, et al \"The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients.\" Eur J Clin Pharmacol 43 (1992): 173-7[8] McLay JS, McMurray JJ, Bridges AB, Fraser CG, Struthers AD \"Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure.\" Am Heart J 126 (1993): 879-86[9] Burnakis TG, Mioduch HJ \"Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia.\" Arch Intern Med 144 (1984): 2371-2[10] Motwani JG, Fenwick MK, Morton JJ, Struthers AD \"Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure.\" Circulation 86 (1992): 439-45[11] Cerner Multum, Inc. \"Australian Product Information.\" O 0[12] Reader C, Peyregne EA, Suarez LD \"Amrinone therapy in congestive cardiomyopathy.\" Am Heart J 105 (1983): 1045[13] Thind GS \"Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis.\" J Clin Hypertens 1 (1985): 337-43[14] Fujimura A, Shimokawa Y, Ebihara A \"Influence of captopril on urinary excretion of furosemide in hypertensive subjects.\" J Clin Pharmacol 30 (1990): 538-42[15] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[16] Good JM, Brady AJ, Noormohamed FH, Oakley CM, Cleland JG \"Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition.\" Circulation 90 (1994): 220-4[17] Champ JD \"Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension.\" Am J Med Sci 305 (1993): 25-7[18] Radley AS, Fitzpatrick RW \"An evaluation of the potential interaction between enalapril and amiloride.\" J Clin Pharm Ther 12 (1987): 319-23[19] \"Product Information. Aceon (perindopril).\" Solvay Pharmaceuticals Inc, Marietta, GA.[20] \"Product Information. Capoten (captopril).\" Bristol-Myers Squibb, Princeton, NJ.[21] Lederle RM \"Captopril and hydrochlorothiazide in the fixed combination multicenter trial.\" J Cardiovasc Pharmacol 7 (1985): S63-9[22] \"Product Information. Zestrel (lisinopril)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[23] Lee HB, Blaufox MD \"Renal functional response to captopril during diuretic therapy.\" J Nucl Med 33 (1992): 739-43[24] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[25] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[26] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Indapamide, Bempedoic acid, Indapamide", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, Tioconazole, Brinzolamide, More", "updated_at": 1767369485}, {"id": 139067, "ingredient1": "Rapacuronium", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139226/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Trichlormethiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139068, "ingredient1": "Rasagiline", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139227/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Opicapone, Rotigotine, Tolcapone, Bromocriptine, Pergolide", "updated_at": 1767369485}, {"id": 139069, "ingredient1": "Remimazolam", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139228/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, Lemborexant, More", "updated_at": 1767369485}, {"id": 139070, "ingredient1": "Repaglinide", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139229/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tinidazole, Ascorbic acid, Oxytetracycline, Amphotericin B, Sumatriptan, Zonisamide, Tioconazole, Econazole, Mafenide, Brinzolamide, Furazolidone, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 139071, "ingredient1": "Reserpine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139230/", "reference_text": "[1] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[2] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991): 919-25[3] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[4] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992): 520-3[5] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975): 431-6", "alternatives_a": "Methyldopa", "alternatives_b": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "updated_at": 1767369485}, {"id": 139072, "ingredient1": "Riociguat", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Riociguat may potentiate the action of antihypertensive agents and other vasodilators. Symptomatic hypotension may occur. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation and blood pressure decreases.", "source": "DDInter", "management_text": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139231/", "reference_text": "[1] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Macitentan, Metyrosine", "updated_at": 1767369485}, {"id": 139073, "ingredient1": "Rocuronium", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139232/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139074, "ingredient1": "Rofecoxib", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.", "source": "DDInter", "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.", "mechanism_text": "Antagonism", "recommendation": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139233/", "reference_text": "[1] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV \"Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.\" Eur J Clin Pharmacol 48 (1995): 247-51[2] Favre L, Glasson P, Vallotton MB \"Reversible acute renal failure from combined triamterene and indomethacin.\" Ann Intern Med 96 (1982): 317-20[3] Bennett WM \"Drug interactions and consequences of sodium restriction.\" Am J Clin Nutr 65 (1997): S678-81[4] Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA \"The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.\" Int J Clin Pharmacol Ther 32 (1994): 12-8[5] Allan SG, Knox J, Kerr F \"Interaction between diuretics and indomethacin.\" Br Med J 283 (1981): 1611[6] Mor R, Pitlik S, Rosenfeld JB \"Indomethacin- and Moduretic--induced hyperkalemia.\" Isr J Med Sci 19 (1983): 535-7[7] Desaulles E, Schwartz J \"A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.\" Br J Pharmacol 65 (1979): 193-6[8] Watkins J, Abbot EC, Hensby CN, Webster J, Dollery CT \"Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.\" Br Med J 281 (1980): 702-5[9] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981): 663-7[10] Gehr T, Sica DA, Steigler BW, Marshall C \"Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I).\" Clin Pharmacol Ther 47 (1990): 200[11] Ahmad S \"Indomethacin-bumetanide interaction: an alert.\" Am J Cardiol 54 (1984): 246-7[12] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[13] Gurwitz JH, Everitt DE, Monane M, et al \"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.\" J Gerontol A Biol Sci Med Sci 51 (1996): m74-9[14] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A \"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.\" Arch Intern Med 158 (1998): 1108-12[15] McCarthy JT, Torres VE, Romero JC, et al \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982): 289-96[16] Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA \"The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.\" Br J Clin Pharmacol 23 (1987): 55-63[17] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988): 58-62[18] Smith DE, Brater DC, Lin ET, Benet LZ \"Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.\" J Pharmacokinet Biopharm 7 (1979): 265-74[19] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[20] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[21] Brater DC, Fox WR, Chennavasin P \"Interaction studies with bumetanide and furosemide: effects of probenecid and of indomethacin on response to bumetanide in man.\" J Clin Pharmacol 21 (1981): 647-53[22] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[23] Poe TE, Scott RB, Keith JF Jr \"Interaction of indomethacin with furosemide.\" J Fam Pract 16 (1983): 610-6[24] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983): 407-15[25] Pedrinelli R, Magagna A, Arzilli F, et al \"Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.\" Clin Pharmacol Ther 28 (1980): 722-31[26] Weinberg MS, Quigg RJ, Salant DJ, Bernard DB \"Anuric renal failure precipitated by indomethacin and triamterene.\" Nephron 40 (1985): 216-8", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Vemurafenib, Darunavir, Tioconazole, Furazolidone, Diiodohydroxyquinoline, More", "alternatives_b": "Misoprostol, Chondroitin sulfate, Glucosamine", "updated_at": 1767369485}, {"id": 139075, "ingredient1": "Rosiglitazone", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139234/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139076, "ingredient1": "Safinamide", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139235/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "Opicapone, Rotigotine, Tolcapone, Bromocriptine, Pergolide", "updated_at": 1767369485}, {"id": 139077, "ingredient1": "Salmeterol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.", "source": "DDInter", "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139236/", "reference_text": "[1] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[3] Lipworth BJ, McDevitt DG, Struthers AD \"Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol.\" Am J Med 86 (1989): 653-7[4] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[5] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[6] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[7] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[8] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, Oxytetracycline, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Isoprenaline", "updated_at": 1767369485}, {"id": 139078, "ingredient1": "Saxagliptin", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139237/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Probenecid, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 139079, "ingredient1": "Scopolamine", "ingredient2": "Metolazone", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139238/", "reference_text": "[1] Osman MA, Welling PG \"Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide.\" Curr Ther Res Clin Exp 34 (1983): 404-8[2] Beermann B, Groschinsky-Grind M \"Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline.\" Eur J Clin Pharmacol 13 (1978): 385-7", "alternatives_a": "Furosemide, Bumetanide, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, More", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, Lemborexant, More", "updated_at": 1767369485}, {"id": 139080, "ingredient1": "Secobarbital", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139239/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, Lemborexant, More", "alternatives_b": "Trichlormethiazide, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 139081, "ingredient1": "Selegiline", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139240/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "Opicapone, Rotigotine, Tolcapone, Bromocriptine, Pergolide", "updated_at": 1767369485}, {"id": 139082, "ingredient1": "Selexipag", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139241/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985): 1070-1[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 139083, "ingredient1": "Sertraline", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139242/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Sulfadiazine, Probenecid, Chloramphenicol, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 139084, "ingredient1": "Sibutramine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139243/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Dexfenfluramine, Ephedrine, Fenfluramine, Phentermine, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 139085, "ingredient1": "Sildenafil", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.", "source": "DDInter", "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139244/", "reference_text": "[1] \"Product Information. Stendra (avanafil).\" Vivus Inc, Mountain View, CA.[2] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[3] \"Product Information. Levitra (vardenafil).\" Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Ciclopirox, More", "alternatives_b": "Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, Oxytetracycline, Zonisamide, More", "updated_at": 1767369485}, {"id": 139086, "ingredient1": "Sitagliptin", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139245/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 139087, "ingredient1": "Solifenacin", "ingredient2": "Metolazone", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139246/", "reference_text": "[1] Osman MA, Welling PG \"Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide.\" Curr Ther Res Clin Exp 34 (1983): 404-8[2] Beermann B, Groschinsky-Grind M \"Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline.\" Eur J Clin Pharmacol 13 (1978): 385-7", "alternatives_a": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Silodosin", "updated_at": 1767369485}, {"id": 139088, "ingredient1": "Sotalol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139247/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Esmolol, Carteolol, Penbutolol, Ivabradine", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Darunavir, More", "updated_at": 1767369485}, {"id": 139089, "ingredient1": "Sulindac", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.", "source": "DDInter", "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.", "mechanism_text": "Antagonism", "recommendation": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139248/", "reference_text": "[1] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV \"Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.\" Eur J Clin Pharmacol 48 (1995): 247-51[2] Favre L, Glasson P, Vallotton MB \"Reversible acute renal failure from combined triamterene and indomethacin.\" Ann Intern Med 96 (1982): 317-20[3] Bennett WM \"Drug interactions and consequences of sodium restriction.\" Am J Clin Nutr 65 (1997): S678-81[4] Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA \"The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.\" Int J Clin Pharmacol Ther 32 (1994): 12-8[5] Allan SG, Knox J, Kerr F \"Interaction between diuretics and indomethacin.\" Br Med J 283 (1981): 1611[6] Mor R, Pitlik S, Rosenfeld JB \"Indomethacin- and Moduretic--induced hyperkalemia.\" Isr J Med Sci 19 (1983): 535-7[7] Desaulles E, Schwartz J \"A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.\" Br J Pharmacol 65 (1979): 193-6[8] Watkins J, Abbot EC, Hensby CN, Webster J, Dollery CT \"Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.\" Br Med J 281 (1980): 702-5[9] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981): 663-7[10] Gehr T, Sica DA, Steigler BW, Marshall C \"Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I).\" Clin Pharmacol Ther 47 (1990): 200[11] Ahmad S \"Indomethacin-bumetanide interaction: an alert.\" Am J Cardiol 54 (1984): 246-7[12] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[13] Gurwitz JH, Everitt DE, Monane M, et al \"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.\" J Gerontol A Biol Sci Med Sci 51 (1996): m74-9[14] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A \"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.\" Arch Intern Med 158 (1998): 1108-12[15] McCarthy JT, Torres VE, Romero JC, et al \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982): 289-96[16] Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA \"The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.\" Br J Clin Pharmacol 23 (1987): 55-63[17] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988): 58-62[18] Smith DE, Brater DC, Lin ET, Benet LZ \"Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.\" J Pharmacokinet Biopharm 7 (1979): 265-74[19] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[20] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[21] Brater DC, Fox WR, Chennavasin P \"Interaction studies with bumetanide and furosemide: effects of probenecid and of indomethacin on response to bumetanide in man.\" J Clin Pharmacol 21 (1981): 647-53[22] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[23] Poe TE, Scott RB, Keith JF Jr \"Interaction of indomethacin with furosemide.\" J Fam Pract 16 (1983): 610-6[24] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983): 407-15[25] Pedrinelli R, Magagna A, Arzilli F, et al \"Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.\" Clin Pharmacol Ther 28 (1980): 722-31[26] Weinberg MS, Quigg RJ, Salant DJ, Bernard DB \"Anuric renal failure precipitated by indomethacin and triamterene.\" Nephron 40 (1985): 216-8", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "Misoprostol, Chondroitin sulfate, Glucosamine", "updated_at": 1767369485}, {"id": 139090, "ingredient1": "Tadalafil", "ingredient2": "Metolazone", "severity": "Minor", "effect": "Based on their pharmacology, phosphodiesterase-5 (PDE5) inhibitors may conceivably potentiate the hypotensive effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139249/", "reference_text": "[1] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[3] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[4] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, More", "updated_at": 1767369485}, {"id": 139091, "ingredient1": "Temazepam", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139250/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, Lemborexant, More", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, Tioconazole, Furazolidone, More", "updated_at": 1767369485}, {"id": 139092, "ingredient1": "Terazosin", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139251/", "reference_text": "[1] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[2] Cohen J \"Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.\" Am Heart J 122 (1991): 919-25[3] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[4] Achari R, Laddu A \"Terazosin: a new alpha adrenoceptor blocking drug.\" J Clin Pharmacol 32 (1992): 520-3[5] Kuokkanen K, Mattila MJ \"Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patient.\" Curr Ther Res Clin Exp 17 (1975): 431-6", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, Vemurafenib, Darunavir, More", "alternatives_b": "Silodosin", "updated_at": 1767369485}, {"id": 139093, "ingredient1": "Terbutaline", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.", "source": "DDInter", "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139252/", "reference_text": "[1] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[3] Lipworth BJ, McDevitt DG, Struthers AD \"Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol.\" Am J Med 86 (1989): 653-7[4] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[5] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[6] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[7] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals, East Hanover, NJ.[8] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "Isoprenaline, Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Isoprenaline", "updated_at": 1767369485}, {"id": 139094, "ingredient1": "Tetrabenazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139253/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Trichlormethiazide, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 139095, "ingredient1": "Thiethylperazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139254/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "alternatives_b": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 139096, "ingredient1": "Thioridazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.", "source": "DDInter", "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139255/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Darunavir, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 139097, "ingredient1": "Thiothixene", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139256/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 139098, "ingredient1": "Timolol", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139257/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Esmolol, Carteolol, Penbutolol, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Travoprost, Carteolol, More", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, Darunavir, Ketoconazole, More", "updated_at": 1767369485}, {"id": 139099, "ingredient1": "Tizanidine", "ingredient2": "Metolazone", "severity": "Major", "effect": "Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.", "source": "DDInter", "management_text": "A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.", "mechanism_text": "Synergism", "recommendation": "A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139258/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, Tioconazole, More", "alternatives_b": "Chlorzoxazone, Chlormezanone", "updated_at": 1767369485}, {"id": 139100, "ingredient1": "Tolazamide", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139259/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Ketoconazole, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 139101, "ingredient1": "Tolbutamide", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139260/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Amphotericin B, Clindamycin, Ciclopirox, Tioconazole, Brinzolamide, Clotrimazole, More", "alternatives_b": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, More", "updated_at": 1767369485}, {"id": 139102, "ingredient1": "Tolmetin", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.", "source": "DDInter", "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.", "mechanism_text": "Antagonism", "recommendation": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139261/", "reference_text": "[1] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV \"Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.\" Eur J Clin Pharmacol 48 (1995): 247-51[2] Favre L, Glasson P, Vallotton MB \"Reversible acute renal failure from combined triamterene and indomethacin.\" Ann Intern Med 96 (1982): 317-20[3] Bennett WM \"Drug interactions and consequences of sodium restriction.\" Am J Clin Nutr 65 (1997): S678-81[4] Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA \"The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.\" Int J Clin Pharmacol Ther 32 (1994): 12-8[5] Allan SG, Knox J, Kerr F \"Interaction between diuretics and indomethacin.\" Br Med J 283 (1981): 1611[6] Mor R, Pitlik S, Rosenfeld JB \"Indomethacin- and Moduretic--induced hyperkalemia.\" Isr J Med Sci 19 (1983): 535-7[7] Desaulles E, Schwartz J \"A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.\" Br J Pharmacol 65 (1979): 193-6[8] Watkins J, Abbot EC, Hensby CN, Webster J, Dollery CT \"Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.\" Br Med J 281 (1980): 702-5[9] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981): 663-7[10] Gehr T, Sica DA, Steigler BW, Marshall C \"Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I).\" Clin Pharmacol Ther 47 (1990): 200[11] Ahmad S \"Indomethacin-bumetanide interaction: an alert.\" Am J Cardiol 54 (1984): 246-7[12] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[13] Gurwitz JH, Everitt DE, Monane M, et al \"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.\" J Gerontol A Biol Sci Med Sci 51 (1996): m74-9[14] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A \"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.\" Arch Intern Med 158 (1998): 1108-12[15] McCarthy JT, Torres VE, Romero JC, et al \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982): 289-96[16] Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA \"The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.\" Br J Clin Pharmacol 23 (1987): 55-63[17] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988): 58-62[18] Smith DE, Brater DC, Lin ET, Benet LZ \"Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.\" J Pharmacokinet Biopharm 7 (1979): 265-74[19] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[20] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[21] Brater DC, Fox WR, Chennavasin P \"Interaction studies with bumetanide and furosemide: effects of probenecid and of indomethacin on response to bumetanide in man.\" J Clin Pharmacol 21 (1981): 647-53[22] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[23] Poe TE, Scott RB, Keith JF Jr \"Interaction of indomethacin with furosemide.\" J Fam Pract 16 (1983): 610-6[24] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983): 407-15[25] Pedrinelli R, Magagna A, Arzilli F, et al \"Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.\" Clin Pharmacol Ther 28 (1980): 722-31[26] Weinberg MS, Quigg RJ, Salant DJ, Bernard DB \"Anuric renal failure precipitated by indomethacin and triamterene.\" Nephron 40 (1985): 216-8", "alternatives_a": "Misoprostol, Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 139103, "ingredient1": "Tolterodine", "ingredient2": "Metolazone", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139262/", "reference_text": "[1] Osman MA, Welling PG \"Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide.\" Curr Ther Res Clin Exp 34 (1983): 404-8[2] Beermann B, Groschinsky-Grind M \"Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline.\" Eur J Clin Pharmacol 13 (1978): 385-7", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 139104, "ingredient1": "Toremifene", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Drugs that decrease renal calcium excretion, such as the thiazide diuretics, may increase the risk of hypercalcemia in patients receiving toremifene.", "source": "DDInter", "management_text": "Monitoring of calcium levels is recommended. Toremifene should be discontinued if severe hypercalcemia occurs. Patients should be advised to notify their physician if they experience potential symptoms of hypercalcemia such as lethargy, somnolence, confusion, headache, seizures, ataxia, weakness, muscle pain, irregular heartbeat, anorexia, thirst, or polyuria.", "mechanism_text": "Excretion", "recommendation": "Monitoring of calcium levels is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139263/", "reference_text": "[1] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[2] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[3] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Darolutamide, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 139105, "ingredient1": "Torasemide", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The combination of a thiazide and loop diuretic may produce additive or synergistic effects on diuresis and excretion of electrolytes including sodium, potassium, magnesium, and chloride. Although these agents may be combined therapeutically in some patients with inadequate response to a single agent, the increased risk of dehydration, hypotension, hypokalemia, hypomagnesemia, and hyponatremia should be recognized.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of a thiazide and loop diuretic. Dosages should be titrated slowly and carefully, and electrolytes, BUN, fluid status, blood pressure, and renal function should be monitored regularly. Patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of a thiazide and loop diuretic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139264/", "reference_text": "[1] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[2] Brater DC, Pressley RH, Anderson SA \"Mechanisms of the synergistic combination of metolazone and bumetanide.\" J Pharmacol Exp Ther 233 (1985): 70-4[3] Marone C, Muggli F, Lahn W, Frey FJ \"Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man.\" Eur J Clin Invest 15 (1985): 253-7[4] Nakahama H, Orita Y, Yamazaki M, et al \"Pharmacokinetic and pharmacodynamic interactions between furosemide and hydrochlorothiazide in nephrotic patients.\" Nephron 49 (1988): 223-7[5] Wollam GL, Tarazi RC, Bravo EL, Dustan HP \"Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia.\" Am J Med 72 (1982): 929-38[6] Arnold WC \"Efficacy of metolazone and furosemide in children with furosemide-resistant edema.\" Pediatrics 74 (1984): 872-5[7] Sigurd B, Olesen KH, Wennevold A \"The supra-additive natriuretic effect of addition of bendroflumethiazide and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide.\" Am Heart J 89 (1975): 163-70[8] Haller C, Salbach P, Katus H, Kubler W \"Refractory oedema in congestive heart failure: a contributory role of loop diuretics?\" J Intern Med 237 (1995): 211-4[9] Fliser D, Schroter M, Neubeck M, Ritz E \"Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure.\" Kidney Int 46 (1994): 482-8", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Ciclopirox, More", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Ciclopirox, Darunavir, Ketoconazole, Tioconazole, Brinzolamide, More", "updated_at": 1767369485}, {"id": 139106, "ingredient1": "Tranylcypromine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139265/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992): 106-8[2] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[7] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[8] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[10] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[14] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[15] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[17] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[19] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[22] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[25] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[26] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[31] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 139107, "ingredient1": "Treprostinil", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139266/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985): 1070-1[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "alternatives_b": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Darunavir, More", "updated_at": 1767369485}, {"id": 139108, "ingredient1": "Trifluoperazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.", "source": "DDInter", "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139267/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Darunavir, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 139109, "ingredient1": "Triflupromazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.", "source": "DDInter", "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139268/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pimavanserin", "alternatives_b": "Trichlormethiazide, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 139110, "ingredient1": "Trihexyphenidyl", "ingredient2": "Metolazone", "severity": "Minor", "effect": "Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139269/", "reference_text": "[1] Osman MA, Welling PG \"Influence of propantheline and metoclopramide on the bioavailability of chlorothiazide.\" Curr Ther Res Clin Exp 34 (1983): 404-8[2] Beermann B, Groschinsky-Grind M \"Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline.\" Eur J Clin Pharmacol 13 (1978): 385-7", "alternatives_a": "Bumetanide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139111, "ingredient1": "Alimemazine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139270/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Trichlormethiazide, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "updated_at": 1767369485}, {"id": 139112, "ingredient1": "Trimipramine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139271/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Darunavir, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 139113, "ingredient1": "Troglitazone", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.", "mechanism_text": "Antagonism", "recommendation": "Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139272/", "reference_text": "[1] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966): 623-4[2] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics, New York, NY.[6] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967): 209-10[9] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[10] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968): 798-801[16] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991): 968-70[20] \"Product Information. Zolinza (vorinostat).\" Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[26] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982): 1293-5[32] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974): 85-90[34] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968): 188[36] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980): 611-8[38] \"Product Information. Carafate (sucralfate).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000): 2050-6[40] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[41] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.\" Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996): 861-4[45] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972): 1592-3[47] \"Product Information. Hyperstat I.V. (diazoxide).\" Schering Corp, Kenilworth, NJ.[48] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974): 679-83[51] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990): 474-5[57] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987): 761-4[64] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983): 79-83[67] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972): 1741-2[69] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] \"Product Information. Precose (acarbose).\" Bayer, West Haven, CT.[71] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[72] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973): 438-41[74] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993): 84-7[77] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989): 462-3[80] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb, Princeton, NJ.[81] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993): 557-9[85] \"Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[87] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[88] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[92] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[93] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[94] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum", "alternatives_b": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 139114, "ingredient1": "Tubocurarine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139273/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Trichlormethiazide, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139115, "ingredient1": "Valdecoxib", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.", "source": "DDInter", "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.", "mechanism_text": "Antagonism", "recommendation": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139274/", "reference_text": "[1] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV \"Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.\" Eur J Clin Pharmacol 48 (1995): 247-51[2] Favre L, Glasson P, Vallotton MB \"Reversible acute renal failure from combined triamterene and indomethacin.\" Ann Intern Med 96 (1982): 317-20[3] Bennett WM \"Drug interactions and consequences of sodium restriction.\" Am J Clin Nutr 65 (1997): S678-81[4] Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA \"The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.\" Int J Clin Pharmacol Ther 32 (1994): 12-8[5] Allan SG, Knox J, Kerr F \"Interaction between diuretics and indomethacin.\" Br Med J 283 (1981): 1611[6] Mor R, Pitlik S, Rosenfeld JB \"Indomethacin- and Moduretic--induced hyperkalemia.\" Isr J Med Sci 19 (1983): 535-7[7] Desaulles E, Schwartz J \"A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.\" Br J Pharmacol 65 (1979): 193-6[8] Watkins J, Abbot EC, Hensby CN, Webster J, Dollery CT \"Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.\" Br Med J 281 (1980): 702-5[9] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981): 663-7[10] Gehr T, Sica DA, Steigler BW, Marshall C \"Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I).\" Clin Pharmacol Ther 47 (1990): 200[11] Ahmad S \"Indomethacin-bumetanide interaction: an alert.\" Am J Cardiol 54 (1984): 246-7[12] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[13] Gurwitz JH, Everitt DE, Monane M, et al \"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.\" J Gerontol A Biol Sci Med Sci 51 (1996): m74-9[14] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A \"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.\" Arch Intern Med 158 (1998): 1108-12[15] McCarthy JT, Torres VE, Romero JC, et al \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982): 289-96[16] Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA \"The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.\" Br J Clin Pharmacol 23 (1987): 55-63[17] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988): 58-62[18] Smith DE, Brater DC, Lin ET, Benet LZ \"Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.\" J Pharmacokinet Biopharm 7 (1979): 265-74[19] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61[20] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[21] Brater DC, Fox WR, Chennavasin P \"Interaction studies with bumetanide and furosemide: effects of probenecid and of indomethacin on response to bumetanide in man.\" J Clin Pharmacol 21 (1981): 647-53[22] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[23] Poe TE, Scott RB, Keith JF Jr \"Interaction of indomethacin with furosemide.\" J Fam Pract 16 (1983): 610-6[24] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983): 407-15[25] Pedrinelli R, Magagna A, Arzilli F, et al \"Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.\" Clin Pharmacol Ther 28 (1980): 722-31[26] Weinberg MS, Quigg RJ, Salant DJ, Bernard DB \"Anuric renal failure precipitated by indomethacin and triamterene.\" Nephron 40 (1985): 216-8", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Vemurafenib, Probenecid, Tioconazole, More", "alternatives_b": "Misoprostol, Chondroitin sulfate, Glucosamine", "updated_at": 1767369485}, {"id": 139116, "ingredient1": "Vecuronium", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139275/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139117, "ingredient1": "Venlafaxine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139276/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "alternatives_b": "Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Amphotericin B, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Sulfadiazine, Probenecid, More", "updated_at": 1767369485}, {"id": 139118, "ingredient1": "Verteporfin", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John's Wort).", "source": "DDInter", "management_text": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139277/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Visudyne (verteporfin)\" Valeant Pharmaceuticals, Costa Mesa, CA.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Aflibercept, Bevacizumab", "alternatives_b": "Tinidazole, Ascorbic acid, Metronidazole, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Darunavir, Ketoconazole, More", "updated_at": 1767369485}, {"id": 139119, "ingredient1": "Vilazodone", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139278/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 139120, "ingredient1": "Vortioxetine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139279/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 139121, "ingredient1": "Zaleplon", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139280/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, Lemborexant, More", "updated_at": 1767369485}, {"id": 139122, "ingredient1": "Ziprasidone", "ingredient2": "Metolazone", "severity": "Major", "effect": "Ziprasidone can cause dose-related prolongation of the QT interval. While clinical data are lacking, the coadministration of ziprasidone and agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential.", "source": "DDInter", "management_text": "Caution is advised when ziprasidone must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with ziprasidone. Patients should be advised to notify their physician if they experience possible signs of an electrolyte imbalance, such as weakness, lethargy, drowsiness, confusion, muscle pains or cramps, dizziness, nausea, vomiting, tachycardia, or an irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when ziprasidone must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139281/", "reference_text": "[1] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Pimavanserin", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More", "updated_at": 1767369485}, {"id": 139123, "ingredient1": "Zolpidem", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139282/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Quazepam, Amobarbital, Butalbital, Ramelteon, Eszopiclone, Tasimelteon, Methohexital, Lemborexant, More", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139124, "ingredient1": "Aluminum hydroxide", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139283/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Esmolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139125, "ingredient1": "Amoxapine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139284/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 139126, "ingredient1": "Metoprolol", "ingredient2": "Arbutamine", "severity": "Moderate", "effect": "Beta-blockers will attenuate the desired effects of arbutamine.", "source": "DDInter", "management_text": "Beta-blockers should be discontinued at least 48 hours before arbutamine is administered.", "mechanism_text": "Antagonism", "recommendation": "Beta-blockers should be discontinued at least 48 hours before arbutamine is administered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139286/", "reference_text": "[1] \"Product Information. GenESA (arbutamine).\" Gensia Inc, San Diego, CA.", "alternatives_a": "Felodipine, Amlodipine, Nebivolol, Nifedipine, Ivabradine, Acetylsalicylic acid, Nebivolol, Carteolol, Nebivolol", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "updated_at": 1767369485}, {"id": 139127, "ingredient1": "Attapulgite", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139287/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol, Carteolol", "alternatives_b": "Pectin, Activated charcoal", "updated_at": 1767369485}, {"id": 139128, "ingredient1": "Belladonna", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139288/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139129, "ingredient1": "Bendroflumethiazide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139289/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Esmolol, Carteolol, Penbutolol, Penbutolol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139130, "ingredient1": "Benzthiazide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139290/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Esmolol, Carteolol, Penbutolol, Penbutolol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139131, "ingredient1": "Bepridil", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.", "source": "DDInter", "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139291/", "reference_text": "[1] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[2] Strauss WE, Egan T, McIntyre KM, Parisi AF \"Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.\" Clin Cardiol 8 (1985): 363-6[3] Pouleur H, Etienne J, Van Mechelen H, et al \"Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.\" Postgrad Med J 60 (1984): 23-8[4] Levine MA, Ogilvie RI, Leenen FH \"Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.\" Clin Pharmacol Ther 43 (1988): 39-48[5] Ronn O, Bengtsson B, Edgar B, Raner S \"Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.\" Drugs 29 (1985): 16-25[6] Bauer LA, Murray K, Horn JR, et al \"Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.\" Eur J Clin Pharmacol 37 (1989): 257-60[7] Yust I, Hoffman M, Aronson RJ \"Life-threatening bradycardic reactions due to beta blocker-diltiazem interactions.\" Isr J Med Sci 28 (1992): 292-4[8] Oesterle SN, Alderman EL, Beier-Scott L, Bain DS, Rothman MT, Schroder JS \"Diltiazem and propranolol in combination: hemodynamic effects following acute intravenous administration.\" Am Heart J 111 (1986): 489-97[9] Hartwell BL, Mark JB \"Combinations of beta blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances?\" Anesth Analg 65 (1986): 905-7[10] Anastassiades CJ \"Nifedipine and beta-blocker drugs.\" Br Med J 281 (1980): 1251-2[11] Packer M \"Combined beta-adrenergic and calcium-entry blockage in angina pectoris.\" N Engl J Med 320 (1989): 709-18[12] Pringle SD, MacEwen CJ \"Severe bradycardia due to interaction of timolol eye drops and verapamil.\" Br Med J 294 (1987): 155-6[13] Tateishi T, Nakashima H, Shitou T, et al \"Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 36 (1989): 67-70[14] Maclean D, Mitchell ET, Coulson RR, Fitzsimons TJ, McDevitt DG \"Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.\" Br J Clin Pharmacol 25 (1988): 425-31[15] Hossack KF \"Conduction abnormalities due to diltiazem.\" N Engl J Med 307 (1982): 953-4[16] Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S \"Pharmacokinetic interactions between felodipine and metoprolol.\" Eur J Clin Pharmacol 31 (1987): 575-8[17] Tateishi T, Ohashi K, Fujimura A, Ebihara A \"The influence of diltiazem versus cimetidine on propranolol metabolism.\" J Clin Pharmacol 32 (1992): 1099-104[18] Sinclair NI, Benzie JL \"Timolol eye drops and verapamil: a dangerous combination.\" Med J Aust 1 (1983): 548[19] Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG \"Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.\" Br J Clin Pharmacol 29 (1990): 497-501[20] Ohman KP, Weiner L, von Schenck H, Karlberg BE \"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.\" Eur J Clin Pharmacol 29 (1985): 149-54[21] Vinceneux P, Canal M, Domart Y, Roux A, Cascio B, Orofiamma B, Larribaud J, Flouvat B, Carbon C \"Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 153-8[22] Nievel JG, Havard CW, Douglas-Jones AP \"Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension.\" Eur J Clin Pharmacol 33 (1987): 21-5[23] Strauss WE, Parisi AF \"Combines use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina.\" Ann Intern Med 109 (1988): 570-81[24] Takahashi H, Ohashi N, Motokawa K, Sato S, Naito H \"Poisoning caused by the combined ingestion of nifedipine and metoprolol.\" J Toxicol Clin Toxicol 31 (1993): 631-7[25] Rosenkranz B, Ledermann H, Frolich JC \"Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers.\" J Cardiovasc Pharmacol 8 (1986): 943-9[26] Leon MB, Rosing DR, Bonow RO, Epstein SE \"Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.\" Am J Cardiol 55 (1985): b69-80[27] Rocha P, Guerret M, David D, Marchand X, Kahn JC \"Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.\" Cardiovasc Drugs Ther 4 (1990): 1525-32[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[35] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[37] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[38] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[39] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[40] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[41] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[42] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[43] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[44] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139132, "ingredient1": "Berotralstat", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.", "source": "DDInter", "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139292/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.", "alternatives_a": "Acetylsalicylic acid, Bisoprolol, Atenolol, Sotalol, Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, More", "alternatives_b": "Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 139133, "ingredient1": "Bromfenac", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139293/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Ivabradine, Carteolol", "alternatives_b": "Fluocinolone acetonide, Fluorometholone", "updated_at": 1767369485}, {"id": 139134, "ingredient1": "Butabarbital", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with barbiturates may decrease the plasma concentrations and pharmacologic effects of certain beta-blockers when administered orally. The proposed mechanism is barbiturate induction of hepatic microsomal and first-pass metabolism.", "source": "DDInter", "management_text": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days. Pharmacologic response to beta-blockers should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy, and the beta-blocker dosage adjusted as necessary. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact.", "mechanism_text": "Metabolism", "recommendation": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139294/", "reference_text": "[1] Mantyla R, Mannisto P, Nykanen S, Koponen A, Lamminsivu U \"Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers.\" Eur J Clin Pharmacol 24 (1983): 227-30[2] Seideman P, Borg K, Haglund K, Von Bahr C, \"Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.\" Br J Clin Pharmacol 23 (1987): 267-71[3] Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C \"Influence of pentobarbital on metoprolol plasma levels.\" Clin Pharmacol Ther 26 (1979): 326-9[4] Sotaniemi EA, Anttila M, Pelkonen RO, Jarvensivu P, Sundquist H \"Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.\" Clin Pharmacol Ther 26 (1979): 153-61[5] Branch RA, Herman RJ \"Enzyme induction and beta-adrenergic receptor blocking drugs.\" Br J Clin Pharmacol 17 (1984): s77-84[6] Collste P, Seideman P, Borg K, Haglund K, Von Bahr C \"Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol.\" Clin Pharmacol Ther 25 (1979): 423-7", "alternatives_a": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "alternatives_b": "Acetylsalicylic acid, Carteolol", "updated_at": 1767369485}, {"id": 139135, "ingredient1": "Calcium carbonate", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139295/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Ivabradine, Esmolol", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 139136, "ingredient1": "Calcium citrate", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139296/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Esmolol", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 139137, "ingredient1": "Calcium glubionate anhydrous", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139297/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Esmolol", "alternatives_b": "Calcium glucoheptonate", "updated_at": 1767369485}, {"id": 139138, "ingredient1": "Calcium gluconate", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139298/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Esmolol", "alternatives_b": "Calcium glucoheptonate, Deoxycholic acid, Magnesium sulfate, Aminobenzoic acid, Ivermectin, Caffeine, Abrocitinib, Dupilumab, Tralokinumab, Brimonidine, Povidone-iodine", "updated_at": 1767369485}, {"id": 139139, "ingredient1": "Calcium lactate", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139299/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Esmolol", "alternatives_b": "Calcium glucoheptonate", "updated_at": 1767369485}, {"id": 139140, "ingredient1": "Chlormezanone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139300/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Timolol, Carteolol, Timolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139141, "ingredient1": "Chlorphenesin", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139301/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Carvedilol, Nifedipine, Ivabradine, Acetylsalicylic acid, Carvedilol, Timolol, Carteolol, Timolol", "alternatives_b": "Flucytosine, Tioconazole, Thiabendazole, Griseofulvin", "updated_at": 1767369485}, {"id": 139142, "ingredient1": "Clidinium", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139302/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139143, "ingredient1": "Dezocine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139303/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Acebutolol, Nadolol, Esmolol, More", "alternatives_b": "Tapentadol, Naltrexone, Oxymorphone", "updated_at": 1767369485}, {"id": 139144, "ingredient1": "Diflunisal", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139304/", "reference_text": "[1] Keber I, Jerse M, Keber D, Stegnar M \"The influence of combined treatment with propranolol and acetylsalicylic acid on platelet aggregation in coronary heart disease.\" Br J Clin Pharmacol 7 (1979): 287-91[2] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002): 1015-1022[3] Sziegoleit W, Rausch J, Polak G, et al \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol in humans.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30[4] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[5] Spahn H, Langguth P, Kirch W, et al \"Pharmacokinetics of salicylates administered with metoprolol.\" Arzneimittelforschung 36 (1986): 1697-9[6] Sziegoleit W, Rausch J , Polak G, Gyorgy M, Dekov E, Bekes M \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30", "alternatives_a": "Ivabradine", "alternatives_b": "Ziconotide", "updated_at": 1767369485}, {"id": 139145, "ingredient1": "Dimenhydrinate", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139305/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Acebutolol, Penbutolol, Betaxolol, Carteolol, Acebutolol, Penbutolol", "alternatives_b": "Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, Azatadine, More", "updated_at": 1767369485}, {"id": 139146, "ingredient1": "Doxacurium", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139306/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139147, "ingredient1": "Ephedrine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of ephedrine by blocking beta-1 adrenergic receptors in the heart. Noncardioselective beta-blockers can antagonize the bronchodilating effects of ephedrine by blocking beta-2 adrenergic receptors in smooth muscles of the bronchial tree. The interaction is less likely to occur with cardioselective beta-blockers, which generally have little effect on beta-2 adrenergic receptors at therapeutic dosages.", "source": "DDInter", "management_text": "Clinicians should be alert to the potential for diminished cardiac response when parenteral ephedrine is used in patients treated with beta-blockers, including ophthalmic formulations. Noncardioselective beta-blockers, including ophthalmic formulations, should generally be avoided in patients using ephedrine-containing preparations for bronchospastic diseases. If beta-blocker therapy is necessary, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer. However, caution is advised, especially with higher dosages of the beta-blocker.", "mechanism_text": "Antagonism", "recommendation": "Clinicians should be alert to the potential for diminished cardiac response when parenteral ephedrine is used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139307/", "reference_text": "[1] \"Product Information. Ephedrine Sulfate (ephedrine).\" Akorn Inc, Buffalo Grove, IL.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "Tropicamide, Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ipratropium, Hyaluronic acid, Nedocromil, Beclomethasone dipropionate, Droxidopa, Amrinone, More", "updated_at": 1767369485}, {"id": 139148, "ingredient1": "Epoprostenol", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139308/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985): 1070-1[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ivabradine", "alternatives_b": "Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "updated_at": 1767369485}, {"id": 139149, "ingredient1": "Ergometrine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids. The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation. In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.", "source": "DDInter", "management_text": "Except for increased awareness of the interaction, no specific intervention appears to be necessary. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Except for increased awareness of the interaction, no specific intervention appears to be necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139309/", "reference_text": "[1] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Venter CP, Joubert PH, Buys AC \"Severe peripheral ischaemia during concomitant use of beta blockers and ergot alkaloids.\" Br Med J 289 (1984): 288-9[3] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Blank NK, Rieder MJ \"Paradoxical response to propranolol in migraine.\" Lancet 2 (1973): 1336[5] Baumrucker JF \"Drug interaction: propranolol and cafergot.\" N Engl J Med 288 (1973): 916-7[6] Gandy W \"Dihydroergotamine interaction with propranolol .\" Ann Emerg Med 19 (1990): 221[7] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[10] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[11] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[14] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[16] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[17] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[18] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[19] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[21] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[25] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[26] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[27] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[29] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[31] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[32] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[33] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[34] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[35] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[36] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[37] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[38] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Felodipine, Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Dinoprostone, Oxytocin", "updated_at": 1767369485}, {"id": 139150, "ingredient1": "Ertugliflozin", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139310/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, Dulaglutide, More", "updated_at": 1767369485}, {"id": 139151, "ingredient1": "Escitalopram", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Escitalopram may increase the plasma concentrations of metoprolol. Administration of 20 mg/day escitalopram for 21 days resulted in a 50% increase of the maximum plasma concentration and an 82% increase of the AUC of metoprolol (single 100 mg dose); however, no clinically significant effects on blood pressure or heart rate occurred. The mechanism may be related to inhibition of CYP450 2D6 metabolism. It may be advisable to monitor patients for increased pharmacological effects of metoprolol.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139311/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[3] \"Product Information. Lopressor (metoprolol).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Felodipine, Amlodipine, Propranolol, Carvedilol, Nebivolol, Bisoprolol, Atenolol, Acebutolol, Labetalol, Nadolol, Propranolol, More", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 139152, "ingredient1": "Etacrynic acid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139312/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139153, "ingredient1": "Ethiodized oil", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139313/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139154, "ingredient1": "Etodolac", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139314/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Ivabradine", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine", "updated_at": 1767369485}, {"id": 139155, "ingredient1": "Fedratinib", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139315/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation, Summit, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Acetylsalicylic acid, Bisoprolol, Atenolol, Sotalol, Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 139156, "ingredient1": "Fenoldopam", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "The use of fenoldopam in combination with beta-blockers has not been studied. Theoretically, beta-blockers may potentiate the risk of severe, symptomatic hypotension by inhibiting the sympathetic reflex response to fenoldopam-induced blood pressure decreases.", "source": "DDInter", "management_text": "Concomitant use of fenoldopam with beta-blockers should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of fenoldopam with beta-blockers should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139316/", "reference_text": "[1] \"Product Information. Corlopam (fenoldopam).\" Neurex, Menlo Park, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "updated_at": 1767369485}, {"id": 139157, "ingredient1": "Fludrocortisone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139317/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ivabradine, Sotalol, Esmolol, Sotalol, Sotalol", "alternatives_b": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "updated_at": 1767369485}, {"id": 139158, "ingredient1": "Fluvoxamine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited clinical data suggest that selective serotonin reuptake inhibitors (SSRIs) may potentiate the pharmacologic effects of some beta-blockers. The proposed mechanism is SSRI inhibition (competitive and/or noncompetitive) of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of beta-blockers such as carvedilol, labetalol, metoprolol, nebivolol, propranolol, and timolol. Paroxetine and norfluoxetine (the active metabolite of fluoxetine), in particular, are potent inhibitors of CYP450 2D6 and may be more likely than other SSRIs to cause the interaction. On the other hand, fluvoxamine is a potent inhibitor of CYP450 1A2 and may significantly interact with propranolol, which is a substrate of both CYP450 2D6 and 1A2.", "source": "DDInter", "management_text": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate. Cardiac function should be closely monitored and the beta-blocker dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of SSRI in patients who are stabilized on their beta-blocker regimen. Due to the long half-life of fluoxetine and its active metabolite, norfluoxetine, the risk of an interaction may exist for an extended period (up to several weeks) after discontinuation of fluoxetine. To avoid the interaction, use of beta-blockers that are primarily eliminated by the kidney such as atenolol, acebutolol, betaxolol, carteolol, and nadolol may be considered.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139319/", "reference_text": "[1] Walley T, Pirmohamed M, Proudlove C, Maxwell D \"Interaction of metoprolol and fluoxetine.\" Lancet 341 (1993): 967-8[2] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[3] Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS \"Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.\" Clin Pharmacol Ther 64 (1998): 257-68[4] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[5] Ereshefsky L \"Treating depression: potential drug-drug interactions: commentary.\" J Clin Psychopharmacol 16 (suppl (1996): s50-3[6] Hemeryck A, Lefebvre RA, DeVriendt C, Belpaire FM \"Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.\" Clin Pharmacol Ther 67 (2000): 283-91[7] Perucca E, Gatti G, Spina E \"Clinical pharmacokinetics of fluvoxamine.\" Clin Pharmacokinet 27 (1994): 175-90[8] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM \"Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.\" J Clin Pharmacol 41 (2001): 443-51[9] Nemeroff CB, Devane CL, Pollock BG \"Newer antidepressants and the cytochrome p450 system.\" Am J Psychiatry 153 (1996): 311-20[10] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM \"Inhibition by fluoxetine of cytochrome P450 2D6 activity.\" Clin Pharmacol Ther 53 (1993): 401-9[13] Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S \"Fluvoxamine is a potent inhibitor of cytochrome P4501A2.\" Biochem Pharmacol 45 (1993): 1211-4[14] Drake WM, Gordon GD \"Heart block in a patient on propranolol and fluoxetine.\" Lancet 343 (1994): 425-6[15] Hemeryck A, DeVriendt CA, Belpaire FM \"Metoprolol-paroxetine interaction in human liver microsomes: Stereoselective aspects and prediction of the in vivo interaction.\" Drug Metab Disposition 29 (2001): 656-63[16] Richelson E \"Pharmacokinetic interactions of antidepressants.\" J Clin Psychiatry 59 (1998): 22-6[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[20] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Bisoprolol, Sotalol, Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Sotalol, Pindolol, More", "updated_at": 1767369485}, {"id": 139159, "ingredient1": "Gadobenic acid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139320/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 139160, "ingredient1": "Gadobutrol", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139321/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 139161, "ingredient1": "Gadodiamide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139322/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Ferumoxsil", "alternatives_b": "Ivabradine, Carteolol", "updated_at": 1767369485}, {"id": 139162, "ingredient1": "Gadofosveset trisodium", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139323/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 139163, "ingredient1": "Gadopentetic acid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139324/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 139164, "ingredient1": "Gadoteric acid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139325/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 139165, "ingredient1": "Gadoteridol", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139326/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Carteolol", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 139166, "ingredient1": "Gadoversetamide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139327/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Felodipine, Ivabradine, Carteolol", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 139167, "ingredient1": "Gadoxetic acid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139328/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 139168, "ingredient1": "Galantamine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.", "source": "DDInter", "management_text": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139329/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Cognex (tacrine).\" Parke-Davis, Morris Plains, NJ.[3] Tiseo PJ, Perdomo CA, Friedhoff LT \"Concurrent administration of donepezil HCI and digoxin: assessment of pharmacokinetic changes.\" Br J Clin Pharmacol 46(Suppl 1) (1998): 40-4[4] Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL \"Drug interactions with cholinesterase inhibitors : an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (vidal, british national formulary).\" Drug Saf 30 (2007): 1063-71[5] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Ginkgo biloba, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139169, "ingredient1": "Garlic", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139330/", "reference_text": "[1] Tattelman E \"Health effects of garlic.\" Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM \"Effects of natural health products on blood pressure.\" Ann Pharmacother 39 (2005): 712-20", "alternatives_a": "Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139170, "ingredient1": "Givosiran", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with givosiran may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2 and/or CYP450 2D6. The proposed mechanism is decreased clearance due to givosiran-mediated inhibition of CYP450 1A2 and 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution and monitoring are recommended when givosiran is given with drugs that are substrates of CYP450 1A2 and/or 2D6. Concomitant use should generally be avoided with CYP450 1A2 or 2D6 substrates that have a narrow therapeutic range where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, the dosage of the CYP450 1A2 or 2D6 substrate should be reduced according to approved product labeling or clinical response and tolerance. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever givosiran is added to or withdrawn from therapy with these drugs.", "mechanism_text": "Metabolism", "recommendation": "Caution and monitoring are recommended when givosiran is given with drugs that are substrates of CYP450 1A2 and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139331/", "reference_text": "[1] \"Product Information. Givlaari (givosiran).\" Alnylam Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139171, "ingredient1": "Glucagon", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Beta-blockers may blunt the hyperglycemic reaction to glucagon by interfering with beta-adrenergic-mediated hyperglycemic counter-regulatory mechanisms.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139332/", "reference_text": "[1] Mills GA, Horn JR \"B-blockers and glucose control.\" Drug Intell Clin Pharm 19 (1985): 246-51[2] Smith RC, Wilkinson J, Hull RL \"Glucagon for propranolol overdose.\" JAMA 254 (1985): 2412[3] Smith RC, Wilkinson DO, Hull RL \"Glucagon for propranolol overdose.\" JAMA 254 (1985): 2412[4] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J \"Effects of B-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man.\" Int J Clin Pharmacol 14 (1976): 189-94[5] Pun KK, Yeung CK, Chak W, et al \"Effects of selective and non-selective beta-blockers on the alanine and free fatty acid responses to glucagon challenge in hemodialysis patients.\" Clin Nephrol 26 (1986): 222-6", "alternatives_a": "Felodipine, Amlodipine, Nebivolol, Nifedipine, Ivabradine, Acetylsalicylic acid, Nebivolol, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139172, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates. The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139333/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc, South San Francisco, CA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Nadolol, Esmolol, Betaxolol, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139173, "ingredient1": "Guanadrel", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139334/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139174, "ingredient1": "Guanfacine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Use of central alpha-2 adrenergic agonists, such as clonidine or guanfacine, with beta-blockers may have synergistic pharmacodynamic effects resulting in AV block, bradycardia, and hypotension. In addition, sinus node dysfunction may also be enhanced. Abrupt withdrawal of an alpha-2 agonist or both the alpha-2 agonist and the beta-blocker may also result in rebound hypertensive effects. The proposed mechanism is related to increased catecholamine release after alpha-2 agonist withdrawal which, when combined with concurrent beta-blockade, results in unopposed vasoconstriction.", "source": "DDInter", "management_text": "Until more information is available, caution and close monitoring of blood pressure are recommended for patients receiving guanfacine with a beta-blocker. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some patients. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, headaches, or reduced or irregular heart rate.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, caution and close monitoring of blood pressure are recommended for patients receiving guanfacine with a beta-blocker.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139335/", "reference_text": "[1] Bailey RR, Neale TJ \"Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockage.\" Br Med J 1 (1976): 942-3[2] Jounela AJ, Lilja M \"Interactions between beta-blockers and clonidine.\" Ann Clin Res 16 (1984): 181-2[3] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.[4] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[5] Strauss FG, Franklin SS, Lewin AJ, Maxwell MH \"Withdrawal of antihypertensive therapy. Hypertensive crisis in renovascular hypertension.\" JAMA 238 (1977): 1734-6[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Lilja M, Jounela AJ, Juustila H, Mattila MJ \"Interaction of clonidine and beta-blockers.\" Acta Med Scand 207 (1980): 173-6[8] Perks D, Fisher GC \"Esmolol and clonidine: a possible interaction.\" Anaesthesia 47 (1992): 533-4[9] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Deserpidine", "updated_at": 1767369485}, {"id": 139175, "ingredient1": "Halazepam", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139336/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Timolol, Carteolol, Timolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139176, "ingredient1": "Diamorphine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139337/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Nalmefene, Disulfiram, Levacetylmethadol, Naltrexone", "updated_at": 1767369485}, {"id": 139177, "ingredient1": "Hydroflumethiazide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139338/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Esmolol, Carteolol, Penbutolol, Penbutolol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139178, "ingredient1": "Hydromorphone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139339/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ivabradine, Penbutolol, Carteolol, Penbutolol", "alternatives_b": "Tapentadol, Naltrexone, Oxymorphone", "updated_at": 1767369485}, {"id": 139179, "ingredient1": "Hydroxychloroquine", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Hydroxychloroquine may increase serum levels of metoprolol. The proposed mechanism is inhibition of CYP450 2D6 hepatic metabolism by hydroxychloroquine. Clinicians should be aware of the possibility of an interaction if adverse beta-blocker effects occur.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139340/", "reference_text": "[1] Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M \"Influence of hydroxychloroquine on the bioavailability of oral metoprolol.\" Br J Clin Pharmacol 49 (2000): 549-54[2] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[3] \"Product Information. Lopressor (metoprolol).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Nebivolol, Acebutolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Timolol, Acebutolol, Nebivolol, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 139180, "ingredient1": "Hydroxyzine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139341/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139181, "ingredient1": "Iloperidone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139342/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 139182, "ingredient1": "Iloprost", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139343/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985): 1070-1[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ivabradine", "alternatives_b": "Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "updated_at": 1767369485}, {"id": 139183, "ingredient1": "Imatinib", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.", "source": "DDInter", "management_text": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139344/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Bisoprolol, Sotalol, Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Sotalol, Acebutolol, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 139184, "ingredient1": "Imipramine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139345/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139185, "ingredient1": "Indacaterol", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139346/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 139186, "ingredient1": "Indapamide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139347/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Ivabradine", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139187, "ingredient1": "Insulin human", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139348/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "updated_at": 1767369485}, {"id": 139188, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139349/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139189, "ingredient1": "Insulin lispro", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139350/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "updated_at": 1767369485}, {"id": 139190, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139351/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139191, "ingredient1": "Insulin human (zinc)", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139352/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "updated_at": 1767369485}, {"id": 139192, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139353/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "updated_at": 1767369485}, {"id": 139193, "ingredient1": "Iodipamide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139354/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139194, "ingredient1": "Iodixanol", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139355/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139195, "ingredient1": "Iohexol", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139356/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139196, "ingredient1": "Iopanoic acid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139357/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139197, "ingredient1": "Ioversol", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139358/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Felodipine, Amlodipine, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139198, "ingredient1": "Ioxilan", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139359/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139199, "ingredient1": "Iopodic acid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139360/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139200, "ingredient1": "Isoetharine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139361/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139201, "ingredient1": "Metoprolol", "ingredient2": "Kaolin", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139362/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol", "alternatives_b": "Pectin, Activated charcoal", "updated_at": 1767369485}, {"id": 139202, "ingredient1": "Metoprolol", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Ophthalmic beta blocker solutions are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Additive effects of beta blockade may occur in patients receiving both oral and ophthalmic beta blocking agents.", "source": "DDInter", "management_text": "Blood pressure and intraocular pressure monitoring is recommended during concurrent use. Patients should be advised to notify their physician if they experience a slow pulse, irregular heartbeat, dizziness, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Blood pressure and intraocular pressure monitoring is recommended during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139363/", "reference_text": "[1] \"Product Information. Timoptic (timolol ophthalmic).\" Merck & Co, Inc, West Point, PA.[2] \"Product Information. Acupress (carteolol ophthalmic).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139203, "ingredient1": "Metoprolol", "ingredient2": "Licorice", "severity": "Moderate", "effect": "Licorice use has been associated with hypertension and may antagonize the effects of antihypertensive agents. Glycyrrhizic acid, a component of licorice, is hydrolyzed in the intestine to a metabolite (glycyrrhetinic acid) that causes mineralocorticoid and renin-suppressing effects.", "source": "DDInter", "management_text": "Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products. Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139364/", "reference_text": "[1] Cumming AM \"Metabolic effects of licorice.\" Br Med J 1 (1977): 906[2] Epstein MT, Espiner EA, Donald RA, Hughes H \"Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects.\" Br Med J 1 (1977): 488-90[3] Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR \"Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age.\" Lancet 2 (1987): 821-4[4] Elinav E, Chajek-Shaul T \"Licorice consumption causing severe hypokalemic paralysis.\" Mayo Clin Proc 78 (2003): 767-8[5] Rosseel M, Schoors D \"Chewing gum and hypokalaemia.\" Lancet 341 (1993): 175[6] Clyburn EB, DiPette DJ \"Hypertension induced by drugs and other substances.\" Semin Nephrol 15 (1995): 72-86[7] Lin SH, Yang SS, Chau T, Halperin ML \"An unusual cause of hypokalemic paralysis: chronic licorice ingestion.\" Am J Med Sci 325 (2003): 153-6[8] de Klerk GJ, Nieuwenhuis MG, Beutler JJ \"Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum.\" BMJ 314 (1997): 731[9] Nielsen I, Pedersen RS \"Life-threatening hypokalaemia caused by liquorice ingestion.\" Lancet 1 (1984): 1305[10] Cumming AM, Boddy K, Brown JJ, et al \"Severe hypokalaemia with paralysis induced by small doses of liquorice.\" Postgrad Med J 56 (1980): 526-9[11] Cumming A \"Severe reduction of serum potassium induced by licorice.\" Nurs Times 72 (1976): 367-70[12] Epstein MT, Espiner EA, Donald RA, Hughes H \"Liquorice toxicity and the renin-angiotensin-aldosterone axis in man.\" Br Med J 1 (1977): 209-10[13] Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S \"Liquorice-induced rise in blood pressure: a linear dose-response relationship.\" J Hum Hypertens 15 (2001): 549-52[14] Edwards CR \"Lessons from licorice.\" N Engl J Med 325 (1991): 1242-3[15] Ishikawa S, Kato M, Tokuda T, Momoi H, Sekijima Y, Higuchi M, Yanagisawa N \"Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa.\" Int J Eating Disorder 26 (1999): 111-4[16] Holmes AM, Young J, Marrott PK, Prentice E \"Pseudohyperaldosteronism induced by habitual ingestion of liquorice.\" Postgrad Med J 46 (1970): 625-9[17] Bannister B, Ginsburg R, Shneerson J \"Cardiac arrest due to liquorice-induced hypokalaemia.\" Br Med J 2 (1977): 738-9[18] Richard CL, Jurgens TM \"Effects of natural health products on blood pressure.\" Ann Pharmacother 39 (2005): 712-20[19] Farese RV, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R \"Licorice-induced hypermineralocorticoidism.\" N Engl J Med 325 (1991): 1223-7[20] Dellow EL, Unwin RJ, Honour JW \"Pontefract cakes can be bad for you: refractory hypertension and liquorice excess.\" Nephrol Dial Transplant 14 (1999): 218-20", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139204, "ingredient1": "Metoprolol", "ingredient2": "Magaldrate", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139365/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Esmolol, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139205, "ingredient1": "Metoprolol", "ingredient2": "Magnesium carbonate", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139366/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Esmolol", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, Methionine, Deferasirox, More", "updated_at": 1767369485}, {"id": 139206, "ingredient1": "Metoprolol", "ingredient2": "Magnesium hydroxide", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139367/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Esmolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 139207, "ingredient1": "Metoprolol", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139368/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Ivabradine", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 139208, "ingredient1": "Metoprolol", "ingredient2": "Mephentermine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139369/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Carteolol", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "updated_at": 1767369485}, {"id": 139209, "ingredient1": "Metoprolol", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139370/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139210, "ingredient1": "Metoprolol", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139371/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 139211, "ingredient1": "Metoprolol", "ingredient2": "Metaraminol", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139372/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Carteolol", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "updated_at": 1767369485}, {"id": 139212, "ingredient1": "Metoprolol", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139373/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, Azatadine, More", "updated_at": 1767369485}, {"id": 139213, "ingredient1": "Metoprolol", "ingredient2": "Methimazole", "severity": "Moderate", "effect": "The clearance of some beta-blockers with high extraction ratios may be reduced when a euthyroid state is achieved after the addition of antithyroid agents. Sotalol, nadolol, carteolol, and atenolol, which are primarily eliminated by the kidney, do not appear to be affected by changes in thyroid function.", "source": "DDInter", "management_text": "The patient should be closely monitored for altered efficacy and safety while achieving a euthyroid state or when the antithyroid agent dosage is added, discontinued, or changed. Beta blocker dose reductions may be required.", "mechanism_text": "Others", "recommendation": "The patient should be closely monitored for altered efficacy and safety while achieving a euthyroid state or when the antithyroid agent dosage is added, discontinued, or changed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139374/", "reference_text": "[1] Aro A, Anttila M, Korhonen T, Sundquist H \"Pharmacokinetics of propranolol and sotalol in hyperthyroidism.\" Eur J Clin Pharmacol 21 (1982): 373-7[2] Feely J, Stevenson IH, Crooks J \"Increased clearance of propranolol in thyrotoxicosis.\" Ann Intern Med 94 (1981): 472-4[3] Feely J, Crooks J, Stevenson IH \"The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration.\" Br J Clin Pharmacol 12 (1981): 73-8[4] Feely J, Crooks J, Stevenson IH \"Plasma propranolol steady state concentrations in thyroid disorders.\" Eur J Clin Pharmacol 19 (1981): 329-33[5] Hallengren B, Nilsson OR, Karlberg BE, Melander A, Tegler L, Wahlin-Boll E \"Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 21 (1982): 379-84", "alternatives_a": "Felodipine, Nebivolol, Nifedipine, Bisoprolol, Ivabradine, Sotalol, Nadolol, Esmolol, Betaxolol, Nebivolol, Bisoprolol, More", "alternatives_b": "Potassium perchlorate", "updated_at": 1767369485}, {"id": 139214, "ingredient1": "Metoprolol", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139375/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 139215, "ingredient1": "Metoprolol", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "The antihypertensive effects of methoxyflurane and beta blockers may be additive. The combination may cause profound hypotension. Older anesthetics such as methoxyflurane have more severe circulatory depressant effects in the presence of beta-blockade.", "source": "DDInter", "management_text": "It is currently recommended that beta blocker therapy not be routinely withdrawn prior to surgery. However, in general, patients taking beta blockers should not be anaesthetized with methoxyflurane. Instead, an anesthetic with minimal negative inotropic activity may be considered. If methoxyflurane must be used, beta blocker therapy should be withdrawn gradually and generally completed 24 to 48 hours before anesthesia.", "mechanism_text": "Synergism", "recommendation": "It is currently recommended that beta blocker therapy not be routinely withdrawn prior to surgery.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139376/", "reference_text": "[1] \"Product Information. Lopressor (metoprolol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Hunter JM \"Synergism between halothane and labetalol.\" Anaesthesia 34 (1979): 257-9[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Scott DB, Buckley FP, Littlewood DG, Macrae WR, Arthur GR, Drummond GB \"Circulatory effects of labetalol during halothane anaesthesia.\" Anaesthesia 33 (1978): 145-56", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Ziconotide", "updated_at": 1767369485}, {"id": 139216, "ingredient1": "Metoprolol", "ingredient2": "Methysergide", "severity": "Moderate", "effect": "Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids. The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation. In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.", "source": "DDInter", "management_text": "Except for increased awareness of the interaction, no specific intervention appears to be necessary. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Except for increased awareness of the interaction, no specific intervention appears to be necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139377/", "reference_text": "[1] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Venter CP, Joubert PH, Buys AC \"Severe peripheral ischaemia during concomitant use of beta blockers and ergot alkaloids.\" Br Med J 289 (1984): 288-9[3] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Blank NK, Rieder MJ \"Paradoxical response to propranolol in migraine.\" Lancet 2 (1973): 1336[5] Baumrucker JF \"Drug interaction: propranolol and cafergot.\" N Engl J Med 288 (1973): 916-7[6] Gandy W \"Dihydroergotamine interaction with propranolol .\" Ann Emerg Med 19 (1990): 221[7] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[10] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[11] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[14] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[15] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[16] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[17] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[18] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[19] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[21] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[22] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[23] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[25] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[26] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[27] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[29] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[31] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[32] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[33] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[34] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[35] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[36] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[37] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[38] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Eptinezumab, Rimegepant, Ubrogepant, Galcanezumab, Atogepant, Erenumab, Fremanezumab", "alternatives_b": "Felodipine, Acetylsalicylic acid, Ivabradine", "updated_at": 1767369485}, {"id": 139217, "ingredient1": "Metoprolol", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139378/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139218, "ingredient1": "Midodrine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Midodrine, an alpha-1 adrenergic agent may lead to bradycardia if administered concomitantly with any agent that directly or indirectly reduces heart rate. This may be most important for beta blockers and tricyclic antidepressants.", "source": "DDInter", "management_text": "Patients should be advised to discontinue midodrine if they experience signs or symptoms of decreased heart rate (i.e., slow pulse, dizziness, syncope, cardiac awareness) and to contact their provider for reevaluation.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised to discontinue midodrine if they experience signs or symptoms of decreased heart rate (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139379/", "reference_text": "[1] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "updated_at": 1767369485}, {"id": 139219, "ingredient1": "Mirabegron", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with mirabegron may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by mirabegron.", "source": "DDInter", "management_text": "Caution is advised if mirabegron must be used concomitantly with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mirabegron is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if mirabegron must be used concomitantly with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139380/", "reference_text": "[1] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Felodipine, Amlodipine, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, Esmolol, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 139220, "ingredient1": "Mirtazapine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139381/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139221, "ingredient1": "Morphine (liposomal)", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139382/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol, Carteolol, Penbutolol, Penbutolol", "alternatives_b": "Eluxadoline, Diphenoxylate, Difenoxin, Tapentadol, Naltrexone, Oxymorphone", "updated_at": 1767369485}, {"id": 139222, "ingredient1": "Nateglinide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139383/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ivabradine", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, Dulaglutide, More", "updated_at": 1767369485}, {"id": 139223, "ingredient1": "Nefazodone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Nefazodone may potentiate the hypotensive effect of many drugs including vasodilators and antihypertensive agents. Orthostatic hypotension may occur.", "source": "DDInter", "management_text": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139384/", "reference_text": "[1] \"Product Information. Serzone (nefazodone).\" Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139224, "ingredient1": "Neostigmine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Severe bradycardia and hypotension may develop during concomitant administration of some beta-blockers and anticholinesterase agents. The mechanism is unknown but may involve additive effects.", "source": "DDInter", "management_text": "The patient's hemodynamic status should be monitored during coadministration. Patients should be advised to notify their physician if they experience syncope, orthostasis, or a slow pulse.", "mechanism_text": "Others", "recommendation": "The patient's hemodynamic status should be monitored during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139385/", "reference_text": "[1] Eldor J, Hoffman B, Davidson JT \"Prolonged bradycardia and hypotension after neostigmine administration in a patient receiving atenolol.\" Anaesthesia 42 (1987): 1294-7", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine", "alternatives_b": "Ambenonium, Bethanechol, Methazolamide, Acetylcholine, Betaxolol, Diclofenamide, Carteolol, Brimonidine, Timolol, Levobunolol", "updated_at": 1767369485}, {"id": 139225, "ingredient1": "Nicardipine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.", "source": "DDInter", "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139386/", "reference_text": "[1] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[2] Strauss WE, Egan T, McIntyre KM, Parisi AF \"Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.\" Clin Cardiol 8 (1985): 363-6[3] Pouleur H, Etienne J, Van Mechelen H, et al \"Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.\" Postgrad Med J 60 (1984): 23-8[4] Levine MA, Ogilvie RI, Leenen FH \"Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.\" Clin Pharmacol Ther 43 (1988): 39-48[5] Ronn O, Bengtsson B, Edgar B, Raner S \"Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.\" Drugs 29 (1985): 16-25[6] Bauer LA, Murray K, Horn JR, et al \"Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.\" Eur J Clin Pharmacol 37 (1989): 257-60[7] Yust I, Hoffman M, Aronson RJ \"Life-threatening bradycardic reactions due to beta blocker-diltiazem interactions.\" Isr J Med Sci 28 (1992): 292-4[8] Oesterle SN, Alderman EL, Beier-Scott L, Bain DS, Rothman MT, Schroder JS \"Diltiazem and propranolol in combination: hemodynamic effects following acute intravenous administration.\" Am Heart J 111 (1986): 489-97[9] Hartwell BL, Mark JB \"Combinations of beta blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances?\" Anesth Analg 65 (1986): 905-7[10] Anastassiades CJ \"Nifedipine and beta-blocker drugs.\" Br Med J 281 (1980): 1251-2[11] Packer M \"Combined beta-adrenergic and calcium-entry blockage in angina pectoris.\" N Engl J Med 320 (1989): 709-18[12] Pringle SD, MacEwen CJ \"Severe bradycardia due to interaction of timolol eye drops and verapamil.\" Br Med J 294 (1987): 155-6[13] Tateishi T, Nakashima H, Shitou T, et al \"Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 36 (1989): 67-70[14] Maclean D, Mitchell ET, Coulson RR, Fitzsimons TJ, McDevitt DG \"Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.\" Br J Clin Pharmacol 25 (1988): 425-31[15] Hossack KF \"Conduction abnormalities due to diltiazem.\" N Engl J Med 307 (1982): 953-4[16] Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S \"Pharmacokinetic interactions between felodipine and metoprolol.\" Eur J Clin Pharmacol 31 (1987): 575-8[17] Tateishi T, Ohashi K, Fujimura A, Ebihara A \"The influence of diltiazem versus cimetidine on propranolol metabolism.\" J Clin Pharmacol 32 (1992): 1099-104[18] Sinclair NI, Benzie JL \"Timolol eye drops and verapamil: a dangerous combination.\" Med J Aust 1 (1983): 548[19] Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG \"Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.\" Br J Clin Pharmacol 29 (1990): 497-501[20] Ohman KP, Weiner L, von Schenck H, Karlberg BE \"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.\" Eur J Clin Pharmacol 29 (1985): 149-54[21] Vinceneux P, Canal M, Domart Y, Roux A, Cascio B, Orofiamma B, Larribaud J, Flouvat B, Carbon C \"Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 153-8[22] Nievel JG, Havard CW, Douglas-Jones AP \"Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension.\" Eur J Clin Pharmacol 33 (1987): 21-5[23] Strauss WE, Parisi AF \"Combines use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina.\" Ann Intern Med 109 (1988): 570-81[24] Takahashi H, Ohashi N, Motokawa K, Sato S, Naito H \"Poisoning caused by the combined ingestion of nifedipine and metoprolol.\" J Toxicol Clin Toxicol 31 (1993): 631-7[25] Rosenkranz B, Ledermann H, Frolich JC \"Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers.\" J Cardiovasc Pharmacol 8 (1986): 943-9[26] Leon MB, Rosing DR, Bonow RO, Epstein SE \"Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.\" Am J Cardiol 55 (1985): b69-80[27] Rocha P, Guerret M, David D, Marchand X, Kahn JC \"Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.\" Cardiovasc Drugs Ther 4 (1990): 1525-32[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[35] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[37] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[38] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[39] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[40] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[41] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[42] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[43] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[44] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Felodipine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139226, "ingredient1": "Nilotinib", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter and/or CYP450 2D6, CYP450 3A4, or UGT1A1 isoenzymes. The mechanism is decreased clearance via these routes due to inhibition by nilotinib.", "source": "DDInter", "management_text": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nilotinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139387/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Acetylsalicylic acid, Nebivolol, Bisoprolol, Atenolol, Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 139227, "ingredient1": "Nimodipine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.", "source": "DDInter", "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139388/", "reference_text": "[1] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[2] Strauss WE, Egan T, McIntyre KM, Parisi AF \"Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.\" Clin Cardiol 8 (1985): 363-6[3] Pouleur H, Etienne J, Van Mechelen H, et al \"Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.\" Postgrad Med J 60 (1984): 23-8[4] Levine MA, Ogilvie RI, Leenen FH \"Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.\" Clin Pharmacol Ther 43 (1988): 39-48[5] Ronn O, Bengtsson B, Edgar B, Raner S \"Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.\" Drugs 29 (1985): 16-25[6] Bauer LA, Murray K, Horn JR, et al \"Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.\" Eur J Clin Pharmacol 37 (1989): 257-60[7] Yust I, Hoffman M, Aronson RJ \"Life-threatening bradycardic reactions due to beta blocker-diltiazem interactions.\" Isr J Med Sci 28 (1992): 292-4[8] Oesterle SN, Alderman EL, Beier-Scott L, Bain DS, Rothman MT, Schroder JS \"Diltiazem and propranolol in combination: hemodynamic effects following acute intravenous administration.\" Am Heart J 111 (1986): 489-97[9] Hartwell BL, Mark JB \"Combinations of beta blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances?\" Anesth Analg 65 (1986): 905-7[10] Anastassiades CJ \"Nifedipine and beta-blocker drugs.\" Br Med J 281 (1980): 1251-2[11] Packer M \"Combined beta-adrenergic and calcium-entry blockage in angina pectoris.\" N Engl J Med 320 (1989): 709-18[12] Pringle SD, MacEwen CJ \"Severe bradycardia due to interaction of timolol eye drops and verapamil.\" Br Med J 294 (1987): 155-6[13] Tateishi T, Nakashima H, Shitou T, et al \"Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 36 (1989): 67-70[14] Maclean D, Mitchell ET, Coulson RR, Fitzsimons TJ, McDevitt DG \"Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.\" Br J Clin Pharmacol 25 (1988): 425-31[15] Hossack KF \"Conduction abnormalities due to diltiazem.\" N Engl J Med 307 (1982): 953-4[16] Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S \"Pharmacokinetic interactions between felodipine and metoprolol.\" Eur J Clin Pharmacol 31 (1987): 575-8[17] Tateishi T, Ohashi K, Fujimura A, Ebihara A \"The influence of diltiazem versus cimetidine on propranolol metabolism.\" J Clin Pharmacol 32 (1992): 1099-104[18] Sinclair NI, Benzie JL \"Timolol eye drops and verapamil: a dangerous combination.\" Med J Aust 1 (1983): 548[19] Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG \"Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.\" Br J Clin Pharmacol 29 (1990): 497-501[20] Ohman KP, Weiner L, von Schenck H, Karlberg BE \"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.\" Eur J Clin Pharmacol 29 (1985): 149-54[21] Vinceneux P, Canal M, Domart Y, Roux A, Cascio B, Orofiamma B, Larribaud J, Flouvat B, Carbon C \"Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 153-8[22] Nievel JG, Havard CW, Douglas-Jones AP \"Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension.\" Eur J Clin Pharmacol 33 (1987): 21-5[23] Strauss WE, Parisi AF \"Combines use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina.\" Ann Intern Med 109 (1988): 570-81[24] Takahashi H, Ohashi N, Motokawa K, Sato S, Naito H \"Poisoning caused by the combined ingestion of nifedipine and metoprolol.\" J Toxicol Clin Toxicol 31 (1993): 631-7[25] Rosenkranz B, Ledermann H, Frolich JC \"Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers.\" J Cardiovasc Pharmacol 8 (1986): 943-9[26] Leon MB, Rosing DR, Bonow RO, Epstein SE \"Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.\" Am J Cardiol 55 (1985): b69-80[27] Rocha P, Guerret M, David D, Marchand X, Kahn JC \"Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.\" Cardiovasc Drugs Ther 4 (1990): 1525-32[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[35] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[37] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[38] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[39] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[40] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[41] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[42] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[43] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[44] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139228, "ingredient1": "Nisoldipine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.", "source": "DDInter", "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139389/", "reference_text": "[1] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[2] Strauss WE, Egan T, McIntyre KM, Parisi AF \"Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.\" Clin Cardiol 8 (1985): 363-6[3] Pouleur H, Etienne J, Van Mechelen H, et al \"Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.\" Postgrad Med J 60 (1984): 23-8[4] Levine MA, Ogilvie RI, Leenen FH \"Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.\" Clin Pharmacol Ther 43 (1988): 39-48[5] Ronn O, Bengtsson B, Edgar B, Raner S \"Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.\" Drugs 29 (1985): 16-25[6] Bauer LA, Murray K, Horn JR, et al \"Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.\" Eur J Clin Pharmacol 37 (1989): 257-60[7] Yust I, Hoffman M, Aronson RJ \"Life-threatening bradycardic reactions due to beta blocker-diltiazem interactions.\" Isr J Med Sci 28 (1992): 292-4[8] Oesterle SN, Alderman EL, Beier-Scott L, Bain DS, Rothman MT, Schroder JS \"Diltiazem and propranolol in combination: hemodynamic effects following acute intravenous administration.\" Am Heart J 111 (1986): 489-97[9] Hartwell BL, Mark JB \"Combinations of beta blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances?\" Anesth Analg 65 (1986): 905-7[10] Anastassiades CJ \"Nifedipine and beta-blocker drugs.\" Br Med J 281 (1980): 1251-2[11] Packer M \"Combined beta-adrenergic and calcium-entry blockage in angina pectoris.\" N Engl J Med 320 (1989): 709-18[12] Pringle SD, MacEwen CJ \"Severe bradycardia due to interaction of timolol eye drops and verapamil.\" Br Med J 294 (1987): 155-6[13] Tateishi T, Nakashima H, Shitou T, et al \"Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 36 (1989): 67-70[14] Maclean D, Mitchell ET, Coulson RR, Fitzsimons TJ, McDevitt DG \"Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.\" Br J Clin Pharmacol 25 (1988): 425-31[15] Hossack KF \"Conduction abnormalities due to diltiazem.\" N Engl J Med 307 (1982): 953-4[16] Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S \"Pharmacokinetic interactions between felodipine and metoprolol.\" Eur J Clin Pharmacol 31 (1987): 575-8[17] Tateishi T, Ohashi K, Fujimura A, Ebihara A \"The influence of diltiazem versus cimetidine on propranolol metabolism.\" J Clin Pharmacol 32 (1992): 1099-104[18] Sinclair NI, Benzie JL \"Timolol eye drops and verapamil: a dangerous combination.\" Med J Aust 1 (1983): 548[19] Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG \"Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.\" Br J Clin Pharmacol 29 (1990): 497-501[20] Ohman KP, Weiner L, von Schenck H, Karlberg BE \"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.\" Eur J Clin Pharmacol 29 (1985): 149-54[21] Vinceneux P, Canal M, Domart Y, Roux A, Cascio B, Orofiamma B, Larribaud J, Flouvat B, Carbon C \"Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 153-8[22] Nievel JG, Havard CW, Douglas-Jones AP \"Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension.\" Eur J Clin Pharmacol 33 (1987): 21-5[23] Strauss WE, Parisi AF \"Combines use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina.\" Ann Intern Med 109 (1988): 570-81[24] Takahashi H, Ohashi N, Motokawa K, Sato S, Naito H \"Poisoning caused by the combined ingestion of nifedipine and metoprolol.\" J Toxicol Clin Toxicol 31 (1993): 631-7[25] Rosenkranz B, Ledermann H, Frolich JC \"Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers.\" J Cardiovasc Pharmacol 8 (1986): 943-9[26] Leon MB, Rosing DR, Bonow RO, Epstein SE \"Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.\" Am J Cardiol 55 (1985): b69-80[27] Rocha P, Guerret M, David D, Marchand X, Kahn JC \"Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.\" Cardiovasc Drugs Ther 4 (1990): 1525-32[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[35] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[37] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[38] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[39] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[40] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[41] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[42] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[43] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[44] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139229, "ingredient1": "Norepinephrine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139390/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "updated_at": 1767369485}, {"id": 139230, "ingredient1": "Octreotide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Somatostatin analogs (e.g., octreotide, lanreotide) can decrease heart rate and may potentiate the bradycardic effects of drugs like beta-blockers, calcium channel blockers, digitalis glycosides, and certain antiarrhythmic agents (e.g., class I antiarrhythmics, adenosine, amiodarone).", "source": "DDInter", "management_text": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers. Heart rate and blood pressure should be monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139391/", "reference_text": "[1] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[3] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[5] Katz MD, Erstad BL \"Octreotide, a new somatostatin analogue.\" Clin Pharm 8 (1989): 255-73[6] Ho PJ, Boyajy LD, Greenstein E, Barkan AL \"Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.\" Dig Dis Sci 38 (1993): 309-15[7] Landgraf R, Landgraf-Leurs MM, Nusser J, et al \"Effect of somatostatin analogue (SMS201-995) on cyclosporine levels.\" Transplantation 44 (1987): 724-5", "alternatives_a": "Nafarelin, Elagolix, Cetrorelix, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 139231, "ingredient1": "Olanzapine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139392/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Ivabradine", "alternatives_b": "Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 139232, "ingredient1": "Oliceridine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139393/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Tapentadol, Naltrexone, Oxymorphone", "updated_at": 1767369485}, {"id": 139233, "ingredient1": "Opium", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139394/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Penbutolol, Carteolol, Penbutolol", "alternatives_b": "Eluxadoline, Diphenoxylate, Difenoxin, Tapentadol, Naltrexone, Oxymorphone", "updated_at": 1767369485}, {"id": 139234, "ingredient1": "Oxybutynin", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139395/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Ivabradine, Esmolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 139235, "ingredient1": "Ozanimod", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "The risk of transient bradycardia and atrioventricular (AV) block may be increased during initiation of ozanimod treatment in patients receiving other drugs that slow heart rate or AV conduction such as beta-blockers, certain calcium channel blockers (e.g., diltiazem, verapamil), and digitalis. Ozanimod can cause a decrease in heart rate during initiation of therapy.", "source": "DDInter", "management_text": "Ozanimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate. In addition, advice from a cardiologist should be sought if coadministration of ozanimod is considered in patients with significant QT prolongation (QTcF greater than 450 msec in males or 470 msec in females), patients with arrhythmias requiring treatment with Class 1a or Class III antiarrhythmic agents, patients with ischemic heart disease, heart failure, history of cardiac arrest or myocardial infarction, cerebrovascular disease, or uncontrolled hypertension. Use of ozanimod in patients with a history of second-degree Mobitz type II or higher AV block, sick-sinus syndrome, or sinoatrial heart block is considered contraindicated unless the patient has a functioning pacemaker.", "mechanism_text": "Synergism", "recommendation": "Ozanimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139396/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 139236, "ingredient1": "Pancuronium", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139397/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Ivabradine", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139237, "ingredient1": "Panobinostat", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with panobinostat may increase the plasma concentrations of drugs that are substrates of CYP450 2D6. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by panobinostat.", "source": "DDInter", "management_text": "Given the high interpatient variability with respect to magnitude of interaction, concomitant use of panobinostat with sensitive CYP450 2D6 substrates (e.g., atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine) or CYP450 2D6 substrates that have a narrow therapeutic index (e.g., pimozide, thioridazine) should generally be avoided. Caution is advised when panobinostat is used with other drugs that are metabolized by CYP450 2D6.", "mechanism_text": "Metabolism", "recommendation": "Given the high interpatient variability with respect to magnitude of interaction, concomitant use of panobinostat with sensitive CYP450 2D6 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139398/", "reference_text": "[1] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Felodipine, Amlodipine, Bisoprolol, Atenolol, Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, More", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 139238, "ingredient1": "Paraldehyde", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139399/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Carteolol", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139239, "ingredient1": "Paroxetine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited clinical data suggest that selective serotonin reuptake inhibitors (SSRIs) may potentiate the pharmacologic effects of some beta-blockers. The proposed mechanism is SSRI inhibition (competitive and/or noncompetitive) of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of beta-blockers such as carvedilol, labetalol, metoprolol, nebivolol, propranolol, and timolol. Paroxetine and norfluoxetine (the active metabolite of fluoxetine), in particular, are potent inhibitors of CYP450 2D6 and may be more likely than other SSRIs to cause the interaction. On the other hand, fluvoxamine is a potent inhibitor of CYP450 1A2 and may significantly interact with propranolol, which is a substrate of both CYP450 2D6 and 1A2.", "source": "DDInter", "management_text": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate. Cardiac function should be closely monitored and the beta-blocker dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of SSRI in patients who are stabilized on their beta-blocker regimen. Due to the long half-life of fluoxetine and its active metabolite, norfluoxetine, the risk of an interaction may exist for an extended period (up to several weeks) after discontinuation of fluoxetine. To avoid the interaction, use of beta-blockers that are primarily eliminated by the kidney such as atenolol, acebutolol, betaxolol, carteolol, and nadolol may be considered.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139400/", "reference_text": "[1] Walley T, Pirmohamed M, Proudlove C, Maxwell D \"Interaction of metoprolol and fluoxetine.\" Lancet 341 (1993): 967-8[2] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[3] Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS \"Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.\" Clin Pharmacol Ther 64 (1998): 257-68[4] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[5] Ereshefsky L \"Treating depression: potential drug-drug interactions: commentary.\" J Clin Psychopharmacol 16 (suppl (1996): s50-3[6] Hemeryck A, Lefebvre RA, DeVriendt C, Belpaire FM \"Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.\" Clin Pharmacol Ther 67 (2000): 283-91[7] Perucca E, Gatti G, Spina E \"Clinical pharmacokinetics of fluvoxamine.\" Clin Pharmacokinet 27 (1994): 175-90[8] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM \"Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.\" J Clin Pharmacol 41 (2001): 443-51[9] Nemeroff CB, Devane CL, Pollock BG \"Newer antidepressants and the cytochrome p450 system.\" Am J Psychiatry 153 (1996): 311-20[10] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM \"Inhibition by fluoxetine of cytochrome P450 2D6 activity.\" Clin Pharmacol Ther 53 (1993): 401-9[13] Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S \"Fluvoxamine is a potent inhibitor of cytochrome P4501A2.\" Biochem Pharmacol 45 (1993): 1211-4[14] Drake WM, Gordon GD \"Heart block in a patient on propranolol and fluoxetine.\" Lancet 343 (1994): 425-6[15] Hemeryck A, DeVriendt CA, Belpaire FM \"Metoprolol-paroxetine interaction in human liver microsomes: Stereoselective aspects and prediction of the in vivo interaction.\" Drug Metab Disposition 29 (2001): 656-63[16] Richelson E \"Pharmacokinetic interactions of antidepressants.\" J Clin Psychiatry 59 (1998): 22-6[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[20] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ivabradine, Esmolol, Betaxolol, Carteolol, Penbutolol, Penbutolol", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 139240, "ingredient1": "Pasireotide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "The risk of significant bradycardia and atrioventricular (AV) block may be increased during concomitant treatment of pasireotide with other drugs that slow heart rate or AV conduction such as beta-blockers, calcium channel blockers, atazanavir, digitalis, flecainide, lacosamide, mefloquine, moricizine, and propafenone.", "source": "DDInter", "management_text": "Pasireotide has not been studied in patients receiving other bradycardic drugs. Because bradycardia and AV block are recognized risk factors for torsade de pointes arrhythmia, electrocardiographic monitoring is recommended prior to initiation of pasireotide and during treatment. Dose adjustments of beta blockers and calcium channel blockers or correction of electrolyte disturbances may be necessary.", "mechanism_text": "Synergism", "recommendation": "Pasireotide has not been studied in patients receiving other bradycardic drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139401/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Nafarelin, Elagolix, Cetrorelix, Ganirelix, Relugolix, Gonadorelin", "updated_at": 1767369485}, {"id": 139241, "ingredient1": "Pentobarbital", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with barbiturates may decrease the plasma concentrations and pharmacologic effects of certain beta-blockers when administered orally. The proposed mechanism is barbiturate induction of hepatic microsomal and first-pass metabolism.", "source": "DDInter", "management_text": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days. Pharmacologic response to beta-blockers should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy, and the beta-blocker dosage adjusted as necessary. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact.", "mechanism_text": "Metabolism", "recommendation": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139402/", "reference_text": "[1] Mantyla R, Mannisto P, Nykanen S, Koponen A, Lamminsivu U \"Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers.\" Eur J Clin Pharmacol 24 (1983): 227-30[2] Seideman P, Borg K, Haglund K, Von Bahr C, \"Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.\" Br J Clin Pharmacol 23 (1987): 267-71[3] Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C \"Influence of pentobarbital on metoprolol plasma levels.\" Clin Pharmacol Ther 26 (1979): 326-9[4] Sotaniemi EA, Anttila M, Pelkonen RO, Jarvensivu P, Sundquist H \"Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.\" Clin Pharmacol Ther 26 (1979): 153-61[5] Branch RA, Herman RJ \"Enzyme induction and beta-adrenergic receptor blocking drugs.\" Br J Clin Pharmacol 17 (1984): s77-84[6] Collste P, Seideman P, Borg K, Haglund K, Von Bahr C \"Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol.\" Clin Pharmacol Ther 25 (1979): 423-7", "alternatives_a": "Acetylsalicylic acid, Bisoprolol, Atenolol, Sotalol, Nadolol, Esmolol, Betaxolol, Bisoprolol, Carteolol, Sotalol, Pindolol, More", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139242, "ingredient1": "Pentoxifylline", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pentoxifylline is used in combination with hypotensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139403/", "reference_text": "[1] \"Product Information. Trental (pentoxifylline).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Ivabradine", "alternatives_b": "Cyclandelate, Isoxsuprine, Tolazoline, Phentolamine, Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 139243, "ingredient1": "Perphenazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139404/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139244, "ingredient1": "Phenelzine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139405/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 139245, "ingredient1": "Phenobarbital", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with barbiturates may decrease the plasma concentrations and pharmacologic effects of certain beta-blockers when administered orally. The proposed mechanism is barbiturate induction of hepatic microsomal and first-pass metabolism.", "source": "DDInter", "management_text": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days. Pharmacologic response to beta-blockers should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy, and the beta-blocker dosage adjusted as necessary. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact.", "mechanism_text": "Metabolism", "recommendation": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139406/", "reference_text": "[1] Mantyla R, Mannisto P, Nykanen S, Koponen A, Lamminsivu U \"Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers.\" Eur J Clin Pharmacol 24 (1983): 227-30[2] Seideman P, Borg K, Haglund K, Von Bahr C, \"Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.\" Br J Clin Pharmacol 23 (1987): 267-71[3] Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C \"Influence of pentobarbital on metoprolol plasma levels.\" Clin Pharmacol Ther 26 (1979): 326-9[4] Sotaniemi EA, Anttila M, Pelkonen RO, Jarvensivu P, Sundquist H \"Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.\" Clin Pharmacol Ther 26 (1979): 153-61[5] Branch RA, Herman RJ \"Enzyme induction and beta-adrenergic receptor blocking drugs.\" Br J Clin Pharmacol 17 (1984): s77-84[6] Collste P, Seideman P, Borg K, Haglund K, Von Bahr C \"Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol.\" Clin Pharmacol Ther 25 (1979): 423-7", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian, Ethotoin, Brivaracetam, Rufinamide, More", "updated_at": 1767369485}, {"id": 139246, "ingredient1": "Phenoxybenzamine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139407/", "reference_text": "[1] Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin JA \"Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.\" Arch Intern Med 148 (1988): 539-43[2] Chrysant SG \"Experience with terazosin administered in combination with other antihypertensive agents.\" Am J Med 80 (1986): 55-61[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[4] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[5] Rubin P, Jackson G, Blaschke T \"Studies on the clinical pharmacology of prazosin II: the influence of indomethacin and of propranolol on the action and disposition of prazosin.\" Br J Clin Pharmacol 10 (1980): 33-9[6] Elliott HL, McLean K, Sumner DJ, Meredith PA, Reid JL \"Immediate cardiovascular responses to oral prazosin: effects of concurrent beta-blockers.\" Clin Pharmacol Ther 29 (1981): 303-9[7] Seideman P, Grahnen A, Haglund K, Lindstrom B, Von Bahr C \"Prazosin first dose phenomenon during combined treatment with a B-adrenoceptor blocker in hypertensive patients.\" Br J Clin Pharmacol 13 (1982): 865-70[8] Stokes GS, Mennie BA, Gellatly R, Hill A \"On the combination of alpha- and beta-adrenoceptor blockade in hypertension.\" Clin Pharmacol Ther 34 (1983): 576-82", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "Cyclandelate, Isoxsuprine, Tolazoline, Phentolamine", "updated_at": 1767369485}, {"id": 139247, "ingredient1": "Phenylbutazone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139408/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Carteolol", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 139248, "ingredient1": "Physostigmine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Severe bradycardia and hypotension may develop during concomitant administration of some beta-blockers and anticholinesterase agents. The mechanism is unknown but may involve additive effects.", "source": "DDInter", "management_text": "The patient's hemodynamic status should be monitored during coadministration. Patients should be advised to notify their physician if they experience syncope, orthostasis, or a slow pulse.", "mechanism_text": "Others", "recommendation": "The patient's hemodynamic status should be monitored during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139409/", "reference_text": "[1] Eldor J, Hoffman B, Davidson JT \"Prolonged bradycardia and hypotension after neostigmine administration in a patient receiving atenolol.\" Anaesthesia 42 (1987): 1294-7", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine", "alternatives_b": "Methazolamide, Acetylcholine, Betaxolol, Diclofenamide, Carteolol, Brimonidine, Timolol, Levobunolol, Hydroxocobalamin, Fomepizole, Ipecac, More", "updated_at": 1767369485}, {"id": 139249, "ingredient1": "Pipecuronium", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139410/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139250, "ingredient1": "Piroxicam", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139411/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Ivabradine", "alternatives_b": "Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide, Fluocinolone acetonide, Fluorometholone", "updated_at": 1767369485}, {"id": 139251, "ingredient1": "Polythiazide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139412/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Esmolol, Carteolol, Penbutolol, Penbutolol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139252, "ingredient1": "Prednisone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139413/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ivabradine, Esmolol", "alternatives_b": "Beclomethasone dipropionate, Olsalazine", "updated_at": 1767369485}, {"id": 139253, "ingredient1": "Primidone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with barbiturates may decrease the plasma concentrations and pharmacologic effects of certain beta-blockers when administered orally. The proposed mechanism is barbiturate induction of hepatic microsomal and first-pass metabolism.", "source": "DDInter", "management_text": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days. Pharmacologic response to beta-blockers should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy, and the beta-blocker dosage adjusted as necessary. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact.", "mechanism_text": "Metabolism", "recommendation": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139414/", "reference_text": "[1] Mantyla R, Mannisto P, Nykanen S, Koponen A, Lamminsivu U \"Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers.\" Eur J Clin Pharmacol 24 (1983): 227-30[2] Seideman P, Borg K, Haglund K, Von Bahr C, \"Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.\" Br J Clin Pharmacol 23 (1987): 267-71[3] Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C \"Influence of pentobarbital on metoprolol plasma levels.\" Clin Pharmacol Ther 26 (1979): 326-9[4] Sotaniemi EA, Anttila M, Pelkonen RO, Jarvensivu P, Sundquist H \"Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.\" Clin Pharmacol Ther 26 (1979): 153-61[5] Branch RA, Herman RJ \"Enzyme induction and beta-adrenergic receptor blocking drugs.\" Br J Clin Pharmacol 17 (1984): s77-84[6] Collste P, Seideman P, Borg K, Haglund K, Von Bahr C \"Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol.\" Clin Pharmacol Ther 25 (1979): 423-7", "alternatives_a": "Bisoprolol, Sotalol, Nadolol, Esmolol, Betaxolol, Bisoprolol, Carteolol, Sotalol, Pindolol, Nadolol, Bisoprolol, More", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian, Ethotoin, Brivaracetam, Rufinamide, More", "updated_at": 1767369485}, {"id": 139254, "ingredient1": "Procainamide", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Some oral beta-blockers may decrease the clearance and increase the serum half-life of procainamide. Increased procainamide half-life and/or serum levels may result. The mechanism and clinical significance of this effect are unknown. Data are available for metoprolol and propranolol only and have been conflicting. If procainamide levels are elevated, reduction either of the beta-blocker dosage or of the procainamide dosage may be considered.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139415/", "reference_text": "[1] Dorian P, Newman D, Berman N, Hardy J, Mitchell J \"Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.\" J Am Coll Cardiol 22 (1993): 106-13[2] Ochs HR, Carstens G, Roberts GM, Greenblatt DJ \"Metoprolol or propranolol does not alter the kinetics of procainamide.\" J Cardiovasc Pharmacol 5 (1983): 392-5[3] Olanoff LS, Walle T, Cowart TD, et al \"Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis.\" Clin Pharmacol Ther 40 (1986): 408-14[4] Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ \"Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.\" Br J Clin Pharmacol 17 (1984): s45-50", "alternatives_a": "Felodipine, Amlodipine, Carvedilol, Nebivolol, Nifedipine, Bisoprolol, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, More", "alternatives_b": "Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139255, "ingredient1": "Procarbazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139416/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 139256, "ingredient1": "Procyclidine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139417/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139257, "ingredient1": "Promazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139418/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 139258, "ingredient1": "Promethazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139419/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, Azatadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139259, "ingredient1": "Propafenone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Propafenone may significantly increase serum levels and effects of some oral beta-blockers. The proposed mechanism is inhibition of CYP450 2D6 first-pass metabolism and decreased hepatic clearance. Data are available for metoprolol and propranolol only; however, other hepatically metabolized oral beta-blockers may also be affected. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact. In addition, negative inotropic effects may be potentiated.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for hypotension, heart failure, bradycardia, arrhythmias, and mental status changes. Beta-blocker dosage may be decreased if necessary.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for hypotension, heart failure, bradycardia, arrhythmias, and mental status changes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139420/", "reference_text": "[1] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[2] \"Product Information. Cartrol (carteolol).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, Rames A, Lecocq B, Jaillon P \"Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers.\" J Cardiovasc Pharmacol 18 (1991): 28-34[4] \"Product Information. Inderal (propranolol).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Barbey JT \"Clinical pharmacology and beta-blocking efficacy of propafenone.\" J Cardiovasc Pharmacol 17 (1991): s41-3[6] Janku I, Perlik F, Tkaczykova M, Brodanova M \"Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects.\" Eur J Clin Pharmacol 42 (1992): 337-40[7] \"Product Information. Blocadren (timolol).\" Merck & Co, Inc, West Point, PA.[8] McTavish D, Campoli-Richards D, Sorkin EM \"Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.\" Drugs 45 (1993): 232-58[9] Wagner F, Kalusche D, Trenk D, et al \"Drug interaction between propafenone and metoprolol.\" Br J Clin Pharmacol 24 (1987): 213-20[10] Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F \"Effect of aging on the pharmacokinetics of acebutolol enantiomers.\" J Clin Pharmacol 32 (1992): 148-56[11] McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW \"Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin.\" Clin Pharmacol Ther 38 (1985): 409-13[12] Stagni G, Davis PJ, Ludden TM \"Human pharmacokinetics of betaxolol enantiomers.\" J Pharm Sci 80 (1991): 321-4[13] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[14] \"Product Information. Normodyne (labetalol).\" Schering Laboratories, Kenilworth, NJ.[15] \"Product Information. Brevibloc (esmolol).\" DuPont Pharmaceuticals, Wilmington, DE.[16] Kowey PR, Kirsten EB, Fu CJ, Mason WD \"Interaction between propranolol and propafenone in healthy volunteers.\" J Clin Pharmacol 29 (1989): 512-7[17] \"Product Information. Levatol (penbutolol).\" Reed and Carnrick, Jersey City, NJ.[18] Ahmad S \"Metoprolol-induced delirium perpetuated by propafenone.\" Am Fam Physician 44 (1991): 1142,4[19] Morgan T \"Clinical pharmacokinetics and pharmacodynamics of carvedilol.\" Clin Pharmacokinet 26 (1994): 335-46[20] Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H \"Drug interaction between propafenone and metoprolol.\" Br J Clin Pharmacol 24 (1987): 213-20[21] \"Product Information. Rhythmol (propafenone).\" Knoll Pharmaceutical Company, Whippany, NJ.[22] Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y \"Pharmacokinetics of carteolol in patients with impaired renal function.\" Eur J Clin Pharmacol 43 (1992): 417-21[23] \"Product Information. Corgard (nadolol).\" Bristol-Myers Squibb, Princeton, NJ.[24] \"Product Information. Tenormin (atenolol).\" ICN Pharmaceuticals Inc, Cost Mesa, CA.[25] Seffart G ed. \"Drug Dosage in Renal Insufficiency.\" Dordrecht, South Holland, : Kluwer Academic Publishers (1991):[26] Smith RL \"Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.\" Eur J Clin Pharmacol 28 (1985): 77-84", "alternatives_a": "Amlodipine, Nifedipine, Bisoprolol, Nadolol, Esmolol, Betaxolol, Bisoprolol, Carteolol, Pindolol, Nadolol, Bisoprolol, Pindolol", "alternatives_b": "Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139260, "ingredient1": "Propantheline", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139421/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol", "alternatives_b": "Papaverine, Isometheptene", "updated_at": 1767369485}, {"id": 139261, "ingredient1": "Propiomazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139422/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139262, "ingredient1": "Propylthiouracil", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "The clearance of some beta-blockers with high extraction ratios may be reduced when a euthyroid state is achieved after the addition of antithyroid agents. Sotalol, nadolol, carteolol, and atenolol, which are primarily eliminated by the kidney, do not appear to be affected by changes in thyroid function.", "source": "DDInter", "management_text": "The patient should be closely monitored for altered efficacy and safety while achieving a euthyroid state or when the antithyroid agent dosage is added, discontinued, or changed. Beta blocker dose reductions may be required.", "mechanism_text": "Others", "recommendation": "The patient should be closely monitored for altered efficacy and safety while achieving a euthyroid state or when the antithyroid agent dosage is added, discontinued, or changed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139423/", "reference_text": "[1] Aro A, Anttila M, Korhonen T, Sundquist H \"Pharmacokinetics of propranolol and sotalol in hyperthyroidism.\" Eur J Clin Pharmacol 21 (1982): 373-7[2] Feely J, Stevenson IH, Crooks J \"Increased clearance of propranolol in thyrotoxicosis.\" Ann Intern Med 94 (1981): 472-4[3] Feely J, Crooks J, Stevenson IH \"The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration.\" Br J Clin Pharmacol 12 (1981): 73-8[4] Feely J, Crooks J, Stevenson IH \"Plasma propranolol steady state concentrations in thyroid disorders.\" Eur J Clin Pharmacol 19 (1981): 329-33[5] Hallengren B, Nilsson OR, Karlberg BE, Melander A, Tegler L, Wahlin-Boll E \"Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 21 (1982): 379-84", "alternatives_a": "Felodipine, Amlodipine, Nebivolol, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Nadolol, Esmolol, Betaxolol, More", "alternatives_b": "Potassium perchlorate", "updated_at": 1767369485}, {"id": 139263, "ingredient1": "Protriptyline", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139424/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 139264, "ingredient1": "Metoprolol", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139425/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, More", "updated_at": 1767369485}, {"id": 139265, "ingredient1": "Quazepam", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139426/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Nifedipine, Ivabradine", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139266, "ingredient1": "Quetiapine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139427/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139267, "ingredient1": "Racepinephrine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139428/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139268, "ingredient1": "Ranolazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with ranolazine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. Ranolazine has been shown in vitro to be an inhibitor of CYP450 2D6. However, concomitant use of ranolazine with other drugs that are metabolized by CYP450 2D6 such as tricyclic antidepressants and antipsychotics has not been studied.", "source": "DDInter", "management_text": "Caution is advised if ranolazine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ranolazine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ranolazine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139429/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.", "alternatives_a": "Regadenoson, Ubidecarenone", "alternatives_b": "Bisoprolol, Acebutolol, Labetalol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Acebutolol, Labetalol, Bisoprolol, More", "updated_at": 1767369485}, {"id": 139269, "ingredient1": "Rapacuronium", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139430/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139270, "ingredient1": "Rasagiline", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139431/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Opicapone, Rotigotine, Tolcapone, Pergolide, Amantadine", "updated_at": 1767369485}, {"id": 139271, "ingredient1": "Repaglinide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139432/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ivabradine", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, Dulaglutide, More", "updated_at": 1767369485}, {"id": 139272, "ingredient1": "Reserpine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139433/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Deserpidine, Deserpidine", "alternatives_b": "Felodipine, Acetylsalicylic acid, Amlodipine, Ivabradine", "updated_at": 1767369485}, {"id": 139273, "ingredient1": "Riociguat", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Riociguat may potentiate the action of antihypertensive agents and other vasodilators. Symptomatic hypotension may occur. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation and blood pressure decreases.", "source": "DDInter", "management_text": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139434/", "reference_text": "[1] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Macitentan, Metyrosine", "updated_at": 1767369485}, {"id": 139274, "ingredient1": "Rivastigmine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.", "source": "DDInter", "management_text": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139435/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Cognex (tacrine).\" Parke-Davis, Morris Plains, NJ.[3] Tiseo PJ, Perdomo CA, Friedhoff LT \"Concurrent administration of donepezil HCI and digoxin: assessment of pharmacokinetic changes.\" Br J Clin Pharmacol 46(Suppl 1) (1998): 40-4[4] Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL \"Drug interactions with cholinesterase inhibitors : an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (vidal, british national formulary).\" Drug Saf 30 (2007): 1063-71[5] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Ginkgo biloba, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139275, "ingredient1": "Rocuronium", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139436/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Ivabradine", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139276, "ingredient1": "Rolapitant", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. Rolapitant is a moderate CYP450 2D6 inhibitor, with inhibitory effect lasting at least 7 days after a single dose.", "source": "DDInter", "management_text": "Caution is advised when rolapitant is prescribed with drugs that are significantly metabolized by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when rolapitant is prescribed with drugs that are significantly metabolized by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139437/", "reference_text": "[1] \"Product Information. Varubi (rolapitant).\" Tesaro Inc., Waltham, MA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139277, "ingredient1": "Safinamide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139438/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Opicapone, Rotigotine, Tolcapone, Pergolide, Amantadine", "updated_at": 1767369485}, {"id": 139278, "ingredient1": "Salmeterol", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139439/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Ipratropium, Beclomethasone dipropionate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139279, "ingredient1": "Salsalate", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139440/", "reference_text": "[1] Keber I, Jerse M, Keber D, Stegnar M \"The influence of combined treatment with propranolol and acetylsalicylic acid on platelet aggregation in coronary heart disease.\" Br J Clin Pharmacol 7 (1979): 287-91[2] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002): 1015-1022[3] Sziegoleit W, Rausch J, Polak G, et al \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol in humans.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30[4] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[5] Spahn H, Langguth P, Kirch W, et al \"Pharmacokinetics of salicylates administered with metoprolol.\" Arzneimittelforschung 36 (1986): 1697-9[6] Sziegoleit W, Rausch J , Polak G, Gyorgy M, Dekov E, Bekes M \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30", "alternatives_a": "Ivabradine", "alternatives_b": "Ziconotide", "updated_at": 1767369485}, {"id": 139280, "ingredient1": "Scopolamine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139441/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Nifedipine, Ivabradine, Esmolol", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian, Tropicamide", "updated_at": 1767369485}, {"id": 139281, "ingredient1": "Secobarbital", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with barbiturates may decrease the plasma concentrations and pharmacologic effects of certain beta-blockers when administered orally. The proposed mechanism is barbiturate induction of hepatic microsomal and first-pass metabolism.", "source": "DDInter", "management_text": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days. Pharmacologic response to beta-blockers should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy, and the beta-blocker dosage adjusted as necessary. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact.", "mechanism_text": "Metabolism", "recommendation": "Barbiturates may variously reduce the effects of certain beta-blockers when given for more than a few days.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139442/", "reference_text": "[1] Mantyla R, Mannisto P, Nykanen S, Koponen A, Lamminsivu U \"Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers.\" Eur J Clin Pharmacol 24 (1983): 227-30[2] Seideman P, Borg K, Haglund K, Von Bahr C, \"Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.\" Br J Clin Pharmacol 23 (1987): 267-71[3] Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C \"Influence of pentobarbital on metoprolol plasma levels.\" Clin Pharmacol Ther 26 (1979): 326-9[4] Sotaniemi EA, Anttila M, Pelkonen RO, Jarvensivu P, Sundquist H \"Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity.\" Clin Pharmacol Ther 26 (1979): 153-61[5] Branch RA, Herman RJ \"Enzyme induction and beta-adrenergic receptor blocking drugs.\" Br J Clin Pharmacol 17 (1984): s77-84[6] Collste P, Seideman P, Borg K, Haglund K, Von Bahr C \"Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol.\" Clin Pharmacol Ther 25 (1979): 423-7", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139282, "ingredient1": "Selegiline", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139443/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Ivabradine", "alternatives_b": "Opicapone, Rotigotine, Tolcapone, Pergolide, Amantadine", "updated_at": 1767369485}, {"id": 139283, "ingredient1": "Selexipag", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139444/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985): 1070-1[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "updated_at": 1767369485}, {"id": 139284, "ingredient1": "Sertraline", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited clinical data suggest that selective serotonin reuptake inhibitors (SSRIs) may potentiate the pharmacologic effects of some beta-blockers. The proposed mechanism is SSRI inhibition (competitive and/or noncompetitive) of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of beta-blockers such as carvedilol, labetalol, metoprolol, nebivolol, propranolol, and timolol. Paroxetine and norfluoxetine (the active metabolite of fluoxetine), in particular, are potent inhibitors of CYP450 2D6 and may be more likely than other SSRIs to cause the interaction. On the other hand, fluvoxamine is a potent inhibitor of CYP450 1A2 and may significantly interact with propranolol, which is a substrate of both CYP450 2D6 and 1A2.", "source": "DDInter", "management_text": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate. Cardiac function should be closely monitored and the beta-blocker dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of SSRI in patients who are stabilized on their beta-blocker regimen. Due to the long half-life of fluoxetine and its active metabolite, norfluoxetine, the risk of an interaction may exist for an extended period (up to several weeks) after discontinuation of fluoxetine. To avoid the interaction, use of beta-blockers that are primarily eliminated by the kidney such as atenolol, acebutolol, betaxolol, carteolol, and nadolol may be considered.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139445/", "reference_text": "[1] Walley T, Pirmohamed M, Proudlove C, Maxwell D \"Interaction of metoprolol and fluoxetine.\" Lancet 341 (1993): 967-8[2] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[3] Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS \"Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.\" Clin Pharmacol Ther 64 (1998): 257-68[4] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[5] Ereshefsky L \"Treating depression: potential drug-drug interactions: commentary.\" J Clin Psychopharmacol 16 (suppl (1996): s50-3[6] Hemeryck A, Lefebvre RA, DeVriendt C, Belpaire FM \"Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.\" Clin Pharmacol Ther 67 (2000): 283-91[7] Perucca E, Gatti G, Spina E \"Clinical pharmacokinetics of fluvoxamine.\" Clin Pharmacokinet 27 (1994): 175-90[8] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM \"Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.\" J Clin Pharmacol 41 (2001): 443-51[9] Nemeroff CB, Devane CL, Pollock BG \"Newer antidepressants and the cytochrome p450 system.\" Am J Psychiatry 153 (1996): 311-20[10] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM \"Inhibition by fluoxetine of cytochrome P450 2D6 activity.\" Clin Pharmacol Ther 53 (1993): 401-9[13] Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S \"Fluvoxamine is a potent inhibitor of cytochrome P4501A2.\" Biochem Pharmacol 45 (1993): 1211-4[14] Drake WM, Gordon GD \"Heart block in a patient on propranolol and fluoxetine.\" Lancet 343 (1994): 425-6[15] Hemeryck A, DeVriendt CA, Belpaire FM \"Metoprolol-paroxetine interaction in human liver microsomes: Stereoselective aspects and prediction of the in vivo interaction.\" Drug Metab Disposition 29 (2001): 656-63[16] Richelson E \"Pharmacokinetic interactions of antidepressants.\" J Clin Psychiatry 59 (1998): 22-6[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[20] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Esmolol, Betaxolol, Penbutolol, Carteolol, Pindolol, Pindolol, Penbutolol", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 139285, "ingredient1": "Sildenafil", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.", "source": "DDInter", "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139446/", "reference_text": "[1] \"Product Information. Stendra (avanafil).\" Vivus Inc, Mountain View, CA.[2] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[3] \"Product Information. Levitra (vardenafil).\" Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 139286, "ingredient1": "Silodosin", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139447/", "reference_text": "[1] Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin JA \"Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.\" Arch Intern Med 148 (1988): 539-43[2] Chrysant SG \"Experience with terazosin administered in combination with other antihypertensive agents.\" Am J Med 80 (1986): 55-61[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[4] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[5] Rubin P, Jackson G, Blaschke T \"Studies on the clinical pharmacology of prazosin II: the influence of indomethacin and of propranolol on the action and disposition of prazosin.\" Br J Clin Pharmacol 10 (1980): 33-9[6] Elliott HL, McLean K, Sumner DJ, Meredith PA, Reid JL \"Immediate cardiovascular responses to oral prazosin: effects of concurrent beta-blockers.\" Clin Pharmacol Ther 29 (1981): 303-9[7] Seideman P, Grahnen A, Haglund K, Lindstrom B, Von Bahr C \"Prazosin first dose phenomenon during combined treatment with a B-adrenoceptor blocker in hypertensive patients.\" Br J Clin Pharmacol 13 (1982): 865-70[8] Stokes GS, Mennie BA, Gellatly R, Hill A \"On the combination of alpha- and beta-adrenoceptor blockade in hypertension.\" Clin Pharmacol Ther 34 (1983): 576-82", "alternatives_a": "Acetylsalicylic acid, Amlodipine, Nifedipine, Ivabradine", "alternatives_b": "Solifenacin", "updated_at": 1767369485}, {"id": 139287, "ingredient1": "Salicylic acid (sodium)", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139448/", "reference_text": "[1] Keber I, Jerse M, Keber D, Stegnar M \"The influence of combined treatment with propranolol and acetylsalicylic acid on platelet aggregation in coronary heart disease.\" Br J Clin Pharmacol 7 (1979): 287-91[2] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002): 1015-1022[3] Sziegoleit W, Rausch J, Polak G, et al \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol in humans.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30[4] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[5] Spahn H, Langguth P, Kirch W, et al \"Pharmacokinetics of salicylates administered with metoprolol.\" Arzneimittelforschung 36 (1986): 1697-9[6] Sziegoleit W, Rausch J , Polak G, Gyorgy M, Dekov E, Bekes M \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Penbutolol, Carteolol, Penbutolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139288, "ingredient1": "Stiripentol", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6. The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use. Dosage adjustments may be required if increased plasma levels or effects are observed.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139449/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Acetylsalicylic acid, Bisoprolol, Atenolol, Sotalol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Sotalol, More", "alternatives_b": "Ethotoin, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Phensuximide, More", "updated_at": 1767369485}, {"id": 139289, "ingredient1": "Sucralfate", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139450/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Ivabradine, Esmolol", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 139290, "ingredient1": "Sulfinpyrazone", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Sulfinpyrazone may reduce the antihypertensive effect of beta-blockers. The mechanism may be related to induction of beta-blocker metabolism or inhibition of prostaglandin synthesis by sulfinpyrazone.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139451/", "reference_text": "[1] Ferrara LA, Mancini M, Marotta T, Pasanisi F, Fasano ML \"Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.\" Eur J Clin Pharmacol 29 (1986): 717-9", "alternatives_a": "Felodipine, Amlodipine, Nebivolol, Nifedipine, Nebivolol, Nebivolol", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase", "updated_at": 1767369485}, {"id": 139291, "ingredient1": "Sunitinib", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "There is clinical evidence that sunitinib can prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, lopinavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.", "source": "DDInter", "management_text": "Caution is advised if sunitinib is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.g., marked first-degree AV block; second-degree or higher AV block; sick sinus syndrome without pacemaker) or severe cardiac disease such as myocardial ischemia or heart failure. Patients should be advised to notify their doctor if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if sunitinib is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139452/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[3] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 139292, "ingredient1": "Tacrine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.", "source": "DDInter", "management_text": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139453/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Cognex (tacrine).\" Parke-Davis, Morris Plains, NJ.[3] Tiseo PJ, Perdomo CA, Friedhoff LT \"Concurrent administration of donepezil HCI and digoxin: assessment of pharmacokinetic changes.\" Br J Clin Pharmacol 46(Suppl 1) (1998): 40-4[4] Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL \"Drug interactions with cholinesterase inhibitors : an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (vidal, british national formulary).\" Drug Saf 30 (2007): 1063-71[5] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Ginkgo biloba, Aducanumab", "updated_at": 1767369485}, {"id": 139293, "ingredient1": "Tadalafil", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Based on their pharmacology, phosphodiesterase-5 (PDE5) inhibitors may conceivably potentiate the hypotensive effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139454/", "reference_text": "[1] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[3] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[4] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Ivabradine", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Solifenacin, More", "updated_at": 1767369485}, {"id": 139294, "ingredient1": "Tasimelteon", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "INTERVAL: Coadministration with beta-blockers may diminish the therapeutic effects of tasimelteon. Beta-blockers have been shown to reduce the production of melatonin via inhibition of beta-1 adrenergic receptors; therefore, the efficacy of tasimelteon, which acts as an agonist at melatonin MT1 and MT2 receptors, may be reduced.", "source": "DDInter", "management_text": "Product labeling for tasimelteon suggests avoiding the nighttime administration of beta-blockers.", "mechanism_text": "Antagonism", "recommendation": "Product labeling for tasimelteon suggests avoiding the nighttime administration of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139455/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139295, "ingredient1": "Telithromycin", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with telithromycin may increase the plasma concentrations of metoprolol. The proposed mechanism is telithromycin inhibition of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of metoprolol.", "source": "DDInter", "management_text": "In patients treated with metoprolol for heart failure, the increased exposure to metoprolol may be of clinical importance, thus coadministration with telithromycin should be considered with caution. Excessive beta blockade may worsen heart failure in patients who have dependency to sympathetic stimulation in maintaining hemodynamic function.", "mechanism_text": "Metabolism", "recommendation": "In patients treated with metoprolol for heart failure, the increased exposure to metoprolol may be of clinical importance, thus coadministration with telithromycin should be considered with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139456/", "reference_text": "[1] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals, Bridgewater, NJ.[2] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[3] \"Product Information. Lopressor (metoprolol).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Nebivolol, Bisoprolol, Nadolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol, Pindolol, More", "alternatives_b": "Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 139296, "ingredient1": "Temazepam", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139457/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 139297, "ingredient1": "Terazosin", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139458/", "reference_text": "[1] Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin JA \"Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.\" Arch Intern Med 148 (1988): 539-43[2] Chrysant SG \"Experience with terazosin administered in combination with other antihypertensive agents.\" Am J Med 80 (1986): 55-61[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[4] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[5] Rubin P, Jackson G, Blaschke T \"Studies on the clinical pharmacology of prazosin II: the influence of indomethacin and of propranolol on the action and disposition of prazosin.\" Br J Clin Pharmacol 10 (1980): 33-9[6] Elliott HL, McLean K, Sumner DJ, Meredith PA, Reid JL \"Immediate cardiovascular responses to oral prazosin: effects of concurrent beta-blockers.\" Clin Pharmacol Ther 29 (1981): 303-9[7] Seideman P, Grahnen A, Haglund K, Lindstrom B, Von Bahr C \"Prazosin first dose phenomenon during combined treatment with a B-adrenoceptor blocker in hypertensive patients.\" Br J Clin Pharmacol 13 (1982): 865-70[8] Stokes GS, Mennie BA, Gellatly R, Hill A \"On the combination of alpha- and beta-adrenoceptor blockade in hypertension.\" Clin Pharmacol Ther 34 (1983): 576-82", "alternatives_a": "Ivabradine", "alternatives_b": "Solifenacin", "updated_at": 1767369485}, {"id": 139298, "ingredient1": "Terbinafine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with terbinafine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by terbinafine, which is expected to occur in patients who are CYP450 2D6 extensive metabolizers (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "Caution is advised if terbinafine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever terbinafine is added to or withdrawn from therapy. Due to the long elimination half-life of terbinafine, especially following prolonged use, such interactions may be observed for several months after discontinuation of terbinafine therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if terbinafine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139459/", "reference_text": "[1] Van der Kuy PH, Hooymans PM, Verkaaik AJ \"Nortriptyline intoxication induced by terbinafine.\" BMJ 316 (1998): 441[2] \"Product Information. Lamisil (terbinafine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL \"Investigation of terbinafine as a CYP2D6 inhibitor in vivo.\" Clin Pharmacol Ther 65 (1999): 465-72[4] Gupta AK, Katz HI, Shear NH \"Terbinafine and potential drug interactions - Reply.\" J Am Acad Dermatol 43 (2000): 883-4[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Bisoprolol, Ivabradine, Sotalol, Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Sotalol, More", "alternatives_b": "Flucytosine, Tioconazole, Thiabendazole, Griseofulvin, Griseofulvin", "updated_at": 1767369485}, {"id": 139299, "ingredient1": "Terbutaline", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139460/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 139300, "ingredient1": "Tetrabenazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139461/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Penbutolol, Carteolol, Penbutolol", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 139301, "ingredient1": "Thalidomide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Thalidomide can cause bradycardia and may have additive effects with other drugs that decrease heart rate. Cases of bradycardia have been associated with thalidomide use, some requiring medical interventions. The clinical significance and underlying etiology of the bradycardia observed with thalidomide treatment have not been established. However, the potential for additive bradycardic effects should be considered when used with other drugs that slow cardiac conduction such as beta-blockers, calcium channel blockers, digitalis, flecainide, moricizine, and propafenone. Non-cardiac drugs that may also cause bradycardia include atazanavir, lacosamide, lithium, mefloquine, succinylcholine, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents. Because bradycardia is a risk factor for torsade de pointes arrhythmia, concerns also exist when thalidomide is used with drugs that prolong the QT interval or cause torsade de pointes.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat. A dose reduction of thalidomide or discontinuation may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139462/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139302, "ingredient1": "Thallous Chloride", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference by these drugs.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference by these drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139463/", "reference_text": "[1] \"Product Information. Thallous Chloride Tl 201 (thallous chloride Tl-201).\" GE Healthcare, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Nuclear Pharmacy Website. University of Arkansas for Medical Sciences. College of Pharmacy \"Drug - Radiopharmaceutical Interactions. Available from: URL: http://nuclearpharmacy.uams.edu/nicki.html#tl.\" ([cited Feb2015]):", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139303, "ingredient1": "Thiethylperazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139464/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, Azatadine, More", "updated_at": 1767369485}, {"id": 139304, "ingredient1": "Thioridazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139465/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 139305, "ingredient1": "Thiothixene", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139466/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Ivabradine", "alternatives_b": "Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 139306, "ingredient1": "Ticagrelor", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "Ventricular pauses and bradycardia, mostly asymptomatic, have been observed in clinical studies with ticagrelor.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139467/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139307, "ingredient1": "Tocainide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "The concomitant use of tocainide and beta-blockers may have additive effects on cardiac index, left ventricular function, and pulmonary wedge pressure. While significant interactions have not been reported in studies, cases of asystole have been reported in patients with preexisting electrophysiologic abnormalities after tocainide and metoprolol were coadministered. The mechanism is not known, but may be related to an additive effect on the sinus node or conduction system, especially in patients with sick sinus syndrome. Cases of confusion and paranoia have also been reported after coadministration of tocainide and propranolol.", "source": "DDInter", "management_text": "The concomitant use of tocainide and beta blockers should probably be avoided in patients with atrioventricular conduction abnormalities or sick sinus syndrome. This combination should be used cautiously in other patients, with careful dose titration and close clinical and electrocardiographic monitoring for efficacy and safety.", "mechanism_text": "Synergism", "recommendation": "The concomitant use of tocainide and beta blockers should probably be avoided in patients with atrioventricular conduction abnormalities or sick sinus syndrome.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139468/", "reference_text": "[1] Roden DM, Woosley RL \"Tocainide.\" N Engl J Med 315 (1986): 41-5[2] Rubino M, Jackson E \"Severe paranoia with concomitant tocainide and propranolol therapy.\" Clin Pharm 1 (1982): 177-9[3] Ikram H \"Hemodynamic and electrophysiologic interactions between antiarrhythmic drugs and beta blockers, with special reference to tocainide.\" Am Heart J 100 (1980): 1076-80", "alternatives_a": "Felodipine, Amlodipine, Nebivolol, Nifedipine, Ivabradine, Acetylsalicylic acid, Nebivolol, Nebivolol", "alternatives_b": "Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139308, "ingredient1": "Tofacitinib", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Tofacitinib has been shown to decrease heart rate and prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta-blockers, digoxin, alpha-2 adrenoceptor agonists) may result in elevated risk of conduction disturbances and atrioventricular block.", "source": "DDInter", "management_text": "According to the manufacturer, concomitant use of tofacitinib with other agents that lower heart rate and/or prolong the PR interval should be avoided when possible. Caution is advised if concomitant use is necessary, particularly in patients with known conduction problems or severe cardiac disease. An ECG should be considered in these patients before initiating concomitant therapy and after titration to steady-state. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeats.", "mechanism_text": "Synergism", "recommendation": "According to the manufacturer, concomitant use of tofacitinib with other agents that lower heart rate and/or prolong the PR interval should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139469/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 139309, "ingredient1": "Tolazamide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139470/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, Dulaglutide, More", "updated_at": 1767369485}, {"id": 139310, "ingredient1": "Tolbutamide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139471/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Felodipine, Amlodipine, Ivabradine", "alternatives_b": "Methylene blue, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, Histamine, More", "updated_at": 1767369485}, {"id": 139311, "ingredient1": "Tolterodine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139472/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Ivabradine, Esmolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 139312, "ingredient1": "Torasemide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139473/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 139313, "ingredient1": "Tranylcypromine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139474/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 139314, "ingredient1": "Treprostinil", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139475/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985): 1070-1[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ivabradine", "alternatives_b": "Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "updated_at": 1767369485}, {"id": 139315, "ingredient1": "Triamterene", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139476/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol, Carteolol, Penbutolol, Penbutolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139316, "ingredient1": "Triazolam", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139477/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Ivabradine, Timolol, Timolol", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139317, "ingredient1": "Trichlormethiazide", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139478/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Carteolol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139318, "ingredient1": "Trifluoperazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139479/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 139319, "ingredient1": "Triflupromazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139480/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 139320, "ingredient1": "Trihexyphenidyl", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139481/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Ivabradine, Esmolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139321, "ingredient1": "Alimemazine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139482/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, Azatadine, More", "updated_at": 1767369485}, {"id": 139322, "ingredient1": "Trimipramine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139483/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nifedipine", "alternatives_b": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "updated_at": 1767369485}, {"id": 139323, "ingredient1": "Tubocurarine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139484/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139324, "ingredient1": "Tyropanoic acid", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139485/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139325, "ingredient1": "Vecuronium", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139486/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Ivabradine", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139326, "ingredient1": "Vemurafenib", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Coadministration with vemurafenib may increase the plasma concentrations of drugs that are substrates of the CYP450 1A2 and/or 2D6 isoenzymes. The mechanism is decreased clearance due to inhibition of CYP450 1A2 and 2D6 activity by vemurafenib. The interaction has been studied with caffeine and dextromethorphan, probe substrates for CYP450 1A2 and 2D6, respectively.", "source": "DDInter", "management_text": "Caution is advised if vemurafenib must be used concurrently with drugs that undergo metabolism by CYP450 1A2 and/or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever vemurafenib is added to or withdrawn from therapy. Concomitant use of vemurafenib and substrates of CYP450 1A2 and/or 2D6 with a narrow therapeutic index (e.g., antiarrhythmics; theophylline) should be avoided if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if vemurafenib must be used concurrently with drugs that undergo metabolism by CYP450 1A2 and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139487/", "reference_text": "[1] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Acetylsalicylic acid, Atenolol, Acebutolol, Labetalol, Nadolol, Esmolol, Betaxolol, More", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139327, "ingredient1": "Zileuton", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Zileuton is believed to inhibit the hepatic metabolism of propranolol. Propranolol serum concentrations may increase by as much as 100% with a resultant increase in beta blockade.", "source": "DDInter", "management_text": "It is unknown if this interaction will occur with other beta-blockers; however, if zileuton and a beta-blocker must be given concomitantly, the patient should be monitored for orthostatic hypotension, cardiac arrhythmias, bradycardia, and heart failure, and beta-blocker dosage should be decreased if necessary.", "mechanism_text": "Metabolism", "recommendation": "It is unknown if this interaction will occur with other beta-blockers; however, if zileuton and a beta-blocker must be given concomitantly, the patient should be monitored for orthostatic hypotension, cardiac arrhythmias, bradycardia, and heart failure, and beta-blocker dosage should be decreased if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139488/", "reference_text": "[1] \"Product Information. Zylo Filmtab (zileuton).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Acetylsalicylic acid, Atenolol, Ivabradine, Sotalol, Nadolol, Esmolol, Carteolol, Sotalol, Atenolol, Nadolol, Atenolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139328, "ingredient1": "Ziprasidone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139489/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139329, "ingredient1": "Zolmitriptan", "ingredient2": "Metoprolol", "severity": "Minor", "effect": "After one week of dosing with zolmitriptan and propranolol 160 mg/day, the Cmax and AUC of zolmitriptan increased 1.5 times while the Cmax and AUC of the N-desmethyl metabolite decreased by 30% and 15%, respectively. The mechanism of the interaction has not been described. It does not appear that any special precautions are necessary when coadministering zolmitriptan with beta-blockers, although further post-marketing studies will help to define this interaction.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139490/", "reference_text": "[1] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Felodipine, Amlodipine, Nebivolol, Nifedipine, Ivabradine, Nebivolol, Nebivolol", "alternatives_b": "Frovatriptan, Eptinezumab, Rimegepant, Ubrogepant, Galcanezumab, Atogepant, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 139330, "ingredient1": "Zolpidem", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139491/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ivabradine", "alternatives_b": "Suvorexant, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139331, "ingredient1": "Acetohexamide", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139492/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139332, "ingredient1": "Aminophylline", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139493/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139333, "ingredient1": "Copanlisib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of copanlisib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of copanlisib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139494/", "reference_text": "[1] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139334, "ingredient1": "Dicoumarol", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139495/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Betrixaban, Clopidogrel, Cilostazol, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139335, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John's wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139496/", "reference_text": "[1] \"Product Information. Adriamycin PFS (doxorubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Riggs CE Jr, Engel S, Wesley M, Wiernik PH, Bachur NR \"Doxorubicin pharmacokinetics: prochlorperazine and barbiturate effects.\" Clin Pharmacol Ther 31 (1982): 263[3] \"Product Information. Doxil (doxorubicin liposomal).\" Sequis Pharmaceuticals Inc, Menlo Park, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "updated_at": 1767369485}, {"id": 139336, "ingredient1": "Entrectinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of entrectinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of entrectinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139497/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139337, "ingredient1": "Ergometrine", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139498/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Misoprostol, Dinoprostone, Oxytocin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 139338, "ingredient1": "Ergotamine", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139499/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 139339, "ingredient1": "Etonogestrel", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139500/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Estetrol, Estradiol", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 139340, "ingredient1": "Everolimus", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139501/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 139341, "ingredient1": "Flibanserin", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of flibanserin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of flibanserin should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139502/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139342, "ingredient1": "Fostamatinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration of fostamatinib with inducers of CYP450 3A4 may decrease exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration. Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of fostamatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of fostamatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139503/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals, South San Francisco, CA.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 139343, "ingredient1": "Fostemsavir", "ingredient2": "Metreleptin", "severity": "Minor", "effect": "Coadministration of fostemsavir with moderate or weak CYP450 3A4 inducers may decrease the plasma concentrations of temsavir, the active moiety of fostemsavir. According to the prescribing information, temsavir is a substrate of CYP450 3A4, esterases, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP).", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139504/", "reference_text": "[1] \"Product Information. Rukobia (fostemsavir).\" ViiV Healthcare, Research Triangle Park, NC.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 139344, "ingredient1": "Gilteritinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein may decrease the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of gilteritinib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of gilteritinib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139505/", "reference_text": "[1] \"Product Information. Xospata (gilteritinib).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139345, "ingredient1": "Glasdegib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of glasdegib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of glasdegib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139506/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "updated_at": 1767369485}, {"id": 139346, "ingredient1": "Glipizide", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139507/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139347, "ingredient1": "Glyburide", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139508/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139348, "ingredient1": "Guanfacine", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of diminished therapeutic response to guanfacine should be considered during coadministration with CYP450 3A4 inducers. Pharmacologic response to guanfacine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of diminished therapeutic response to guanfacine should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139509/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Kiechel JR, Lavene D, Guerret M, Comoy E, Godin M, Fillastre JP \"Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure.\" Eur J Clin Pharmacol 25 (1983): 463-6[3] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[4] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Methyldopa, Clonidine, Deserpidine", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139349, "ingredient1": "Idelalisib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139510/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139350, "ingredient1": "Imatinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of imatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139511/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Bolton AE, Peng B, Hubert M, et al. \"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.\" Cancer Chemother Pharmacol 53 (2004): 102-6[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[7] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[19] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 139351, "ingredient1": "Insulin human", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139512/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139352, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139513/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139353, "ingredient1": "Insulin lispro", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139514/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139354, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139515/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139355, "ingredient1": "Insulin human (zinc)", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139516/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139356, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139517/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139357, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..", "source": "DDInter", "management_text": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139518/", "reference_text": "[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ \"Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.\" Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF \"Clinical drugs that interact with St. John's wort and implication in drug development.\" Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al \"Irinotecan therapy in adults with recurrent or progressive malignant glioma.\" J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K \"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer.\" Int J Clin Oncol 9 (2004): 206-9[5] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. \"A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.\" Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al \"Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.\" Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. \"Influence of phenytoin on the disposition of irinotecan: a case report.\" J Pediatr Hematol Oncol 24 (2002): 130-3[9] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A \"Modulation of irinotecan(CPT-11)metabolism by St. John's wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603.\" ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al \"Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.\" Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al \"Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme.\" Pharmacotherapy 20 (2000): 353[13] Kuhn JG \"Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report.\" Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A \"Effects of St. John's Wort on Irinotecan Metabolism.\" J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al \"Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.\" Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[17] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[18] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[23] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[24] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139358, "ingredient1": "Metreleptin", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lonafarnib. In vitro, lonafarnib has been shown to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of lonafarnib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of lonafarnib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139519/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139359, "ingredient1": "Metreleptin", "ingredient2": "Methysergide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139520/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[7] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 139360, "ingredient1": "Midostaurin", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of midostaurin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of midostaurin should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139521/", "reference_text": "[1] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y \"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.\" Cancer Chemother Pharmacol 72 (2013): 1223-34[2] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139361, "ingredient1": "Nateglinide", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139522/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139362, "ingredient1": "Nilotinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of nilotinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Patients receiving nilotinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to nilotinib. Concomitant use should be avoided if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving nilotinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to nilotinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139523/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139363, "ingredient1": "Nitisinone", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139524/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139364, "ingredient1": "Norgestrel", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139525/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Megestrol acetate, Progesterone, Estradiol, Megestrol acetate, Estetrol, Estradiol", "updated_at": 1767369485}, {"id": 139365, "ingredient1": "Olaparib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inducers. The potential for decreased efficacy of olaparib should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139526/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "updated_at": 1767369485}, {"id": 139366, "ingredient1": "Oliceridine", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139527/", "reference_text": "[1] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984): 1287-8[2] Tong TG, Pond SM, Kreek MJ, et al \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981): 349-51[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988): 623-9[4] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[5] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[6] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996): 925-6[7] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976): 1104-6[8] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000): 405-7[12] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation, Weston, FL.[13] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999): 957-62[14] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc, Birmingham, AL.[15] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991): 443-4[16] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977): 1211[17] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[18] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976): 227[19] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999): 1004-5[20] \"Product Information. Zohydro ER (HYDROcodone).\" Zogenix, Inc, San Diego, CA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "alternatives_b": "Naltrexone, Oxymorphone, Pentazocine, Buprenorphine, Morphine, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, Dihydrocodeine, Naloxone, More", "updated_at": 1767369485}, {"id": 139367, "ingredient1": "Osilodrostat", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or 2B6 may decrease the plasma concentrations of osilodrostat, which is partially metabolized by these isoenzymes. According to the product labeling, multiple CYP450 isoenzymes (CYP450 3A4, 2B6, and 2D6) and UDP-glucuronosyltransferases contribute to osilodrostat metabolism, and no single pathway contributes greater than 25% to the total clearance. Some of the known CYP450 3A4 and 2B6 inducers also induce UDP-glucuronosyltransferases.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer. An increase in the dosage of osilodrostat may be required. Dosage adjustments should be based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations of their signs and symptoms. A reduction in dosage of osilodrostat may be required if the CYP450 3A4 and/or 2B6 inducer is discontinued during treatment with osilodrostat.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139528/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Ketoconazole", "updated_at": 1767369485}, {"id": 139368, "ingredient1": "Osimertinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme. Reduced therapeutic efficacy of osimertinib may occur. However, no pharmacokinetic data are available from drug interaction studies.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of osimertinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of osimertinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139529/", "reference_text": "[1] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139369, "ingredient1": "Oxtriphylline", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139530/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139370, "ingredient1": "Palbociclib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139531/", "reference_text": "[1] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139371, "ingredient1": "Panobinostat", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme. The interaction has not been evaluated clinically, but simulations using physiologically-based pharmacokinetic (PBPK) models suggest an approximately 70% decrease in panobinostat systemic exposure in the presence of potent CYP450 3A4 inducers.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers. The potential for decreased efficacy of panobinostat should be considered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139532/", "reference_text": "[1] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More", "updated_at": 1767369485}, {"id": 139372, "ingredient1": "Pemigatinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of pemigatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of pemigatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139533/", "reference_text": "[1] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[2] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139373, "ingredient1": "Pimavanserin", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of diminished therapeutic response to pimavanserin should be considered during coadministration with CYP450 3A4 inducers. The manufacturer recommends coadministration with strong or moderate CYP450 3A4 inducers be avoided.", "mechanism_text": "Metabolism", "recommendation": "The possibility of diminished therapeutic response to pimavanserin should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139534/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Pimozide, Trifluoperazine, Paliperidone, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 139374, "ingredient1": "Praziquantel", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of praziquantel, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved. Alternative agents for schistosomiasis should be considered whenever possible in patients receiving treatment with a CYP450 3A4 inducer. Otherwise, clinical response to praziquantel should be closely monitored.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139535/", "reference_text": "[1] Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M \"Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers.\" Clin Pharmacol Ther 72 (2002): 505-13[2] Bittencourt PR, Gracia CM, Martins R, et al \"Phenytoin and carbamazepine decrease oral bioavailability of praziquantel.\" Neurology 42 (1992): 492-6[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Biltricide (praziquantel).\" Bayer, West Haven, CT.[5] Castro N, Medina R, Sotelo J, Jung H \"Bioavailability of praziquantel increases with concomitant administration of food.\" Antimicrob Agents Chemother 44 (2000): 2903-4[6] Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J \"Interaction between grapefruit juice and praziquantel in humans.\" Antimicrob Agents Chemother 46 (2002): 1614-6", "alternatives_a": "Triclabendazole, Oxamniquine", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 139375, "ingredient1": "Quetiapine", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary. Patients should be advised to notify their physician if their symptoms worsen or their condition changes.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139536/", "reference_text": "[1] \"Quetiapine for schizophrenia.\" Med Lett Drugs Ther 39 (1997): 117-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Wong YWJ, Yeh C, Thyrum PT \"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.\" J Clin Psychopharmacol 21 (2001): 89-93[4] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB \"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.\" Br J Clin Pharmacol 61 (2006): 58-69[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Pimozide, Trifluoperazine, Paliperidone, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 139376, "ingredient1": "Ramelteon", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations and pharmacologic effects of ramelteon, which is metabolized by CYP450 1A2 and, to a lesser extent, by CYP450 3A4 and the 2C subfamily of isoenzymes.", "source": "DDInter", "management_text": "The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St. John's wort. Other known inducers include aminoglutethimide, bexarotene, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, mitotane, modafinil, nafcillin, nevirapine, rifabutin, rifapentine, barbiturates and various other anticonvulsants, although the extent to which they interact with ramelteon is unknown.", "mechanism_text": "Metabolism", "recommendation": "The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139537/", "reference_text": "[1] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139377, "ingredient1": "Relugolix", "ingredient2": "Metreleptin", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139538/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc., Brisbane, CA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Tamoxifen, Anastrozole, Aminoglutethimide, More", "updated_at": 1767369485}, {"id": 139378, "ingredient1": "Repaglinide", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139539/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139379, "ingredient1": "Ribociclib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ribociclib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine. Pharmacologic effects of ribociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy. Alternative treatment may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139540/", "reference_text": "[1] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[5] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139380, "ingredient1": "Ripretinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and anti-tumor activities of ripretinib and its active metabolite (DP-5439). The proposed mechanism is induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the ripretinib dosage adjusted as necessary. Patients should be monitored for loss of anti-tumor activity.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139541/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139381, "ingredient1": "Rolapitant", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of rolapitant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139542/", "reference_text": "[1] \"Product Information. Varubi (rolapitant).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "Nabilone, Granisetron, Scopolamine, Dronabinol, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "updated_at": 1767369485}, {"id": 139382, "ingredient1": "Selpercatinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme. When selpercatinib was coadministered with multiple doses of rifampin, a potent CYP450 3A4 inducer, selpercatinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 70% and 87%, respectively.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of selpercatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of selpercatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139543/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139383, "ingredient1": "Selumetinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of selumetinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of selumetinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139544/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139384, "ingredient1": "Silodosin", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of silodosin, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139545/", "reference_text": "[1] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.", "alternatives_a": "Tamsulosin, Terazosin, Alfuzosin, Tadalafil, Finasteride, Dutasteride, Solifenacin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 139385, "ingredient1": "Sirolimus", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139546/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More", "updated_at": 1767369485}, {"id": 139386, "ingredient1": "Sonidegib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of sonidegib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of sonidegib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139547/", "reference_text": "[1] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "updated_at": 1767369485}, {"id": 139387, "ingredient1": "Sorafenib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sorafenib, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of sorafenib should be considered during coadministration with CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of sorafenib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139548/", "reference_text": "[1] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139388, "ingredient1": "Stiripentol", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 1A2, 2C19, and/or 3A4 may decrease the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of stiripentol should be considered during coadministration with CYP450 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of stiripentol should be considered during coadministration with CYP450 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139549/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[14] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[15] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[16] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More", "updated_at": 1767369485}, {"id": 139389, "ingredient1": "Sunitinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sunitinib and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or dose increase for sunitinib may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139550/", "reference_text": "[1] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[7] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[8] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[14] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 139390, "ingredient1": "Suvorexant", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of suvorexant should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the suvorexant dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139551/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139391, "ingredient1": "Tacrolimus", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139552/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Eliglustat, Laronidase, More", "updated_at": 1767369485}, {"id": 139392, "ingredient1": "Tasimelteon", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139553/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "updated_at": 1767369485}, {"id": 139393, "ingredient1": "Tazemetostat", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme. This may lead to reduced efficacy of tazemetostat.", "source": "DDInter", "management_text": "Caution and clinical monitoring is recommended if tazemetostat is to be used concomitantly with CYP450 3A4 inducers.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring is recommended if tazemetostat is to be used concomitantly with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139554/", "reference_text": "[1] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.[2] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc, Cambridge, MA.", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "updated_at": 1767369485}, {"id": 139394, "ingredient1": "Telithromycin", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of telithromycin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers. Pharmacologic response to telithromycin should be monitored closely during coadministration, and alternative treatment given if an interaction is suspected. Whenever possible, telithromycin should preferably not be used during or within 2 weeks after discontinuation of treatment with a CYP450 3A4 inducer.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139555/", "reference_text": "[1] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm.\" ([2001]):[2] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals, Bridgewater, NJ.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Clindamycin, Troleandomycin, Dirithromycin, Azithromycin, Clarithromycin, Erythromycin, Lincomycin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139395, "ingredient1": "Temsirolimus", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin. Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139556/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "alternatives_b": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Eliglustat, Laronidase, More", "updated_at": 1767369485}, {"id": 139396, "ingredient1": "Ticagrelor", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided. Otherwise, caution is advised, and patients should be closely monitored for diminished clinical response to ticagrelor therapy. Alternative treatment may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139557/", "reference_text": "[1] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Weeks P, Sieg A, Vahdat K, Raissi F, Nathan S \"Improved ticagrelor antiplatelet effect on discontinuation of phenytoin.\" Ann Pharmacother 48 (2014): 644-7[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Teng R, Mitchell P, Butler K \"Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects.\" Eur J Clin Pharmacol 69 (2013): 877-83[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Betrixaban, Clopidogrel, Cilostazol, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139397, "ingredient1": "Tolazamide", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139558/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 139398, "ingredient1": "Tolbutamide", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Since treatment of leptin deficiency in patients with generalized lipodystrophy tends to improve insulin sensitivity and leads to a reduction in food intake, patients receiving metreleptin may require adjustments in their antidiabetic medications. In particular, large dosage reductions of insulin or insulin secretagogue (e.g., sulfonylurea, meglitinide) may be necessary in some patients to minimize the risk of hypoglycemia.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.", "mechanism_text": "Synergism", "recommendation": "Blood glucose should be closely monitored in patients receiving insulin, especially at high dosages, or insulin secretagogue during concomitant treatment with metreleptin, and appropriate changes made to the antidiabetic drug regimen as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139559/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, Folic acid, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139399, "ingredient1": "Toremifene", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of toremifene. According to the product labeling, toremifene is primarily metabolized by CYP450 3A4 to N-demethyltoremifene, an antiestrogenic metabolite with weak in vivo antitumor potency but whose serum concentrations are 2 to 4 times higher than those of toremifene at steady state. The extent to which other, less potent CYP450 3A4 inducers may affect toremifene is unknown.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of toremifene should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or a dose adjustment of toremifene may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of toremifene should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139560/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ \"Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin.\" Clin Pharmacol Ther 64 (1998): 648-54[5] Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P \"Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes.\" Biochem Pharmacol 47 (1994): 1883-95[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[16] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[17] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139400, "ingredient1": "Trabectedin", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139561/", "reference_text": "[1] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Machiels JP, Staddon A, Herremans C, et al. \"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.\" Cancer Chemother Pharmacol 74 (2014): 729-37[4] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139401, "ingredient1": "Tucatinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with CYP450 3A4 inducers may decrease the plasma concentrations of tucatinib, which is primarily metabolized by CYP450 2C8 and to a lesser extent by CYP450 3A4.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of tucatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of tucatinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139562/", "reference_text": "[1] \"Product Information. Tukysa (tucatinib).\" Seattle Genetics Inc, Bothell, WA.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139402, "ingredient1": "Ubrogepant", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with moderate or weak inducers of CYP450 3A4 may decrease the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme. Dedicated drug interaction studies have not been conducted to assess concomitant use of ubrogepant with moderate or weak CYP450 3A4 inducers.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers. If needed, a second 100 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139563/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, More", "updated_at": 1767369485}, {"id": 139403, "ingredient1": "Vemurafenib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of vemurafenib, which has been shown in vitro to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of vemurafenib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or a dose adjustment of vemurafenib may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of vemurafenib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139564/", "reference_text": "[1] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139404, "ingredient1": "Venetoclax", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of venetoclax, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of venetoclax should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of venetoclax should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139565/", "reference_text": "[1] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "updated_at": 1767369485}, {"id": 139405, "ingredient1": "Voriconazole", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations of voriconazole, which is metabolized by CYP450 2C19, 2C9, and/or 3A4.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of voriconazole should be considered during coadministration with CYP450 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of voriconazole should be considered during coadministration with CYP450 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139566/", "reference_text": "[1] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[2] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[13] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Fluconazole, Caspofungin, Amphotericin B, Itraconazole, Miconazole, Micafungin, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139406, "ingredient1": "Zanubrutinib", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of zanubrutinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of zanubrutinib should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139567/", "reference_text": "[1] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Fedratinib, Bosutinib, Vandetanib, Ibrutinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139407, "ingredient1": "Abarelix", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139568/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Darolutamide, Anastrozole, Aminoglutethimide", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139408, "ingredient1": "Amoxapine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139569/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139409, "ingredient1": "Astemizole", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139570/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139410, "ingredient1": "Bedaquiline", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139571/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "alternatives_b": "Capreomycin, Rifamycin, Streptomycin, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 139411, "ingredient1": "Benznidazole", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139572/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Rabeprazole, Dexlansoprazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, Bismuth subcitrate potassium, More", "alternatives_b": "Miltefosine, Nifurtimox", "updated_at": 1767369485}, {"id": 139412, "ingredient1": "Bepridil", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139573/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139413, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139574/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139414, "ingredient1": "Chlorpromazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139575/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Tinidazole, More", "updated_at": 1767369485}, {"id": 139415, "ingredient1": "Cisapride", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139576/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139416, "ingredient1": "Daunorubicin (liposomal)", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139577/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139417, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139578/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 139418, "ingredient1": "Elotuzumab", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139579/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Rabeprazole, Dexlansoprazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, Bismuth subcitrate potassium, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 139419, "ingredient1": "Entrectinib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139580/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139420, "ingredient1": "Enzalutamide", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139581/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Nizatidine, Ranitidine, Amoxicillin, Quinacrine, Secnidazole, More", "alternatives_b": "Darolutamide, Anastrozole, Aminoglutethimide", "updated_at": 1767369485}, {"id": 139421, "ingredient1": "Epirubicin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139582/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139422, "ingredient1": "Eribulin", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139583/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 139423, "ingredient1": "Escitalopram", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139584/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Ranitidine, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "updated_at": 1767369485}, {"id": 139424, "ingredient1": "Etravirine", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139585/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Tetracycline, Levofloxacin, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Amoxicillin, Lansoprazole, Quinacrine, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More", "updated_at": 1767369485}, {"id": 139425, "ingredient1": "Ezogabine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139586/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Brivaracetam, Cenobamate, Ethosuximide, Lacosamide, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, Mephenytoin, More", "updated_at": 1767369485}, {"id": 139426, "ingredient1": "Fingolimod", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139587/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, More", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 139427, "ingredient1": "Flecainide", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139588/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, More", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 139428, "ingredient1": "Fluconazole", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139589/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Metronidazole, Cefixime, Flucytosine, Anidulafungin, Micafungin, Oteseconazole, Salicylic acid, Selenium Sulfide, Thiabendazole, Griseofulvin, More", "alternatives_b": "Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Furazolidone, Nitazoxanide, Sulfamethizole, Mafenide, Tinidazole, More", "updated_at": 1767369485}, {"id": 139429, "ingredient1": "Fluoxetine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139590/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Atovaquone, More", "updated_at": 1767369485}, {"id": 139430, "ingredient1": "Fluphenazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139591/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, More", "updated_at": 1767369485}, {"id": 139431, "ingredient1": "Flutamide", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139592/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Darolutamide, Anastrozole, Aminoglutethimide", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139432, "ingredient1": "Foscarnet", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139593/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More", "alternatives_b": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Nizatidine, Ranitidine, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 139433, "ingredient1": "Fostemsavir", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139594/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More", "updated_at": 1767369485}, {"id": 139434, "ingredient1": "Gatifloxacin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139595/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin, Tinidazole, More", "alternatives_b": "Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Povidone-iodine, Enoxacin, More", "updated_at": 1767369485}, {"id": 139435, "ingredient1": "Gemifloxacin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139596/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, More", "alternatives_b": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "updated_at": 1767369485}, {"id": 139436, "ingredient1": "Gilteritinib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139597/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139437, "ingredient1": "Glasdegib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139598/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 139438, "ingredient1": "Golimumab", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139599/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Rabeprazole, Dexlansoprazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, Bismuth subcitrate potassium, More", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 139439, "ingredient1": "Goserelin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139600/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Megestrol acetate, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, More", "updated_at": 1767369485}, {"id": 139440, "ingredient1": "Granisetron", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139601/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Rolapitant, Nabilone, Dronabinol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Tinidazole, More", "updated_at": 1767369485}, {"id": 139441, "ingredient1": "Grepafloxacin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139602/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 139442, "ingredient1": "Halofantrine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139603/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 139443, "ingredient1": "Haloperidol", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139604/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Tinidazole, Quinacrine, More", "updated_at": 1767369485}, {"id": 139444, "ingredient1": "Halothane", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139605/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Thiopental, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Ketamine", "updated_at": 1767369485}, {"id": 139445, "ingredient1": "Histrelin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139606/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Megestrol acetate, Diethylstilbestrol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 139446, "ingredient1": "Hydroxyzine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139607/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Nitazoxanide, More", "updated_at": 1767369485}, {"id": 139447, "ingredient1": "Ibutilide", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139608/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Moricizine, Tocainide, Bretylium, Mexiletine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139448, "ingredient1": "Idarubicin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139609/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Valrubicin, Plicamycin, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 139449, "ingredient1": "Iloperidone", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139610/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 139450, "ingredient1": "Imipramine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139611/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Vonoprazan, Amoxicillin, Tinidazole, Quinacrine, More", "updated_at": 1767369485}, {"id": 139451, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139612/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "Pantoprazole, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139452, "ingredient1": "Metronidazole", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139613/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139453, "ingredient1": "Metronidazole", "ingredient2": "Levacetylmethadol", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139614/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Nalmefene, Diamorphine, Acamprosate, Naltrexone", "updated_at": 1767369485}, {"id": 139454, "ingredient1": "Metronidazole", "ingredient2": "Lomefloxacin", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139615/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Povidone-iodine, Enoxacin, More", "updated_at": 1767369485}, {"id": 139455, "ingredient1": "Metronidazole", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of lonafarnib. In vitro, lonafarnib has been shown to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1. Increased exposure to lonafarnib may increase the risk and/or severity of adverse effects such as nausea, vomiting, diarrhea, anorexia, electrolyte disturbances, liver enzyme elevations, myelosuppression, infection, and hypertension.", "source": "DDInter", "management_text": "The manufacturer recommends avoiding concomitant use of lonafarnib with CYP450 2C9 inhibitors. If coadministration is required, patients should be closely monitored for common adverse effects as well as arrhythmias and events such as syncope and heart palpitations, since the effect of increased exposures on the QT interval is unknown.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends avoiding concomitant use of lonafarnib with CYP450 2C9 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139616/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tetracycline, Levofloxacin, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Ranitidine, Amoxicillin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139456, "ingredient1": "Metronidazole", "ingredient2": "Mesoridazine", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139617/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 139457, "ingredient1": "Metronidazole", "ingredient2": "Methotrimeprazine", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139618/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 139458, "ingredient1": "Midostaurin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139619/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139459, "ingredient1": "Mifepristone", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139620/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Bazedoxifene, Prasterone", "alternatives_b": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, Amoxicillin, More", "updated_at": 1767369485}, {"id": 139460, "ingredient1": "Mirtazapine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139621/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Nitazoxanide, Trimetrexate, More", "updated_at": 1767369485}, {"id": 139461, "ingredient1": "Naxitamab", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139622/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Rabeprazole, Dexlansoprazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, Bismuth subcitrate potassium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139462, "ingredient1": "Nelarabine", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139623/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Rabeprazole, Dexlansoprazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, Bismuth subcitrate potassium, More", "alternatives_b": "Pemetrexed, Cladribine, Trifluridine, Floxuridine, Pralatrexate, Decitabine, Azacitidine, Tioguanine", "updated_at": 1767369485}, {"id": 139463, "ingredient1": "Nilotinib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139624/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Quinacrine, Secnidazole, Atovaquone, Furazolidone, Nitazoxanide, Trimetrexate, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139464, "ingredient1": "Nilutamide", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139625/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Darolutamide, Anastrozole, Aminoglutethimide", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139465, "ingredient1": "Norfloxacin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139626/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Levofloxacin, More", "alternatives_b": "Tinidazole, Metronidazole, Cefixime, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 139466, "ingredient1": "Nortriptyline", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139627/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Atovaquone, More", "updated_at": 1767369485}, {"id": 139467, "ingredient1": "Ofloxacin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139628/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Tinidazole, Quinacrine, Secnidazole, Furazolidone, More", "alternatives_b": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Metronidazole, Cefixime, Rifamycin, Kanamycin, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139468, "ingredient1": "Olanzapine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139629/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Furazolidone, More", "updated_at": 1767369485}, {"id": 139469, "ingredient1": "Oliceridine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139630/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Pentazocine, Dihydrocodeine, Codeine", "updated_at": 1767369485}, {"id": 139470, "ingredient1": "Ondansetron", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139631/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Rolapitant, Nabilone, Dronabinol", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Nitazoxanide, Trimetrexate, Mafenide, More", "updated_at": 1767369485}, {"id": 139471, "ingredient1": "Osilodrostat", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139632/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin, Lansoprazole, Quinacrine, Secnidazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139472, "ingredient1": "Osimertinib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139633/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139473, "ingredient1": "Oxytocin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139634/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Methylergometrine, Ergometrine, Dinoprostone, Terlipressin, Desmopressin", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 139474, "ingredient1": "Ozanimod", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139635/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, More", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 139475, "ingredient1": "Paclitaxel (protein-bound)", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139636/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139476, "ingredient1": "Panobinostat", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139637/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 139477, "ingredient1": "Pasireotide", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139638/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin", "updated_at": 1767369485}, {"id": 139478, "ingredient1": "Pazopanib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139639/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Amoxicillin, Tinidazole, Quinacrine, Secnidazole, Atovaquone, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139479, "ingredient1": "Perflutren", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139640/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139480, "ingredient1": "Perphenazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139641/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, More", "updated_at": 1767369485}, {"id": 139481, "ingredient1": "Pimavanserin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139642/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 139482, "ingredient1": "Pimozide", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139643/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 139483, "ingredient1": "Pitavastatin", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139644/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Rabeprazole, Dexlansoprazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, Bismuth subcitrate potassium, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Clofibrate, Lomitapide, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 139484, "ingredient1": "Pitolisant", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139645/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 139485, "ingredient1": "Polatuzumab vedotin", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139646/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Esomeprazole, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 139486, "ingredient1": "Pomalidomide", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139647/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, More", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 139487, "ingredient1": "Ponatinib", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139648/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Tetracycline, Levofloxacin, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Amoxicillin, Quinacrine, Atovaquone, Furazolidone, Nitazoxanide, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139488, "ingredient1": "Posaconazole", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139649/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Amoxicillin, Tinidazole, Quinacrine, Secnidazole, Atovaquone, More", "alternatives_b": "Flucytosine, Anidulafungin, Micafungin, Oteseconazole", "updated_at": 1767369485}, {"id": 139489, "ingredient1": "Primaquine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139650/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 139490, "ingredient1": "Probucol", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139651/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Clofibrate, Lomitapide, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 139491, "ingredient1": "Procainamide", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139652/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, More", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 139492, "ingredient1": "Promazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139653/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 139493, "ingredient1": "Propafenone", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139654/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, More", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 139494, "ingredient1": "Protriptyline", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139655/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139495, "ingredient1": "Quetiapine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139656/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Atovaquone, Furazolidone, Nitazoxanide, More", "alternatives_b": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "updated_at": 1767369485}, {"id": 139496, "ingredient1": "Quinidine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "The combination of ciprofloxacin and metronidazole has been reported to increase the serum concentration of quinidine in a patient treated for atrial fibrillation and suspected diverticulitis. The exact mechanism of interaction is unknown. Neither metronidazole nor ciprofloxacin are known to significantly inhibit CYP450 3A4, the isoenzyme responsible for the metabolism of quinidine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139657/", "reference_text": "[1] Cooke CE, Sklar GE, Nappi JM \"Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole?\" Ann Pharmacother 30 (1996): 364-6[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[12] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[13] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[14] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Moricizine, Tocainide, Bretylium, Mexiletine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Atovaquone, More", "updated_at": 1767369485}, {"id": 139497, "ingredient1": "Quinine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139658/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "alternatives_b": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, Vonoprazan, More", "updated_at": 1767369485}, {"id": 139498, "ingredient1": "Ranolazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139659/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ubidecarenone, Regadenoson, Alprostadil, Ivabradine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Tinidazole, More", "updated_at": 1767369485}, {"id": 139499, "ingredient1": "Relugolix", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139660/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, Aminoglutethimide", "updated_at": 1767369485}, {"id": 139500, "ingredient1": "Ribociclib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139661/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, Vonoprazan, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139501, "ingredient1": "Romidepsin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139662/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 139502, "ingredient1": "Rucaparib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139663/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 139503, "ingredient1": "Selpercatinib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139664/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Quinacrine, Secnidazole, Atovaquone, Furazolidone, Nitazoxanide, Trimetrexate, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139504, "ingredient1": "Sertraline", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139665/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Nitazoxanide, Trimetrexate, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "updated_at": 1767369485}, {"id": 139505, "ingredient1": "Sevoflurane", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139666/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, More", "alternatives_b": "Thiopental, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Ketamine", "updated_at": 1767369485}, {"id": 139506, "ingredient1": "Siponimod", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139667/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Amoxicillin, More", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 139507, "ingredient1": "Iodide I-123", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139668/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Clarithromycin, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139508, "ingredient1": "Solifenacin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139669/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Avanafil, More", "updated_at": 1767369485}, {"id": 139509, "ingredient1": "Sorafenib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139670/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Amoxicillin, Tinidazole, Quinacrine, More", "updated_at": 1767369485}, {"id": 139510, "ingredient1": "Sotalol", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139671/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Nebivolol, Nebivolol, Ivabradine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Tinidazole, More", "updated_at": 1767369485}, {"id": 139511, "ingredient1": "Sparfloxacin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139672/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "updated_at": 1767369485}, {"id": 139512, "ingredient1": "Sunitinib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139673/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139513, "ingredient1": "Telavancin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139674/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 139514, "ingredient1": "Telbivudine", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139675/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Rabeprazole, Dexlansoprazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, Bismuth subcitrate potassium, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More", "updated_at": 1767369485}, {"id": 139515, "ingredient1": "Telithromycin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139676/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Tinidazole, Quinacrine, More", "alternatives_b": "Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 139516, "ingredient1": "Terbutaline", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139677/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ephedrine, Orciprenaline, Pirbuterol, Formoterol, Isoprenaline, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Olodaterol, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139517, "ingredient1": "Terfenadine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139678/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 139518, "ingredient1": "Teriflunomide", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139679/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Nizatidine, Esomeprazole, More", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 139519, "ingredient1": "Tetrabenazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139680/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 139520, "ingredient1": "Thioridazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139681/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 139521, "ingredient1": "Tipranavir", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "Ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, and tipranavir capsules all contain alcohol, which may produce a disulfiram-like reaction when coadministered with drugs that can inhibit aldehyde dehydrogenase (ALDH) such as nitroimidazoles (e.g., metronidazole, tinidazole), nitrofurans (e.g., furazolidone, nifurtimox), and cephalosporins with an N-methylthiotetrazole (NMTT) side chain that structurally resembles disulfiram. Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the 'disulfiram reaction'. Symptoms include flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion. Severe reactions may result in respiratory depression, cardiovascular collapse, arrhythmia, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death. The interaction is well established for disulfiram.", "source": "DDInter", "management_text": "Until further information is available, use of ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, or tipranavir capsules with nitroimidazoles (including vaginal formulations), nitrofurans, and certain cephalosporins should be avoided if possible.", "mechanism_text": "Others", "recommendation": "Until further information is available, use of ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, or tipranavir capsules with nitroimidazoles (including vaginal formulations), nitrofurans, and certain cephalosporins should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139682/", "reference_text": "[1] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[3] Uri JV, Parks DB \"Disulfiram-like reaction to certain cephalosporins.\" Ther Drug Monit 5 (1983): 219-24[4] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[5] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[6] \"Product Information. Metrogel-Vaginal (metronidazole).\" Curatek Pharmaceuticals Ltd, Elk Grove Village, IL.[7] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[8] \"Product Information. Tindamax (tinidazole).\" Presutti Laboratories Inc, Arlington Heights, IL.[9] Neu HC, Prince AS \"Interaction between moxalactam and alcohol.\" Lancet June (1980): 1422[10] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[11] Cina SJ, Russell RA, Conradi SE \"Sudden death due to metronidazole/ethanol interaction.\" Am J Forensic Med Pathol 17 (1996): 343-6[12] Elenbaas RM \"Drug therapy reviews: management of the disulfiram-alcohol reaction.\" Am J Hosp Pharm 34 (1977): 827-31[13] Freundt KJ, Schreiner E, Christmann-Kleiss U \"Cefamandole: a competitive inhibitor of aldehyde dehydrogenase.\" Infection 13 (1985): 91[14] van Ieperen L \"Sudden death during disulfiram-ethanol reaction.\" S Afr Med J 66 (1984): 165[15] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[16] Foster TS, Raehl CL, Wilson HD \"Disulfiram-like reaction associated with a parenteral cephalosporin.\" Am J Hosp Pharm 37 (1980): 858-9[17] Buening MK, et al \"Disulfiram-like reaction to beta-lactams.\" JAMA 245 (1981): 2047[18] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[19] Kline SS, Mauro VF, Forney RB Jr, et al \"Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia.\" Antimicrob Agents Chemother 31 (1987): 1328-31[20] Freundt KJ, Kitson TM \"Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole.\" Infection 14 (1986): 44-7[21] McMahon FG, Ryan JR, Jain AK, LaCorte W, Ginzler F \"Absence of disulfiram-type reactions to single and multiple doses of cefonicid: a placebo-controlled study.\" J Antimicrob Chemother 20 (1987): 913-8[22] Umeda S, Arai T \"Disulfiram-like reaction to moxalactam after celiac plexus alcohol block.\" Anesth Analg 64 (1985): 377[23] Reeves DS, Davies AJ \"Antabuse effect with cephalosporins.\" Lancet 2 (1980): 540[24] McMahon FG \"Disulfiram-like reaction to a cephalosporin.\" JAMA 243 (1980): 2397[25] Portier H, Chalopin JM, Freysz M, Tanter Y \"Interaction between cephalosporins and alcohol.\" Lancet 08/02/80 (1980): 263[26] Shimada J, Hayashi Y, Nakamura K \"Cefmetazole: clinical evaluation of efficacy and safety in Japan.\" Drugs Exp Clin Res 11 (1985): 181-94[27] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[28] Brown KR, Guglielmo BJ, Pons VG, Jacobs RA \"Theophylline elixir, moxalactam, and a disulfiram reaction.\" Ann Intern Med 97 (1982): 621-2[29] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[30] Jones RO \"Death following the ingestion of alcohol in an antabuse treated patient.\" Can Med Assoc J 60 (1949): 609-12[31] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[32] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[33] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Nizatidine, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, More", "updated_at": 1767369485}, {"id": 139522, "ingredient1": "Tizanidine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139683/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Chlorzoxazone, Chlormezanone", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Tinidazole, Quinacrine, Secnidazole, Atovaquone, More", "updated_at": 1767369485}, {"id": 139523, "ingredient1": "Tocilizumab", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139684/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Rabeprazole, Dexlansoprazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, Bismuth subcitrate potassium, More", "alternatives_b": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 139524, "ingredient1": "Toremifene", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139685/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Darolutamide, Anastrozole, Aminoglutethimide", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 139525, "ingredient1": "Trabectedin", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139686/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Topotecan", "updated_at": 1767369485}, {"id": 139526, "ingredient1": "Triclabendazole", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139687/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Praziquantel, Oxamniquine", "updated_at": 1767369485}, {"id": 139527, "ingredient1": "Trifluoperazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139688/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 139528, "ingredient1": "Triflupromazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139689/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 139529, "ingredient1": "Alimemazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139690/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "updated_at": 1767369485}, {"id": 139530, "ingredient1": "Trimipramine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139691/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, More", "updated_at": 1767369485}, {"id": 139531, "ingredient1": "Valbenazine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139692/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 139532, "ingredient1": "Vandetanib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139693/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Nizatidine, Vonoprazan, Amoxicillin, Tinidazole, Quinacrine, More", "alternatives_b": "Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More", "updated_at": 1767369485}, {"id": 139533, "ingredient1": "Vasopressin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139694/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139534, "ingredient1": "Vemurafenib", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139695/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Darunavir, More", "updated_at": 1767369485}, {"id": 139535, "ingredient1": "Venlafaxine", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139696/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Tinidazole, Quinacrine, Secnidazole, Nitazoxanide, Trimetrexate, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 139536, "ingredient1": "Vincristine (liposome)", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139697/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Topotecan", "alternatives_b": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 139537, "ingredient1": "Voriconazole", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139698/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Flucytosine, Anidulafungin, Micafungin, Oteseconazole", "alternatives_b": "Tinidazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Vonoprazan, Amoxicillin, Tinidazole, Quinacrine, Secnidazole, Atovaquone, More", "updated_at": 1767369485}, {"id": 139538, "ingredient1": "Ziprasidone", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139699/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Amoxicillin, Tinidazole, Quinacrine, Secnidazole, More", "updated_at": 1767369485}, {"id": 139539, "ingredient1": "Amoxapine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139700/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139540, "ingredient1": "Azatadine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139701/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139541, "ingredient1": "Butabarbital", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139702/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139542, "ingredient1": "Pentoxyverine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139703/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 139543, "ingredient1": "Clofedanol", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139704/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 139544, "ingredient1": "Chloral hydrate", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139705/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139545, "ingredient1": "Chlormezanone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139706/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139546, "ingredient1": "Chlorphenesin", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139707/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "updated_at": 1767369485}, {"id": 139547, "ingredient1": "Chlorpromazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139708/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139548, "ingredient1": "Cyclizine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139709/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 139549, "ingredient1": "Cyproheptadine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139710/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139550, "ingredient1": "Dexbrompheniramine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139711/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139551, "ingredient1": "Dezocine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139712/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 139552, "ingredient1": "Dimenhydrinate", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139713/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 139553, "ingredient1": "Ertugliflozin", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139714/", "reference_text": "[1] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb, Princeton, NJ.[5] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals, Titusville, NJ.[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Macitentan", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "updated_at": 1767369485}, {"id": 139554, "ingredient1": "Escitalopram", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139715/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 139555, "ingredient1": "Eslicarbazepine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139716/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Bosentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139556, "ingredient1": "Estazolam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139717/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139557, "ingredient1": "Eszopiclone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139718/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "updated_at": 1767369485}, {"id": 139558, "ingredient1": "Ethchlorvynol", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139719/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139559, "ingredient1": "Ethosuximide", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139720/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "updated_at": 1767369485}, {"id": 139560, "ingredient1": "Ethotoin", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139721/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139561, "ingredient1": "Ezogabine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139722/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139562, "ingredient1": "Felbamate", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139723/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Bosentan, Ambrisentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139563, "ingredient1": "Fenoldopam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "The use of fenoldopam with other hypotensive agents has not been studied. However, these combinations would theoretically increase the risk of severe symptomatic hypotension.", "source": "DDInter", "management_text": "Caution is strongly advised during concurrent use. Inpatient monitoring of the heart rate and blood pressure is recommended. Sublingual nitroglycerin has been used safely with fenoldopam.", "mechanism_text": "Synergism", "recommendation": "Caution is strongly advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139724/", "reference_text": "[1] \"Product Information. Corlopam (fenoldopam).\" Neurex, Menlo Park, CA.[2] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.", "alternatives_a": "Bosentan, Ambrisentan, Macitentan", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Isoprenaline, More", "updated_at": 1767369485}, {"id": 139564, "ingredient1": "Flavoxate", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139725/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 139565, "ingredient1": "Fluphenazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139726/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139566, "ingredient1": "Flurazepam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139727/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139567, "ingredient1": "Fluvoxamine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139728/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Riociguat", "updated_at": 1767369485}, {"id": 139568, "ingredient1": "Fosphenytoin", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139729/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ambrisentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139569, "ingredient1": "Gabapentin", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139730/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Macitentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139570, "ingredient1": "Garlic", "ingredient2": "Metyrosine", "severity": "Minor", "effect": "Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139731/", "reference_text": "[1] Tattelman E \"Health effects of garlic.\" Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM \"Effects of natural health products on blood pressure.\" Ann Pharmacother 39 (2005): 712-20", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139571, "ingredient1": "Guanfacine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Use of guanfacine in combination with antihypertensive agents may result in additive pharmacodynamic effects such as hypotension and syncope.", "source": "DDInter", "management_text": "Caution is advised during coadministration of these agents. Dosage adjustments may be required and hemodynamic responses should be monitored during concomitant therapy. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139732/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.", "alternatives_a": "Ambrisentan, Macitentan", "alternatives_b": "Rauwolfia serpentina root, Reserpine, Methyldopa, Deserpidine", "updated_at": 1767369485}, {"id": 139572, "ingredient1": "Halazepam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139733/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139573, "ingredient1": "Haloperidol", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139734/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139574, "ingredient1": "Diamorphine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139735/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 139575, "ingredient1": "Hydromorphone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139736/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Bosentan, Riociguat, Macitentan, Tadalafil", "updated_at": 1767369485}, {"id": 139576, "ingredient1": "Hydroxyzine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139737/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Macitentan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139577, "ingredient1": "Iloperidone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139738/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "updated_at": 1767369485}, {"id": 139578, "ingredient1": "Imipramine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139739/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139579, "ingredient1": "Metyrosine", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139740/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139580, "ingredient1": "Metyrosine", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139741/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 139581, "ingredient1": "Metyrosine", "ingredient2": "Licorice", "severity": "Moderate", "effect": "Licorice use has been associated with hypertension and may antagonize the effects of antihypertensive agents. Glycyrrhizic acid, a component of licorice, is hydrolyzed in the intestine to a metabolite (glycyrrhetinic acid) that causes mineralocorticoid and renin-suppressing effects.", "source": "DDInter", "management_text": "Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products. Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139742/", "reference_text": "[1] Cumming AM \"Metabolic effects of licorice.\" Br Med J 1 (1977): 906[2] Epstein MT, Espiner EA, Donald RA, Hughes H \"Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects.\" Br Med J 1 (1977): 488-90[3] Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR \"Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age.\" Lancet 2 (1987): 821-4[4] Elinav E, Chajek-Shaul T \"Licorice consumption causing severe hypokalemic paralysis.\" Mayo Clin Proc 78 (2003): 767-8[5] Rosseel M, Schoors D \"Chewing gum and hypokalaemia.\" Lancet 341 (1993): 175[6] Clyburn EB, DiPette DJ \"Hypertension induced by drugs and other substances.\" Semin Nephrol 15 (1995): 72-86[7] Lin SH, Yang SS, Chau T, Halperin ML \"An unusual cause of hypokalemic paralysis: chronic licorice ingestion.\" Am J Med Sci 325 (2003): 153-6[8] de Klerk GJ, Nieuwenhuis MG, Beutler JJ \"Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum.\" BMJ 314 (1997): 731[9] Nielsen I, Pedersen RS \"Life-threatening hypokalaemia caused by liquorice ingestion.\" Lancet 1 (1984): 1305[10] Cumming AM, Boddy K, Brown JJ, et al \"Severe hypokalaemia with paralysis induced by small doses of liquorice.\" Postgrad Med J 56 (1980): 526-9[11] Cumming A \"Severe reduction of serum potassium induced by licorice.\" Nurs Times 72 (1976): 367-70[12] Epstein MT, Espiner EA, Donald RA, Hughes H \"Liquorice toxicity and the renin-angiotensin-aldosterone axis in man.\" Br Med J 1 (1977): 209-10[13] Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S \"Liquorice-induced rise in blood pressure: a linear dose-response relationship.\" J Hum Hypertens 15 (2001): 549-52[14] Edwards CR \"Lessons from licorice.\" N Engl J Med 325 (1991): 1242-3[15] Ishikawa S, Kato M, Tokuda T, Momoi H, Sekijima Y, Higuchi M, Yanagisawa N \"Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa.\" Int J Eating Disorder 26 (1999): 111-4[16] Holmes AM, Young J, Marrott PK, Prentice E \"Pseudohyperaldosteronism induced by habitual ingestion of liquorice.\" Postgrad Med J 46 (1970): 625-9[17] Bannister B, Ginsburg R, Shneerson J \"Cardiac arrest due to liquorice-induced hypokalaemia.\" Br Med J 2 (1977): 738-9[18] Richard CL, Jurgens TM \"Effects of natural health products on blood pressure.\" Ann Pharmacother 39 (2005): 712-20[19] Farese RV, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R \"Licorice-induced hypermineralocorticoidism.\" N Engl J Med 325 (1991): 1223-7[20] Dellow EL, Unwin RJ, Honour JW \"Pontefract cakes can be bad for you: refractory hypertension and liquorice excess.\" Nephrol Dial Transplant 14 (1999): 218-20", "alternatives_a": "Riociguat, Macitentan, Tadalafil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139582, "ingredient1": "Metyrosine", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139743/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139583, "ingredient1": "Metyrosine", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139744/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139584, "ingredient1": "Metyrosine", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139745/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "updated_at": 1767369485}, {"id": 139585, "ingredient1": "Metyrosine", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139746/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 139586, "ingredient1": "Metyrosine", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139747/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "updated_at": 1767369485}, {"id": 139587, "ingredient1": "Midazolam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139748/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "updated_at": 1767369485}, {"id": 139588, "ingredient1": "Mirtazapine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139749/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Riociguat, Macitentan", "updated_at": 1767369485}, {"id": 139589, "ingredient1": "Morphine (liposomal)", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139750/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Loperamide, Eluxadoline, Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139590, "ingredient1": "Nefazodone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139751/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139591, "ingredient1": "Nortriptyline", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139752/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Riociguat, Ambrisentan, Macitentan", "updated_at": 1767369485}, {"id": 139592, "ingredient1": "Oliceridine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139753/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 139593, "ingredient1": "Opicapone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139754/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 139594, "ingredient1": "Opium", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139755/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Loperamide, Eluxadoline, Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 139595, "ingredient1": "Oxazepam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139756/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139596, "ingredient1": "Oxcarbazepine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139757/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ambrisentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139597, "ingredient1": "Oxymorphone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139758/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 139598, "ingredient1": "Paraldehyde", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139759/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139599, "ingredient1": "Paramethadione", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139760/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139600, "ingredient1": "Paroxetine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139761/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Riociguat, Macitentan", "updated_at": 1767369485}, {"id": 139601, "ingredient1": "Pentobarbital", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139762/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139602, "ingredient1": "Pentoxifylline", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pentoxifylline is used in combination with hypotensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139763/", "reference_text": "[1] \"Product Information. Trental (pentoxifylline).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Riociguat, Macitentan", "alternatives_b": "Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Niacin, Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, More", "updated_at": 1767369485}, {"id": 139603, "ingredient1": "Perampanel", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139764/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139604, "ingredient1": "Pergolide", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139765/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 139605, "ingredient1": "Perphenazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139766/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "updated_at": 1767369485}, {"id": 139606, "ingredient1": "Phenacemide", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139767/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139607, "ingredient1": "Phenelzine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139768/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Bosentan, Riociguat, Ambrisentan, Macitentan", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 139608, "ingredient1": "Phenindamine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139769/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 139609, "ingredient1": "Phensuximide", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139770/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139610, "ingredient1": "Phenytoin", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139771/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Ambrisentan", "updated_at": 1767369485}, {"id": 139611, "ingredient1": "Pramipexole", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139772/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Apomorphine, Amantadine, Cabergoline", "alternatives_b": "Riociguat, Macitentan", "updated_at": 1767369485}, {"id": 139612, "ingredient1": "Primidone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139773/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ambrisentan", "alternatives_b": "Nitrazepam, Zopiclone, Lacosamide", "updated_at": 1767369485}, {"id": 139613, "ingredient1": "Procyclidine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139774/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139614, "ingredient1": "Promazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139775/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139615, "ingredient1": "Propiomazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139776/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139616, "ingredient1": "Protriptyline", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139777/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139617, "ingredient1": "Quazepam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139778/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139618, "ingredient1": "Ramelteon", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139779/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139619, "ingredient1": "Rasagiline", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139780/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Bosentan, Riociguat, Ambrisentan, Macitentan", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 139620, "ingredient1": "Remifentanil", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139781/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "updated_at": 1767369485}, {"id": 139621, "ingredient1": "Remimazolam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139782/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139622, "ingredient1": "Riociguat", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Riociguat may potentiate the action of antihypertensive agents and other vasodilators. Symptomatic hypotension may occur. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation and blood pressure decreases.", "source": "DDInter", "management_text": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139783/", "reference_text": "[1] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Riociguat, Macitentan", "alternatives_b": "Macitentan, Metyrosine, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139623, "ingredient1": "Rotigotine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139784/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Apomorphine, Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 139624, "ingredient1": "Rufinamide", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139785/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ambrisentan, Tadalafil", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139625, "ingredient1": "Secobarbital", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139786/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139626, "ingredient1": "Sertraline", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139787/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Macitentan", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 139627, "ingredient1": "Sibutramine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139788/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 139628, "ingredient1": "St. John's Wort", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139789/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ambrisentan", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 139629, "ingredient1": "Stiripentol", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139790/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139630, "ingredient1": "Suvorexant", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139791/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139631, "ingredient1": "Tapentadol", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139792/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 139632, "ingredient1": "Tasimelteon", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139793/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139633, "ingredient1": "Temazepam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139794/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Riociguat, Macitentan", "updated_at": 1767369485}, {"id": 139634, "ingredient1": "Tetrabenazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139795/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 139635, "ingredient1": "Thalidomide", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Patients should be advised to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Dosage reductions may be necessary. Thalidomide should preferably be administered at bedtime to reduce the impact of somnolence. Alcohol use is not recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139796/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 139636, "ingredient1": "Thiethylperazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139797/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139637, "ingredient1": "Thiopental", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139798/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Nitrazepam, Zopiclone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139638, "ingredient1": "Thioridazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139799/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139639, "ingredient1": "Thiothixene", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139800/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "updated_at": 1767369485}, {"id": 139640, "ingredient1": "Tiagabine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139801/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139641, "ingredient1": "Tizanidine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects. In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation. Tizanidine itself is a central alpha-2 adrenergic agonist. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.", "source": "DDInter", "management_text": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position. Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139802/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Riociguat, Macitentan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139642, "ingredient1": "Tolcapone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139803/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Apomorphine, Amantadine, Cabergoline", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139643, "ingredient1": "Topiramate", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139804/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Riociguat, Ambrisentan, Macitentan", "updated_at": 1767369485}, {"id": 139644, "ingredient1": "Tranylcypromine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139805/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Bosentan, Riociguat, Ambrisentan, Macitentan", "updated_at": 1767369485}, {"id": 139645, "ingredient1": "Triazolam", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139806/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139646, "ingredient1": "Trifluoperazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139807/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "updated_at": 1767369485}, {"id": 139647, "ingredient1": "Triflupromazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139808/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Clozapine, Olanzapine, Pimozide, Risperidone, Loxapine, Paliperidone", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139648, "ingredient1": "Trihexyphenidyl", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139809/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139649, "ingredient1": "Alimemazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139810/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 139650, "ingredient1": "Trimethadione", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139811/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139651, "ingredient1": "Trimethobenzamide", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Coadministration of metyrosine in combination with haloperidol, phenothiazines, or other dopamine antagonists may increase the risk of extrapyramidal disorders. Extrapyramidal effects have been reported during metyrosine therapy. The mechanism is inhibition of catecholamine synthesis by metyrosine. In addition, sedative effects of both drugs may be increased.", "source": "DDInter", "management_text": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "When concurrent use is required, patients should be monitored for extrapyramidal symptoms and instructed to notify their physician if they experience symptoms such as bradykinesia, hypertonia, rigidity, restlessness, and dysphagia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139812/", "reference_text": "[1] \"Product Information. Demser (metyrosine).\" Merck & Co, Inc, West Point, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139652, "ingredient1": "Trimipramine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139813/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139653, "ingredient1": "Tripelennamine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139814/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine", "updated_at": 1767369485}, {"id": 139654, "ingredient1": "Triprolidine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139815/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "updated_at": 1767369485}, {"id": 139655, "ingredient1": "Valbenazine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139816/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 139656, "ingredient1": "Valerian", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139817/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139657, "ingredient1": "Venlafaxine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139818/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Riociguat, Macitentan", "updated_at": 1767369485}, {"id": 139658, "ingredient1": "Verteporfin", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.", "source": "DDInter", "management_text": "If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.", "mechanism_text": "Antagonism", "recommendation": "If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139819/", "reference_text": "[1] \"Product Information. Visudyne (verteporfin)\" Valeant Pharmaceuticals, Costa Mesa, CA.[2] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.", "alternatives_a": "Aflibercept, Bevacizumab", "alternatives_b": "Riociguat, Macitentan", "updated_at": 1767369485}, {"id": 139659, "ingredient1": "Vigabatrin", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139820/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139660, "ingredient1": "Zaleplon", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139821/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139661, "ingredient1": "Ziconotide", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139822/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Methoxyflurane, Salsalate, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 139662, "ingredient1": "Zolpidem", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139823/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Riociguat, Macitentan", "updated_at": 1767369485}, {"id": 139663, "ingredient1": "Zonisamide", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139824/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Lacosamide, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, More", "updated_at": 1767369485}, {"id": 139664, "ingredient1": "Aminophylline", "ingredient2": "Mexiletine", "severity": "Major", "effect": "Coadministration with mexiletine may increase the serum concentrations of theophylline. The proposed mechanism is inhibition of the CYP450 1A2-mediated metabolism of theophylline by mexiletine.", "source": "DDInter", "management_text": "Caution is advised when theophylline is used with mexiletine. Close monitoring of serum theophylline levels is recommended, particularly following the addition, discontinuation or change of dosage of mexiletine, and the theophylline dosage adjusted accordingly. Patients should be advised to notify their physician if they experience signs of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, palpitations, and cardiac arrhythmia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when theophylline is used with mexiletine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139825/", "reference_text": "[1] Ueno K, Miyai K, Kato M, et al \"Mechanism of interaction between theophylline and mexiletine.\" DICP 25 (1991): 727-30[2] Katz A, Buskila D, Sukenik S \"Oral mexiletine-theophylline interaction.\" Int J Cardiol 17 (1987): 227-8[3] Stoysich AM, Mohiuddin SM, Destache CJ, et al \"Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers.\" J Clin Pharmacol 31 (1991): 354-7[4] Stanley R, Comer T, Taylor JL, Saliba D \"Mexiletine-theophylline interaction.\" Am J Med 86 (1989): 733-4[5] Kessler KM, Interian A, Cox M, et al \"Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline.\" Am Heart J 117 (1989): 964-6[6] Ueno K, Miyai K, Seki T, Kawaguchi Y \"Interaction between theophylline and mexiletine.\" DICP 24 (1990): 471-2[7] Hurwitz A, Vacek JL, Botteron GW, et al \"Mexiletine effects on theophylline disposition.\" Clin Pharmacol Ther 50 (1991): 299-307[8] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[9] Loi CM, Wei X, Vestal RE \"Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers.\" Clin Pharmacol Ther 49 (1991): 571-80", "alternatives_a": "Quinidine, Dronedarone, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Ibutilide", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 139665, "ingredient1": "Ammonium chloride", "ingredient2": "Mexiletine", "severity": "Minor", "effect": "Agents that acidify the urine enhance the plasma clearance of mexiletine. The result may be decreased plasma mexiletine levels and decreased effectiveness. The clinical significance is unknown. It is recommended that such drugs or diet be discontinued or that mexiletine dosage increased as needed and tolerated.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139826/", "reference_text": "[1] Mitchell BG, Clements JA, Pottage A, Prescott LF \"Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.\" Br J Clin Pharmacol 16 (1983): 281-4", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Tadalafil, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 139666, "ingredient1": "Mexiletine", "ingredient2": "Arbutamine", "severity": "Major", "effect": "Arbutamine may precipitate or exacerbate supraventricular or ventricular arrhythmias due to its sympathomimetic effects.", "source": "DDInter", "management_text": "The manufacturer recommends that arbutamine not be given concurrently with proarrhythmic drugs.", "mechanism_text": "Synergism", "recommendation": "The manufacturer recommends that arbutamine not be given concurrently with proarrhythmic drugs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139827/", "reference_text": "[1] \"Product Information. GenESA (arbutamine).\" Gensia Inc, San Diego, CA.[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Dofetilide, Dronedarone, Ibutilide", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Phenylephrine, Fenoldopam, Metaraminol, More", "updated_at": 1767369485}, {"id": 139667, "ingredient1": "Berotralstat", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.", "source": "DDInter", "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139828/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.", "alternatives_a": "Lidocaine, Tocainide, Procainamide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 139668, "ingredient1": "Chlorpromazine", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with moderate or strong CYP450 1A2 inhibitors may increase the plasma concentrations and risk of adverse effects of chlorpromazine. The proposed mechanism is inhibition of CYP450 1A2-mediated metabolism of chlorpromazine, which has been shown to be metabolized by this isoenzyme. This interaction has been studied in vitro, but clinical data evaluating the interaction are not available.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if chlorpromazine is used concomitantly with moderate or strong CYP450 1A2 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring of chlorpromazine should be considered whenever a moderate or strong CYP450 1A2 inhibitor is added to or withdrawn from therapy. Patients should be advised to monitor for signs and symptoms of chlorpromazine-related adverse reactions.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if chlorpromazine is used concomitantly with moderate or strong CYP450 1A2 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139829/", "reference_text": "[1] Wojcikowski J, Boksa J, Daniel WA \"Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines.\" Biochem Pharmacol 80 (2010): 1252-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 139669, "ingredient1": "Echinacea", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with echinacea may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to echinacea-mediated inhibition of CYP450 1A2.", "source": "DDInter", "management_text": "Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever echinacea is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139830/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100", "alternatives_a": "Tocainide, Procainamide, Flecainide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139670, "ingredient1": "Enoxacin", "ingredient2": "Mexiletine", "severity": "Minor", "effect": "The coadministration of certain quinolone antibiotics and mexiletine may result in modestly elevated plasma concentrations of the latter. The proposed mechanism is inhibition of CYP450 1A2 hepatic metabolism of mexiletine. The clinical significance is unknown. Discontinuation or change of dosage may be necessary if an interaction is suspected.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139831/", "reference_text": "[1] McLellan RA, Drobitch RK, Monshouwer M, Renton KW \"Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human.\" Drug Metab Dispos 24 (1996): 1134-8[2] Labbe L, Lefez C, Gilbert M, O'Hara G, Turgeon J \"Ciprofloxacin (CIPRO) decreases mexiletine (MEX) clearance in smokers and non-smokers.\" Clin Pharmacol Ther 57 (1995): 210", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Flecainide, Disopyramide, Dofetilide, Bretylium, More", "alternatives_b": "Gatifloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Grepafloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "updated_at": 1767369485}, {"id": 139671, "ingredient1": "Etanercept", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139832/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "alternatives_b": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139672, "ingredient1": "Ethotoin", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Hydantoins may induce the hepatic metabolism of mexiletine. Plasma mexiletine levels and mexiletine effectiveness may be decreased.", "source": "DDInter", "management_text": "It is recommended that the antiarrhythmic effectiveness of mexiletine be monitored and that mexiletine dosage be increased as needed. Also, when hydantoin is withdrawn, the clinician should be aware of the risk of mexiletine toxicity.", "mechanism_text": "Metabolism", "recommendation": "It is recommended that the antiarrhythmic effectiveness of mexiletine be monitored and that mexiletine dosage be increased as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139833/", "reference_text": "[1] Begg EJ, Chinwah PM, Webb C, Day RO, Wade DN \"Enhanced metabolism of mexiletine after phenytoin administration.\" Br J Clin Pharmacol 14 (1982): 219-23[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Amiodarone, Dronedarone, Tocainide, Propafenone, Procainamide, Flecainide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 139673, "ingredient1": "Etravirine", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with etravirine may decrease the plasma concentrations of certain antiarrhythmic agents. The proposed mechanism is etravirine induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of antiarrhythmics such as amiodarone, bepridil, disopyramide, lidocaine, and quinidine.", "source": "DDInter", "management_text": "Caution is advised if etravirine is prescribed to patients receiving antiarrhythmic agents. Drug concentration monitoring is recommended, if available.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if etravirine is prescribed to patients receiving antiarrhythmic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139834/", "reference_text": "[1] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.[2] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[3] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71[6] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.", "alternatives_a": "Tocainide, Procainamide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 139674, "ingredient1": "Fedratinib", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139835/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation, Summit, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Lidocaine, Tocainide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 139675, "ingredient1": "Fluphenazine", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "The risk of seizures may be increased during coadministration of fluphenazine with any substance that can reduce the seizure threshold, such as aminophylline, antidepressants, antipsychotics, opioids, carbapenems, etc. These agents are often individually epileptogenic and may have additive effects when combined. Many of these agents also exhibit CNS- and/or respiratory-depressant effects, which may be enhanced during their concomitant use with fluphenazine.", "source": "DDInter", "management_text": "Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139836/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 139676, "ingredient1": "Fluvoxamine", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with fluvoxamine may increase the serum concentrations of mexiletine. The proposed mechanism is decreased clearance of mexiletine due to inhibition of the CYP450 1A2 and possibly 2D6 isoenzymes by fluvoxamine.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with fluvoxamine and mexiletine. Serum mexiletine levels and electrocardiographic readings should be monitored closely and the dosage adjusted accordingly, particularly following initiation or discontinuation of fluvoxamine in patients who are stabilized on their antiarrhythmic regimen.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with fluvoxamine and mexiletine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139837/", "reference_text": "[1] Kusumoto M, Ueno K, Oda A, Takeda K, Mashimo K, Takaya K, Fujimura Y, Nishihori T, Tanaka K \"Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.\" Clin Pharmacol Ther 69 (2001): 104-7[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Citalopram, Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Isocarboxazid, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "Tocainide, Procainamide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139677, "ingredient1": "Fosphenytoin", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Hydantoins may induce the hepatic metabolism of mexiletine. Plasma mexiletine levels and mexiletine effectiveness may be decreased.", "source": "DDInter", "management_text": "It is recommended that the antiarrhythmic effectiveness of mexiletine be monitored and that mexiletine dosage be increased as needed. Also, when hydantoin is withdrawn, the clinician should be aware of the risk of mexiletine toxicity.", "mechanism_text": "Metabolism", "recommendation": "It is recommended that the antiarrhythmic effectiveness of mexiletine be monitored and that mexiletine dosage be increased as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139838/", "reference_text": "[1] Begg EJ, Chinwah PM, Webb C, Day RO, Wade DN \"Enhanced metabolism of mexiletine after phenytoin administration.\" Br J Clin Pharmacol 14 (1982): 219-23[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Propafenone, Tocainide, Procainamide, Flecainide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 139678, "ingredient1": "Ginkgo biloba", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139839/", "reference_text": "[1] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002): 325-7[2] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001): 523-5[3] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[4] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001): 344[5] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006): 323-9[6] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001): 524-32[7] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001): 280-1[8] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005): 755-8", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine", "updated_at": 1767369485}, {"id": 139679, "ingredient1": "Givosiran", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with givosiran may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2 and/or CYP450 2D6. The proposed mechanism is decreased clearance due to givosiran-mediated inhibition of CYP450 1A2 and 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution and monitoring are recommended when givosiran is given with drugs that are substrates of CYP450 1A2 and/or 2D6. Concomitant use should generally be avoided with CYP450 1A2 or 2D6 substrates that have a narrow therapeutic range where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, the dosage of the CYP450 1A2 or 2D6 substrate should be reduced according to approved product labeling or clinical response and tolerance. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever givosiran is added to or withdrawn from therapy with these drugs.", "mechanism_text": "Metabolism", "recommendation": "Caution and monitoring are recommended when givosiran is given with drugs that are substrates of CYP450 1A2 and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139840/", "reference_text": "[1] \"Product Information. Givlaari (givosiran).\" Alnylam Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Tocainide, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139680, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates. The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139841/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc, South San Francisco, CA.", "alternatives_a": "Amiodarone, Dronedarone, Lidocaine, Tocainide, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139681, "ingredient1": "Golimumab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139842/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139682, "ingredient1": "Guselkumab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139843/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139683, "ingredient1": "Imatinib", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.", "source": "DDInter", "management_text": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139844/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tocainide, Procainamide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 139684, "ingredient1": "Infliximab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139845/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "alternatives_b": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139685, "ingredient1": "Iohexol", "ingredient2": "Mexiletine", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139846/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "Propafenone, Dronedarone, Tocainide, Flecainide, Bretylium, Moricizine", "alternatives_b": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "updated_at": 1767369485}, {"id": 139686, "ingredient1": "Mexiletine", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil). Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine). Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139847/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine)\" Organon, West Orange, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Moricizine", "alternatives_b": "Chloroprocaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "updated_at": 1767369485}, {"id": 139687, "ingredient1": "Mexiletine", "ingredient2": "Lindane", "severity": "Moderate", "effect": "Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).", "source": "DDInter", "management_text": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139848/", "reference_text": "[1] Cox R, Krupnick J, Bush N, Houpt A \"Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.\" J Miss State Med Assoc 41 (2000): 690-2[2] Matsuoka LY \"Convulsions following application of gamma benzene hexachloride.\" J Am Acad Dermatol 5 (1981): 98-9[3] \"Product Information. Kwell (lindane).\" Reed and Carnrick, Jersey City, NJ.[4] Telch J, Jarvis DA \"Acute intoxication with lindane (gamma benzene hexachloride).\" Can Med Assoc J 126 (1982): 662-3[5] Pramanik AK, Hansen RC \"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children.\" Arch Dermatol 115 (1979): 1224-5[6] Ramchander V, Cameron ES, Reid HF \"Lindane toxicity in an infant.\" West Indian Med J 40 (1991): 41-3[7] Tenenbein M \"Seizures after lindane therapy.\" J Am Geriatr Soc 39 (1991): 394-5[8] Solomon BA, Haut SR, Carr EM, Shalita AR \"Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem.\" J Fam Pract 40 (1995): 291-6[9] Munk ZM, Nantel A \"Acute lindane poisoning with development of muscle necrosis.\" Can Med Assoc J 117 (1977): 1050-4", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Disulfiram", "updated_at": 1767369485}, {"id": 139688, "ingredient1": "Mexiletine", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Hydantoins may induce the hepatic metabolism of mexiletine. Plasma mexiletine levels and mexiletine effectiveness may be decreased.", "source": "DDInter", "management_text": "It is recommended that the antiarrhythmic effectiveness of mexiletine be monitored and that mexiletine dosage be increased as needed. Also, when hydantoin is withdrawn, the clinician should be aware of the risk of mexiletine toxicity.", "mechanism_text": "Metabolism", "recommendation": "It is recommended that the antiarrhythmic effectiveness of mexiletine be monitored and that mexiletine dosage be increased as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139849/", "reference_text": "[1] Begg EJ, Chinwah PM, Webb C, Day RO, Wade DN \"Enhanced metabolism of mexiletine after phenytoin administration.\" Br J Clin Pharmacol 14 (1982): 219-23[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Amiodarone, Dronedarone, Tocainide, Propafenone, Procainamide, Flecainide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 139689, "ingredient1": "Mexiletine", "ingredient2": "Methionine", "severity": "Minor", "effect": "Agents that acidify the urine enhance the plasma clearance of mexiletine. The result may be decreased plasma mexiletine levels and decreased effectiveness. The clinical significance is unknown. It is recommended that such drugs or diet be discontinued or that mexiletine dosage increased as needed and tolerated.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139850/", "reference_text": "[1] Mitchell BG, Clements JA, Pottage A, Prescott LF \"Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.\" Br J Clin Pharmacol 16 (1983): 281-4", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139690, "ingredient1": "Mirabegron", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with mirabegron may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by mirabegron.", "source": "DDInter", "management_text": "Caution is advised if mirabegron must be used concomitantly with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mirabegron is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if mirabegron must be used concomitantly with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139851/", "reference_text": "[1] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Quinidine, Lidocaine, Tocainide, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Tadalafil, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 139691, "ingredient1": "Mirtazapine", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration of mirtazapine with drugs that inhibit one or more of its metabolic pathways may result in increased plasma concentrations of mirtazapine. In vitro data from human liver microsomes indicate that CYP450 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite, while CYP450 3A4 is primarily responsible for the formation of the N-desmethyl and N-oxide metabolites.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4. Therapeutic response to mirtazapine should be monitored more closely following initiation, discontinuation, or dosing change of CYP450 inhibitors, and the mirtazapine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139852/", "reference_text": "[1] Sitsen JM, Maris FA, Timmer CJ \"Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects.\" Eur J Clin Pharmacol 56 (2000): 389-94[2] \"Product Information. Remeron (mirtazapine).\" Organon, West Orange, NJ.[3] Stormer E, von Moltke LL, Shader RI, Greenblatt DJ \"Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4\" Drug Metab Dispos 28 (2000): 1168-75[4] Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H \"Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.\" Biochem Pharmacol 93 (2015): 104-9[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Citalopram, Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Isocarboxazid, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "Tocainide, Moricizine, Bretylium", "updated_at": 1767369485}, {"id": 139692, "ingredient1": "Nalidixic acid", "ingredient2": "Mexiletine", "severity": "Minor", "effect": "The coadministration of certain quinolone antibiotics and mexiletine may result in modestly elevated plasma concentrations of the latter. The proposed mechanism is inhibition of CYP450 1A2 hepatic metabolism of mexiletine. The clinical significance is unknown. Discontinuation or change of dosage may be necessary if an interaction is suspected.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139853/", "reference_text": "[1] McLellan RA, Drobitch RK, Monshouwer M, Renton KW \"Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human.\" Drug Metab Dispos 24 (1996): 1134-8[2] Labbe L, Lefez C, Gilbert M, O'Hara G, Turgeon J \"Ciprofloxacin (CIPRO) decreases mexiletine (MEX) clearance in smokers and non-smokers.\" Clin Pharmacol Ther 57 (1995): 210", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Flecainide, Disopyramide, Dofetilide, Bretylium, More", "alternatives_b": "Gatifloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Grepafloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "updated_at": 1767369485}, {"id": 139693, "ingredient1": "Nilotinib", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter and/or CYP450 2D6, CYP450 3A4, or UGT1A1 isoenzymes. The mechanism is decreased clearance via these routes due to inhibition by nilotinib.", "source": "DDInter", "management_text": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nilotinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139854/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Pexidartinib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 139694, "ingredient1": "Norfloxacin", "ingredient2": "Mexiletine", "severity": "Minor", "effect": "The coadministration of certain quinolone antibiotics and mexiletine may result in modestly elevated plasma concentrations of the latter. The proposed mechanism is inhibition of CYP450 1A2 hepatic metabolism of mexiletine. The clinical significance is unknown. Discontinuation or change of dosage may be necessary if an interaction is suspected.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139855/", "reference_text": "[1] McLellan RA, Drobitch RK, Monshouwer M, Renton KW \"Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human.\" Drug Metab Dispos 24 (1996): 1134-8[2] Labbe L, Lefez C, Gilbert M, O'Hara G, Turgeon J \"Ciprofloxacin (CIPRO) decreases mexiletine (MEX) clearance in smokers and non-smokers.\" Clin Pharmacol Ther 57 (1995): 210", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Gatifloxacin, More", "updated_at": 1767369485}, {"id": 139695, "ingredient1": "Octreotide", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Somatostatin analogs (e.g., octreotide, lanreotide) can decrease heart rate and may potentiate the bradycardic effects of drugs like beta-blockers, calcium channel blockers, digitalis glycosides, and certain antiarrhythmic agents (e.g., class I antiarrhythmics, adenosine, amiodarone).", "source": "DDInter", "management_text": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers. Heart rate and blood pressure should be monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139856/", "reference_text": "[1] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[3] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[5] Katz MD, Erstad BL \"Octreotide, a new somatostatin analogue.\" Clin Pharm 8 (1989): 255-73[6] Ho PJ, Boyajy LD, Greenstein E, Barkan AL \"Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.\" Dig Dis Sci 38 (1993): 309-15[7] Landgraf R, Landgraf-Leurs MM, Nusser J, et al \"Effect of somatostatin analogue (SMS201-995) on cyclosporine levels.\" Transplantation 44 (1987): 724-5", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Bretylium, Ibutilide", "updated_at": 1767369485}, {"id": 139696, "ingredient1": "Ofloxacin", "ingredient2": "Mexiletine", "severity": "Minor", "effect": "The coadministration of certain quinolone antibiotics and mexiletine may result in modestly elevated plasma concentrations of the latter. The proposed mechanism is inhibition of CYP450 1A2 hepatic metabolism of mexiletine. The clinical significance is unknown. Discontinuation or change of dosage may be necessary if an interaction is suspected.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139857/", "reference_text": "[1] McLellan RA, Drobitch RK, Monshouwer M, Renton KW \"Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human.\" Drug Metab Dispos 24 (1996): 1134-8[2] Labbe L, Lefez C, Gilbert M, O'Hara G, Turgeon J \"Ciprofloxacin (CIPRO) decreases mexiletine (MEX) clearance in smokers and non-smokers.\" Clin Pharmacol Ther 57 (1995): 210", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Gatifloxacin, Levofloxacin, Gemifloxacin, Lomefloxacin, Grepafloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin, Tinidazole, More", "updated_at": 1767369485}, {"id": 139697, "ingredient1": "Oxtriphylline", "ingredient2": "Mexiletine", "severity": "Major", "effect": "Coadministration with mexiletine may increase the serum concentrations of theophylline. The proposed mechanism is inhibition of the CYP450 1A2-mediated metabolism of theophylline by mexiletine.", "source": "DDInter", "management_text": "Caution is advised when theophylline is used with mexiletine. Close monitoring of serum theophylline levels is recommended, particularly following the addition, discontinuation or change of dosage of mexiletine, and the theophylline dosage adjusted accordingly. Patients should be advised to notify their physician if they experience signs of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, palpitations, and cardiac arrhythmia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when theophylline is used with mexiletine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139858/", "reference_text": "[1] Ueno K, Miyai K, Kato M, et al \"Mechanism of interaction between theophylline and mexiletine.\" DICP 25 (1991): 727-30[2] Katz A, Buskila D, Sukenik S \"Oral mexiletine-theophylline interaction.\" Int J Cardiol 17 (1987): 227-8[3] Stoysich AM, Mohiuddin SM, Destache CJ, et al \"Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers.\" J Clin Pharmacol 31 (1991): 354-7[4] Stanley R, Comer T, Taylor JL, Saliba D \"Mexiletine-theophylline interaction.\" Am J Med 86 (1989): 733-4[5] Kessler KM, Interian A, Cox M, et al \"Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline.\" Am Heart J 117 (1989): 964-6[6] Ueno K, Miyai K, Seki T, Kawaguchi Y \"Interaction between theophylline and mexiletine.\" DICP 24 (1990): 471-2[7] Hurwitz A, Vacek JL, Botteron GW, et al \"Mexiletine effects on theophylline disposition.\" Clin Pharmacol Ther 50 (1991): 299-307[8] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[9] Loi CM, Wei X, Vestal RE \"Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers.\" Clin Pharmacol Ther 49 (1991): 571-80", "alternatives_a": "Quinidine, Lidocaine, Dronedarone, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Ibutilide", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 139698, "ingredient1": "Panobinostat", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with panobinostat may increase the plasma concentrations of drugs that are substrates of CYP450 2D6. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by panobinostat.", "source": "DDInter", "management_text": "Given the high interpatient variability with respect to magnitude of interaction, concomitant use of panobinostat with sensitive CYP450 2D6 substrates (e.g., atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine) or CYP450 2D6 substrates that have a narrow therapeutic index (e.g., pimozide, thioridazine) should generally be avoided. Caution is advised when panobinostat is used with other drugs that are metabolized by CYP450 2D6.", "mechanism_text": "Metabolism", "recommendation": "Given the high interpatient variability with respect to magnitude of interaction, concomitant use of panobinostat with sensitive CYP450 2D6 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139859/", "reference_text": "[1] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 139699, "ingredient1": "Paroxetine", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with certain selective serotonin reuptake inhibitors (SSRIs) may increase the plasma concentrations of antiarrhythmic agents that are metabolized by CYP450 2D6 such as encainide, flecainide, mexiletine, and propafenone. The mechanism is decreased drug clearance due to inhibition of the isoenzyme by some SSRIs. The interaction has been studied specifically with fluoxetine and propafenone.", "source": "DDInter", "management_text": "Caution is advised if certain SSRIs, particularly fluoxetine or paroxetine, must be used concomitantly with antiarrhythmic agents that are metabolized by CYP450 2D6. Lower initial dosages of the antiarrhythmic agent may be appropriate. Patients who are already stabilized on their antiarrhythmic regimen should be monitored for altered effects on myocardial conduction following addition or discontinuation of SSRI therapy (up to 2 weeks for most SSRIs and 5 weeks for fluoxetine due to its long half-life), and the antiarrhythmic dosage adjusted if necessary. Alternatively, an antidepressant that does not interfere with 2D6 metabolism may be considered, such as citalopram, escitalopram, or venlafaxine.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if certain SSRIs, particularly fluoxetine or paroxetine, must be used concomitantly with antiarrhythmic agents that are metabolized by CYP450 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139860/", "reference_text": "[1] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cai WM, Chen B, Zhou Y, Zhang YD \"Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.\" Clin Pharmacol Ther 66 (1999): 516-21[3] Hemeryck A, DeVriendt C, Belpaire FM \"Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: In vitro studies using human liver microsomes.\" J Clin Psychopharmacol 20 (2000): 428-34[4] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[5] Alfaro CL, Lam YWF, Simpson J, Ereshefsky L \"CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.\" J Clin Psychopharmacol 19 (1999): 155-63[6] Kusumoto M, Ueno K, Oda A, Takeda K, Mashimo K, Takaya K, Fujimura Y, Nishihori T, Tanaka K \"Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.\" Clin Pharmacol Ther 69 (2001): 104-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tocainide, Procainamide, Disopyramide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Citalopram, Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Isocarboxazid, Amoxapine, Imipramine, Esketamine, More", "updated_at": 1767369485}, {"id": 139700, "ingredient1": "Pentoxifylline", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of pentoxifylline and its active hydroxy metabolite (M1), both of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to pentoxifylline should be monitored more closely whenever a potent or moderate CYP450 1A2 inhibitor is added to or withdrawn from therapy, and the pentoxifylline dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience serious adverse effects such as bleeding, angina, or arrhythmias.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to pentoxifylline should be monitored more closely whenever a potent or moderate CYP450 1A2 inhibitor is added to or withdrawn from therapy, and the pentoxifylline dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139861/", "reference_text": "[1] \"Product Information. Trental (pentoxifylline).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P \"A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans.\" Br J Clin Pharmacol 61 (2006): 138-47", "alternatives_a": "Lidocaine, Dronedarone, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Niacin, Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, More", "updated_at": 1767369485}, {"id": 139701, "ingredient1": "Phenytoin", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Hydantoins may induce the hepatic metabolism of mexiletine. Plasma mexiletine levels and mexiletine effectiveness may be decreased.", "source": "DDInter", "management_text": "It is recommended that the antiarrhythmic effectiveness of mexiletine be monitored and that mexiletine dosage be increased as needed. Also, when hydantoin is withdrawn, the clinician should be aware of the risk of mexiletine toxicity.", "mechanism_text": "Metabolism", "recommendation": "It is recommended that the antiarrhythmic effectiveness of mexiletine be monitored and that mexiletine dosage be increased as needed.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139862/", "reference_text": "[1] Begg EJ, Chinwah PM, Webb C, Day RO, Wade DN \"Enhanced metabolism of mexiletine after phenytoin administration.\" Br J Clin Pharmacol 14 (1982): 219-23[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, Paramethadione, More", "alternatives_b": "Propafenone, Tocainide, Procainamide, Flecainide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139702, "ingredient1": "Pirfenidone", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of pirfenidone, which is primarily (70% to 80%) metabolized by the isoenzyme. Other CYP450 isoenzymes also contribute to a minor extent, including CYP450 2C9, 2C19, 2D6, and 2E1. Concomitant inhibition of one or more of these isoenzymes in addition to CYP450 1A2 is expected to further increase the magnitude of interaction.", "source": "DDInter", "management_text": "Caution is advised when pirfenidone is used concomitantly with CYP450 1A2 inhibitors. Patients should be closely monitored for adverse reactions such as hepatotoxicity, photosensitivity, rash, nausea, diarrhea, vomiting and dyspepsia, and consideration be given to dosage reduction, brief interruption, or permanent discontinuation of pirfenidone if clinically necessary in accordance with the product labeling. Coadministration of pirfenidone with CYP450 1A2 inhibitors in addition to inhibitors of other CYP450 isoenzymes involved in the metabolism of pirfenidone should be avoided, including significant inhibitors of CYP450 2C9 (e.g., amiodarone, fluconazole, imatinib, gemfibrozil, miconazole), 2C19 (e.g., chloramphenicol, cimetidine, esomeprazole, fluconazole, lansoprazole, omeprazole), and/or 2D6 (e.g., bupropion, cinacalcet, fluoxetine, paroxetine, quinidine, terbinafine).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pirfenidone is used concomitantly with CYP450 1A2 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139863/", "reference_text": "[1] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139703, "ingredient1": "Monopotassium phosphate", "ingredient2": "Mexiletine", "severity": "Minor", "effect": "Agents that acidify the urine enhance the plasma clearance of mexiletine. The result may be decreased plasma mexiletine levels and decreased effectiveness. The clinical significance is unknown. It is recommended that such drugs or diet be discontinued or that mexiletine dosage increased as needed and tolerated.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139864/", "reference_text": "[1] Mitchell BG, Clements JA, Pottage A, Prescott LF \"Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.\" Br J Clin Pharmacol 16 (1983): 281-4", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139704, "ingredient1": "Pramipexole", "ingredient2": "Mexiletine", "severity": "Minor", "effect": "Drugs that are secreted by the renal tubules via the cationic transport system may decrease the oral clearance of pramipexole by approximately 20%. The mechanism is competitive inhibition of tubular secretion of pramipexole. This interaction is not likely to be of clinical importance, although it may be prudent to monitor the patient for increased adverse effects due to pramipexole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139865/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Mirapex (pramipexole).\" Boehringer Ingelheim, Ridgefield, CT.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Amiodarone, Dronedarone, Tocainide, Propafenone, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Apomorphine, Opicapone, Cabergoline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 139705, "ingredient1": "Quinidine", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Quinidine may reduce the hepatic metabolism of mexiletine in extensive debrisoquine metabolizers. The mechanism is inhibition of CYP450 2D6. Serum mexiletine levels and risk of toxicity may be increased. The pharmacologic properties of these drugs may be additive and even though the concurrent use of quinidine and mexiletine has been beneficial in some patients, the risk of proarrhythmic effects may be increased.", "source": "DDInter", "management_text": "The patient should be monitored for clinical, laboratory, and electrocardiographic signs and symptoms of mexiletine toxicity after quinidine has been added to the regimen. Patients should be advised to notify their physician if they experience nausea, vomiting, dizziness, drowsiness, blurry vision, increased irregular heartbeat, numbness or tingling, seizures, or syncope.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The patient should be monitored for clinical, laboratory, and electrocardiographic signs and symptoms of mexiletine toxicity after quinidine has been added to the regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139866/", "reference_text": "[1] Duff HJ, Rahmberg M, Sheldon RS \"Role of quinidine in the mexiletine-quinidine interaction: Electrophysiologic correlates of enhanced antiarrhythmic efficiency.\" J Cardiovasc Pharmacol 16 (1990): 685-92[2] Duff HJ, Kolodgie FD, Roden DM, Woosley RL \"Electropharmacologic synergism with mexiletine and quinidine.\" J Cardiovasc Pharmacol 8 (1986): 840-6[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Quinidine, Tocainide, Moricizine, Bretylium", "alternatives_b": "Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139706, "ingredient1": "Ramelteon", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations and pharmacologic effects of ramelteon, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when ramelteon is used with CYP450 1A2 inhibitors. A reduction in the ramelteon dosage may be necessary in patients who experience excessive sedation or other adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ramelteon is used with CYP450 1A2 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139867/", "reference_text": "[1] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.", "alternatives_a": "Quinidine, Lidocaine, Dronedarone, Tocainide, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "updated_at": 1767369485}, {"id": 139707, "ingredient1": "Ranolazine", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with ranolazine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. Ranolazine has been shown in vitro to be an inhibitor of CYP450 2D6. However, concomitant use of ranolazine with other drugs that are metabolized by CYP450 2D6 such as tricyclic antidepressants and antipsychotics has not been studied.", "source": "DDInter", "management_text": "Caution is advised if ranolazine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ranolazine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ranolazine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139868/", "reference_text": "[1] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[2] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Lidocaine, Moricizine, Bretylium, Tocainide", "updated_at": 1767369485}, {"id": 139708, "ingredient1": "Rasagiline", "ingredient2": "Mexiletine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of rasagiline, which is primarily metabolized by the isoenzyme. Because the MAO-B selectivity of rasagiline may diminish with increasing dosage above the recommended range of 0.5 to 1 mg/day, there may be an increased risk of hypertensive crisis and other adverse reactions associated with nonselective inhibition of MAO if the maximum dosage is used in the presence of ciprofloxacin or other CYP450 1A2 inhibitors.", "source": "DDInter", "management_text": "Rasagiline should be prescribed at a maximum dosage of 0.5 mg/day during coadministration with moderate or potent CYP450 1A2 inhibitors. Patients should be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, confusion, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms.", "mechanism_text": "Metabolism", "recommendation": "Rasagiline should be prescribed at a maximum dosage of 0.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139869/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[4] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[5] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[6] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[7] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[8] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[9] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[10] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[11] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[12] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[13] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[14] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8", "alternatives_a": "Quinidine, Lidocaine, Dronedarone, Tocainide, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Apomorphine, Opicapone, Cabergoline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 139709, "ingredient1": "Rifampicin", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Rifampin may decrease the plasma concentrations of mexiletine by inducing its CYP450 hepatic metabolism.", "source": "DDInter", "management_text": "Patients receiving both drugs should be monitored for inadequate response to mexiletine. Mexiletine dosage should be increased as necessary.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving both drugs should be monitored for inadequate response to mexiletine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139870/", "reference_text": "[1] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[2] Pentikainen PJ, Koivula IH, Hiltunen HA \"Effect of rifampicin treatment on the kinetics of mexiletine.\" Eur J Clin Pharmacol 23 (1982): 261-6", "alternatives_a": "Procainamide, Flecainide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, More", "updated_at": 1767369485}, {"id": 139710, "ingredient1": "Rilonacept", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139871/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139711, "ingredient1": "Roflumilast", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with CYP450 1A2 inhibitors or dual CYP450 1A2/3A4 inhibitors may increase the systemic exposure to roflumilast and its pharmacologically active N-oxide metabolite.", "source": "DDInter", "management_text": "Treatment with roflumilast should be re-evaluated if an interaction is suspected and persistent intolerability occurs. Patients should be advised to contact their physician if they experience increased frequency and/or severity of side effects such as diarrhea, nausea, abdominal pain, weight loss, and headache.", "mechanism_text": "Metabolism", "recommendation": "Treatment with roflumilast should be re-evaluated if an interaction is suspected and persistent intolerability occurs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139872/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[3] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[6] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Quinidine, Lidocaine, Dronedarone, Tocainide, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 139712, "ingredient1": "Rolapitant", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. Rolapitant is a moderate CYP450 2D6 inhibitor, with inhibitory effect lasting at least 7 days after a single dose.", "source": "DDInter", "management_text": "Caution is advised when rolapitant is prescribed with drugs that are significantly metabolized by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when rolapitant is prescribed with drugs that are significantly metabolized by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139873/", "reference_text": "[1] \"Product Information. Varubi (rolapitant).\" Tesaro Inc., Waltham, MA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Amiodarone, Dronedarone, Lidocaine, Tocainide, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Nabilone, Granisetron, Scopolamine, Dronabinol, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "updated_at": 1767369485}, {"id": 139713, "ingredient1": "Ropivacaine", "ingredient2": "Mexiletine", "severity": "Minor", "effect": "Ropivacaine serum concentrations may increase when given with drugs metabolized by the cytochrome P-450 isoenzyme 1A2. The theorized mechanism is via competitive inhibition. Information is only available from in vitro studies. Theophylline and mexiletine, drugs metabolized by CYP450 1A2, may participate in this interaction.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139874/", "reference_text": "[1] \"Product Information. Naropin (ropivacaine).\" Astra USA, Westborough, MA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Chloroprocaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Quinidine, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Moricizine", "updated_at": 1767369485}, {"id": 139714, "ingredient1": "Sarilumab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139875/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139715, "ingredient1": "Satralizumab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139876/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139716, "ingredient1": "Secukinumab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139877/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139717, "ingredient1": "Sertraline", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with certain selective serotonin reuptake inhibitors (SSRIs) may increase the plasma concentrations of antiarrhythmic agents that are metabolized by CYP450 2D6 such as encainide, flecainide, mexiletine, and propafenone. The mechanism is decreased drug clearance due to inhibition of the isoenzyme by some SSRIs. The interaction has been studied specifically with fluoxetine and propafenone.", "source": "DDInter", "management_text": "Caution is advised if certain SSRIs, particularly fluoxetine or paroxetine, must be used concomitantly with antiarrhythmic agents that are metabolized by CYP450 2D6. Lower initial dosages of the antiarrhythmic agent may be appropriate. Patients who are already stabilized on their antiarrhythmic regimen should be monitored for altered effects on myocardial conduction following addition or discontinuation of SSRI therapy (up to 2 weeks for most SSRIs and 5 weeks for fluoxetine due to its long half-life), and the antiarrhythmic dosage adjusted if necessary. Alternatively, an antidepressant that does not interfere with 2D6 metabolism may be considered, such as citalopram, escitalopram, or venlafaxine.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if certain SSRIs, particularly fluoxetine or paroxetine, must be used concomitantly with antiarrhythmic agents that are metabolized by CYP450 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139878/", "reference_text": "[1] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Cai WM, Chen B, Zhou Y, Zhang YD \"Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.\" Clin Pharmacol Ther 66 (1999): 516-21[3] Hemeryck A, DeVriendt C, Belpaire FM \"Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: In vitro studies using human liver microsomes.\" J Clin Psychopharmacol 20 (2000): 428-34[4] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[5] Alfaro CL, Lam YWF, Simpson J, Ereshefsky L \"CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.\" J Clin Psychopharmacol 19 (1999): 155-63[6] Kusumoto M, Ueno K, Oda A, Takeda K, Mashimo K, Takaya K, Fujimura Y, Nishihori T, Tanaka K \"Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.\" Clin Pharmacol Ther 69 (2001): 104-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Citalopram, Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Isocarboxazid, Amoxapine, Imipramine, Esketamine, More", "updated_at": 1767369485}, {"id": 139718, "ingredient1": "Siltuximab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139879/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139719, "ingredient1": "Simeprevir", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with simeprevir may increase the plasma concentrations of certain antiarrhythmic agents that are metabolized by CYP450 1A2 or 3A4 such as amiodarone, disopyramide, flecainide, mexiletine, propafenone, and quinidine. In vivo, simeprevir mildly inhibits CYP450 1A2 and intestinal CYP450 3A4, but does not affect hepatic CYP450 3A4 activity. Serious and/or life-threatening reactions including cardiac arrhythmias like torsade de pointes may occur if antiarrhythmic drug levels are significantly increased.", "source": "DDInter", "management_text": "Caution is advised if simeprevir is prescribed in combination with antiarrhythmic agents that are metabolized by CYP450 1A2 or 3A4. Pharmacologic response and plasma antiarrhythmic drug levels should be monitored more closely whenever simeprevir is added to or withdrawn from therapy, and the antiarrhythmic dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if simeprevir is prescribed in combination with antiarrhythmic agents that are metabolized by CYP450 1A2 or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139880/", "reference_text": "[1] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[3] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71[6] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Lidocaine, Dronedarone, Tocainide, Procainamide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Tamsulosin, Tinidazole, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 139720, "ingredient1": "Stiripentol", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2, 2C19, and/or 3A4 may increase the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways.", "source": "DDInter", "management_text": "Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors. Patients should be monitored for potentially increased adverse effects such as anorexia, nausea, vomiting, weight loss, somnolence, dizziness, confusion, difficulty concentrating, ataxia, hypotonia, tremor, hyperkinesia, dysarthria, suicidal ideation/behaviour, neutropenia, and thrombocytopenia. Dosage adjustments for stiripentol or alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139881/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[7] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Tocainide, Procainamide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 139721, "ingredient1": "Tasimelteon", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4. Patients should be monitored for excessive sedation and other side effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139882/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Quinidine, Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "updated_at": 1767369485}, {"id": 139722, "ingredient1": "Terbinafine", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with terbinafine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by terbinafine, which is expected to occur in patients who are CYP450 2D6 extensive metabolizers (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "Caution is advised if terbinafine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever terbinafine is added to or withdrawn from therapy. Due to the long elimination half-life of terbinafine, especially following prolonged use, such interactions may be observed for several months after discontinuation of terbinafine therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if terbinafine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139883/", "reference_text": "[1] Van der Kuy PH, Hooymans PM, Verkaaik AJ \"Nortriptyline intoxication induced by terbinafine.\" BMJ 316 (1998): 441[2] \"Product Information. Lamisil (terbinafine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL \"Investigation of terbinafine as a CYP2D6 inhibitor in vivo.\" Clin Pharmacol Ther 65 (1999): 465-72[4] Gupta AK, Katz HI, Shear NH \"Terbinafine and potential drug interactions - Reply.\" J Am Acad Dermatol 43 (2000): 883-4[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tocainide, Dronedarone, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Econazole, Flucytosine, Tioconazole, More", "updated_at": 1767369485}, {"id": 139723, "ingredient1": "Tizanidine", "ingredient2": "Mexiletine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 1A2 may significantly increase the plasma concentrations and pharmacologic effects of tizanidine, which is a sensitive substrate of the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of tizanidine with CYP450 1A2 inhibitors should generally be avoided. Otherwise, caution is advised if coadministration is required. Dosage adjustments may be necessary in patients who experience excessive adverse effects of tizanidine such as drowsiness, dizziness, lightheadedness, hypotension, and bradycardia.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of tizanidine with CYP450 1A2 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139884/", "reference_text": "[1] Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ \"Fluvoxamine drastically increases concentrations and effects of tizanidine: A potentially hazardous interaction.\" Clin Pharmacol Ther 75 (2004): 331-41[2] \"Product Information. Vioxx (rofecoxib).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.[4] Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ \"Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.\" Clin Pharmacol Ther 76 (2004): 598-606[5] Momo K, Doki K, Hosono H, Homma M, Kohda Y \"Drug interaction of tizanidine and fluvoxamine.\" Clin Pharmacol Ther 76 (2004): 509-10[6] Momo K, Homma M, Kohda Y, Ohkoshi N, Yoshizawa T, Tamaoka A \"Drug interaction of tizanidine and ciprofloxacin: Case report.\" Clin Pharmacol Ther 80 (2006): 717-9[7] Granfors MT, Backman JT, Laitila J, Neuvonen PJ \"Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro.\" Br J Clin Pharmacol 57 (2004): 349-53[8] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Orphenadrine, Chlorzoxazone, Baclofen, Cyclobenzaprine, Methocarbamol, Chlormezanone", "updated_at": 1767369485}, {"id": 139724, "ingredient1": "Tocilizumab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139885/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139725, "ingredient1": "Tofacitinib", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Tofacitinib has been shown to decrease heart rate and prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta-blockers, digoxin, alpha-2 adrenoceptor agonists) may result in elevated risk of conduction disturbances and atrioventricular block.", "source": "DDInter", "management_text": "According to the manufacturer, concomitant use of tofacitinib with other agents that lower heart rate and/or prolong the PR interval should be avoided when possible. Caution is advised if concomitant use is necessary, particularly in patients with known conduction problems or severe cardiac disease. An ECG should be considered in these patients before initiating concomitant therapy and after titration to steady-state. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeats.", "mechanism_text": "Synergism", "recommendation": "According to the manufacturer, concomitant use of tofacitinib with other agents that lower heart rate and/or prolong the PR interval should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139886/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139726, "ingredient1": "Ustekinumab", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139887/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, More", "updated_at": 1767369485}, {"id": 139727, "ingredient1": "Vemurafenib", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with vemurafenib may increase the plasma concentrations of drugs that are substrates of the CYP450 1A2 and/or 2D6 isoenzymes. The mechanism is decreased clearance due to inhibition of CYP450 1A2 and 2D6 activity by vemurafenib. The interaction has been studied with caffeine and dextromethorphan, probe substrates for CYP450 1A2 and 2D6, respectively.", "source": "DDInter", "management_text": "Caution is advised if vemurafenib must be used concurrently with drugs that undergo metabolism by CYP450 1A2 and/or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever vemurafenib is added to or withdrawn from therapy. Concomitant use of vemurafenib and substrates of CYP450 1A2 and/or 2D6 with a narrow therapeutic index (e.g., antiarrhythmics; theophylline) should be avoided if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if vemurafenib must be used concurrently with drugs that undergo metabolism by CYP450 1A2 and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139888/", "reference_text": "[1] \"Product Information. Zelboraf (vemurafenib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Tamsulosin, Tinidazole, Hydroflumethiazide, Chlorothiazide, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 139728, "ingredient1": "Zolmitriptan", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of zolmitriptan, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "It is recommended that not more than 5 mg of zolmitriptan be taken in a 24-hour period during concomitant use with CYP450 1A2 inhibitors. Patients should be advised to notify their doctor promptly if they experience increased sedation, dizziness, paraesthesia, chest pain or tightness, shortness of breath, and/or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "It is recommended that not more than 5 mg of zolmitriptan be taken in a 24-hour period during concomitant use with CYP450 1A2 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139889/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, More", "alternatives_b": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 139729, "ingredient1": "Acetohexamide", "ingredient2": "Miconazole", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the plasma concentrations of sulfonylureas, many of which have been found to be substrates of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9. Blood glucose should be closely monitored, and the sulfonylurea dosage adjusted as necessary. Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the azole antifungal agent, and contact their physician.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139890/", "reference_text": "[1] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[2] \"Product Information. Monistat (miconazole).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[3] Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG \"Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.\" Pharmacogenomics 10 (2009): 1781-7[4] Jeong S, Nguyen PD, Desta Z \"Comprehensive in vitro inhibition analysis of eight cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A.\" Antimicrob Agents Chemother 53 (2009): 541-51[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[8] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998): 525-38[9] Rowe BR, Thorpe J, Barnett A \"Safety of fluconazole in women taking oral hypoglycaemic agents.\" Lancet 339 (1992): 255-6[10] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[11] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[12] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[13] Shon JH, Yoon YR, Kim MJ, et al. \"Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.\" Br J Clin Pharmacol 59 (2005): 552-63[14] Venkatakrishnan K, von Moltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.\" Clin Pharmacokinet 38 (2000): 111-80[15] Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT \"Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.\" Clin Pharmacol Ther 72 (2002): 326-32[16] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[17] Tirkkonen T, Heikkila P, Huupponen R, Laine K \"Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.\" J Intern Med 268 (2010): 359-66[18] Shobha JC, Muppidi MR \"Interaction between voriconazole and glimepiride.\" J Postgrad Med 56 (2010): 44-5[19] Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.\" Drug Metab Disposition 28 (2000): 475-81[20] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[21] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[22] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[23] Holstein A, Plaschke A, Ptak M, et al. \"Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.\" Br J Clin Pharmacol 60 (2005): 103-6[24] Back DJ, Tjia JF, Karbwang J, Colbert J \"In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones.\" Br J Clin Pharmacol 26 (1988): 23-9[25] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[27] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[28] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[31] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[32] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[35] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139730, "ingredient1": "Amphotericin B (cholesteryl sulfate)", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Imidazole and triazole antifungal agents may antagonize the effects of amphotericin. The clinical significance is unknown. Caution is urged if combination therapy is necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139891/", "reference_text": "[1] \"Product Information. Fungizone (amphotericin B).\" Apothecon Inc, Plainsboro, NJ.[2] Saag MS, Powderly WG, Cloud GA, et al \"Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis.\" N Engl J Med 326 (1992): 83-9[3] \"Product Information. Ambisome (amphotericin B liposomal)\" Nexstar Pharmaceuticals, San Dimas, CA.[4] \"Product Information. Abelcet (amphotericin B).\" Liposome Company Inc, The, Princeton, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, More", "alternatives_b": "Rifamycin, Amphotericin B, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Caspofungin, Anidulafungin, Amphotericin B, Oteseconazole, Salicylic acid, More", "updated_at": 1767369485}, {"id": 139731, "ingredient1": "Amphotericin B (liposomal)", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Imidazole and triazole antifungal agents may antagonize the effects of amphotericin. The clinical significance is unknown. Caution is urged if combination therapy is necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139892/", "reference_text": "[1] \"Product Information. Fungizone (amphotericin B).\" Apothecon Inc, Plainsboro, NJ.[2] Saag MS, Powderly WG, Cloud GA, et al \"Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis.\" N Engl J Med 326 (1992): 83-9[3] \"Product Information. Ambisome (amphotericin B liposomal)\" Nexstar Pharmaceuticals, San Dimas, CA.[4] \"Product Information. Abelcet (amphotericin B).\" Liposome Company Inc, The, Princeton, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, More", "alternatives_b": "Rifamycin, Amphotericin B, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Caspofungin, Anidulafungin, Amphotericin B, Oteseconazole, Salicylic acid, More", "updated_at": 1767369485}, {"id": 139732, "ingredient1": "Amprenavir", "ingredient2": "Miconazole", "severity": "Minor", "effect": "The coadministration with drugs that are inhibitors of the CYP450 3A4 enzymatic pathway may increase the plasma concentrations of amprenavir, which is metabolized by CYP450 3A4. The possibility of prolonged and/or increased pharmacologic effects of amprenavir should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, or a rash.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139893/", "reference_text": "[1] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[2] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[3] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139733, "ingredient1": "Anisindione", "ingredient2": "Miconazole", "severity": "Major", "effect": "Systemically or even topically administered miconazole may increase the plasma concentrations and hypoprothrombinemic effect of warfarin. The proposed mechanism is miconazole inhibition of CYP450 2C9, the isoenzyme responsible for the metabolic clearance of the more active S(-) enantiomer of warfarin.", "source": "DDInter", "management_text": "Patients receiving warfarin or other oral anticoagulants should be closely monitored during concomitant therapy with miconazole. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of miconazole therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Some authorities consider the use of oral miconazole with warfarin to be contraindicated. Although vaginally administered miconazole is generally less than 2% absorbed in healthy women of childbearing age, increased absorption may occur in the presence of atrophic vaginal epithelium. Therefore, the same precaution is applicable when vaginal formulations of miconazole is prescribed to women receiving oral anticoagulant therapy.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving warfarin or other oral anticoagulants should be closely monitored during concomitant therapy with miconazole.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139894/", "reference_text": "[1] Colquhoun MC, Daly M, Stewart P, Beeley L \"Interaction between warfarin and miconazole oral gel.\" Lancet 1 (1987): 695-6[2] Shenfield GM, Page M \"Potentiation of warfarin action by miconazole oral gel.\" Aust N Z J Med 21 (1991): 928[3] Watson PG, Lochan RG, Redding VJ \"Drug interaction with coumarin derivative anticoagulants.\" Br Med J 285 (1982): 1045-6[4] Gutierrez MA, Olalla I, Muruzabal MJ, Ortiz M, Peralta FG \"Miconazole oral gel enhances acenocoumarol anticoagulant activity. Report of three cases.\" Eur J Clin Pharmacol 52(Suppl) (1997): A132[5] Evans J, Orme DS, Sedgwick ML, Youngs GR \"Treating oral candidiasis: potentially fatal.\" Br Dent J 182 (1997): 452[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Ortin M, Olalla JI, Muruzabal MJ, Peralta FG, Gutierrez MA \"Miconazole oral gel enhances acenocoumarol anticoagulant activity: A report of three cases.\" Ann Pharmacother 33 (1999): 175-7[8] Visser LE, Penning-Van Beest FJ, Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.\" Clin Pharmacol Ther 71 (2002): 496-502[9] Marco M \"Retroperitoneal haematoma and small bowel intramural haematoma caused by warfarin and miconazole interaction.\" Int J Oral Maxillofac Surg 27 (1998): 485[10] Ariyaratnam S, Thakker NS, Sloan P, Thornhill MH \"Potentiation of warfarin anticoagulant activity by miconazole oral gel.\" BMJ 314 (1997): 349[11] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[12] Pemberton MN, Sloan P, Ariyaratnam S, Thakker NS, Thornhill MH \"Derangement of warfarin anticoagulation by miconazole oral gel.\" Br Dent J 184 (1998): 68-9[13] Thirion DJ, Farquhar Zannetti LA \"Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories.\" Pharmacotherapy 20 (2000): 98-9[14] Pemberton M, Sloan P, Ariyaratnam S, Thakker NS, Thornhill MH \"Treating oral candidiasis: potentially fatal.\" Br Dent J 183 (1997): 87[15] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[16] O'Reilly RA, Goulart DA, Kunze KL, et al \"Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects.\" Clin Pharmacol Ther 51 (1992): 656-67[17] Devaraj A, O'Beirne JP, Veasey R, Dunk AA \"Interaction between warfarin and topical miconazole cream.\" BMJ 325 (2002): 77[18] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[19] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[20] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[21] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[22] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[23] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[24] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[25] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[26] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[27] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[28] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[29] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[30] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[31] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[34] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[35] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[36] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[37] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[38] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[39] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[40] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[41] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[42] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[43] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[48] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[49] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[50] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[51] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[52] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[53] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[54] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Paromomycin, Caspofungin, Micafungin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139734, "ingredient1": "Astemizole", "ingredient2": "Miconazole", "severity": "Major", "effect": "Coadministration with azole antifungal agents may significantly increase the plasma concentrations of astemizole. The proposed mechanism is azole inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of astemizole. High plasma levels of astemizole have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia and torsade de pointes; cardiac arrest; and sudden death.", "source": "DDInter", "management_text": "The use of astemizole with most azole antifungal agents is considered contraindicated. Some authorities consider concomitant administration of astemizole and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole (AU). Loratadine, cetirizine, or fexofenadine may be safer alternatives during therapy with azole antifungal agents.", "mechanism_text": "Metabolism", "recommendation": "The use of astemizole with most azole antifungal agents is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139895/", "reference_text": "[1] Venkatakrishnan K, von Moltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.\" Clin Pharmacokinet 38 (2000): 111-80[2] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[3] Smith SJ \"Cardiovascular toxicity of antihistamines.\" Otolaryngol Head Neck Surg 111 Suppl (1994): 348-54[4] \"Product Information. Sporonox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[5] Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso PJ, Lynch JJ \"Cardiac electrophysiological actions of the histamine h-1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine.\" Circ Res 76 (1995): 110-9[6] \"Product Information. Hismanal (astemizole).\" Janssen Pharmaceutica, Titusville, NJ.[7] Heidemann SM, Sarnaik AP \"Arrhythmias after astemizole overdose.\" Pediatr Emerg Care 12 (1996): 102-4[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Snook J, Boothman-Burrell D, Watkins J, Colin-Jones D \"Torsade de pointes ventricular tachycardia associated with astemizole overdose.\" Br J Clin Pract 42 (1988): 257-9[11] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[12] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[13] Goss JE, Ramo BW, Blake K \"Torsades de pointes associated with astemizole (hismanal) therapy.\" Arch Intern Med 153 (1993): 2705[14] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[15] Berul CI, Morad M \"Regulation of potassium channels by nonsedating antihistamines.\" Circulation 91 (1995): 2220-5[16] Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R \"Cardiovascular safety of fexofenadine HCl.\" Am J Cardiol 83 (1999): 1451-4[17] Tsai WC, Tsai LM, Chen JH \"Combined use of astemizole and ketoconazole resulting in torsade de pointes.\" J Formos Med Assoc 96 (1997): 144-6[18] \"Product Information. Nizoral (ketoconazole).\" Janssen Pharmaceutica, Titusville, NJ. (1992):[19] Simons FE, Kesselman MS, Giddins NG, Pelech AN, Simons KJ \"Astemizole-induced torsade de pointes.\" Lancet 2 (1988): 624[20] Craft TM \"Torsade de pointes after astemizole overdose.\" Br Med J 292 (1986): 660[21] Vorperian VR, Zhou ZF, Mohammad S, Hoon TJ, Studenik C, January CT \"Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole.\" J Am Coll Cardiol 28 (1996): 1556-61[22] Saviuc P, Danel V, Dixmerias F \"Prolonged QT interval and torsade de pointes following astemizole overdose.\" J Toxicol Clin Toxicol 31 (1993): 121-5[23] Rao KA, Adlakha A, Vermaansil B, Meloy TD, Stanton MS \"Torsades de pointes ventricular tachycardia associated with overdose of astemizole.\" Mayo Clin Proc 69 (1994): 589-93[24] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[25] Ament PW, Paterson A \"Drug interactions with the nonsedating antihistamines.\" Am Fam Physician 56 (1997): 223[26] Honig PK, Cantilena LR \"Ketoconazole and fluconazole drug interactions.\" Arch Intern Med 154 (1994): 1038-41[27] \"Product Information. Hismanal (astemizole).\" Janssen Pharmaceutica, Titusville, NJ.", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "updated_at": 1767369485}, {"id": 139735, "ingredient1": "Bepridil", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most CCBs.", "source": "DDInter", "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139896/", "reference_text": "[1] Sandstrom R, Knutson TW, Knutson L, Jansson B, Lennernas H \"The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans.\" Br J Clin Pharmacol 48 (1999): 180-9[2] Neuvonen PJ, Suhonen R \"Itraconazole interacts with felodipine.\" J Am Acad Dermatol 33 (1995): 134-5[3] Tailor SAN \"Peripheral edema due to nifedipine-itraconazole interaction: a case report.\" Arch Dermatol 132 (1996): 1374[4] Tailor SAN, Gupta AK, Walker SE, Shear NH \"Peripheral edema due to nifedipine-itraconazole interaction: a case report.\" Arch Dermatol 132 (1996): 350-2[5] Jalava KM, Olkkola KT, Neuvonen PJ \"Itraconazole greatly increases plasma concentrations and effects of felodipine.\" Clin Pharmacol Ther 61 (1997): 410-5[6] Rosen T \"Debilitating edema associated with itraconazole therapy.\" Arch Dermatol 130 (1994): 260-1[7] Heinig R, Adelmann HG, Ahr G \"The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine.\" Eur J Clin Pharmacol 55 (1999): 57-60[8] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[9] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[12] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[13] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[14] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[15] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[16] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[17] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[18] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[19] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[21] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[22] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[23] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[24] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[25] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[26] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[27] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[28] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[29] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[30] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[31] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[32] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[33] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[35] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[36] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[37] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[38] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[40] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139736, "ingredient1": "Boceprevir", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration of an azole antifungal agent and hepatitis C virus (HCV) NS3/4A protease inhibitor (boceprevir, telaprevir) may result in increased plasma concentrations of both drugs. The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme. Clinically, high plasma levels of an azole antifungal agent may increase the risk of QT interval prolongation and torsade de pointes arrhythmia.", "source": "DDInter", "management_text": "Caution is advised if azole antifungal agents are used in combination with HCV NS3/4A protease inhibitors. Dosage adjustments may be required. According to the product information for boceprevir and telaprevir, high dosages of ketoconazole and itraconazole (>200 mg/day) should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if azole antifungal agents are used in combination with HCV NS3/4A protease inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139897/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Fluconazole, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 139737, "ingredient1": "Cerivastatin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors that are substrates of the isoenzyme. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death. The interaction has not been studied with clotrimazole troches or miconazole buccal tablets. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 such as lovastatin, simvastatin, and atorvastatin cannot be ruled out.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening musculoskeletal toxicity associated with increased plasma levels of HMG-CoA reductase inhibitors, the concomitant use of lovastatin, red yeast rice (which contains lovastatin), and simvastatin with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. Atorvastatin may be used with caution, although the dosage should start low and probably not exceed 40 mg/day. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. No interaction is expected with fluvastatin and pravastatin, since they are not metabolized by CYP450 3A4.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening musculoskeletal toxicity associated with increased plasma levels of HMG-CoA reductase inhibitors, the concomitant use of lovastatin, red yeast rice (which contains lovastatin), and simvastatin with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139898/", "reference_text": "[1] Neuvonen PJ, Jalava KM \"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 60 (1996): 54-61[2] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on cerivastatin pharmacokinetics.\" Eur J Clin Pharmacol 54 (1999): 851-5[3] Lomaestro BM, Piatek MA \"Update on drug interactions with azole antifungal agents.\" Ann Pharmacother 32 (1998): 915-28[4] Gilad R, Lampl Y \"Rhabdomyolysis induced by simvastatin and ketoconazole treatment.\" Clin Neuropharmacol 22 (1999): 295-7[5] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[6] Horn M \"Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.\" Arch Dermatol 132 (1996): 1254[7] Lees RS, Lees AM \"Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.\" N Engl J Med 333 (1995): 664-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics of atorvastatin.\" Clin Pharmacol Ther 64 (1998): 58-65[10] Kivisto KT, Kantola T, Neuvonen PJ \"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.\" Br J Clin Pharmacol 46 (1998): 49-53[11] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[12] Neuvonen PJ, Kantola T, Kivisto KT \"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.\" Clin Pharmacol Ther 63 (1998): 332-41[13] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[14] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[15] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[16] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[17] McMillan K \"Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors.\" Am J Health Syst Pharm 53 (1996): 2206-14[18] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M \"Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved.\" Drug Metab Dispos 25 (1997): 321-31[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Rosuvastatin, Clofibrate, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139738, "ingredient1": "Cisapride", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of cisapride, which is primarily metabolized by the isoenzyme. The use of cisapride has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the concomitant use with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. Otherwise, patients should be cautioned about the potential for interaction and advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the concomitant use with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139899/", "reference_text": "[1] Bedford TA, Rowbotham DJ \"Cisapride: drug interactions of clinical significance.\" Drug Saf 15 (1996): 167-75[2] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[3] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[4] Gray VS \"Syncopal episodes associated with cisapride and concurrent drugs.\" Ann Pharmacother 32 (1998): 648-51[5] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996): 279-81[6] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995): 765-8[7] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000): 789-800[8] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[9] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[10] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[11] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[12] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996): 279-81[13] Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG \"Red wine-cisapride interaction: Comparison with grapefruit juice.\" Clin Pharmacol Ther 70 (2001): 17-23[14] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998): 1053-6[15] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[16] Kivisto KT, Lilja TJ, Backman JT, Neuvonen PJ \"Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.\" Clin Pharmacol Ther 66 (1999): 448-53[17] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000): 789-800[18] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[19] Gross AS, Goh YD, Addison RS, Shenfield GM \"Influence of grapefruit juice on cisapride pharmacokinetics.\" Clin Pharmacol Ther 65 (1999): 395-401[20] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995): 765-8", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139739, "ingredient1": "Conjugated estrogens (topical)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139900/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Bazedoxifene", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139740, "ingredient1": "Dexamethasone (nasal)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139901/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More", "updated_at": 1767369485}, {"id": 139741, "ingredient1": "Dicoumarol", "ingredient2": "Miconazole", "severity": "Major", "effect": "Systemically or even topically administered miconazole may increase the plasma concentrations and hypoprothrombinemic effect of warfarin. The proposed mechanism is miconazole inhibition of CYP450 2C9, the isoenzyme responsible for the metabolic clearance of the more active S(-) enantiomer of warfarin.", "source": "DDInter", "management_text": "Patients receiving warfarin or other oral anticoagulants should be closely monitored during concomitant therapy with miconazole. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of miconazole therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Some authorities consider the use of oral miconazole with warfarin to be contraindicated. Although vaginally administered miconazole is generally less than 2% absorbed in healthy women of childbearing age, increased absorption may occur in the presence of atrophic vaginal epithelium. Therefore, the same precaution is applicable when vaginal formulations of miconazole is prescribed to women receiving oral anticoagulant therapy.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving warfarin or other oral anticoagulants should be closely monitored during concomitant therapy with miconazole.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139902/", "reference_text": "[1] Colquhoun MC, Daly M, Stewart P, Beeley L \"Interaction between warfarin and miconazole oral gel.\" Lancet 1 (1987): 695-6[2] Shenfield GM, Page M \"Potentiation of warfarin action by miconazole oral gel.\" Aust N Z J Med 21 (1991): 928[3] Watson PG, Lochan RG, Redding VJ \"Drug interaction with coumarin derivative anticoagulants.\" Br Med J 285 (1982): 1045-6[4] Gutierrez MA, Olalla I, Muruzabal MJ, Ortiz M, Peralta FG \"Miconazole oral gel enhances acenocoumarol anticoagulant activity. Report of three cases.\" Eur J Clin Pharmacol 52(Suppl) (1997): A132[5] Evans J, Orme DS, Sedgwick ML, Youngs GR \"Treating oral candidiasis: potentially fatal.\" Br Dent J 182 (1997): 452[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Ortin M, Olalla JI, Muruzabal MJ, Peralta FG, Gutierrez MA \"Miconazole oral gel enhances acenocoumarol anticoagulant activity: A report of three cases.\" Ann Pharmacother 33 (1999): 175-7[8] Visser LE, Penning-Van Beest FJ, Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.\" Clin Pharmacol Ther 71 (2002): 496-502[9] Marco M \"Retroperitoneal haematoma and small bowel intramural haematoma caused by warfarin and miconazole interaction.\" Int J Oral Maxillofac Surg 27 (1998): 485[10] Ariyaratnam S, Thakker NS, Sloan P, Thornhill MH \"Potentiation of warfarin anticoagulant activity by miconazole oral gel.\" BMJ 314 (1997): 349[11] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[12] Pemberton MN, Sloan P, Ariyaratnam S, Thakker NS, Thornhill MH \"Derangement of warfarin anticoagulation by miconazole oral gel.\" Br Dent J 184 (1998): 68-9[13] Thirion DJ, Farquhar Zannetti LA \"Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories.\" Pharmacotherapy 20 (2000): 98-9[14] Pemberton M, Sloan P, Ariyaratnam S, Thakker NS, Thornhill MH \"Treating oral candidiasis: potentially fatal.\" Br Dent J 183 (1997): 87[15] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[16] O'Reilly RA, Goulart DA, Kunze KL, et al \"Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects.\" Clin Pharmacol Ther 51 (1992): 656-67[17] Devaraj A, O'Beirne JP, Veasey R, Dunk AA \"Interaction between warfarin and topical miconazole cream.\" BMJ 325 (2002): 77[18] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[19] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[20] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[21] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[22] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[23] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[24] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[25] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[26] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[27] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[28] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[29] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[30] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[31] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[34] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[35] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[36] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[37] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[38] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[39] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[40] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[41] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[42] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[43] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[48] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[49] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[50] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[51] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[52] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[53] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[54] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6", "alternatives_a": "Betrixaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Paromomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139742, "ingredient1": "Dienestrol (topical)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139903/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139743, "ingredient1": "Diethylstilbestrol", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139904/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin, Goserelin, Bazedoxifene", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139744, "ingredient1": "Entrectinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.", "source": "DDInter", "management_text": "Caution is advised when entrectinib is used with CYP450 3A4 inhibitors. Pharmacologic response to entrectinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the entrectinib dosage adjusted as necessary in accordance with the product labeling. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when entrectinib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139905/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[4] Dimartini A \"Isoniazid, tricyclics and the ''cheese reaction''.\" Int Clin Psychopharmacol 10 (1995): 197-8[5] \"Product Information. INH (isoniazid).\" Ciba Pharmaceuticals, Summit, NJ.[6] Smith CK, Durack DT \"Isoniazid and reaction to cheese.\" Ann Intern Med 88 (1978): 520-1[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Self TH, Chrisman CR, Baciewicz AM, Bronze MS \"Isoniazid drug and food interactions.\" Am J Med Sci 317 (1999): 304-11[9] Uragoda CG, Kottegoda SR \"Adverse reactions to isoniazid on ingestion of fish with a high histamine content.\" Tubercle 58 (1977): 83-9", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139745, "ingredient1": "Enzalutamide", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4.", "source": "DDInter", "management_text": "Pharmacologic response to enzalutamide should be monitored more closely whenever a CYP450 2C8 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience increased side effects such as seizure, asthenia, fatigue, diarrhea, arthralgia, musculoskeletal pain, paresthesia, hot flushes, peripheral edema, headache, dizziness, insomnia, hematuria, anxiety, and hypertension.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to enzalutamide should be monitored more closely whenever a CYP450 2C8 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139906/", "reference_text": "[1] \"Product Information. Xtandi (enzalutamide).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Micafungin, Amphotericin B, More", "alternatives_b": "Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, More", "updated_at": 1767369485}, {"id": 139746, "ingredient1": "Eplerenone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 including azole antifungal agents may increase the plasma concentrations of eplerenone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if eplerenone is prescribed in combination with miconazole mucous membrane preparations. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if eplerenone is prescribed in combination with miconazole mucous membrane preparations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139907/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Amiloride, Triamterene", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139747, "ingredient1": "Ergometrine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 including azole antifungal agents may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors. Clinical ergotism has been reported, which can lead to gangrene and myocardial infarction in severe cases. Even small, single doses of ergotamine have resulted in clinically significant interactions, occasionally resulting in surgical amputation or death.", "source": "DDInter", "management_text": "Concomitant use of ergot derivatives with fluconazole at high, multiple doses or clotrimazole and miconazole mucous membrane preparations should generally be avoided, if possible. Otherwise, close monitoring for adverse effects such as peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of ergotism such as paresthesia, tingling of fingers, cold or painful extremities, numbness, muscle cramps, abdominal pain, rapid pulse, or chest pain.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ergot derivatives with fluconazole at high, multiple doses or clotrimazole and miconazole mucous membrane preparations should generally be avoided, if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139908/", "reference_text": "[1] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[2] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[3] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[4] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[6] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[7] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[8] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[9] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[10] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[11] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[13] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[14] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[15] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[16] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[17] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[18] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[19] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[20] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[21] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[24] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[25] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[26] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[33] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[34] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[35] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[36] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[37] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[38] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[39] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[40] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[41] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[42] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[43] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[44] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[48] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[49] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[50] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[51] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Misoprostol, Dinoprostone, Oxytocin", "updated_at": 1767369485}, {"id": 139748, "ingredient1": "Ergotamine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 including azole antifungal agents may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors. Clinical ergotism has been reported, which can lead to gangrene and myocardial infarction in severe cases. Even small, single doses of ergotamine have resulted in clinically significant interactions, occasionally resulting in surgical amputation or death.", "source": "DDInter", "management_text": "Concomitant use of ergot derivatives with fluconazole at high, multiple doses or clotrimazole and miconazole mucous membrane preparations should generally be avoided, if possible. Otherwise, close monitoring for adverse effects such as peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of ergotism such as paresthesia, tingling of fingers, cold or painful extremities, numbness, muscle cramps, abdominal pain, rapid pulse, or chest pain.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ergot derivatives with fluconazole at high, multiple doses or clotrimazole and miconazole mucous membrane preparations should generally be avoided, if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139909/", "reference_text": "[1] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[2] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[3] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[4] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[6] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[7] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[8] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[9] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[10] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[11] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[13] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[14] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[15] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[16] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[17] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[18] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[19] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[20] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[21] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[24] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[25] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[26] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[33] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[34] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[35] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[36] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[37] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[38] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[39] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[40] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[41] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[42] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[43] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[44] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[48] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[49] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[50] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[51] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139749, "ingredient1": "Erlotinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors. A dosage reduction or temporary interruption of therapy should be considered in patients who experience undue adverse effects of erlotinib such as severe diarrhea (i.e., that which is unresponsive to loperamide or results in dehydration), severe skin reactions, or severe liver function test abnormalities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139910/", "reference_text": "[1] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[2] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.[3] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[4] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139750, "ingredient1": "Escitalopram", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139911/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More", "updated_at": 1767369485}, {"id": 139751, "ingredient1": "Esterified estrogens", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139912/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139752, "ingredient1": "Estradiol (topical)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139913/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Dienogest, Bazedoxifene, Testosterone, Prasterone, Methyltestosterone, Megestrol acetate, Dienogest, Estetrol, Nafarelin, Octreotide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139753, "ingredient1": "Estrone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139914/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Bazedoxifene", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139754, "ingredient1": "Estrone sulfate", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139915/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139755, "ingredient1": "Estrone sulfate (topical)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139916/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139756, "ingredient1": "Eszopiclone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of both zopiclone and its pharmacologically active S(-) enantiomer, eszopiclone. Zopiclone has been shown in vitro to be metabolized by CYP450 3A4 and CYP450 2C8, while eszopiclone is primarily metabolized by CYP450 3A4 and 2E1 via demethylation and oxidation.", "source": "DDInter", "management_text": "Caution is advised when zopiclone or eszopiclone is coadministered with moderate CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected. Patients should be advised to avoid driving or operating hazardous machinery until they know how these medications affect them, preferably at least 12 hours after administration of the hypnotic.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when zopiclone or eszopiclone is coadministered with moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139917/", "reference_text": "[1] Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Bretano C, Jaillon P \"Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism.\" Drug Metab Dispos 27 (1999): 1068-73[2] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[3] \"Product Information. Imovane (zopiclone).\" Rhone-Poulenc Rorer Canada Inc, Laval, IN.[4] Aranko K, Luurila H, Backman JT, Neuvonen PJ, Olkkola KT \"The effect of erythromycin on the pharmacokinetics and pharmacodymanics of zopiclone.\" Br J Clin Pharmacol 38 (1994): 363-7[5] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Alderman CP, Gebauer MG, Gilbert AL, Condon JT \"Possible interaction of zopiclone and nefazodone.\" Ann Pharmacother 35 (2001): 1378-80[8] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139757, "ingredient1": "Ethotoin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Miconazole may increase plasma hydantoin concentrations. Phenytoin toxicity has been reported with concurrent parenteral and oral miconazole. The mechanism may be related to inhibition of hepatic CYP450 2C9, the major metabolic pathway for phenytoin.", "source": "DDInter", "management_text": "If miconazole and hydantoins must be used concomitantly, caution is recommended, as is close observation for clinical and laboratory evidence of altered phenytoin effect. Patients should be advised to notify their physician if they experience symptoms of possible hydantoin toxicity, including drowsiness, visual disturbances, change in mental status, seizures, nausea, or ataxia.", "mechanism_text": "Metabolism", "recommendation": "If miconazole and hydantoins must be used concomitantly, caution is recommended, as is close observation for clinical and laboratory evidence of altered phenytoin effect.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139918/", "reference_text": "[1] Rolan PE, Somogyi AA, Drew MJ, et al \"Phenytoin intoxication during treatment with parenteral miconazole.\" Br Med J (Clin Res Ed) 287 (1983): 1760[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139758, "ingredient1": "Etonogestrel", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139919/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Dienogest, Estetrol", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139759, "ingredient1": "Etravirine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration of etravirine with a drug that is both a substrate as well as inhibitor of CYP450 3A4 may result in increased plasma concentrations of etravirine and decreased plasma concentrations of the other drug. Etravirine itself is a substrate and inducer of CYP450 3A4. Theoretically, etravirine may induce metabolism of the coadministered drug while its own metabolism may be inhibited by the coadministered drug.", "source": "DDInter", "management_text": "Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with a drug that is an inhibitor of CYP450 3A4. In addition, dosage adjustments may be required for the coadministered drug if it is also a substrate of CYP450 3A4.", "mechanism_text": "Metabolism", "recommendation": "Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with a drug that is an inhibitor of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139920/", "reference_text": "[1] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.[2] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 139760, "ingredient1": "Everolimus", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139921/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Nystatin, Rifamycin, Paromomycin, Rifaximin, Flucytosine, Anidulafungin, Caspofungin, Oteseconazole, Salicylic acid, Selenium Sulfide, Thiabendazole, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139761, "ingredient1": "Felodipine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most CCBs.", "source": "DDInter", "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139922/", "reference_text": "[1] Sandstrom R, Knutson TW, Knutson L, Jansson B, Lennernas H \"The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans.\" Br J Clin Pharmacol 48 (1999): 180-9[2] Neuvonen PJ, Suhonen R \"Itraconazole interacts with felodipine.\" J Am Acad Dermatol 33 (1995): 134-5[3] Tailor SAN \"Peripheral edema due to nifedipine-itraconazole interaction: a case report.\" Arch Dermatol 132 (1996): 1374[4] Tailor SAN, Gupta AK, Walker SE, Shear NH \"Peripheral edema due to nifedipine-itraconazole interaction: a case report.\" Arch Dermatol 132 (1996): 350-2[5] Jalava KM, Olkkola KT, Neuvonen PJ \"Itraconazole greatly increases plasma concentrations and effects of felodipine.\" Clin Pharmacol Ther 61 (1997): 410-5[6] Rosen T \"Debilitating edema associated with itraconazole therapy.\" Arch Dermatol 130 (1994): 260-1[7] Heinig R, Adelmann HG, Ahr G \"The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine.\" Eur J Clin Pharmacol 55 (1999): 57-60[8] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[9] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[12] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[13] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[14] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[15] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[16] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[17] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[18] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[19] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[21] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[22] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[23] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[24] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[25] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[26] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[27] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[28] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[29] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[30] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[31] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[32] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[33] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[35] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[36] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[37] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[38] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[40] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Nebivolol, Bisoprolol, Sotalol, Clevidipine, Moexipril, Perindopril, Bisoprolol, Benazepril, Quinapril, Trandolapril, Captopril, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139762, "ingredient1": "Fesoterodine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered. Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary. Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.", "mechanism_text": "Metabolism", "recommendation": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139923/", "reference_text": "[1] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 139763, "ingredient1": "Fexofenadine", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with ketoconazole has been shown to significantly increase the oral bioavailability of fexofenadine. The proposed mechanism is ketoconazole inhibition of the intestinal efflux of fexofenadine via P-glycoprotein transporter. No studies have been performed using other azole antifungal agents, but similar results are possible given their similarities to ketoconazole. Fexofenadine had no effect on the pharmacokinetics of ketoconazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139924/", "reference_text": "[1] \"Product Information. Allegra-D (fexofenadine-pseudoephedrine).\" Chattem Consumer Products, Chattanooga, TN.[2] \"Product Information. Allegra (fexofenadine).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Bailey DG, Dresser GK, Munoz C, Freemar DJ, Kim RB \"Reduction of fexofenadine bioavailability by fruit juices.\" Clin Pharmacol Ther 69 (2001): PI-82[4] Dresser GK, Bailey DG, Leake BF, et al. \"Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.\" Clin Pharmacol Ther 71 (2002): 11-20", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Caspofungin, Micafungin, Amphotericin B, More", "updated_at": 1767369485}, {"id": 139764, "ingredient1": "Flibanserin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19.", "source": "DDInter", "management_text": "Caution is advised when flibanserin is used with multiple weak CYP450 3A4 inhibitors. Patients should be monitored for signs and symptoms of hypotension, syncope, and central nervous system depression.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when flibanserin is used with multiple weak CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139925/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Bromocriptine", "updated_at": 1767369485}, {"id": 139765, "ingredient1": "Fluconazole", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with fluconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4-mediated metabolism by fluconazole, a moderate inhibitor of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when fluconazole is used with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fluconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fluconazole is used with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139926/", "reference_text": "[1] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[2] Assan R, Fredj G, Larger E, Feutren G, Bismuth H \"FK 506/fluconazole interaction enhances FK 506 nephrotoxicity.\" Diabete Metab 20 (1994): 49-52[3] Ulivelli M, Rubegni P, Nuti D, Bartalini S, Giannini F, Rossi S \"Clinical evidence of fluconazole-induced carbamazepine toxicity.\" J Neurol 251 (2004): 622-3[4] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[5] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[6] Canafax DM, Graves NM, Hilligoss DM, et al \"Interaction between cyclosporine and fluconazole in renal allograft recipients.\" Transplantation 51 (1991): 1014-8[7] Hilbert J, Messig M, Kuye O, Friedman H \"Evaluation of interaction between fluconazole and an oral contraceptive in healthy women.\" Obstet Gynecol 98 (2001): 218-23[8] Finch CK, Green CA, Self TH \"Fluconazole-carbamazepine interaction.\" South Med J 95 (2002): 1099-100[9] Torregrosa V, De la Torre M, Campistol JM, et al \"Interaction of fluconazole with ciclosporin A.\" Nephron 60 (1992): 125-6[10] Tsouli S, Maranis S, Kyritsis AP \"Fluconazole-carbamazepine interaction in a patient with bipolar disorder.\" Psychiatry Clin Neurosci 65 (2011): 112[11] Barbara JA, Clarkson AR, LaBrooy J, et al \"Candida albicans arthritis in a renal allograft recipient with an interaction between cyclosporin and fluconazole.\" Nephrol Dial Transplant 8 (1993): 263-6[12] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[13] Sugar AM, Saunders C, Idelson BA, Bernard DB \"Interaction of fluconazole and cyclosporine.\" Ann Intern Med 110 (1989): 844[14] Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR \"Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients.\" Transplantation 61 (1996): 1268-72[15] Baciewicz AM, Baciewicz FA, Jr \"Ketoconazole and fluconazole drug interactions.\" Arch Intern Med 153 (1993): 1970-6[16] Bedford TA, Rowbotham DJ \"Cisapride: drug interactions of clinical significance.\" Drug Saf 15 (1996): 167-75[17] Lopez-Gil JA \"Fluconazole-cyclosporin interaction: a dose-dependent effect?\" Ann Pharmacother 27 (1993): 427-30[18] Nair DR, Morris HH \"Potential fluconazole-induced carbamazepine toxicity.\" Ann Pharmacother 33 (1999): 790-2", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Micafungin, Caspofungin, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Fluconazole, Micafungin, Oteseconazole, More", "updated_at": 1767369485}, {"id": 139766, "ingredient1": "Flunisolide (nasal)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139927/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139767, "ingredient1": "Fluorometholone (ophthalmic)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139928/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Mometasone furoate, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone, Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139768, "ingredient1": "Fluvoxamine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with fluvoxamine may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to competitive inhibition of CYP450 3A4 activity by fluvoxamine.", "source": "DDInter", "management_text": "Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fluvoxamine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139929/", "reference_text": "[1] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[2] Damkier P, Hansen LL, Brosen K \"Effect of fluvoxamine on the pharmacokinetics of quinidine.\" Eur J Clin Pharmacol 55 (1999): 451-6[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139769, "ingredient1": "Fosaprepitant", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139930/", "reference_text": "[1] \"Product Information. Emend for Injection (fosaprepitant).\" Merck & Company Inc, West Point, PA.[2] \"Product Information. Emend (aprepitant).\" Merck & Company Inc, West Point, PA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139770, "ingredient1": "Fosphenytoin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Miconazole may increase plasma hydantoin concentrations. Phenytoin toxicity has been reported with concurrent parenteral and oral miconazole. The mechanism may be related to inhibition of hepatic CYP450 2C9, the major metabolic pathway for phenytoin.", "source": "DDInter", "management_text": "If miconazole and hydantoins must be used concomitantly, caution is recommended, as is close observation for clinical and laboratory evidence of altered phenytoin effect. Patients should be advised to notify their physician if they experience symptoms of possible hydantoin toxicity, including drowsiness, visual disturbances, change in mental status, seizures, nausea, or ataxia.", "mechanism_text": "Metabolism", "recommendation": "If miconazole and hydantoins must be used concomitantly, caution is recommended, as is close observation for clinical and laboratory evidence of altered phenytoin effect.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139931/", "reference_text": "[1] Rolan PE, Somogyi AA, Drew MJ, et al \"Phenytoin intoxication during treatment with parenteral miconazole.\" Br Med J (Clin Res Ed) 287 (1983): 1760[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, Amphotericin B, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "updated_at": 1767369485}, {"id": 139771, "ingredient1": "Fostamatinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration of fostamatinib with inhibitors of CYP450 3A4 may increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration. Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9. In vitro, R406 is also a substrate of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Patients should be monitored for toxicities of fostamatinib during concomitant use of potent or moderate CYP450 3A4 inhibitors or dual CYP450 3A4/P-gp inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139932/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals, South San Francisco, CA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 139772, "ingredient1": "Gefitinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of gefitinib, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of gefitinib (250 mg single dose) with the potent inhibitor itraconazole (200 mg once a day for 12 days) increased the mean gefitinib systemic exposure (AUC) by 88% in healthy male volunteers.", "source": "DDInter", "management_text": "Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience possible symptoms of gefitinib toxicity such as severe diarrhea, nausea, dyspnea, cough, and fever.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139933/", "reference_text": "[1] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[2] \"Product Information. Iressa (gefitinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139773, "ingredient1": "Gilteritinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when gilteritinib is used with CYP450 3A4 and/or P-gp inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, pancreatitis, liver transaminase and bilirubin elevations, edema, infections and stomatitis, and the gilteritinib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when gilteritinib is used with CYP450 3A4 and/or P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139934/", "reference_text": "[1] \"Product Information. Xospata (gilteritinib).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Xospata (gilteritinib).\" Astellas Pharma US, Inc, Deerfield, IL.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139774, "ingredient1": "Glasdegib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when glasdegib is used with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, anemia, febrile neutropenia, thrombocytopenia, hemorrhage, edema and mucositis, and the glasdegib dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when glasdegib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139935/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 139775, "ingredient1": "Glipizide", "ingredient2": "Miconazole", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the plasma concentrations of sulfonylureas, many of which have been found to be substrates of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9. Blood glucose should be closely monitored, and the sulfonylurea dosage adjusted as necessary. Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the azole antifungal agent, and contact their physician.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139936/", "reference_text": "[1] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[2] \"Product Information. Monistat (miconazole).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[3] Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG \"Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.\" Pharmacogenomics 10 (2009): 1781-7[4] Jeong S, Nguyen PD, Desta Z \"Comprehensive in vitro inhibition analysis of eight cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A.\" Antimicrob Agents Chemother 53 (2009): 541-51[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[8] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998): 525-38[9] Rowe BR, Thorpe J, Barnett A \"Safety of fluconazole in women taking oral hypoglycaemic agents.\" Lancet 339 (1992): 255-6[10] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[11] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[12] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[13] Shon JH, Yoon YR, Kim MJ, et al. \"Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.\" Br J Clin Pharmacol 59 (2005): 552-63[14] Venkatakrishnan K, von Moltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.\" Clin Pharmacokinet 38 (2000): 111-80[15] Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT \"Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.\" Clin Pharmacol Ther 72 (2002): 326-32[16] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[17] Tirkkonen T, Heikkila P, Huupponen R, Laine K \"Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.\" J Intern Med 268 (2010): 359-66[18] Shobha JC, Muppidi MR \"Interaction between voriconazole and glimepiride.\" J Postgrad Med 56 (2010): 44-5[19] Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.\" Drug Metab Disposition 28 (2000): 475-81[20] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[21] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[22] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[23] Holstein A, Plaschke A, Ptak M, et al. \"Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.\" Br J Clin Pharmacol 60 (2005): 103-6[24] Back DJ, Tjia JF, Karbwang J, Colbert J \"In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones.\" Br J Clin Pharmacol 26 (1988): 23-9[25] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[27] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[28] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[31] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[32] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[35] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139776, "ingredient1": "Glyburide", "ingredient2": "Miconazole", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the plasma concentrations of sulfonylureas, many of which have been found to be substrates of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9. Blood glucose should be closely monitored, and the sulfonylurea dosage adjusted as necessary. Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the azole antifungal agent, and contact their physician.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139937/", "reference_text": "[1] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[2] \"Product Information. Monistat (miconazole).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[3] Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG \"Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.\" Pharmacogenomics 10 (2009): 1781-7[4] Jeong S, Nguyen PD, Desta Z \"Comprehensive in vitro inhibition analysis of eight cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A.\" Antimicrob Agents Chemother 53 (2009): 541-51[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[8] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998): 525-38[9] Rowe BR, Thorpe J, Barnett A \"Safety of fluconazole in women taking oral hypoglycaemic agents.\" Lancet 339 (1992): 255-6[10] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[11] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[12] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[13] Shon JH, Yoon YR, Kim MJ, et al. \"Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.\" Br J Clin Pharmacol 59 (2005): 552-63[14] Venkatakrishnan K, von Moltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.\" Clin Pharmacokinet 38 (2000): 111-80[15] Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT \"Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.\" Clin Pharmacol Ther 72 (2002): 326-32[16] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[17] Tirkkonen T, Heikkila P, Huupponen R, Laine K \"Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.\" J Intern Med 268 (2010): 359-66[18] Shobha JC, Muppidi MR \"Interaction between voriconazole and glimepiride.\" J Postgrad Med 56 (2010): 44-5[19] Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.\" Drug Metab Disposition 28 (2000): 475-81[20] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[21] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[22] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[23] Holstein A, Plaschke A, Ptak M, et al. \"Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.\" Br J Clin Pharmacol 60 (2005): 103-6[24] Back DJ, Tjia JF, Karbwang J, Colbert J \"In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones.\" Br J Clin Pharmacol 26 (1988): 23-9[25] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[27] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[28] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[31] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[32] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[35] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, Caspofungin, Posaconazole, More", "updated_at": 1767369485}, {"id": 139777, "ingredient1": "Grepafloxacin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.", "source": "DDInter", "management_text": "Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139938/", "reference_text": "[1] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.", "alternatives_a": "Enoxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139778, "ingredient1": "Guanfacine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when guanfacine is used with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as hypotension, bradycardia and sedation , and the guanfacine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when guanfacine is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139939/", "reference_text": "[1] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[6] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Methyldopa, Deserpidine", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139779, "ingredient1": "Halofantrine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139940/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 139780, "ingredient1": "Ibrutinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors. Patients should be closely monitored for signs of ibrutinib toxicity such as myelosuppression, bleeding, infection, and renal impairment. Dosage reduction in accordance with ibrutinib product labeling may be necessary if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ibrutinib is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139941/", "reference_text": "[1] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc, Sunnyvale, CA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc, Sunnyvale, CA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139781, "ingredient1": "Iloperidone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139942/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, More", "updated_at": 1767369485}, {"id": 139782, "ingredient1": "Imatinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Imatinib is a substrate of the CYP450 3A4 isoenzyme as well as a potent competitive inhibitor of the CYP450 2C9, 2D6 and 3A4 isoenzymes. Some drugs that are known inhibitors of CYP450 3A4 are also metabolized by one or more of the isoenzymes inhibited by imatinib. Theoretically, coadministration of imatinib with those drugs may result in mutually elevated plasma drug concentrations due to competitive and noncompetitive inhibition of CYP450 activities.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin. In addition, clinical and laboratory monitoring for potentially increased pharmacologic effects of coadministered medications is recommended, especially those with a narrow therapeutic range.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139943/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Flucytosine, Micafungin, Caspofungin, More", "updated_at": 1767369485}, {"id": 139783, "ingredient1": "Imipramine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "The coadministration with azole antifungal agents may increase the plasma concentrations of some tricyclic antidepressants (TCAs). Elevated TCA levels may result in CNS toxicity, anticholinergic symptoms, and QT interval prolongation. The mechanism is decreased TCA clearance due to azole-related inhibition of the CYP450 3A4 isoenzyme, which is partially responsible for the metabolism of TCAs like amitriptyline, clomipramine, imipramine, and possibly others.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary. Serum TCA levels should be monitored following initiation or discontinuation of azole antifungal therapy. Patients should be advised to notify their caregiver if they experience excessive dry mouth, visual disturbances, urinary retention, dizziness, syncope, fast or irregular heartbeat, constipation, or seizures.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139944/", "reference_text": "[1] Dorsey ST, Biblio LA \"Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline.\" Am J Emerg Med 18 (2000): 227-9[2] Gannon RH \"Fluconazole-nortriptyline drug interaction.\" Ann Pharmacother 26 (1992): 1456[3] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E \"Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.\" Br J Clin Pharmacol 43 (1997): 315-8[4] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E \"Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.\" Br J Clin Pharmacol 43 (1997): 315-8[5] Robinson RF, Nahata MC, Olshefski RS \"Syncope associated with concurrent amitriptyline and fluconazole therapy.\" Ann Pharmacother 34 (2000): 1406-9[6] Newberry DL, Bass SN, Mbanefo CO \"A fluconazole/amitriptyline drug interaction in three male adults.\" Clin Infect Dis 24 (1997): 270-1", "alternatives_a": "Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139784, "ingredient1": "Indacaterol", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139945/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Epinephrine, Olodaterol, Cromoglicic acid, Ipratropium, Bitolterol, Orciprenaline, More", "updated_at": 1767369485}, {"id": 139785, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or UGT1A1 may increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 and UGT1A1 are the isoenzymes responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors. Patients should be monitored for toxicities such as diarrhea, myelosuppression, thromboembolism, and interstitial lung disease, and the irinotecan dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when irinotecan is prescribed with CYP450 3A4 or UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139946/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[7] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139786, "ingredient1": "Miconazole", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil). Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine). Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139947/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine)\" Organon, West Orange, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139787, "ingredient1": "Miconazole", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139948/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, More", "alternatives_b": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 139788, "ingredient1": "Miconazole", "ingredient2": "Lomitapide", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139949/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Micafungin, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Rosuvastatin, Clofibrate, More", "updated_at": 1767369485}, {"id": 139789, "ingredient1": "Miconazole", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139950/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 139790, "ingredient1": "Miconazole", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Miconazole may increase plasma hydantoin concentrations. Phenytoin toxicity has been reported with concurrent parenteral and oral miconazole. The mechanism may be related to inhibition of hepatic CYP450 2C9, the major metabolic pathway for phenytoin.", "source": "DDInter", "management_text": "If miconazole and hydantoins must be used concomitantly, caution is recommended, as is close observation for clinical and laboratory evidence of altered phenytoin effect. Patients should be advised to notify their physician if they experience symptoms of possible hydantoin toxicity, including drowsiness, visual disturbances, change in mental status, seizures, nausea, or ataxia.", "mechanism_text": "Metabolism", "recommendation": "If miconazole and hydantoins must be used concomitantly, caution is recommended, as is close observation for clinical and laboratory evidence of altered phenytoin effect.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139951/", "reference_text": "[1] Rolan PE, Somogyi AA, Drew MJ, et al \"Phenytoin intoxication during treatment with parenteral miconazole.\" Br Med J (Clin Res Ed) 287 (1983): 1760[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139791, "ingredient1": "Miconazole", "ingredient2": "Methysergide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 including azole antifungal agents may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors. Clinical ergotism has been reported, which can lead to gangrene and myocardial infarction in severe cases. Even small, single doses of ergotamine have resulted in clinically significant interactions, occasionally resulting in surgical amputation or death.", "source": "DDInter", "management_text": "Concomitant use of ergot derivatives with fluconazole at high, multiple doses or clotrimazole and miconazole mucous membrane preparations should generally be avoided, if possible. Otherwise, close monitoring for adverse effects such as peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of ergotism such as paresthesia, tingling of fingers, cold or painful extremities, numbness, muscle cramps, abdominal pain, rapid pulse, or chest pain.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ergot derivatives with fluconazole at high, multiple doses or clotrimazole and miconazole mucous membrane preparations should generally be avoided, if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139952/", "reference_text": "[1] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF \"Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient.\" Antimicrob Agents Chemother 41 (1997): 1207[2] Montero A, Giovannoni AG, Tvrde PL \"Leg ischemia in a patient receiving ritonavir and ergotamine.\" Ann Intern Med 130 (1999): 329[3] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F \"Clinical ergotism induced by ritonavir.\" Scand J Infect Dis 33 (2001): 788-9[4] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[6] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W \"Cerebral ergotism under treatment with ergotamine and ritonavir.\" Neurology 57 (2001): 743-4[7] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[8] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[9] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[10] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[11] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Liaudet L, Buclin T, Jaccard C, Eckert P \"Severe ergotism associated with interaction between ritonavir and ergotamine.\" Br Med J 318 (1999): 771[13] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP \"Ergotism related to concurrent administration of ergotamine tartrate and indinavir.\" JAMA 281 (1999): 987[14] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[15] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[16] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[17] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[18] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[19] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[20] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[21] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[24] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[25] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[26] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[33] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[34] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[35] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[36] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[37] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[38] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[39] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[40] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[41] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[42] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[43] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[44] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[48] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[49] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[50] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[51] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139792, "ingredient1": "Midazolam", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of benzodiazepines that are primarily metabolized by the isoenzyme. Overall, pharmacodynamic changes associated with the interaction include increased and prolonged sedation, enhanced benzodiazepine-related EEG effects, and increased impairment of psychomotor performance. The interaction has not been studied with clotrimazole troches or miconazole buccal tablets. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 such as triazolam and midazolam cannot be ruled out.", "source": "DDInter", "management_text": "Given the potential for significant interaction, the concomitant use of triazolam with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. The same precaution probably applies also to oral midazolam and high dosages of intravenous midazolam. Otherwise, patients should be cautioned about the potential for interaction and monitored for potentially excessive or prolonged CNS and respiratory depression if these agents are used together. Alternatively, benzodiazepines that are not metabolized by CYP450 3A4 (e.g., lorazepam, oxazepam, temazepam) may be considered in patients requiring treatment with azole antifungal agents.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for significant interaction, the concomitant use of triazolam with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139953/", "reference_text": "[1] Greenblatt DJ, Vonmoltke LL, Harmatz JS, Harrel LM, Tobias S, Shader RI, Wright CE \"Interaction of triazolam and ketoconazole.\" Lancet 345 (1995): 191[2] Varhe A, Olkkola KT, Neuvonen PJ \"Effect of fluconazole dose on the extent of fluconazole-triazolam interaction.\" Br J Clin Pharmacol 42 (1996): 465-70[3] Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ \"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.\" Eur J Clin Pharmacol 54 (1998): 53-8[4] Ahonen J, Olkkola KT, Neuvonen PJ \"Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam.\" Ther Drug Monit 18 (1996): 124-7[5] Vanakoski J, Mattila MJ, Vainio P, Idanpaanheikkila JJ, Tornwall M \"150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects.\" Int J Clin Pharmacol Ther 33 (1995): 518-23[6] Vonmoltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI \"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.\" J Clin Pharmacol 36 (1996): 783-91[7] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Ahonen J, Olkkola KT, Neuvonen PJ \"Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.\" Br J Clin Pharmacol 40 (1995): 270-2[9] Neuvonen PJ, Varhe A, Olkkola KT \"The effect of ingestion time interval on the interaction between itraconazole and triazolam.\" Clin Pharmacol Ther 60 (1996): 326-31[10] Greenblatt DJ, Wright CE, vonMoltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI \"Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences.\" Clin Pharmacol Ther 64 (1998): 237-47[11] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Vonmoltke LL, Greenblatt DJ, Cotreaubibbo MM, Harmatz JS, Shader RI \"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.\" Br J Clin Pharmacol 38 (1994): 23-31[13] Olkkola KT, Backman JT, Neuvonen PJ \"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 55 (1994): 481-5[14] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[15] Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K \"Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam.\" Psychopharmacology 139 (1998): 269-73[16] Varhe A, Olkkola KT, Neuvonen PJ \"Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 56 (1994): 601-7[17] Varhe A, Olkkola KT, Neuvonen PJ \"Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism.\" Br J Clin Pharmacol 41 (1996): 319-23[18] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[19] Tsunoda SM, Velez RL, vonMoltke LL, Greenblatt DJ \"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole.\" Clin Pharmacol Ther 66 (1999): 461-71[20] Brown MW, Maldonado AL, Meredith CG, Speeg KV \"Effect of ketoconazole on hepatic oxidative drug metabolism.\" Clin Pharmacol Ther 37 (1985): 290-7[21] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[23] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[24] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[25] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[26] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Flucytosine, Anidulafungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139793, "ingredient1": "Midostaurin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when midostaurin is used with CYP450 3A4 inhibitors. Patients should be closely monitored for increased adverse reactions (e.g., nausea, vomiting, diarrhea, edema, hyperglycemia, hyperuricemia, QT prolongation, neutropenia, lymphopenia, thrombocytopenia, anemia), especially during the first week of consecutive midostaurin administration in patients with advanced systemic mastocytosis and during the first week of midostaurin administration in each cycle of chemotherapy in patients with acute myeloid leukemia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when midostaurin is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139954/", "reference_text": "[1] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y \"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.\" Cancer Chemother Pharmacol 72 (2013): 1223-34[2] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139794, "ingredient1": "Mifepristone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mifepristone, which is primarily metabolized by the isoenzyme. The clinical impact of this interaction has not been studied.", "source": "DDInter", "management_text": "Due to its potent antiglucocorticoid effects and potential to cause dose-related prolongation of the QT interval, caution is advised if mifepristone is prescribed in combination with CYP450 3A4 inhibitors, particularly when used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome.", "mechanism_text": "Metabolism", "recommendation": "Due to its potent antiglucocorticoid effects and potential to cause dose-related prolongation of the QT interval, caution is advised if mifepristone is prescribed in combination with CYP450 3A4 inhibitors, particularly when used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139955/", "reference_text": "[1] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[2] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[5] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.", "alternatives_a": "Raloxifene, Prasterone, Danazol, Bazedoxifene", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139795, "ingredient1": "Mirabegron", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme. However, in vivo results indicate that CYP450 3A4 may play a limited role in the overall elimination. No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139956/", "reference_text": "[1] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 139796, "ingredient1": "Nateglinide", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the plasma concentrations of nateglinide. The interaction stems from simultaneous inhibition of CYP450 2C9 and 3A4, the isoenzymes responsible for the metabolic clearance of nateglinide.", "source": "DDInter", "management_text": "Caution is advised if nateglinide is used in combination with azole antifungal agents that inhibit both CYP450 2C9 and 3A4. Blood glucose should be closely monitored, and the nateglinide dosage adjusted as necessary. Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nateglinide is used in combination with azole antifungal agents that inhibit both CYP450 2C9 and 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139957/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Niemi M, Neuvonen M, Juntti-Patinen L, Backman JT, Neuvonen PJ \"Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.\" Clin Pharmacol Ther 74 (2003): 25-31[3] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998): 525-38[4] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ \"Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.\" Br J Clin Pharmacol 60 (2005): 208-17[6] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[9] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[16] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[17] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139797, "ingredient1": "Nefazodone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with nefazodone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nefazodone.", "source": "DDInter", "management_text": "Caution is advised if nefazodone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. A lower initial dosage, as well as clinical and laboratory monitoring, may be appropriate for some drugs.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nefazodone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139958/", "reference_text": "[1] \"Product Information. Serzone (nefazodone).\" Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More", "updated_at": 1767369485}, {"id": 139798, "ingredient1": "Nelfinavir", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with nelfinavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nelfinavir.", "source": "DDInter", "management_text": "Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nelfinavir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139959/", "reference_text": "[1] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.", "alternatives_a": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Micafungin, More", "updated_at": 1767369485}, {"id": 139799, "ingredient1": "Nicardipine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most CCBs.", "source": "DDInter", "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139960/", "reference_text": "[1] Sandstrom R, Knutson TW, Knutson L, Jansson B, Lennernas H \"The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans.\" Br J Clin Pharmacol 48 (1999): 180-9[2] Neuvonen PJ, Suhonen R \"Itraconazole interacts with felodipine.\" J Am Acad Dermatol 33 (1995): 134-5[3] Tailor SAN \"Peripheral edema due to nifedipine-itraconazole interaction: a case report.\" Arch Dermatol 132 (1996): 1374[4] Tailor SAN, Gupta AK, Walker SE, Shear NH \"Peripheral edema due to nifedipine-itraconazole interaction: a case report.\" Arch Dermatol 132 (1996): 350-2[5] Jalava KM, Olkkola KT, Neuvonen PJ \"Itraconazole greatly increases plasma concentrations and effects of felodipine.\" Clin Pharmacol Ther 61 (1997): 410-5[6] Rosen T \"Debilitating edema associated with itraconazole therapy.\" Arch Dermatol 130 (1994): 260-1[7] Heinig R, Adelmann HG, Ahr G \"The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine.\" Eur J Clin Pharmacol 55 (1999): 57-60[8] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[9] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[12] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[13] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[14] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[15] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[16] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[17] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[18] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[19] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[21] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[22] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[23] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[24] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[25] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[26] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[27] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[28] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[29] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[30] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[31] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[32] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[33] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[35] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[36] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[37] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[38] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[40] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Clevidipine", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Nystatin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, Caspofungin, More", "updated_at": 1767369485}, {"id": 139800, "ingredient1": "Nilotinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139961/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139801, "ingredient1": "Nimodipine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most CCBs.", "source": "DDInter", "management_text": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139962/", "reference_text": "[1] Sandstrom R, Knutson TW, Knutson L, Jansson B, Lennernas H \"The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans.\" Br J Clin Pharmacol 48 (1999): 180-9[2] Neuvonen PJ, Suhonen R \"Itraconazole interacts with felodipine.\" J Am Acad Dermatol 33 (1995): 134-5[3] Tailor SAN \"Peripheral edema due to nifedipine-itraconazole interaction: a case report.\" Arch Dermatol 132 (1996): 1374[4] Tailor SAN, Gupta AK, Walker SE, Shear NH \"Peripheral edema due to nifedipine-itraconazole interaction: a case report.\" Arch Dermatol 132 (1996): 350-2[5] Jalava KM, Olkkola KT, Neuvonen PJ \"Itraconazole greatly increases plasma concentrations and effects of felodipine.\" Clin Pharmacol Ther 61 (1997): 410-5[6] Rosen T \"Debilitating edema associated with itraconazole therapy.\" Arch Dermatol 130 (1994): 260-1[7] Heinig R, Adelmann HG, Ahr G \"The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine.\" Eur J Clin Pharmacol 55 (1999): 57-60[8] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[9] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[12] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[13] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[14] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[15] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[16] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[17] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[18] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[19] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[20] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[21] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[22] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[23] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[24] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[25] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[26] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[27] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[28] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[29] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[30] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[31] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[32] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[33] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[34] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[35] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[36] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[37] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[38] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[40] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Clevidipine", "alternatives_b": "Rifamycin, Amphotericin B, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, More", "updated_at": 1767369485}, {"id": 139802, "ingredient1": "Nisoldipine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139963/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Clevidipine", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139803, "ingredient1": "Norgestrel", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139964/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Megestrol acetate, Dienogest, Megestrol acetate, Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 139804, "ingredient1": "Nortriptyline", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "The coadministration with azole antifungal agents may increase the plasma concentrations of some tricyclic antidepressants (TCAs). Elevated TCA levels may result in CNS toxicity, anticholinergic symptoms, and QT interval prolongation. The mechanism is decreased TCA clearance due to azole-related inhibition of the CYP450 3A4 isoenzyme, which is partially responsible for the metabolism of TCAs like amitriptyline, clomipramine, imipramine, and possibly others.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary. Serum TCA levels should be monitored following initiation or discontinuation of azole antifungal therapy. Patients should be advised to notify their caregiver if they experience excessive dry mouth, visual disturbances, urinary retention, dizziness, syncope, fast or irregular heartbeat, constipation, or seizures.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139965/", "reference_text": "[1] Dorsey ST, Biblio LA \"Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline.\" Am J Emerg Med 18 (2000): 227-9[2] Gannon RH \"Fluconazole-nortriptyline drug interaction.\" Ann Pharmacother 26 (1992): 1456[3] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E \"Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.\" Br J Clin Pharmacol 43 (1997): 315-8[4] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E \"Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.\" Br J Clin Pharmacol 43 (1997): 315-8[5] Robinson RF, Nahata MC, Olshefski RS \"Syncope associated with concurrent amitriptyline and fluconazole therapy.\" Ann Pharmacother 34 (2000): 1406-9[6] Newberry DL, Bass SN, Mbanefo CO \"A fluconazole/amitriptyline drug interaction in three male adults.\" Clin Infect Dis 24 (1997): 270-1", "alternatives_a": "Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139805, "ingredient1": "Olaparib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors. A dosage reduction may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of olaparib with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139966/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 139806, "ingredient1": "Oliceridine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139967/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Dihydrocodeine, More", "updated_at": 1767369485}, {"id": 139807, "ingredient1": "Osimertinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when osimertinib is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as diarrhea, QT prolongation, torsade de pointes arrhythmia, and cardiomyopathy (e.g., cardiac failure, pulmonary edema, ejection fraction decreases), and the osimertinib dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osimertinib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139968/", "reference_text": "[1] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139808, "ingredient1": "Ospemifene", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with drugs that are known to inhibit both CYP450 3A4 and 2C9 may increase the plasma concentrations of ospemifene, which is primarily metabolized by these isoenzymes, with additional contribution from CYP450 2C19 and other pathways. The interaction has been studied with fluconazole, a moderate CYP450 3A4/potent CYP450 2C9/moderate CYP450 2C19 inhibitor.", "source": "DDInter", "management_text": "Caution is advised if ospemifene is used in combination with drugs that are inhibitors of both CYP450 3A4 and 2C9. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ospemifene is used in combination with drugs that are inhibitors of both CYP450 3A4 and 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139969/", "reference_text": "[1] \"Product Information. Osphena (ospemifene).\" Shionogi USA Inc, Florham Park, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Osphena (ospemifene).\" Shionogi USA Inc, Florham Park, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Raloxifene, Prasterone, Danazol, Bazedoxifene", "updated_at": 1767369485}, {"id": 139809, "ingredient1": "Paclitaxel (protein-bound)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.", "source": "DDInter", "management_text": "Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.", "mechanism_text": "Metabolism", "recommendation": "Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139970/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K \"Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma.\" Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J \"Drug interactions of paclitaxel metabolism in human liver microsomes.\" J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D \"Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.\" Drugs 48 (1994): 794-847[5] \"Product Information. Abraxane (paclitaxel protein-bound).\" American Pharmaceutical Partners, Schaumberg, IL.[6] \"Product Information. Taxol (paclitaxel).\" Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM \"Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract).\" Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[9] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. \"Australian Product Information.\" O 0[12] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ \"Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.\" Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139810, "ingredient1": "Palbociclib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when palbociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for palbociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, patients should be monitored for increased adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when palbociclib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139971/", "reference_text": "[1] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139811, "ingredient1": "Panobinostat", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when panobinostat is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as nausea, vomiting, diarrhea, anorexia, peripheral edema, cardiotoxicity, ECG abnormalities, electrolyte disturbances, bleeding complications, hepatotoxicity and myelosuppression, and the dosage of panobinostat adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when panobinostat is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139972/", "reference_text": "[1] Hamberg P, Woo MM, Chen LC, et al. \"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\" Cancer Chemother Pharmacol 68 (2011): 805-13[2] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 139812, "ingredient1": "Paricalcitol", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when paricalcitol is used with potent CYP450 3A4 inhibitors. Serum calcium and phosphorus levels should be monitored closely. If clinically significant hypercalcemia develops, the paricalcitol dose should be reduced or interrupted and support therapy administered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when paricalcitol is used with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139973/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zemplar (paricalcitol).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139813, "ingredient1": "Pazopanib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pazopanib, which is primarily metabolized by the isoenzyme. Although not studied, the interaction may increase the risk of QT interval prolongation and torsade de pointes arrhythmia as well as severe and fatal hepatotoxicity associated with the use of pazopanib.", "source": "DDInter", "management_text": "Caution is advised if pazopanib is prescribed in combination with inhibitors of CYP450 3A4. Pharmacologic response to pazopanib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the pazopanib dosage adjusted as necessary. Patients should have liver function tests (ALT, AST, bilirubin), electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. In addition, they should seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pazopanib is prescribed in combination with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139974/", "reference_text": "[1] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139814, "ingredient1": "Pexidartinib", "ingredient2": "Miconazole", "severity": "Major", "effect": "Coadministration of pexidartinib with moderate CYP450 3A4 inhibitors may significantly increase the plasma concentrations and the incidence and severity of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4, the primary isoenzyme responsible for the metabolic clearance of pexidartinib.", "source": "DDInter", "management_text": "The use of pexidartinib with a moderate CYP450 3A4 inhibitor should generally be avoided. If concomitant use is required, the dose of pexidartinib should be reduced according to the manufacturer's recommendations. If concomitant use of a moderate CYP450 3A4 inhibitor is discontinued, the dose of pexidartinib may be increased, after 3 plasma half-lives of the moderate CYP450 3A4 inhibitor, to the dose that was used prior to starting the moderate CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of pexidartinib with a moderate CYP450 3A4 inhibitor should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139975/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Micafungin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139815, "ingredient1": "Phenytoin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Miconazole may increase plasma hydantoin concentrations. Phenytoin toxicity has been reported with concurrent parenteral and oral miconazole. The mechanism may be related to inhibition of hepatic CYP450 2C9, the major metabolic pathway for phenytoin.", "source": "DDInter", "management_text": "If miconazole and hydantoins must be used concomitantly, caution is recommended, as is close observation for clinical and laboratory evidence of altered phenytoin effect. Patients should be advised to notify their physician if they experience symptoms of possible hydantoin toxicity, including drowsiness, visual disturbances, change in mental status, seizures, nausea, or ataxia.", "mechanism_text": "Metabolism", "recommendation": "If miconazole and hydantoins must be used concomitantly, caution is recommended, as is close observation for clinical and laboratory evidence of altered phenytoin effect.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139976/", "reference_text": "[1] Rolan PE, Somogyi AA, Drew MJ, et al \"Phenytoin intoxication during treatment with parenteral miconazole.\" Br Med J (Clin Res Ed) 287 (1983): 1760[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[4] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[5] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[6] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[9] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[10] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[11] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[12] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[13] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6[14] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[15] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[16] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[17] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Flucytosine, Anidulafungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139816, "ingredient1": "Pimavanserin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme. High plasma levels of pimavanserin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as peripheral edema and QT prolongation, and the pimavanserin dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pimavanserin is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139977/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, More", "updated_at": 1767369485}, {"id": 139817, "ingredient1": "Pimecrolimus (topical)", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Theoretically, coadministration with CYP450 3A inhibitors may increase the plasma concentrations of pimecrolimus, which has been shown in vitro to undergo metabolism by this subfamily of hepatic microsomal enzymes. Although clinically significant drug interactions are not expected due to minimal systemic absorption of topically administered pimecrolimus, the possibility cannot be ruled out.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139978/", "reference_text": "[1] \"Product Information. Elidel (pimecrolimus topical).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139818, "ingredient1": "Pimozide", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of pimozide, which is partially metabolized by the isoenzyme. The use of pimozide has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death. The interaction has not been studied with clotrimazole troches or miconazole buccal tablets. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 such as pimozide cannot be ruled out.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, the concomitant use with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. Otherwise, patients should be cautioned about the potential for interaction and advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, the concomitant use with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139979/", "reference_text": "[1] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[2] Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ \"Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication.\" Am J Med Sci 309 (1995): 315-6[3] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[4] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[5] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[6] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[7] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.", "alternatives_a": "Fluphenazine, Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, More", "updated_at": 1767369485}, {"id": 139819, "ingredient1": "Pirfenidone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 may increase the plasma concentrations of pirfenidone, especially when used in addition to a moderate or potent CYP450 1A2 inhibitor. Pirfenidone is primarily (70% to 80%) metabolized by CYP450 1A2, with minor contribution from CYP450 2C9, 2C19, 2D6, and 2E1.", "source": "DDInter", "management_text": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.g., certain fluoroquinolones, oral contraceptives, deferasirox, methoxsalen, mexiletine, thiabendazole, ticlopidine, zileuton) should be avoided. No particular precaution is necessary if pirfenidone and CYP450 2C9, 2C19, 2D6, and/or 2E1 inhibitors are coadministered without a moderate or potent CYP450 1A2 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139980/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc, Brisbane, CA.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 139820, "ingredient1": "Polatuzumab vedotin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when polatuzumab vedotin is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139981/", "reference_text": "[1] \"Product Information. Polivy (polatuzumab vedotin).\" Genentech, South San Francisco, CA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 139821, "ingredient1": "Ponatinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if ponatinib is used in combination with moderate CYP450 3A4 inhibitors. Patients should be monitored for potentially increased side effects such as thromboembolism, ischemia, congestive heart failure, hypertension, hepatotoxicity, pancreatitis, myelosuppression, hemorrhage, and fluid retention.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ponatinib is used in combination with moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139982/", "reference_text": "[1] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.[2] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139822, "ingredient1": "Progesterone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139983/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Megestrol acetate, Dienogest, Megestrol acetate, Dienogest", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139823, "ingredient1": "Progesterone (topical)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139984/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139824, "ingredient1": "Quetiapine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary. Patients should be monitored for potentially increased adverse effects such as dizziness, drowsiness, dry mouth, constipation, increased appetite, weight gain, extrapyramidal symptoms, tardive dyskinesia, hyperglycemia, dyslipidemia, hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia), orthostatic hypotension, blood pressure increases (in children and adolescents), QT prolongation, cognitive and motor impairment, dysphagia, and heat-related illnesses due to disruption of body temperature regulation.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139985/", "reference_text": "[1] Spina E, de Leon J \"Metabolic drug interactions with newer antipsychotics: a comparative review.\" Basic Clin Pharmacol Toxicol 100 (2007): 4-22[2] \"Quetiapine for schizophrenia.\" Med Lett Drugs Ther 39 (1997): 117-8[3] DeVane CL, Nemeroff CB \"Clinical pharmacokinetics of quetiapine - An atypical antipsychotic.\" Clin Pharmacokinet 40 (2001): 509-22[4] Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB \"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.\" Br J Clin Pharmacol 61 (2006): 58-69[5] Hantson P, Di Fazio V, Wallemacq P \"Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose.\" Drug Metab Lett 4 (2010): 7-8[6] Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, et al. \"Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine.\" Pharmacopsychiatry 41 (2008): 258-9[7] Spina E, Scordo MG, D'Arrigo C \"Metabolic drug interactions with new psychotropic agents.\" Fundam Clin Pharmacol 17 (2003): 517-38[8] Urichuk L, Prior TI, Dursun S, Baker G \"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.\" Curr Drug Metab 9 (2008): 410-8[9] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[10] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[13] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[14] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[15] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[16] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[17] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[19] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[20] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[21] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[22] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[23] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[24] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[25] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[27] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[28] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[29] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[30] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[31] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[32] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[33] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[34] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[35] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[36] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[37] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[38] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[39] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[40] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[41] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, Caspofungin, Oteseconazole, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, More", "updated_at": 1767369485}, {"id": 139825, "ingredient1": "Quinestrol", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139986/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993): 436[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139826, "ingredient1": "Quinidine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of quinidine, which is primarily metabolized by the isoenzyme. The use of quinidine has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death. The interaction has not been studied with clotrimazole troches or miconazole buccal tablets. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 such as quinidine cannot be ruled out.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of quinidine, the concomitant use with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. Otherwise, patients should be cautioned about the potential for interaction and advised to seek medical attention if they experience signs and symptoms that could indicate quinidine toxicity such as tinnitus, hearing loss, visual disturbances, diarrhea, dizziness, weakness, headache, syncope, and rapid or irregular heartbeats.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of quinidine, the concomitant use with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139987/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[3] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[4] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, Amphotericin B, More", "updated_at": 1767369485}, {"id": 139827, "ingredient1": "Quinine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if quinine is used in combination with potent and moderate CYP450 3A4 inhibitors. Patients should be monitored closely for adverse reactions associated with quinine such as hematologic toxicities and cardiac arrhythmias including torsade de pointes and atrial fibrillation. Patients should be advised to contact their physician if they experience increased side effects such as headache, flushing, sweating, nausea, vomiting, diarrhea, abdominal pain, tinnitus, dizziness, vertigo, hearing impairment, blurred vision, vision impairment, and irregular heart rhythm.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if quinine is used in combination with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139988/", "reference_text": "[1] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Wanwimolruk S, Paine MF, Pusek SN, Watkins PB \"Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?\" Br J Clin Pharmacol 54 (2002): 643-51[4] Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L \"Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.\" Eur J Clin Pharmacol 59 (2003): 23-8[5] Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL \"The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo.\" Clin Pharmacol Ther 66 (1999): 454-60[6] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[7] Zhao XJ, Ishizaki T \"A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (K-i) and type of inhibition.\" Eur J Drug Metab Pharm 24 (1999): 272-8[8] Mirghani RA, Hellgren U, Bertilsson L, Gustafsson LL, Ericsson O \"Metabolism and elimination of quinine in healthy volunteers.\" Eur J Clin Pharmacol (2003):[9] Zhao XJ, Ishizaki T \"Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.\" Br J Clin Pharmacol 44 (1997): 505-11[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[12] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[13] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[15] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[16] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[17] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[18] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[19] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[21] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[22] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[23] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[24] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[25] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[26] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[27] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[28] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[30] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[31] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[32] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[35] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[36] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[37] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[38] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[39] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[40] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[42] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[44] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[45] Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S \"Grapefruit juice has no effect on quinine pharmacokinetics.\" Eur J Clin Pharmacol 55 (1999): 393-8[46] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[47] Hermans K, Stockman D, Van den Branden F \"Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome.\" Am J Med 114 (2003): 511-2[48] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "updated_at": 1767369485}, {"id": 139828, "ingredient1": "Ramelteon", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations and pharmacologic effects of ramelteon, which is partially metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised if ramelteon is prescribed in combination with potent inhibitors of CYP450 3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, delavirdine, nefazodone, protease inhibitors, ketolide and certain macrolide antibiotics) and/or CYP450 2C9 (e.g., fluconazole, gemfibrozil, imatinib, miconazole). A reduction in the ramelteon dosage may be necessary in patients who experience excessive sedation.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ramelteon is prescribed in combination with potent inhibitors of CYP450 3A4 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139989/", "reference_text": "[1] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139829, "ingredient1": "Ranolazine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139990/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Alprostadil, Indomethacin, Ubidecarenone, Adenosine, Regadenoson", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "updated_at": 1767369485}, {"id": 139830, "ingredient1": "Repaglinide", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of repaglinide, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations.", "mechanism_text": "Metabolism", "recommendation": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139991/", "reference_text": "[1] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[2] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[3] Hatorp V, Hansen KT, Thomsen MS \"Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.\" J Clin Pharmacol 43 (2003): 649-60[4] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ \"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.\" Diabetologia 46 (2003): 347-51[5] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[6] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT \"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.\" Br J Clin Pharmacol 56 (2003): 305-14[7] Tornio A, Niemi M, Neuvonen M, et al. \"The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.\" Clin Pharmacol Ther 84 (2008): 403-11[8] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[9] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[10] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[13] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[14] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[15] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[16] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[17] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[18] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[19] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[20] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[21] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[22] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[23] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[24] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[27] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[28] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[30] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[31] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[32] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[33] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[34] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[35] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[36] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[37] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[38] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[39] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139831, "ingredient1": "Retapamulin (topical)", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of retapamulin, which is primarily metabolized by the isoenzyme. However, dosage adjustments are not necessary due to the low systemic exposure to retapamulin following topical application.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139992/", "reference_text": "[1] \"Product Information. Altabax (retapamulin topical).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139832, "ingredient1": "Ribociclib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and risk of adverse effects of ribociclib, which is a substrate of the isoenzyme. Administration of erythromycin, a moderate CYP450 3A4 inhibitor, is predicted to increase ribociclib Cmax and AUC by 1.3- and 1.9-fold, respectively.", "source": "DDInter", "management_text": "Caution is advised when ribociclib is used with CYP450 3A4 inhibitors. Dosage adjustment for ribociclib is not generally considered necessary for suspected interactions with mild to moderate inhibitors. However, some manufacturers of ribociclib recommend that concomitant use with moderate CYP450 3A4 inhibitor verapamil should be avoided (AU, UK). Patients should be monitored for the development of ribociclib-related adverse effects such as infections, neutropenia, leucopenia, anemia, thrombocytopenia, nausea, vomiting, diarrhea, stomatitis, anorexia, alopecia, fatigue, headache, and abnormal liver function.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ribociclib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139993/", "reference_text": "[1] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139833, "ingredient1": "Ripretinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration of CYP450 3A4 inhibitors with ripretinib may increase the plasma concentrations and the risk of adverse effects (e.g., palmar-plantar erythrodysesthesia, hypertension, cardiac dysfunction, arthralgia/myalgia) of ripretinib and its active metabolite (DP-5439). The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139994/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[18] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[19] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[22] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[29] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[30] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[31] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[32] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[33] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[34] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139834, "ingredient1": "Rivaroxaban", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with moderate or potent inhibitors of CYP450 3A4 may increase the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "In patients with significant renal impairment, the use of rivaroxaban with moderate or potent inhibitors of CYP450 3A4 should be approached with caution. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women). Renal function should also be assessed periodically, and treatment with rivaroxaban discontinued if acute renal failure develops. Due to the lack of clinical data, rivaroxaban is not recommended in patients with CrCl below 30 mL/min when used for the prophylaxis of deep vein thrombosis and in patients with CrCl below 15 mL/min when used for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.", "mechanism_text": "Metabolism", "recommendation": "In patients with significant renal impairment, the use of rivaroxaban with moderate or potent inhibitors of CYP450 3A4 should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139995/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Xarelto (rivaroxaban).\" Bayer Inc, Toronto, IA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Betrixaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, More", "updated_at": 1767369485}, {"id": 139835, "ingredient1": "Romidepsin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of romidepsin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when romidepsin is used with potent CYP450 3A4 inhibitors. Patients should have complete blood cell counts, electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when romidepsin is used with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139996/", "reference_text": "[1] \"Product Information. Istodax (romidepsin).\" Gloucester Pharmaceuticals, Cambridge, MA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 139836, "ingredient1": "Ropivacaine", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ropivacaine. Although ropivacaine is primarily metabolized by CYP450 1A2, it has been shown to undergo some metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139997/", "reference_text": "[1] Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT \"The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.\" Anesth Analg 91 (2000): 1207-12[2] Ekstrom G, Gunnarsson UB \"Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.\" Drug Metab Dispos 24 (1996): 955-61[3] Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL \"Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.\" Clin Pharmacol Ther 64 (1998): 484-91[4] McClure JH \"Ropivacaine.\" Br J Anaesth 76 (1996): 300-7[5] \"Product Information. Naropin (ropivacaine).\" Astra USA, Westborough, MA.[6] Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M \"Metabolism and excretion of ropivacaine in humans.\" Drug Metab Dispos 24 (1996): 962-8[7] Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y \"Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450.\" Anesthesiology 82 (1995): 214-20", "alternatives_a": "Lidocaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139837, "ingredient1": "Ruxolitinib", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with mild or moderate inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme. No dosage adjustment is recommended when ruxolitinib is coadministered with mild or moderate CYP450 3A4 inhibitors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139998/", "reference_text": "[1] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139838, "ingredient1": "Salmeterol", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/139999/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Epinephrine, Olodaterol, Cromoglicic acid, Ipratropium, Bitolterol, Orciprenaline, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139839, "ingredient1": "Sibutramine", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme. Inhibitors such as ketoconazole, cimetidine, and erythromycin have caused moderate increases in the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the active metabolites.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140000/", "reference_text": "[1] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[2] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[3] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139840, "ingredient1": "Sildenafil", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140001/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Caspofungin, Micafungin, Amphotericin B, More", "updated_at": 1767369485}, {"id": 139841, "ingredient1": "Silodosin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of silodosin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4. Pharmacologic response to silodosin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the silodosin dosage adjusted as necessary. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if silodosin is prescribed in combination with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140002/", "reference_text": "[1] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[2] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "Finasteride, Terazosin", "updated_at": 1767369485}, {"id": 139842, "ingredient1": "Simvastatin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors that are substrates of the isoenzyme. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death. The interaction has not been studied with clotrimazole troches or miconazole buccal tablets. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 such as lovastatin, simvastatin, and atorvastatin cannot be ruled out.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening musculoskeletal toxicity associated with increased plasma levels of HMG-CoA reductase inhibitors, the concomitant use of lovastatin, red yeast rice (which contains lovastatin), and simvastatin with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. Atorvastatin may be used with caution, although the dosage should start low and probably not exceed 40 mg/day. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. No interaction is expected with fluvastatin and pravastatin, since they are not metabolized by CYP450 3A4.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening musculoskeletal toxicity associated with increased plasma levels of HMG-CoA reductase inhibitors, the concomitant use of lovastatin, red yeast rice (which contains lovastatin), and simvastatin with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140003/", "reference_text": "[1] Neuvonen PJ, Jalava KM \"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 60 (1996): 54-61[2] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on cerivastatin pharmacokinetics.\" Eur J Clin Pharmacol 54 (1999): 851-5[3] Lomaestro BM, Piatek MA \"Update on drug interactions with azole antifungal agents.\" Ann Pharmacother 32 (1998): 915-28[4] Gilad R, Lampl Y \"Rhabdomyolysis induced by simvastatin and ketoconazole treatment.\" Clin Neuropharmacol 22 (1999): 295-7[5] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[6] Horn M \"Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.\" Arch Dermatol 132 (1996): 1254[7] Lees RS, Lees AM \"Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.\" N Engl J Med 333 (1995): 664-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics of atorvastatin.\" Clin Pharmacol Ther 64 (1998): 58-65[10] Kivisto KT, Kantola T, Neuvonen PJ \"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.\" Br J Clin Pharmacol 46 (1998): 49-53[11] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[12] Neuvonen PJ, Kantola T, Kivisto KT \"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.\" Clin Pharmacol Ther 63 (1998): 332-41[13] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[14] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[15] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[16] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[17] McMillan K \"Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors.\" Am J Health Syst Pharm 53 (1996): 2206-14[18] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M \"Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved.\" Drug Metab Dispos 25 (1997): 321-31[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Flucytosine, Anidulafungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139843, "ingredient1": "Sirolimus", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140004/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, More", "alternatives_b": "Rifamycin, Paromomycin, Rifaximin, Anidulafungin, Caspofungin, Oteseconazole, Salicylic acid, Selenium Sulfide, Thiabendazole, Ciclopirox, Terbinafine, More", "updated_at": 1767369485}, {"id": 139844, "ingredient1": "Solifenacin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of solifenacin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of solifenacin such as severe abdominal pain or constipation for 3 or more days. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140005/", "reference_text": "[1] \"Product Information. VESIcare (solifenacin).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 139845, "ingredient1": "Sonidegib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when sonidegib is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for potentially increased adverse reactions, particularly musculoskeletal toxicity, and sonidegib treatment interrupted or discontinued accordingly.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when sonidegib is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140006/", "reference_text": "[1] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 139846, "ingredient1": "Stiripentol", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2, 2C19, and/or 3A4 may increase the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways.", "source": "DDInter", "management_text": "Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors. Patients should be monitored for potentially increased adverse effects such as anorexia, nausea, vomiting, weight loss, somnolence, dizziness, confusion, difficulty concentrating, ataxia, hypotonia, tremor, hyperkinesia, dysarthria, suicidal ideation/behaviour, neutropenia, and thrombocytopenia. Dosage adjustments for stiripentol or alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140007/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[7] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "updated_at": 1767369485}, {"id": 139847, "ingredient1": "Suvorexant", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if suvorexant is prescribed with inhibitors of CYP450 3A4. Patients should be monitored for excessive sedation and other side effects, and the suvorexant dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if suvorexant is prescribed with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140008/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[3] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More", "updated_at": 1767369485}, {"id": 139848, "ingredient1": "Tacrolimus", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140009/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "alternatives_b": "Rifamycin, Paromomycin, Rifaximin, Anidulafungin, Micafungin, Oteseconazole, Salicylic acid, Thiabendazole, Ciclopirox, Econazole, Tioconazole, More", "updated_at": 1767369485}, {"id": 139849, "ingredient1": "Tadalafil", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with drugs that are potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of tadalafil with potent 3A4 inhibitors is not recommended in patients being treated for pulmonary arterial hypertension. In addition, some authorities recommend avoiding concomitant use of tadalafil during and for 2 weeks after treatment with itraconazole in patients with pulmonary arterial hypertension. For erectile dysfunction, tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours when taken on an as needed basis in patients treated concomitantly with a potent CYP450 3A4 inhibitor. When taken on a daily basis, the dose should not exceed 2.5 mg per day. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of tadalafil with potent 3A4 inhibitors is not recommended in patients being treated for pulmonary arterial hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140010/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[8] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139850, "ingredient1": "Tasimelteon", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4. Patients should be monitored for excessive sedation and other side effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if tasimelteon is prescribed in combination with inhibitors of CYP450 1A2 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140011/", "reference_text": "[1] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Hetlioz (tasimelteon).\" Vanda Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More", "updated_at": 1767369485}, {"id": 139851, "ingredient1": "Telaprevir", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration of an azole antifungal agent and hepatitis C virus (HCV) NS3/4A protease inhibitor (boceprevir, telaprevir) may result in increased plasma concentrations of both drugs. The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme. Clinically, high plasma levels of an azole antifungal agent may increase the risk of QT interval prolongation and torsade de pointes arrhythmia.", "source": "DDInter", "management_text": "Caution is advised if azole antifungal agents are used in combination with HCV NS3/4A protease inhibitors. Dosage adjustments may be required. According to the product information for boceprevir and telaprevir, high dosages of ketoconazole and itraconazole (>200 mg/day) should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if azole antifungal agents are used in combination with HCV NS3/4A protease inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140012/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Fluconazole, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 139852, "ingredient1": "Temsirolimus", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration of temsirolimus with inhibitors of CYP450 3A4 may increase the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors. Pharmacologic response to temsirolimus should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the temsirolimus dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if temsirolimus is prescribed in combination with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140013/", "reference_text": "[1] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Rifamycin, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Anidulafungin, Micafungin, Caspofungin, Oteseconazole, Salicylic acid, Selenium Sulfide, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139853, "ingredient1": "Terfenadine", "ingredient2": "Miconazole", "severity": "Major", "effect": "Coadministration with azole antifungal agents may significantly increase the plasma concentrations of terfenadine. The mechanism is azole inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of terfenadine. High plasma levels of terfenadine have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia and torsade de pointes; cardiac arrest; and sudden death. Within the azole class, ketoconazole and itraconazole are considered the most potent inhibitors, while fluconazole is comparatively weak and generally causes clinically significant interactions with CYP450 3A4 substrates only at dosages of 200 mg/day or more.", "source": "DDInter", "management_text": "The use of terfenadine with most azole antifungal agents, including fluconazole at multiple doses of 400 mg or higher, is considered contraindicated. Some authorities consider concomitant administration of terfenadine and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole (AU). Loratadine, cetirizine, or fexofenadine may be safer alternatives during therapy with azole antifungal agents.", "mechanism_text": "Metabolism", "recommendation": "The use of terfenadine with most azole antifungal agents, including fluconazole at multiple doses of 400 mg or higher, is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140014/", "reference_text": "[1] Crane JK, Shih HT \"Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine.\" Am J Med 95 (1993): 445-6[2] Woosley RL, Chen Y, Freiman JP, Gillis RA \"Mechanism of the cardiotoxic actions of terfenadine.\" JAMA 269 (1993): 1532-6[3] Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R \"Cardiovascular safety of fexofenadine HCl.\" Am J Cardiol 83 (1999): 1451-4[4] Eller MG, Okerholm RA \"Pharmacokinetic interaction between terfenadine and ketoconazole.\" Clin Pharmacol Ther 49 (1991): 130[5] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[6] Cantilena LR Jr, Ferguson CL, Monahan BP \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2376[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[8] Kivisto KT, Neuvonen PJ, Klotz U \"Inhibition of terfenadine metabolism - pharmacokinetic and pharmacodynamic consequences.\" Clin Pharmacokinet 27 (1994): 1-5[9] Venkatakrishnan K, von Moltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.\" Clin Pharmacokinet 38 (2000): 111-80[10] \"Product Information. Nizoral (ketoconazole).\" Janssen Pharmaceutica, Titusville, NJ. (1992):[11] June RA, Nasr I \"Torsades de pointes with terfenadine ingestion.\" Am J Emerg Med 15 (1997): 542-3[12] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[15] Jurima-Romet M, Crawford K, Cyr T, Inaba T \"Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.\" Drug Metab Dispos 22 (1994): 849-57[16] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[17] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[18] Honig PK, Cantilena LR \"Ketoconazole and fluconazole drug interactions.\" Arch Intern Med 154 (1994): 1038-41[19] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[20] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[21] Ament PW, Paterson A \"Drug interactions with the nonsedating antihistamines.\" Am Fam Physician 56 (1997): 223[22] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[23] Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR \"Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics.\" J Clin Pharmacol 33 (1993): 1201-6[24] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[25] Honig PK, Worham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR \"The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans.\" Clin Pharmacol Ther 53 (1993): 630-6[26] Vonmoltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI \"Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo.\" J Clin Psychopharmacol 16 (1996): 104-12[27] Smith SJ \"Cardiovascular toxicity of antihistamines.\" Otolaryngol Head Neck Surg 111 Suppl (1994): 348-54[28] \"Product Information. Sporonox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[29] Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso PJ, Lynch JJ \"Cardiac electrophysiological actions of the histamine h-1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine.\" Circ Res 76 (1995): 110-9[30] Berul CI, Morad M \"Regulation of potassium channels by nonsedating antihistamines.\" Circulation 91 (1995): 2220-5[31] \"Product Information. Seldane (terfenadine).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[33] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[34] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[35] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[36] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[37] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[38] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[39] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[40] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[41] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[42] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[43] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[44] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[45] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[46] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[47] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[48] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139854, "ingredient1": "Ticagrelor", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Although administration with moderate CYP450 3A4 inhibitors is thought to be generally safe, it may be advisable to monitor pharmacologic response to ticagrelor more closely following the addition and withdrawal of these agents. Discontinuation of the concomitant medication may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Although administration with moderate CYP450 3A4 inhibitors is thought to be generally safe, it may be advisable to monitor pharmacologic response to ticagrelor more closely following the addition and withdrawal of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140015/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "alternatives_b": "Betrixaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, More", "updated_at": 1767369485}, {"id": 139855, "ingredient1": "Tipranavir", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with azole antifungal agents may substantially increase the plasma concentrations of tipranavir administered in combination with low-dose ritonavir. The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of both tipranavir and ritonavir.", "source": "DDInter", "management_text": "In patients treated with tipranavir/ritonavir, dosages of fluconazole, itraconazole, and ketoconazole exceeding 200 mg/day are not recommended. Due to multiple enzymes involved with voriconazole metabolism, the interaction is difficult to predict and no recommendations are available.", "mechanism_text": "Metabolism", "recommendation": "In patients treated with tipranavir/ritonavir, dosages of fluconazole, itraconazole, and ketoconazole exceeding 200 mg/day are not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140016/", "reference_text": "[1] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, More", "updated_at": 1767369485}, {"id": 139856, "ingredient1": "Tofacitinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140017/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 139857, "ingredient1": "Tolazamide", "ingredient2": "Miconazole", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the plasma concentrations of sulfonylureas, many of which have been found to be substrates of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9. Blood glucose should be closely monitored, and the sulfonylurea dosage adjusted as necessary. Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the azole antifungal agent, and contact their physician.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140018/", "reference_text": "[1] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[2] \"Product Information. Monistat (miconazole).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[3] Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG \"Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.\" Pharmacogenomics 10 (2009): 1781-7[4] Jeong S, Nguyen PD, Desta Z \"Comprehensive in vitro inhibition analysis of eight cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A.\" Antimicrob Agents Chemother 53 (2009): 541-51[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[8] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998): 525-38[9] Rowe BR, Thorpe J, Barnett A \"Safety of fluconazole in women taking oral hypoglycaemic agents.\" Lancet 339 (1992): 255-6[10] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[11] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[12] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[13] Shon JH, Yoon YR, Kim MJ, et al. \"Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.\" Br J Clin Pharmacol 59 (2005): 552-63[14] Venkatakrishnan K, von Moltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.\" Clin Pharmacokinet 38 (2000): 111-80[15] Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT \"Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.\" Clin Pharmacol Ther 72 (2002): 326-32[16] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[17] Tirkkonen T, Heikkila P, Huupponen R, Laine K \"Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.\" J Intern Med 268 (2010): 359-66[18] Shobha JC, Muppidi MR \"Interaction between voriconazole and glimepiride.\" J Postgrad Med 56 (2010): 44-5[19] Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.\" Drug Metab Disposition 28 (2000): 475-81[20] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[21] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[22] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[23] Holstein A, Plaschke A, Ptak M, et al. \"Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.\" Br J Clin Pharmacol 60 (2005): 103-6[24] Back DJ, Tjia JF, Karbwang J, Colbert J \"In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones.\" Br J Clin Pharmacol 26 (1988): 23-9[25] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[27] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[28] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[31] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[32] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[35] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Ertugliflozin, Semaglutide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139858, "ingredient1": "Tolbutamide", "ingredient2": "Miconazole", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the plasma concentrations of sulfonylureas, many of which have been found to be substrates of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9. Blood glucose should be closely monitored, and the sulfonylurea dosage adjusted as necessary. Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the azole antifungal agent, and contact their physician.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when sulfonylureas are used concomitantly with azole antifungal agents that inhibit CYP450 2C9.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140019/", "reference_text": "[1] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[2] \"Product Information. Monistat (miconazole).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[3] Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG \"Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.\" Pharmacogenomics 10 (2009): 1781-7[4] Jeong S, Nguyen PD, Desta Z \"Comprehensive in vitro inhibition analysis of eight cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A.\" Antimicrob Agents Chemother 53 (2009): 541-51[5] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[8] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998): 525-38[9] Rowe BR, Thorpe J, Barnett A \"Safety of fluconazole in women taking oral hypoglycaemic agents.\" Lancet 339 (1992): 255-6[10] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[11] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[12] \"Product Information. Diflucan (fluconazole).\" Roerig Division, New York, NY.[13] Shon JH, Yoon YR, Kim MJ, et al. \"Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.\" Br J Clin Pharmacol 59 (2005): 552-63[14] Venkatakrishnan K, von Moltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.\" Clin Pharmacokinet 38 (2000): 111-80[15] Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT \"Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.\" Clin Pharmacol Ther 72 (2002): 326-32[16] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990): s327-33[17] Tirkkonen T, Heikkila P, Huupponen R, Laine K \"Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.\" J Intern Med 268 (2010): 359-66[18] Shobha JC, Muppidi MR \"Interaction between voriconazole and glimepiride.\" J Postgrad Med 56 (2010): 44-5[19] Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.\" Drug Metab Disposition 28 (2000): 475-81[20] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[21] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[22] Niwa T, Shiraga T, Takagi A \"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes.\" Biol Pharm Bull 28 (2005): 1805-8[23] Holstein A, Plaschke A, Ptak M, et al. \"Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.\" Br J Clin Pharmacol 60 (2005): 103-6[24] Back DJ, Tjia JF, Karbwang J, Colbert J \"In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones.\" Br J Clin Pharmacol 26 (1988): 23-9[25] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[26] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[27] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[28] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[29] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[30] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[31] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[32] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[33] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[34] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[35] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More", "updated_at": 1767369485}, {"id": 139859, "ingredient1": "Tolterodine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the plasma concentrations of tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tolterodine should be considered. Although tolterodine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of tolterodine.", "source": "DDInter", "management_text": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors. Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience an irregular heartbeat, severe blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, or GI upset.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends a maximum tolterodine dosage of 1 mg twice daily in patients receiving concomitant CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140020/", "reference_text": "[1] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L \"Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.\" Br J Clin Pharmacol 48 (1999): 564-72", "alternatives_a": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, Caspofungin, Oteseconazole, More", "updated_at": 1767369485}, {"id": 139860, "ingredient1": "Toremifene", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of toremifene, which is primarily metabolized by the isoenzyme. Because toremifene is associated with dose- and concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy. Complete blood counts, electrolyte levels (calcium, magnesium, potassium), and liver function tests should be obtained periodically. Patients should be advised to contact their physician if they experience vaginal bleeding or potential signs of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity. Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety of toremifene may be appropriate whenever a CYP450 3A inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140021/", "reference_text": "[1] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139861, "ingredient1": "Torasemide", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of torsemide. The interaction has not been evaluated in pharmacokinetic studies; however, torsemide has been shown to undergo metabolism by CYP450 2C9.", "source": "DDInter", "management_text": "Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors. Patients should be monitored for potentially increased adverse effects such as dehydration, hypotension, electrolyte imbalances, hyperglycemia, tinnitus, and hearing loss.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140022/", "reference_text": "[1] Vormfelde SV, Engelhardt S, Zirk A, et al. \"CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.\" Clin Pharmacol Ther 76 (2004): 557-66[2] Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ \"Human hepatic cytochrome p450 2c9 catalyzes the rate-limiting pathway of torsemide metabolism.\" J Pharmacol Exp Ther 272 (1995): 1076-81[3] \"Product Information. Demedex (torsemide).\" Boehringer Mannheim, Gaithersburg, MD.[4] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998): 525-38[5] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Etacrynic acid, Bumetanide, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Rifamycin, Polymyxin B, Fidaxomicin, Rifaximin, Paromomycin, Micafungin, Caspofungin, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, More", "updated_at": 1767369485}, {"id": 139862, "ingredient1": "Trabectedin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when trabectedin is prescribed with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140023/", "reference_text": "[1] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Machiels JP, Staddon A, Herremans C, et al. \"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.\" Cancer Chemother Pharmacol 74 (2014): 729-37[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Topotecan, Teniposide, Etoposide", "updated_at": 1767369485}, {"id": 139863, "ingredient1": "Triamcinolone (nasal)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140024/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Hydrocortisone, Fluocinonide, Methylprednisolone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139864, "ingredient1": "Triamcinolone (ophthalmic)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140025/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Hydrocortisone, Fluocinonide, Methylprednisolone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139865, "ingredient1": "Triazolam", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of benzodiazepines that are primarily metabolized by the isoenzyme. Overall, pharmacodynamic changes associated with the interaction include increased and prolonged sedation, enhanced benzodiazepine-related EEG effects, and increased impairment of psychomotor performance. The interaction has not been studied with clotrimazole troches or miconazole buccal tablets. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 such as triazolam and midazolam cannot be ruled out.", "source": "DDInter", "management_text": "Given the potential for significant interaction, the concomitant use of triazolam with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. The same precaution probably applies also to oral midazolam and high dosages of intravenous midazolam. Otherwise, patients should be cautioned about the potential for interaction and monitored for potentially excessive or prolonged CNS and respiratory depression if these agents are used together. Alternatively, benzodiazepines that are not metabolized by CYP450 3A4 (e.g., lorazepam, oxazepam, temazepam) may be considered in patients requiring treatment with azole antifungal agents.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for significant interaction, the concomitant use of triazolam with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140026/", "reference_text": "[1] Greenblatt DJ, Vonmoltke LL, Harmatz JS, Harrel LM, Tobias S, Shader RI, Wright CE \"Interaction of triazolam and ketoconazole.\" Lancet 345 (1995): 191[2] Varhe A, Olkkola KT, Neuvonen PJ \"Effect of fluconazole dose on the extent of fluconazole-triazolam interaction.\" Br J Clin Pharmacol 42 (1996): 465-70[3] Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ \"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.\" Eur J Clin Pharmacol 54 (1998): 53-8[4] Ahonen J, Olkkola KT, Neuvonen PJ \"Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam.\" Ther Drug Monit 18 (1996): 124-7[5] Vanakoski J, Mattila MJ, Vainio P, Idanpaanheikkila JJ, Tornwall M \"150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects.\" Int J Clin Pharmacol Ther 33 (1995): 518-23[6] Vonmoltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI \"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.\" J Clin Pharmacol 36 (1996): 783-91[7] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Ahonen J, Olkkola KT, Neuvonen PJ \"Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.\" Br J Clin Pharmacol 40 (1995): 270-2[9] Neuvonen PJ, Varhe A, Olkkola KT \"The effect of ingestion time interval on the interaction between itraconazole and triazolam.\" Clin Pharmacol Ther 60 (1996): 326-31[10] Greenblatt DJ, Wright CE, vonMoltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI \"Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences.\" Clin Pharmacol Ther 64 (1998): 237-47[11] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Vonmoltke LL, Greenblatt DJ, Cotreaubibbo MM, Harmatz JS, Shader RI \"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.\" Br J Clin Pharmacol 38 (1994): 23-31[13] Olkkola KT, Backman JT, Neuvonen PJ \"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 55 (1994): 481-5[14] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[15] Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K \"Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam.\" Psychopharmacology 139 (1998): 269-73[16] Varhe A, Olkkola KT, Neuvonen PJ \"Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 56 (1994): 601-7[17] Varhe A, Olkkola KT, Neuvonen PJ \"Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism.\" Br J Clin Pharmacol 41 (1996): 319-23[18] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[19] Tsunoda SM, Velez RL, vonMoltke LL, Greenblatt DJ \"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole.\" Clin Pharmacol Ther 66 (1999): 461-71[20] Brown MW, Maldonado AL, Meredith CG, Speeg KV \"Effect of ketoconazole on hepatic oxidative drug metabolism.\" Clin Pharmacol Ther 37 (1985): 290-7[21] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[23] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[24] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[25] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[26] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More", "alternatives_b": "Rifamycin, Amphotericin B, Polymyxin B, Nystatin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139866, "ingredient1": "Ubrogepant", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with moderate or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors. If needed, a second ubrogepant dose should be avoided within 24 hours of the initial dose when used with moderate CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with moderate or weak CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140027/", "reference_text": "[1] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.[2] \"Product Information. Ubrelvy (ubrogepant).\" Allergan Inc, Irvine, CA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, More", "updated_at": 1767369485}, {"id": 139867, "ingredient1": "Ulipristal", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of ulipristal, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140028/", "reference_text": "[1] \"Product Information. ella (ulipristal).\" Afaxys Inc., Charleston, SC.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Megestrol acetate, Dienogest, Estetrol, Raloxifene, Prasterone, Danazol, Bazedoxifene", "updated_at": 1767369485}, {"id": 139868, "ingredient1": "Upadacitinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140029/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 139869, "ingredient1": "Valdecoxib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of valdecoxib, which is metabolized by these isoenzymes.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of valdecoxib or parecoxib, including serious adverse effects such as gastrointestinal ulceration and bleeding, should be considered during concomitant therapy with CYP450 2C9 or 3A4 inhibitors, particularly combination (2C9/3A4) inhibitors such as fluconazole, fluvoxamine, imatinib, and zafirlukast. Dose reductions of the COX-2 inhibitor may be required.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of valdecoxib or parecoxib, including serious adverse effects such as gastrointestinal ulceration and bleeding, should be considered during concomitant therapy with CYP450 2C9 or 3A4 inhibitors, particularly combination (2C9/3A4) inhibitors such as fluconazole, fluvoxamine, imatinib, and zafirlukast.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140030/", "reference_text": "[1] \"Product Information. Bextra (valdecoxib).\" Pharmacia Corporation, Peapack, NJ.", "alternatives_a": "Rabeprazole, Ketoprofen, Piroxicam, Meclofenamic acid, Sulindac, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, Esomeprazole, More", "alternatives_b": "Rifamycin, Amphotericin B, Polymyxin B, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, Amphotericin B, Posaconazole, More", "updated_at": 1767369485}, {"id": 139870, "ingredient1": "Venetoclax", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of venetoclax, which is a substrate of both the isoenzyme and efflux transporter. Increased venetoclax exposure may potentiate the risk of tumor lysis syndrome, particularly at initiation of therapy and during the dosage ramp-up phase, as well as other adverse effects such as diarrhea, nausea, vomiting, neutropenia, anemia, and thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised when venetoclax is used with inhibitors of CYP450 3A4. Close clinical and laboratory monitoring for the development of tumor lysis syndrome and myelosuppression is recommended following the addition of a CYP450 3A4, and the venetoclax dosage adjusted if necessary. The dosage may be readjusted 2 to 3 days after discontinuation of the inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when venetoclax is used with inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140031/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[4] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[5] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 139871, "ingredient1": "Venlafaxine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of venlafaxine and its metabolite, O-desmethylvenlafaxine (ODV). The possibility of prolonged and/or increased pharmacologic effects of venlafaxine should be considered. Although venlafaxine is primarily metabolized by CYP450 2D6, there is some evidence that CYP450 3A4 may play a minor role, thus any alteration in its activity levels could conceivably affect the metabolism of venlafaxine. The interaction may be of greater concern in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when venlafaxine is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140032/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[9] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[10] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[13] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[14] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[15] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[16] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[17] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[18] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[19] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[20] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[21] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[22] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[23] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[24] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[25] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[26] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[27] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[28] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[29] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[30] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[31] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[32] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[35] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[36] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[37] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[38] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[39] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Paromomycin, Neomycin, Caspofungin, Micafungin, Amphotericin B, More", "updated_at": 1767369485}, {"id": 139872, "ingredient1": "Vilazodone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "When used with moderate CYP450 3A4 inhibitors, the maintenance dosage of vilazodone should be reduced to 20 mg/day in patients who develop intolerable adverse events.", "mechanism_text": "Metabolism", "recommendation": "When used with moderate CYP450 3A4 inhibitors, the maintenance dosage of vilazodone should be reduced to 20 mg/day in patients who develop intolerable adverse events.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140033/", "reference_text": "[1] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[2] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More", "updated_at": 1767369485}, {"id": 139873, "ingredient1": "Vinblastine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140034/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139874, "ingredient1": "Vincristine (liposome)", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140035/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "updated_at": 1767369485}, {"id": 139875, "ingredient1": "Vinorelbine", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140036/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, Micafungin, More", "updated_at": 1767369485}, {"id": 139876, "ingredient1": "Voriconazole", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with voriconazole may increase the plasma concentrations of drugs that are substrates of CYP450 2C19, 2C9, and/or 3A4. The mechanism is decreased clearance due to inhibition of those isoenzymes by voriconazole. Increased plasma levels and/or pharmacologic effects of drugs such as cyclosporine, sirolimus, tacrolimus (3A4 substrates), and warfarin (2C9 substrate) have been reported during coadministration with voriconazole.", "source": "DDInter", "management_text": "Caution is advised if voriconazole must be used concomitantly with medications that undergo metabolism by CYP450 2C19, 2C9 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever voriconazole is added to or withdrawn from therapy. The manufacturer specifically recommends that a dosage reduction be considered for benzodiazepines, statins, long-acting opiates, and vinca alkaloids that are metabolized by the affected isoenzymes when used with voriconazole.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if voriconazole must be used concomitantly with medications that undergo metabolism by CYP450 2C19, 2C9 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140037/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Micafungin, Caspofungin, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, Oteseconazole, Flucytosine, More", "updated_at": 1767369485}, {"id": 139877, "ingredient1": "Zanubrutinib", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when zanubrutinib is used with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as rash, diarrhea, constipation, cough, hemorrhage, infection, cytopenias, and atrial fibrillation or flutter, and the zanubrutinib dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when zanubrutinib is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140038/", "reference_text": "[1] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Pralsetinib, Dabrafenib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Afatinib, More", "updated_at": 1767369485}, {"id": 139878, "ingredient1": "Ziprasidone", "ingredient2": "Miconazole", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may only modestly increase the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140039/", "reference_text": "[1] Miceli JJ, Smith M, Robarge L, Morse T, Laurent A \"The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.\" Br J Clin Pharmacol 49(suppl 1) (2000): s71-6[2] Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D \"Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.\" Br J Clin Pharmacol 49(Suppl 1) (2000): 35S-42S[3] Wilner KD, Hansen RA, Folger CJ, Geoffroy P \"The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid.\" Br J Clin Pharmacol 49(Suppl 1) (2000): 57S-60S[4] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Fluphenazine, Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Micafungin, Caspofungin, Oteseconazole, More", "updated_at": 1767369485}, {"id": 139879, "ingredient1": "Zolpidem", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zolpidem, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when zolpidem is used with CYP450 3A4 inhibitors. Patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them, and to notify their physician if they experience excessive somnolence or dizziness.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when zolpidem is used with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140040/", "reference_text": "[1] Luurila H, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem.\" Eur J Clin Pharmacol 54 (1998): 163-6[2] Greenblatt DJ, vonMoltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol ALB, Counihan M, RothSchechter B, Shader RI \"Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.\" Clin Pharmacol Ther 64 (1998): 661-71[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Greenblatt DJ, von Moltke LL, Harmatz JS, et al. \"Differential impairment of triazolam and zolpidem clearance by ritonavir.\" J Acquir Immune Defic Syndr 24 (2000): 129-36[5] Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT \"Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects.\" Br J Clin Pharmacol 63 (2007): 116-20[6] Farkas D, Volak L, Harmatz J, von Moltke L, Court M, Greenblatt D \"Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem.\" Clin Pharmacol Ther 85 (2009): 644-50[7] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[9] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More", "alternatives_b": "Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Flucytosine, Anidulafungin, Micafungin, Oteseconazole, More", "updated_at": 1767369485}, {"id": 139880, "ingredient1": "Zonisamide", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of zonisamide, which is metabolized by the isoenzyme. While clinical data are lacking, the possibility of prolonged and/or increased pharmacologic effects of zonisamide should be considered.", "source": "DDInter", "management_text": "Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience symptoms such as severe drowsiness, confusion, loss of coordination, depression, aphasia, decreased sweating, fever, loss of seizure control, or slow pulse.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140041/", "reference_text": "[1] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M \"Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.\" Eur J Clin Pharmacol 54 (1998): 177-83[2] \"Product Information. Zonegran (zonisamide)\" Elan Pharmaceuticals, S. San Francisco, CA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Rufinamide, More", "alternatives_b": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, Caspofungin, More", "updated_at": 1767369485}, {"id": 139881, "ingredient1": "Aluminum hydroxide", "ingredient2": "Midazolam", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140042/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139882, "ingredient1": "Aminophylline", "ingredient2": "Midazolam", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140043/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 139883, "ingredient1": "Amoxapine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140044/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Ethchlorvynol, Zopiclone, Nitrazepam", "updated_at": 1767369485}, {"id": 139884, "ingredient1": "Amprenavir", "ingredient2": "Midazolam", "severity": "Major", "effect": "Coadministration with protease inhibitors (PIs) may significantly increase the plasma concentrations and pharmacologic effects of orally administered midazolam and triazolam. The mechanism is PI inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of these benzodiazepines. Within the class, ritonavir is the most potent CYP450 3A4 inhibitor, while saquinavir is considered one of the weaker ones.", "source": "DDInter", "management_text": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with protease inhibitors is considered contraindicated. Caution and close clinical monitoring are recommended when administering parenteral midazolam in combination with protease inhibitors. Appropriate medical management should be readily available in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam may be appropriate, especially if more than a single dose of midazolam is administered.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140045/", "reference_text": "[1] Eagling VA, Back DJ, Barry MG \"Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.\" Br J Clin Pharmacol 44 (1997): 190-4[2] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[3] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[4] Malaty LI, Kuper JJ \"Drug interactions of HIV protease inhibitors.\" Drug Safety 20 (1999): 147-69[5] Merry C, Mulcahy F, Barry M, Gibbons S, Back D \"Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.\" AIDS 11 (1997): 268-9[6] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[7] Barry M, Mulcahy F, Merry C, Gibbons S, Back D \"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.\" Clin Pharmacokinet 36 (1999): 289-304[8] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[9] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001): 1352-63[10] Greenblatt DJ, von Moltke LL, Harmatz JS, et al. \"Differential impairment of triazolam and zolpidem clearance by ritonavir.\" J Acquir Immune Defic Syndr 24 (2000): 129-36[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[13] Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT \"Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.\" Clin Pharmacol Ther 66 (1999): 33-9[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR \"Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.\" J Pharm Sci 87 (1998): 803-7[16] Gill J, Feinberg J \"Saquinavir soft gelatin capsule - A comparative safety review.\" Drug Safety 24 (2001): 223-32[17] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[18] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[19] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[25] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[26] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[27] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R \"Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.\" J Clin Pharmacol 41 (2001): 435-42[28] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[29] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S \"Single-dose pharmacokinetics of indinavir and the effect of food.\" Antimicrob Agents Chemother 42 (1998): 332-8", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 139885, "ingredient1": "Amyl Nitrite", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140046/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 139886, "ingredient1": "Atracurium", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.", "source": "DDInter", "management_text": "Patients should be monitored closely for respiratory difficulty when these agents are used together.", "mechanism_text": "Others", "recommendation": "Patients should be monitored closely for respiratory difficulty when these agents are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140047/", "reference_text": "[1] Feldman SA, Crawley BE \"Diazepam and muscle relaxants.\" Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH \"Benzodiazepines and neuromuscular blocking drugs in patients.\" Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF \"In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium.\" Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139887, "ingredient1": "Azatadine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140048/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone, Dichloralphenazone", "alternatives_b": "Ketotifen, Fexofenadine, Dexchlorpheniramine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "updated_at": 1767369485}, {"id": 139888, "ingredient1": "Bendroflumethiazide", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140049/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Rosuvastatin, Sulfadiazine, Lactic acid, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More", "alternatives_b": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 139889, "ingredient1": "Benzthiazide", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140050/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Ascorbic acid, Rosuvastatin, Sulfadiazine, Lactic acid, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More", "alternatives_b": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, More", "updated_at": 1767369485}, {"id": 139890, "ingredient1": "Bepridil", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140051/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Scopolamine, Eszopiclone, Methohexital, Lemborexant, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139891, "ingredient1": "Berotralstat", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.", "source": "DDInter", "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140052/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 139892, "ingredient1": "Boceprevir", "ingredient2": "Midazolam", "severity": "Major", "effect": "Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may significantly increase the plasma concentrations and pharmacologic effects of orally administered midazolam and triazolam. The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of these benzodiazepines.", "source": "DDInter", "management_text": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with HCV NS3/4A protease inhibitors is considered contraindicated. Caution and close clinical monitoring are recommended when administering parenteral midazolam in combination with these protease inhibitors. Appropriate medical management should be readily available in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam may be appropriate, especially if more than a single dose of midazolam is administered.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with HCV NS3/4A protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140053/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[3] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[7] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 139893, "ingredient1": "Bupivacaine (liposome)", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140054/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meloxicam", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "updated_at": 1767369485}, {"id": 139894, "ingredient1": "Calcium carbonate", "ingredient2": "Midazolam", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140055/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Calcium glucoheptonate, Calcium lactate, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Calcium Phosphate, Ascorbic acid, Calcium citrate, Calcium acetate", "updated_at": 1767369485}, {"id": 139895, "ingredient1": "Pentoxyverine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140056/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 139896, "ingredient1": "Carteolol", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140057/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Latanoprost, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol, More", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, More", "updated_at": 1767369485}, {"id": 139897, "ingredient1": "Clofedanol", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140058/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Benzonatate", "updated_at": 1767369485}, {"id": 139898, "ingredient1": "Chloral hydrate", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140059/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "Nitrazepam, Zopiclone, Midazolam", "updated_at": 1767369485}, {"id": 139899, "ingredient1": "Chlorphenesin", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140060/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone, Dichloralphenazone", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole", "updated_at": 1767369485}, {"id": 139900, "ingredient1": "Chlorpromazine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140061/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin, Methotrimeprazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139901, "ingredient1": "Clotrimazole", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of benzodiazepines that are primarily metabolized by the isoenzyme. Overall, pharmacodynamic changes associated with the interaction include increased and prolonged sedation, enhanced benzodiazepine-related EEG effects, and increased impairment of psychomotor performance. The interaction has not been studied with clotrimazole troches or miconazole buccal tablets. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 such as triazolam and midazolam cannot be ruled out.", "source": "DDInter", "management_text": "Given the potential for significant interaction, the concomitant use of triazolam with clotrimazole or miconazole mucous membrane preparations should be avoided if possible. The same precaution probably applies also to oral midazolam and high dosages of intravenous midazolam. Otherwise, patients should be cautioned about the potential for interaction and monitored for potentially excessive or prolonged CNS and respiratory depression if these agents are used together. Alternatively, benzodiazepines that are not metabolized by CYP450 3A4 (e.g., lorazepam, oxazepam, temazepam) may be considered in patients requiring treatment with azole antifungal agents.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for significant interaction, the concomitant use of triazolam with clotrimazole or miconazole mucous membrane preparations should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140062/", "reference_text": "[1] Greenblatt DJ, Vonmoltke LL, Harmatz JS, Harrel LM, Tobias S, Shader RI, Wright CE \"Interaction of triazolam and ketoconazole.\" Lancet 345 (1995): 191[2] Varhe A, Olkkola KT, Neuvonen PJ \"Effect of fluconazole dose on the extent of fluconazole-triazolam interaction.\" Br J Clin Pharmacol 42 (1996): 465-70[3] Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ \"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.\" Eur J Clin Pharmacol 54 (1998): 53-8[4] Ahonen J, Olkkola KT, Neuvonen PJ \"Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam.\" Ther Drug Monit 18 (1996): 124-7[5] Vanakoski J, Mattila MJ, Vainio P, Idanpaanheikkila JJ, Tornwall M \"150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects.\" Int J Clin Pharmacol Ther 33 (1995): 518-23[6] Vonmoltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI \"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.\" J Clin Pharmacol 36 (1996): 783-91[7] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Ahonen J, Olkkola KT, Neuvonen PJ \"Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.\" Br J Clin Pharmacol 40 (1995): 270-2[9] Neuvonen PJ, Varhe A, Olkkola KT \"The effect of ingestion time interval on the interaction between itraconazole and triazolam.\" Clin Pharmacol Ther 60 (1996): 326-31[10] Greenblatt DJ, Wright CE, vonMoltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI \"Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences.\" Clin Pharmacol Ther 64 (1998): 237-47[11] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Vonmoltke LL, Greenblatt DJ, Cotreaubibbo MM, Harmatz JS, Shader RI \"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.\" Br J Clin Pharmacol 38 (1994): 23-31[13] Olkkola KT, Backman JT, Neuvonen PJ \"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 55 (1994): 481-5[14] \"Product Information. ORAVIG (miconazole).\" Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.[15] Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K \"Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam.\" Psychopharmacology 139 (1998): 269-73[16] Varhe A, Olkkola KT, Neuvonen PJ \"Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 56 (1994): 601-7[17] Varhe A, Olkkola KT, Neuvonen PJ \"Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism.\" Br J Clin Pharmacol 41 (1996): 319-23[18] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[19] Tsunoda SM, Velez RL, vonMoltke LL, Greenblatt DJ \"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole.\" Clin Pharmacol Ther 66 (1999): 461-71[20] Brown MW, Maldonado AL, Meredith CG, Speeg KV \"Effect of ketoconazole on hepatic oxidative drug metabolism.\" Clin Pharmacol Ther 37 (1985): 290-7[21] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[23] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[24] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[25] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[26] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole, Tetracycline, Minocycline, More", "alternatives_b": "Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More", "updated_at": 1767369485}, {"id": 139902, "ingredient1": "Cyproheptadine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140063/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Dexchlorpheniramine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139903, "ingredient1": "Deserpidine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140064/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, Zopiclone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139904, "ingredient1": "Desflurane", "ingredient2": "Midazolam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140065/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Nitrous oxide", "updated_at": 1767369485}, {"id": 139905, "ingredient1": "Dexbrompheniramine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140066/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Dexchlorpheniramine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139906, "ingredient1": "Dezocine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140067/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "Naloxone, Naltrexone, Celecoxib", "updated_at": 1767369485}, {"id": 139907, "ingredient1": "Doxacurium", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.", "source": "DDInter", "management_text": "Patients should be monitored closely for respiratory difficulty when these agents are used together.", "mechanism_text": "Others", "recommendation": "Patients should be monitored closely for respiratory difficulty when these agents are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140068/", "reference_text": "[1] Feldman SA, Crawley BE \"Diazepam and muscle relaxants.\" Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH \"Benzodiazepines and neuromuscular blocking drugs in patients.\" Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF \"In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium.\" Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 139908, "ingredient1": "Echinacea", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140069/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139909, "ingredient1": "Enflurane", "ingredient2": "Midazolam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140070/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrous oxide", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "updated_at": 1767369485}, {"id": 139910, "ingredient1": "Entacapone", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140071/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Ethchlorvynol, Dichloralphenazone, Nitrazepam", "updated_at": 1767369485}, {"id": 139911, "ingredient1": "Entrectinib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with entrectinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by entrectinib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.", "source": "DDInter", "management_text": "Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, lovastatin, macrolide immunosuppressants, midazolam, sildenafil, simvastatin, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever entrectinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140072/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Ethchlorvynol, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 139912, "ingredient1": "Enzalutamide", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Apalutamide and enzalutamide may reduce the effects of oral midazolam. The mechanism may be due to enhanced gut and liver metabolism of midazolam (via CYP450 3A4 enzyme induction).", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for clinical response. Alternative oral sedative hypnotics may be preferable in patients receiving enzalutamide.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for clinical response.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140073/", "reference_text": "[1] \"Product Information. Xtandi (enzalutamide).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Erleada (apalutamide).\" Janssen Biotech, Inc., Horsham, PA, PA.[5] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[6] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[9] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[10] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[11] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 139913, "ingredient1": "Eplerenone", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140074/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Butabarbital, Suvorexant, Secobarbital, Nitrazepam, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, More", "alternatives_b": "Finerenone", "updated_at": 1767369485}, {"id": 139914, "ingredient1": "Erdafitinib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with erdafitinib may alter the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, resulting in increased toxicity or decreased efficacy of these drugs.", "source": "DDInter", "management_text": "Concomitant use of erdafitinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of erdafitinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140075/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 139915, "ingredient1": "Escitalopram", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140076/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone, Thiopental", "alternatives_b": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 139916, "ingredient1": "Esketamine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140077/", "reference_text": "[1] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Melatonin, Nitrazepam, Zopiclone", "alternatives_b": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone, Nitrous oxide", "updated_at": 1767369485}, {"id": 139917, "ingredient1": "Eslicarbazepine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140078/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139918, "ingredient1": "Esmolol", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140079/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acebutolol, Betaxolol, Pindolol, Sotalol", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 139919, "ingredient1": "Estazolam", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140080/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Estazolam", "alternatives_b": "Nitrazepam, Zopiclone, Midazolam", "updated_at": 1767369485}, {"id": 139920, "ingredient1": "Eszopiclone", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140081/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone, Midazolam", "alternatives_b": "Eszopiclone, Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 139921, "ingredient1": "Etanercept", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140082/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "updated_at": 1767369485}, {"id": 139922, "ingredient1": "Etacrynic acid", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140083/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139923, "ingredient1": "Ethosuximide", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140084/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Thiopental, Ethchlorvynol, Methylphenobarbital, Zopiclone", "updated_at": 1767369485}, {"id": 139924, "ingredient1": "Ethotoin", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with some benzodiazepines may alter the serum concentrations of phenytoin. Phenytoin toxicity has been reported in patients treated with various benzodiazepines, including clobazam, chlordiazepoxide, clonazepam, and diazepam. Conversely, phenytoin may reduce the plasma concentrations of some benzodiazepines by inducing their metabolism via hepatic microsomal enzymes.", "source": "DDInter", "management_text": "Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary. Patients should be advised to contact their physician if they experience symptoms of hydantoin toxicity such as nausea, vomiting, tremors, ataxia, lethargy, slurred speech, visual disturbances, or changes in mental status. The potential for diminished or inadequate benzodiazepine effects should be considered during concomitant use with phenytoin.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140085/", "reference_text": "[1] Murphy A, Wilbur K \"Phenytoin-diazepam interaction.\" Ann Pharmacother 37 (2003): 659-63[2] Sennoune S, Mesdjian E, Bonneton J, et al \"Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy.\" Ther Drug Monit 14 (1992): 269-74[3] Scott AK, Khir AS, Steele WH, et al \"Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone.\" Br J Clin Pharmacol 16 (1983): 441-4[4] Shuttleworth E, Wise G, Paulson G \"Choreoathetosis and diphenylhydantoin intoxication.\" JAMA 230 (1974): 1170-1[5] Windorfer A Jr, Sauer W \"Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepin and dipropylacetate.\" Neuropadiatrie 8 (1977): 29-41[6] Saavedra IN, Aguilera LI, Faure E, Galdames DG \"Phenytoin/clonazepam interaction.\" Ther Drug Monit 7 (1985): 481-4[7] Johannessen SI, Strandjord RE, Munthe-Kaas AW \"Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine.\" Acta Neurol Scand 55 (1977): 506-12[8] Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ \"Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.\" Epilepsia 37 (1996): 253-7[9] Zifkin B, Sherwin A, Andermann F \"Phenytoin toxicity due to interaction with clobazam.\" Neurology 41 (1991): 313-4[10] Vajda FJ, Prineas RJ, Lovell RR \"Interaction between phenytoin and the benzodiazepines.\" Br Med J 1 (1971): 346[11] Siris JH, Pippenger CE, Werner WL, Masland RL \"Anticonvulsant drug-serum levels in psychiatric patients with seizure disorders. Effects of certain psychotropic drugs.\" N Y State J Med 74 (1974): 1554-6[12] Kutt H \"Interactions of antiepileptic drugs.\" Epilepsia 16 (1975): 393-402[13] Khoo KC, Mendels J, Rothbart M, et al \"Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam.\" Clin Pharmacol Ther 28 (1980): 368-75[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[18] Cerner Multum, Inc. \"Australian Product Information.\" O 0[19] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[20] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[21] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[22] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[23] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[24] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[25] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[26] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[27] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[28] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[29] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[30] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[31] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[32] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[33] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Ethchlorvynol, Methylphenobarbital, Zopiclone, Nitrazepam", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139925, "ingredient1": "Etidocaine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140086/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 139926, "ingredient1": "Etravirine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with etravirine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by etravirine.", "source": "DDInter", "management_text": "Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever etravirine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140087/", "reference_text": "[1] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.[2] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Paraldehyde, Thiopental, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 139927, "ingredient1": "Ezogabine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140088/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Propiomazine, Nitrazepam, Zopiclone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139928, "ingredient1": "Fedratinib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140089/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation, Summit, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 139929, "ingredient1": "Felbamate", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140090/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Ethchlorvynol, Methylphenobarbital, Zopiclone, Dichloralphenazone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139930, "ingredient1": "Fenoldopam", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140091/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More", "alternatives_b": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More", "updated_at": 1767369485}, {"id": 139931, "ingredient1": "Flavoxate", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140092/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ethchlorvynol, Zopiclone, Thiopental, Nitrazepam", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Trospium, Avanafil, More", "updated_at": 1767369485}, {"id": 139932, "ingredient1": "Flibanserin", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects. The risk of CNS depression is increased if flibanserin is taken during waking hours or with alcohol or other CNS depressants.", "source": "DDInter", "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue. Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin.", "mechanism_text": "Synergism", "recommendation": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140093/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Melatonin, Nitrazepam, Zopiclone, Methohexital", "alternatives_b": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen", "updated_at": 1767369485}, {"id": 139933, "ingredient1": "Fluconazole", "ingredient2": "Midazolam", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of benzodiazepines that are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Although clotrimazole, fluconazole, miconazole, and voriconazole are weaker inhibitors of CYP450 3A4 than itraconazole and ketoconazole, product labelings for alprazolam and triazolam recommend against use with any azole antifungal agent. The same precaution probably applies also to oral midazolam and high dosages of intravenous midazolam. Terbinafine may be an appropriate alternative, as it is not an inhibitor of CYP450 3A4 and has been shown to have no effect on the pharmacokinetics of midazolam and triazolam. Alternatively, benzodiazepines that are not metabolized by CYP450 3A4 (e.g., lorazepam, oxazepam, temazepam) may be considered in patients requiring treatment with azole antifungal agents. Limited data suggest that fluconazole given intermittently (e.g., 150 mg once or once a week) may be safely administered in combination with midazolam and possibly other benzodiazepines.", "mechanism_text": "Metabolism", "recommendation": "Although clotrimazole, fluconazole, miconazole, and voriconazole are weaker inhibitors of CYP450 3A4 than itraconazole and ketoconazole, product labelings for alprazolam and triazolam recommend against use with any azole antifungal agent.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140094/", "reference_text": "[1] Vonmoltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI \"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.\" J Clin Pharmacol 36 (1996): 783-91[2] Ahonen J, Olkkola KT, Neuvonen PJ \"Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.\" Br J Clin Pharmacol 40 (1995): 270-2[3] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Vonmoltke LL, Greenblatt DJ, Cotreaubibbo MM, Harmatz JS, Shader RI \"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.\" Br J Clin Pharmacol 38 (1994): 23-31[5] Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ \"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.\" Eur J Clin Pharmacol 54 (1998): 53-8[6] Greenblatt DJ, Vonmoltke LL, Harmatz JS, Harrel LM, Tobias S, Shader RI, Wright CE \"Interaction of triazolam and ketoconazole.\" Lancet 345 (1995): 191[7] Varhe A, Olkkola KT, Neuvonen PJ \"Effect of fluconazole dose on the extent of fluconazole-triazolam interaction.\" Br J Clin Pharmacol 42 (1996): 465-70[8] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[9] Varhe A, Olkkola KT, Neuvonen PJ \"Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 56 (1994): 601-7[10] Tsunoda SM, Velez RL, vonMoltke LL, Greenblatt DJ \"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole.\" Clin Pharmacol Ther 66 (1999): 461-71[11] Ahonen J, Olkkola KT, Neuvonen PJ \"Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam.\" Ther Drug Monit 18 (1996): 124-7[12] Greenblatt DJ, Wright CE, vonMoltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI \"Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences.\" Clin Pharmacol Ther 64 (1998): 237-47[13] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[14] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[15] Vanakoski J, Mattila MJ, Vainio P, Idanpaanheikkila JJ, Tornwall M \"150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects.\" Int J Clin Pharmacol Ther 33 (1995): 518-23[16] Brown MW, Maldonado AL, Meredith CG, Speeg KV \"Effect of ketoconazole on hepatic oxidative drug metabolism.\" Clin Pharmacol Ther 37 (1985): 290-7[17] Varhe A, Olkkola KT, Neuvonen PJ \"Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism.\" Br J Clin Pharmacol 41 (1996): 319-23[18] Neuvonen PJ, Varhe A, Olkkola KT \"The effect of ingestion time interval on the interaction between itraconazole and triazolam.\" Clin Pharmacol Ther 60 (1996): 326-31[19] Olkkola KT, Backman JT, Neuvonen PJ \"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 55 (1994): 481-5[20] Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K \"Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam.\" Psychopharmacology 139 (1998): 269-73[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[22] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[25] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[28] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[29] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Norfloxacin, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Flucytosine, Anidulafungin, Micafungin, More", "alternatives_b": "Remimazolam, Butabarbital, Secobarbital, Chloral hydrate, Thiopental, Paraldehyde, Amobarbital, Propiomazine, Butalbital, Dexmedetomidine, Methohexital, More", "updated_at": 1767369485}, {"id": 139934, "ingredient1": "Flumazenil", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "The administration of flumazenil can result in convulsions in patients who have been receiving long-term treatment with benzodiazepines for epilepsy or sedation or who have recently received repeated doses of parenteral benzodiazepines. The mechanism is abrupt reversal of the benzodiazepine's anticonvulsive effects. In addition, withdrawal seizures may occur in patients who are physically dependent on benzodiazepines.", "source": "DDInter", "management_text": "The use of flumazenil is not recommended in patients with epilepsy who have been receiving long-term treatment with benzodiazepines. In addition, flumazenil is contraindicated in patients who have received a benzodiazepine to control potentially life-threatening conditions such as status epilepticus or increased intracranial pressure. Extreme caution, dose individualization, and close monitoring is recommended for other patients. Clinicians should be prepared to manage convulsions. Most seizures have been successfully managed with benzodiazepines, phenytoin, or barbiturates.", "mechanism_text": "Antagonism", "recommendation": "The use of flumazenil is not recommended in patients with epilepsy who have been receiving long-term treatment with benzodiazepines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140095/", "reference_text": "[1] \"Product Information. Romazicon (flumazenil).\" Roche Laboratories, Nutley, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 139935, "ingredient1": "Fluoxetine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Several studies have suggested that the effects of benzodiazepines, particularly their effects on psychomotor performance, may be increased by fluoxetine. The mechanism may be related to additive CNS depressant effects and/or inhibition of CYP450 2C19 and/or 3A4 benzodiazepine metabolism by fluoxetine. The clinical implications are uncertain, but effects may be more pronounced in the elderly.", "source": "DDInter", "management_text": "Patients should be monitored for excessive CNS depression and psychomotor impairment. Dose reductions may be required. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them. Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Patients should be monitored for excessive CNS depression and psychomotor impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140096/", "reference_text": "[1] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[2] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[3] Moskowitz H, Burns M \"The effects on performance of two antidepressants, alone and in combination with diazepam.\" Prog Neuropsychopharmacol Biol Psychiatry 12 (1988): 783-92[4] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Ethchlorvynol, Nitrazepam", "updated_at": 1767369485}, {"id": 139936, "ingredient1": "Fluphenazine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140097/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin, Methotrimeprazine", "alternatives_b": "Ethchlorvynol, Zopiclone, Nitrazepam", "updated_at": 1767369485}, {"id": 139937, "ingredient1": "Flurazepam", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140098/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Thiopental, Nitrazepam, Zopiclone, Flurazepam", "alternatives_b": "Nitrazepam, Zopiclone, Midazolam", "updated_at": 1767369485}, {"id": 139938, "ingredient1": "Fluvoxamine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Administration of fluvoxamine with certain benzodiazepines may increase CNS depression (e.g., sedation, ataxia). The mechanism appears to be inhibition of the CYP450 3A4 hepatic oxidative metabolism of the benzodiazepine.", "source": "DDInter", "management_text": "The patient should be observed for increased CNS depression. Dosage adjustments may be required. Lorazepam, temazepam, and oxazepam, which are not metabolized by oxidative metabolism, may be better alternatives if a benzodiazepine is required.", "mechanism_text": "Metabolism", "recommendation": "The patient should be observed for increased CNS depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140099/", "reference_text": "[1] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[2] Fleishaker JC, Hulst LK \"A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.\" Eur J Clin Pharmacol 46 (1994): 35-9[3] Vonmoltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI \"Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.\" J Clin Psychopharmacol 15 (1995): 125-31[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Thiopental, Ethchlorvynol, Zopiclone, Dichloralphenazone", "updated_at": 1767369485}, {"id": 139939, "ingredient1": "Fosamprenavir", "ingredient2": "Midazolam", "severity": "Major", "effect": "Coadministration with protease inhibitors (PIs) may significantly increase the plasma concentrations and pharmacologic effects of orally administered midazolam and triazolam. The mechanism is PI inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of these benzodiazepines. Within the class, ritonavir is the most potent CYP450 3A4 inhibitor, while saquinavir is considered one of the weaker ones.", "source": "DDInter", "management_text": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with protease inhibitors is considered contraindicated. Caution and close clinical monitoring are recommended when administering parenteral midazolam in combination with protease inhibitors. Appropriate medical management should be readily available in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam may be appropriate, especially if more than a single dose of midazolam is administered.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140100/", "reference_text": "[1] Eagling VA, Back DJ, Barry MG \"Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.\" Br J Clin Pharmacol 44 (1997): 190-4[2] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[3] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[4] Malaty LI, Kuper JJ \"Drug interactions of HIV protease inhibitors.\" Drug Safety 20 (1999): 147-69[5] Merry C, Mulcahy F, Barry M, Gibbons S, Back D \"Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.\" AIDS 11 (1997): 268-9[6] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[7] Barry M, Mulcahy F, Merry C, Gibbons S, Back D \"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.\" Clin Pharmacokinet 36 (1999): 289-304[8] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[9] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001): 1352-63[10] Greenblatt DJ, von Moltke LL, Harmatz JS, et al. \"Differential impairment of triazolam and zolpidem clearance by ritonavir.\" J Acquir Immune Defic Syndr 24 (2000): 129-36[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[13] Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT \"Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.\" Clin Pharmacol Ther 66 (1999): 33-9[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR \"Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.\" J Pharm Sci 87 (1998): 803-7[16] Gill J, Feinberg J \"Saquinavir soft gelatin capsule - A comparative safety review.\" Drug Safety 24 (2001): 223-32[17] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[18] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[19] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[25] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[26] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[27] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R \"Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.\" J Clin Pharmacol 41 (2001): 435-42[28] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[29] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S \"Single-dose pharmacokinetics of indinavir and the effect of food.\" Antimicrob Agents Chemother 42 (1998): 332-8", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 139940, "ingredient1": "Fosaprepitant", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of benzodiazepines that are metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.", "source": "DDInter", "management_text": "Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4. The potential for increased pharmacologic effects of the benzodiazepine, including central nervous system and respiratory depression, should be considered. The interaction is not expected to occur with lorazepam, oxazepam or temazepam, which are primarily metabolized via glucuronidation. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140101/", "reference_text": "[1] \"Product Information. Emend (aprepitant).\" Merck & Company Inc, West Point, PA.[2] Hardman JG, Limbird LE, Gilman AG, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th ed.\" New York, NY: McGraw-Hill (2001):[3] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[4] Majumdar AK, McCrea JB, Panebianco DL, et al. \"Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.\" Clin Pharmacol Ther 74 (2003): 150-6", "alternatives_a": "Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Paraldehyde, Ramelteon, Ethchlorvynol, Zopiclone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139941, "ingredient1": "Fosphenytoin", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with some benzodiazepines may alter the serum concentrations of phenytoin. Phenytoin toxicity has been reported in patients treated with various benzodiazepines, including clobazam, chlordiazepoxide, clonazepam, and diazepam. Conversely, phenytoin may reduce the plasma concentrations of some benzodiazepines by inducing their metabolism via hepatic microsomal enzymes.", "source": "DDInter", "management_text": "Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary. Patients should be advised to contact their physician if they experience symptoms of hydantoin toxicity such as nausea, vomiting, tremors, ataxia, lethargy, slurred speech, visual disturbances, or changes in mental status. The potential for diminished or inadequate benzodiazepine effects should be considered during concomitant use with phenytoin.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140102/", "reference_text": "[1] Murphy A, Wilbur K \"Phenytoin-diazepam interaction.\" Ann Pharmacother 37 (2003): 659-63[2] Sennoune S, Mesdjian E, Bonneton J, et al \"Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy.\" Ther Drug Monit 14 (1992): 269-74[3] Scott AK, Khir AS, Steele WH, et al \"Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone.\" Br J Clin Pharmacol 16 (1983): 441-4[4] Shuttleworth E, Wise G, Paulson G \"Choreoathetosis and diphenylhydantoin intoxication.\" JAMA 230 (1974): 1170-1[5] Windorfer A Jr, Sauer W \"Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepin and dipropylacetate.\" Neuropadiatrie 8 (1977): 29-41[6] Saavedra IN, Aguilera LI, Faure E, Galdames DG \"Phenytoin/clonazepam interaction.\" Ther Drug Monit 7 (1985): 481-4[7] Johannessen SI, Strandjord RE, Munthe-Kaas AW \"Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine.\" Acta Neurol Scand 55 (1977): 506-12[8] Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ \"Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.\" Epilepsia 37 (1996): 253-7[9] Zifkin B, Sherwin A, Andermann F \"Phenytoin toxicity due to interaction with clobazam.\" Neurology 41 (1991): 313-4[10] Vajda FJ, Prineas RJ, Lovell RR \"Interaction between phenytoin and the benzodiazepines.\" Br Med J 1 (1971): 346[11] Siris JH, Pippenger CE, Werner WL, Masland RL \"Anticonvulsant drug-serum levels in psychiatric patients with seizure disorders. Effects of certain psychotropic drugs.\" N Y State J Med 74 (1974): 1554-6[12] Kutt H \"Interactions of antiepileptic drugs.\" Epilepsia 16 (1975): 393-402[13] Khoo KC, Mendels J, Rothbart M, et al \"Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam.\" Clin Pharmacol Ther 28 (1980): 368-75[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[18] Cerner Multum, Inc. \"Australian Product Information.\" O 0[19] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[20] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[21] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[22] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[23] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[24] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[25] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[26] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[27] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[28] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[29] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[30] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[31] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[32] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[33] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Nitrazepam, Thiopental, Ethchlorvynol, Zopiclone, Dichloralphenazone", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139942, "ingredient1": "Fospropofol", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly. Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140103/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992): 240-5[2] \"Product Information. Lusedra (fospropofol).\" Eisai Inc, Teaneck, NJ.[3] \"Product Information. Diprivan (propofol).\" Zeneca Pharmaceuticals, Wilmington, DE.[4] Pavlin DJ, Coda B, Shen DD, et al \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996): 23-37[5] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990): 760-5[6] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999): 110-7", "alternatives_a": "Nitrazepam, Butalbital, Scopolamine, Zopiclone, Melatonin, Primidone, Valerian", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139943, "ingredient1": "Fostamatinib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.", "source": "DDInter", "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140104/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals, South San Francisco, CA.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More", "alternatives_b": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 139944, "ingredient1": "Furosemide", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140105/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More", "alternatives_b": "Tinidazole, Ascorbic acid, Rosuvastatin, Sulfadiazine, Lactic acid, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139945, "ingredient1": "Gabapentin", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140106/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam", "alternatives_b": "Lacosamide", "updated_at": 1767369485}, {"id": 139946, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4. Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo.", "source": "DDInter", "management_text": "Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and cyclosporine) should be done with caution and monitoring for reduced efficacy. Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140107/", "reference_text": "[1] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More", "alternatives_b": "Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, Givosiran, More", "updated_at": 1767369485}, {"id": 139947, "ingredient1": "Golimumab", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140108/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 139948, "ingredient1": "Grepafloxacin", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.", "source": "DDInter", "management_text": "Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140109/", "reference_text": "[1] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.", "alternatives_a": "Enoxacin, Gatifloxacin, Norfloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, More", "updated_at": 1767369485}, {"id": 139949, "ingredient1": "Guanabenz", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140110/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139950, "ingredient1": "Guanadrel", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140111/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Valerian, Butabarbital, Secobarbital, Ramelteon, Lemborexant, Zopiclone, Amobarbital, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139951, "ingredient1": "Guanethidine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140112/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Latanoprost, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Levobunolol", "updated_at": 1767369485}, {"id": 139952, "ingredient1": "Guanfacine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140113/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Estazolam, Zopiclone, Tasimelteon, Valerian", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139953, "ingredient1": "Guselkumab", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140114/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Suvorexant, Flurazepam, Methohexital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 139954, "ingredient1": "Halazepam", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140115/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139955, "ingredient1": "Haloperidol", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140116/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin, Methotrimeprazine", "alternatives_b": "Zopiclone", "updated_at": 1767369485}, {"id": 139956, "ingredient1": "Halothane", "ingredient2": "Midazolam", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140117/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Nitrous oxide", "updated_at": 1767369485}, {"id": 139957, "ingredient1": "Diamorphine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140118/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 139958, "ingredient1": "Hydroflumethiazide", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140119/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, More", "alternatives_b": "Tinidazole, Ascorbic acid, Rosuvastatin, Sulfadiazine, Lactic acid, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More", "updated_at": 1767369485}, {"id": 139959, "ingredient1": "Hydromorphone", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140120/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Naloxone, Naltrexone, Celecoxib", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 139960, "ingredient1": "Idelalisib", "ingredient2": "Midazolam", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and pharmacologic effects of orally administered midazolam and triazolam, which undergo intestinal (first-pass) and hepatic metabolism by the isoenzyme", "source": "DDInter", "management_text": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with potent CYP450 3A4 inhibitors is considered contraindicated. Caution and close clinical monitoring are recommended when administering parenteral midazolam in combination with these agents. Appropriate medical management should be readily available in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam may be appropriate, especially if more than a single dose of midazolam is administered.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140121/", "reference_text": "[1] Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ \"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.\" Eur J Clin Pharmacol 54 (1998): 53-8[2] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[3] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[4] Tsunoda SM, Velez RL, vonMoltke LL, Greenblatt DJ \"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole.\" Clin Pharmacol Ther 66 (1999): 461-71[5] Ahonen J, Olkkola KT, Neuvonen PJ \"Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.\" Br J Clin Pharmacol 40 (1995): 270-2[6] Greenblatt DJ, von Moltke LL, Harmatz JS, et al. \"Differential impairment of triazolam and zolpidem clearance by ritonavir.\" J Acquir Immune Defic Syndr 24 (2000): 129-36[7] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[8] Vonmoltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI \"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.\" J Clin Pharmacol 36 (1996): 783-91[9] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[10] Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR \"Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.\" J Pharm Sci 87 (1998): 803-7[11] Brown MW, Maldonado AL, Meredith CG, Speeg KV \"Effect of ketoconazole on hepatic oxidative drug metabolism.\" Clin Pharmacol Ther 37 (1985): 290-7[12] Varhe A, Olkkola KT, Neuvonen PJ \"Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism.\" Br J Clin Pharmacol 41 (1996): 319-23[13] Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT \"Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.\" Clin Pharmacol Ther 66 (1999): 33-9[14] Merry C, Mulcahy F, Barry M, Gibbons S, Back D \"Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.\" AIDS 11 (1997): 268-9[15] Malaty LI, Kuper JJ \"Drug interactions of HIV protease inhibitors.\" Drug Safety 20 (1999): 147-69[16] Greenblatt DJ, Wright CE, vonMoltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI \"Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences.\" Clin Pharmacol Ther 64 (1998): 237-47[17] Neuvonen PJ, Varhe A, Olkkola KT \"The effect of ingestion time interval on the interaction between itraconazole and triazolam.\" Clin Pharmacol Ther 60 (1996): 326-31[18] \"Product Information. Versed (midazolam).\" Roche Laboratories, Nutley, NJ.[19] Olkkola KT, Backman JT, Neuvonen PJ \"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 55 (1994): 481-5[20] Eagling VA, Back DJ, Barry MG \"Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.\" Br J Clin Pharmacol 44 (1997): 190-4[21] Varhe A, Olkkola KT, Neuvonen PJ \"Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 56 (1994): 601-7[22] Greenblatt DJ, Vonmoltke LL, Harmatz JS, Harrel LM, Tobias S, Shader RI, Wright CE \"Interaction of triazolam and ketoconazole.\" Lancet 345 (1995): 191[23] Barry M, Mulcahy F, Merry C, Gibbons S, Back D \"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.\" Clin Pharmacokinet 36 (1999): 289-304[24] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[25] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[26] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[27] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[28] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 139961, "ingredient1": "Ifosfamide", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.", "source": "DDInter", "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.", "mechanism_text": "Synergism", "recommendation": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140122/", "reference_text": "[1] Simonian NA, Gilliam FG, Chiappa KH \"Ifosfamide causes a diazepam-sensitive encephalopathy.\" Neurology 43 (1993): 2700-2[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Nitrazepam, Methohexital, Zopiclone, Primidone, Phenobarbital", "alternatives_b": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, More", "updated_at": 1767369485}, {"id": 139962, "ingredient1": "Iloperidone", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140123/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Amisulpride, Pimavanserin, Methotrimeprazine", "updated_at": 1767369485}, {"id": 139963, "ingredient1": "Imatinib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.", "source": "DDInter", "management_text": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140124/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Quazepam, Paraldehyde, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 139964, "ingredient1": "Imipramine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140125/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Ethchlorvynol, Nitrazepam", "updated_at": 1767369485}, {"id": 139965, "ingredient1": "Indapamide", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140126/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, More", "alternatives_b": "Felodipine, Tinidazole, Ascorbic acid, Rosuvastatin, Sulfadiazine, Lactic acid, Ciclopirox, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, More", "updated_at": 1767369485}, {"id": 139966, "ingredient1": "Indinavir", "ingredient2": "Midazolam", "severity": "Major", "effect": "Coadministration with protease inhibitors (PIs) may significantly increase the plasma concentrations and pharmacologic effects of orally administered midazolam and triazolam. The mechanism is PI inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of these benzodiazepines. Within the class, ritonavir is the most potent CYP450 3A4 inhibitor, while saquinavir is considered one of the weaker ones.", "source": "DDInter", "management_text": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with protease inhibitors is considered contraindicated. Caution and close clinical monitoring are recommended when administering parenteral midazolam in combination with protease inhibitors. Appropriate medical management should be readily available in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam may be appropriate, especially if more than a single dose of midazolam is administered.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140127/", "reference_text": "[1] Eagling VA, Back DJ, Barry MG \"Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.\" Br J Clin Pharmacol 44 (1997): 190-4[2] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[3] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[4] Malaty LI, Kuper JJ \"Drug interactions of HIV protease inhibitors.\" Drug Safety 20 (1999): 147-69[5] Merry C, Mulcahy F, Barry M, Gibbons S, Back D \"Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.\" AIDS 11 (1997): 268-9[6] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[7] Barry M, Mulcahy F, Merry C, Gibbons S, Back D \"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.\" Clin Pharmacokinet 36 (1999): 289-304[8] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[9] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001): 1352-63[10] Greenblatt DJ, von Moltke LL, Harmatz JS, et al. \"Differential impairment of triazolam and zolpidem clearance by ritonavir.\" J Acquir Immune Defic Syndr 24 (2000): 129-36[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[13] Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT \"Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.\" Clin Pharmacol Ther 66 (1999): 33-9[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR \"Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.\" J Pharm Sci 87 (1998): 803-7[16] Gill J, Feinberg J \"Saquinavir soft gelatin capsule - A comparative safety review.\" Drug Safety 24 (2001): 223-32[17] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[18] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[19] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[25] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[26] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[27] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R \"Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.\" J Clin Pharmacol 41 (2001): 435-42[28] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[29] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S \"Single-dose pharmacokinetics of indinavir and the effect of food.\" Antimicrob Agents Chemother 42 (1998): 332-8", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More", "updated_at": 1767369485}, {"id": 139967, "ingredient1": "Infliximab", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140128/", "reference_text": "[1] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC, North Chicago, IL.[2] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Gamifant (emapalumab).\" Sobi Inc, Ardmore, PA.[5] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis, Bridgewater, NJ.[6] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc., Horsham, PA, PA.[9] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.[10] \"Product Information. Ilumya (tildrakizumab).\" Merck & Company Inc, Whitehouse Station, NJ.[11] \"Product Information. Actemra (tocilizumab).\" Genentech, South San Francisco, CA.[12] \"Product Information. Amevive (alefacept).\" Biogen, Cambridge, MA.[13] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[14] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company, Indianapolis, IN.[15] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[16] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[19] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, Secobarbital, More", "updated_at": 1767369485}, {"id": 139968, "ingredient1": "Isoniazid", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Isoniazid may increase the pharmacologic effects of benzodiazepines by decreasing clearance and increasing half-life. The mechanism is related to the inhibition of CYP450 3A4 hepatic oxidative metabolism of benzodiazepines.", "source": "DDInter", "management_text": "Patients on concomitant therapy should be monitored for altered benzodiazepine effects. Dosage reductions may be appropriate if patients experience prolonged or excessive CNS-depressant effects.", "mechanism_text": "Metabolism", "recommendation": "Patients on concomitant therapy should be monitored for altered benzodiazepine effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140129/", "reference_text": "[1] Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ \"Diazepam interaction with antituberculosis drugs.\" Clin Pharmacol Ther 29 (1981): 671-8[2] Ochs HR, Greenblatt DJ, Knuchel M \"Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation.\" Br J Clin Pharmacol 16 (1983): 743-6[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Self TH, Chrisman CR, Baciewicz AM, Bronze MS \"Isoniazid drug and food interactions.\" Am J Med Sci 317 (1999): 304-11[5] Uragoda CG, Kottegoda SR \"Adverse reactions to isoniazid on ingestion of fish with a high histamine content.\" Tubercle 58 (1977): 83-9[6] \"Product Information. INH (isoniazid).\" Ciba Pharmaceuticals, Summit, NJ.[7] Smith CK, Durack DT \"Isoniazid and reaction to cheese.\" Ann Intern Med 88 (1978): 520-1[8] Dimartini A \"Isoniazid, tricyclics and the ''cheese reaction''.\" Int Clin Psychopharmacol 10 (1995): 197-8[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, More", "updated_at": 1767369485}, {"id": 139969, "ingredient1": "Midazolam", "ingredient2": "Kava", "severity": "Moderate", "effect": "A case report suggests that kava may increase the central nervous system adverse effects of benzodiazepines.The exact mechanism of interaction is unknown, but an additive or synergistic CNS effect is suspected.", "source": "DDInter", "management_text": "Until further information is available, concomitant use of kava and benzodiazepines is not recommended. Patients on benzodiazepines should be advised to consult their caregiver before using any alternative medicines.", "mechanism_text": "Others", "recommendation": "Until further information is available, concomitant use of kava and benzodiazepines is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140130/", "reference_text": "[1] Pepping J \"Kava: Piper methysticum.\" Am J Health Syst Pharm 56 (1999): 957-60[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Almeida JC, Grimsley EW \"Coma from the health food store: interaction between kava and alprazolam.\" Ann Intern Med 125 (1996): 940-1[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139970, "ingredient1": "Midazolam", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140131/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, Ethchlorvynol, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 139971, "ingredient1": "Midazolam", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "The central nervous system and respiratory depressant effects of levomethadyl acetate may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.", "source": "DDInter", "management_text": "Caution and dosage adjustments are advisable if CNS depressants are prescribed to patients on levomethadyl acetate maintenance. Alcohol use should be avoided, and patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them. Patients who are known to abuse sedatives, tranquilizers, antidepressants, benzodiazepines, and alcohol should be warned of the risk of serious and potentially fatal overdose if these substances are taken concurrently.", "mechanism_text": "Synergism", "recommendation": "Caution and dosage adjustments are advisable if CNS depressants are prescribed to patients on levomethadyl acetate maintenance.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140132/", "reference_text": "[1] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[2] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[3] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 139972, "ingredient1": "Midazolam", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with lonafarnib may significantly increase the plasma concentrations and pharmacologic effects of midazolam, particularly when given orally. The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of midazolam. Lonafarnib is a potent CYP450 3A time-dependent and mechanism-based inhibitor in vitro.", "source": "DDInter", "management_text": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive midazolam blood levels, concomitant use of midazolam with potent CYP450 3A4 inhibitors such as lonafarnib is considered contraindicated. If midazolam is required in patients treated with lonafarnib, the prescribing information recommends temporarily discontinuing lonafarnib for 10 to 14 days before and 2 days after administration of midazolam.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive midazolam blood levels, concomitant use of midazolam with potent CYP450 3A4 inhibitors such as lonafarnib is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140133/", "reference_text": "[1] Tsunoda SM, Velez RL, vonMoltke LL, Greenblatt DJ \"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole.\" Clin Pharmacol Ther 66 (1999): 461-71[2] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[3] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[4] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[5] Vonmoltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI \"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.\" J Clin Pharmacol 36 (1996): 783-91[6] \"Product Information. Versed (midazolam).\" Roche Laboratories, Nutley, NJ.[7] Olkkola KT, Backman JT, Neuvonen PJ \"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.\" Clin Pharmacol Ther 55 (1994): 481-5[8] Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ \"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.\" Eur J Clin Pharmacol 54 (1998): 53-8[9] Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT \"Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.\" Clin Pharmacol Ther 66 (1999): 33-9[10] Merry C, Mulcahy F, Barry M, Gibbons S, Back D \"Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.\" AIDS 11 (1997): 268-9[11] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[12] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[13] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[15] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[16] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More", "alternatives_b": "Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, Givosiran, More", "updated_at": 1767369485}, {"id": 139973, "ingredient1": "Midazolam", "ingredient2": "Magaldrate", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140134/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139974, "ingredient1": "Midazolam", "ingredient2": "Magnesium carbonate", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140135/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 139975, "ingredient1": "Midazolam", "ingredient2": "Magnesium hydroxide", "severity": "Minor", "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140136/", "reference_text": "[1] Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI \"Diazepam absorption: effect of antacids and food.\" Clin Pharmacol Ther 24 (1978): 600-9[2] Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP \"Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.\" Br J Clin Pharmacol 19 (1985): 839-42[3] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Absorption rate, blood concentrations, and early response to oral chlordiazepoxide.\" Am J Psychiatry 134 (1977): 559-62[4] Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS \"Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids.\" Clin Pharmacol Ther 31 (1982): 180-3[5] Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J \"Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.\" Clin Pharmacol Ther 19 (1976): 234-9[6] Kroboth PD, Smith RB, Rault R, Silver MR, Sorkin MI, Puschett JB, Juhl RP \"Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics.\" Clin Pharmacol Ther 37 (1985): 453-9[7] Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD \"Effect of antacids on absorption of clorazepate.\" Clin Pharmacol Ther 22 (1977): 329-35[8] Nair SG, Gamble JA, Dundee JW, Howard PJ \"The influence of three antacids on the absorption and clinical action of oral diazepam.\" Br J Anaesth 48 (1976): 1175-80[9] Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD \"Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide.\" Clin Pharmacol Ther 24 (1978): 308-15[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Trospium, Avanafil, More", "updated_at": 1767369485}, {"id": 139976, "ingredient1": "Midazolam", "ingredient2": "Melatonin", "severity": "Minor", "effect": "The concomitant use of melatonin and benzodiazepines or nonbenzodiazepine hypnotics may result in a transient enhancement of sedation and impairment of memory, coordination, and attention within 1 hour of coadministration.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140137/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Hartter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K \"Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.\" Br J Clin Pharmacol 56 (2003): 679-682", "alternatives_a": "Melatonin, Nitrazepam, Zopiclone", "alternatives_b": "Nitrazepam, Zopiclone, Midazolam", "updated_at": 1767369485}, {"id": 139977, "ingredient1": "Midazolam", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Coadministration with some benzodiazepines may alter the serum concentrations of phenytoin. Phenytoin toxicity has been reported in patients treated with various benzodiazepines, including clobazam, chlordiazepoxide, clonazepam, and diazepam. Conversely, phenytoin may reduce the plasma concentrations of some benzodiazepines by inducing their metabolism via hepatic microsomal enzymes.", "source": "DDInter", "management_text": "Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary. Patients should be advised to contact their physician if they experience symptoms of hydantoin toxicity such as nausea, vomiting, tremors, ataxia, lethargy, slurred speech, visual disturbances, or changes in mental status. The potential for diminished or inadequate benzodiazepine effects should be considered during concomitant use with phenytoin.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and serum hydantoin levels should be monitored more closely whenever a benzodiazepine is added to or withdrawn from therapy, and the hydantoin dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140138/", "reference_text": "[1] Murphy A, Wilbur K \"Phenytoin-diazepam interaction.\" Ann Pharmacother 37 (2003): 659-63[2] Sennoune S, Mesdjian E, Bonneton J, et al \"Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy.\" Ther Drug Monit 14 (1992): 269-74[3] Scott AK, Khir AS, Steele WH, et al \"Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone.\" Br J Clin Pharmacol 16 (1983): 441-4[4] Shuttleworth E, Wise G, Paulson G \"Choreoathetosis and diphenylhydantoin intoxication.\" JAMA 230 (1974): 1170-1[5] Windorfer A Jr, Sauer W \"Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepin and dipropylacetate.\" Neuropadiatrie 8 (1977): 29-41[6] Saavedra IN, Aguilera LI, Faure E, Galdames DG \"Phenytoin/clonazepam interaction.\" Ther Drug Monit 7 (1985): 481-4[7] Johannessen SI, Strandjord RE, Munthe-Kaas AW \"Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine.\" Acta Neurol Scand 55 (1977): 506-12[8] Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ \"Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.\" Epilepsia 37 (1996): 253-7[9] Zifkin B, Sherwin A, Andermann F \"Phenytoin toxicity due to interaction with clobazam.\" Neurology 41 (1991): 313-4[10] Vajda FJ, Prineas RJ, Lovell RR \"Interaction between phenytoin and the benzodiazepines.\" Br Med J 1 (1971): 346[11] Siris JH, Pippenger CE, Werner WL, Masland RL \"Anticonvulsant drug-serum levels in psychiatric patients with seizure disorders. Effects of certain psychotropic drugs.\" N Y State J Med 74 (1974): 1554-6[12] Kutt H \"Interactions of antiepileptic drugs.\" Epilepsia 16 (1975): 393-402[13] Khoo KC, Mendels J, Rothbart M, et al \"Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam.\" Clin Pharmacol Ther 28 (1980): 368-75[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[18] Cerner Multum, Inc. \"Australian Product Information.\" O 0[19] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[20] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[21] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[22] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[23] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[24] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[25] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[26] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[27] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[28] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[29] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[30] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[31] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[32] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[33] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Lacosamide", "alternatives_b": "Ethchlorvynol, Methylphenobarbital, Zopiclone, Nitrazepam", "updated_at": 1767369485}, {"id": 139978, "ingredient1": "Midazolam", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140139/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ethchlorvynol, Zopiclone, Nitrazepam", "alternatives_b": "Amisulpride, Pimavanserin, Methotrimeprazine", "updated_at": 1767369485}, {"id": 139979, "ingredient1": "Midazolam", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140140/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Chloral hydrate, Nitrazepam, Quazepam, Paraldehyde, Propiomazine, Estazolam, Ethchlorvynol, Zolpidem, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "Ketotifen, Fexofenadine, Dexchlorpheniramine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "updated_at": 1767369485}, {"id": 139980, "ingredient1": "Midazolam", "ingredient2": "Methoxyflurane", "severity": "Minor", "effect": "Benzodiazepines may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required. In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140141/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Diflunisal, Salicylic acid, Choline salicylate, Salsalate", "updated_at": 1767369485}, {"id": 139981, "ingredient1": "Midazolam", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.", "source": "DDInter", "management_text": "Patients should be monitored closely for respiratory difficulty when these agents are used together.", "mechanism_text": "Others", "recommendation": "Patients should be monitored closely for respiratory difficulty when these agents are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140142/", "reference_text": "[1] Feldman SA, Crawley BE \"Diazepam and muscle relaxants.\" Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH \"Benzodiazepines and neuromuscular blocking drugs in patients.\" Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF \"In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium.\" Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139982, "ingredient1": "Mifepristone", "ingredient2": "Midazolam", "severity": "Major", "effect": "Coadministration with mifepristone may significantly increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone.", "source": "DDInter", "management_text": "When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, concomitant use of CYP450 3A4 substrates with narrow therapeutic ranges and high first-pass effect is considered contraindicated. These drugs include lovastatin, simvastatin, cyclosporine, ergot derivatives, fentanyl, oral midazolam, triazolam, pimozide, quinidine, sildenafil, sirolimus, and tacrolimus. The contraindication does not apply when mifepristone is used on a limited basis to terminate a pregnancy, but caution and close monitoring are advisable. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).", "mechanism_text": "Metabolism", "recommendation": "When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, concomitant use of CYP450 3A4 substrates with narrow therapeutic ranges and high first-pass effect is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140143/", "reference_text": "[1] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[2] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[3] He K, Woolf TF, Hollenberg PF \"Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).\" J Pharmacol Exp Ther 288 (1999): 791-7[4] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[5] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[8] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[9] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[10] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[12] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Thiopental, Propiomazine, Meprobamate, Scopolamine, More", "alternatives_b": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene", "updated_at": 1767369485}, {"id": 139983, "ingredient1": "Mirtazapine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140144/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Thiopental, Ethchlorvynol, Dichloralphenazone", "updated_at": 1767369485}, {"id": 139984, "ingredient1": "Morphine (liposomal)", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140145/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Loperamide, Diphenoxylate, Difenoxin, Naloxone, Naltrexone, Celecoxib", "alternatives_b": "Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Methohexital, Ethchlorvynol, Zopiclone, Melatonin", "updated_at": 1767369485}, {"id": 139985, "ingredient1": "Nefazodone", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Nefazodone, when administered with alprazolam or triazolam, has been reported to increase their half-life, area under the plasma concentration-time curve, and peak plasma concentrations. Increased sedation and altered psychomotor performance have resulted. The mechanism appears to be inhibition of the CYP450 3A4 enzyme by nefazodone. This interaction may occur with all benzodiazepines that undergo oxidative metabolism, although it has been reported only with alprazolam and triazolam.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for excessive and prolonged sedation. It may be necessary to adjust benzodiazepine dosage when nefazodone is started or stopped. Lorazepam, oxazepam, and temazepam undergo conjugative metabolism and may be suitable alternatives.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for excessive and prolonged sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140146/", "reference_text": "[1] Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS \"Coadministration of nefazodone and benzodiazepines: 2. a pharmacokinetic interaction study with triazolam.\" J Clin Psychopharmacol 15 (1995): 320-6[2] Kroboth PD, Mcauley JW, Derry CL \"Time-dependent sensitization to triazolam? An observation in three studies.\" J Clin Psychopharmacol 15 (1995): 192-6[3] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[4] Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH \"Coadministration of nefazodone and benzodiazepines: 3. a pharmacokinetic interaction study with alprazolam.\" J Clin Psychopharmacol 15 (1995): 399-408[5] \"Product Information. Serzone (nefazodone).\" Bristol-Myers Squibb, Princeton, NJ.[6] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[7] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[8] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[9] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[10] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[11] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[12] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[13] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[16] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[17] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[18] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[19] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[25] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[26] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[27] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[34] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[35] \"Product Information. Doral (quazepam).\" Wallace Laboratories, Cranbury, NJ.[36] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[37] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[38] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[39] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[40] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[41] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[42] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[43] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Thiopental, Ethchlorvynol, Dichloralphenazone, Nitrazepam", "alternatives_b": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "updated_at": 1767369485}, {"id": 139986, "ingredient1": "Nelfinavir", "ingredient2": "Midazolam", "severity": "Major", "effect": "Coadministration with protease inhibitors (PIs) may significantly increase the plasma concentrations and pharmacologic effects of orally administered midazolam and triazolam. The mechanism is PI inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of these benzodiazepines. Within the class, ritonavir is the most potent CYP450 3A4 inhibitor, while saquinavir is considered one of the weaker ones.", "source": "DDInter", "management_text": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with protease inhibitors is considered contraindicated. Caution and close clinical monitoring are recommended when administering parenteral midazolam in combination with protease inhibitors. Appropriate medical management should be readily available in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam may be appropriate, especially if more than a single dose of midazolam is administered.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for prolonged and/or increased sedation and respiratory depression associated with excessive benzodiazepine blood levels, concomitant use of oral midazolam or triazolam with protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140147/", "reference_text": "[1] Eagling VA, Back DJ, Barry MG \"Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.\" Br J Clin Pharmacol 44 (1997): 190-4[2] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.[3] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[4] Malaty LI, Kuper JJ \"Drug interactions of HIV protease inhibitors.\" Drug Safety 20 (1999): 147-69[5] Merry C, Mulcahy F, Barry M, Gibbons S, Back D \"Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.\" AIDS 11 (1997): 268-9[6] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[7] Barry M, Mulcahy F, Merry C, Gibbons S, Back D \"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.\" Clin Pharmacokinet 36 (1999): 289-304[8] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[9] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001): 1352-63[10] Greenblatt DJ, von Moltke LL, Harmatz JS, et al. \"Differential impairment of triazolam and zolpidem clearance by ritonavir.\" J Acquir Immune Defic Syndr 24 (2000): 129-36[11] \"Product Information. Fortovase (saquinavir)\" Roche Laboratories, Nutley, NJ.[12] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[13] Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT \"Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.\" Clin Pharmacol Ther 66 (1999): 33-9[14] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline, Research Triangle Park, NC.[15] Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR \"Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.\" J Pharm Sci 87 (1998): 803-7[16] Gill J, Feinberg J \"Saquinavir soft gelatin capsule - A comparative safety review.\" Drug Safety 24 (2001): 223-32[17] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[18] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb, Princeton, NJ.[19] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[24] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[25] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[26] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[27] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R \"Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.\" J Clin Pharmacol 41 (2001): 435-42[28] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[29] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S \"Single-dose pharmacokinetics of indinavir and the effect of food.\" Antimicrob Agents Chemother 42 (1998): 332-8", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Meprobamate, Scopolamine, Dexmedetomidine, Methohexital, More", "updated_at": 1767369485}, {"id": 139987, "ingredient1": "Nevirapine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with nevirapine may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of CYP450 3A4. The proposed mechanism is increased clearance due to nevirapine-mediated induction of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates. Dosage adjustments as well as clinical and laboratory monitoring of coadministered drugs should be considered whenever nevirapine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140148/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viramune (nevirapine).\" Boehringer-Ingelheim, Ridgefield, CT.[3] \"Product Information. Viramune XR (nevirapine).\" Boehringer Ingelheim, Ridgefield, CT.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 139988, "ingredient1": "Nilotinib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter and/or CYP450 2D6, CYP450 3A4, or UGT1A1 isoenzymes. The mechanism is decreased clearance via these routes due to inhibition by nilotinib.", "source": "DDInter", "management_text": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nilotinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140149/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Temazepam, Remimazolam, Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Scopolamine, Dexmedetomidine, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 139989, "ingredient1": "Nimodipine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140150/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Nisoldipine, Nicardipine, Isradipine, Celecoxib", "alternatives_b": "Suvorexant, Nitrazepam, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Estazolam, Zopiclone, Tasimelteon, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 139990, "ingredient1": "Nitroglycerin", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140151/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, Ethchlorvynol, More", "alternatives_b": "Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Fluorometholone, Triamcinolone, Zinc gluconate", "updated_at": 1767369485}, {"id": 139991, "ingredient1": "Nortriptyline", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140152/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Nitrazepam", "updated_at": 1767369485}, {"id": 139992, "ingredient1": "Olaparib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140153/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[7] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[10] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ethchlorvynol, More", "alternatives_b": "Pertuzumab, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Mitotane, More", "updated_at": 1767369485}, {"id": 139993, "ingredient1": "Oliceridine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140154/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Naloxone, Naltrexone, Celecoxib", "updated_at": 1767369485}, {"id": 139994, "ingredient1": "Olopatadine (nasal)", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140155/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Melatonin, Nitrazepam, Zopiclone, Methohexital", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139995, "ingredient1": "Opicapone", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140156/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Amantadine, Cabergoline", "updated_at": 1767369485}, {"id": 139996, "ingredient1": "Opium", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140157/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone, Thiopental, Methohexital", "alternatives_b": "Loperamide, Diphenoxylate, Difenoxin, Naloxone, Naltrexone, Celecoxib", "updated_at": 1767369485}, {"id": 139997, "ingredient1": "Osimertinib", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with osimertinib may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. In vitro, osimertinib has been shown to be a competitive inhibitor as well as inducer of CYP450 3A4.", "source": "DDInter", "management_text": "Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of osimertinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140158/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, Ethchlorvynol, More", "alternatives_b": "Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "updated_at": 1767369485}, {"id": 139998, "ingredient1": "Oxcarbazepine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Coadministration with oxcarbazepine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by oxcarbazepine.", "source": "DDInter", "management_text": "Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oxcarbazepine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140159/", "reference_text": "[1] Rosche J, Froscher W, Abendroth D, Liebel J \"Possible oxcarbazepine interaction with cyclosporine serum levels: A single case study.\" Clin Neuropharmacol 24 (2001): 113-6[2] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC \"Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.\" Ther Drug Monit 15 (1993): 39-42[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 139999, "ingredient1": "Oxtriphylline", "ingredient2": "Midazolam", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines. Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam. The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140160/", "reference_text": "[1] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994): 642-5[2] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989): 268[3] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991): 85-7[4] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[5] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981): 767-8[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 140000, "ingredient1": "Oxymorphone", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/140161/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone", "alternatives_b": "Naloxone, Naltrexone, Celecoxib", "updated_at": 1767369485}]